https://www.novartis.com/ 2024-06-06T09:33:38+02:00 daily 1.0 https://www.novartis.com/about/board-directors/william-t-winters 2024-01-25T13:46:06+01:00 daily 1.0 https://www.novartis.com/about/board-directors/ton-buechner 2024-01-25T14:49:48+01:00 daily 1.0 https://www.novartis.com/about/executive-committee/harry-kirsch 2024-01-25T09:07:41+01:00 daily 1.0 https://www.novartis.com/about/board-directors/simon-moroney 2024-01-24T15:09:47+01:00 daily 1.0 https://www.novartis.com/about/board-directors/patrice-bula 2024-05-27T09:19:10+02:00 daily 1.0 https://www.novartis.com/about/board-directors/nancy-c-andrews 2024-01-29T13:40:51+01:00 daily 1.0 https://www.novartis.com/about/board-directors/joerg-reinhardt 2024-01-25T14:57:21+01:00 daily 1.0 https://www.novartis.com/about/board-directors/frans-van-houten 2024-02-13T10:54:22+01:00 daily 1.0 https://www.novartis.com/about/executive-committee/karen-hale 2024-01-25T09:06:05+01:00 daily 1.0 https://www.novartis.com/about/executive-committee/klaus-moosmayer 2024-01-25T09:03:54+01:00 daily 1.0 https://www.novartis.com/about/executive-committee/lutz-hegemann 2024-01-25T09:09:20+01:00 daily 1.0 https://www.novartis.com/about/board-directors/elizabeth-liz-doherty 2024-01-29T13:41:30+01:00 daily 1.0 https://www.novartis.com/about/board-directors/charlotte-pamer-wieser 2024-01-25T09:27:38+01:00 daily 1.0 https://www.novartis.com/about/board-directors/charles-l-sawyers 2024-01-29T13:39:52+01:00 daily 1.0 https://www.novartis.com/about/board-directors/bridgette-heller 2024-01-25T13:53:37+01:00 daily 1.0 https://www.novartis.com/about/executive-committee/vasant-narasimhan 2024-01-25T09:17:45+01:00 daily 1.0 https://www.novartis.com/about/executive-committee/steffen-lang 2024-01-29T13:45:30+01:00 daily 1.0 https://www.novartis.com/about/novartis-and-european-union-eu/novartis-eu-public-affairs-team/julie-chauvet 2023-10-24T09:39:54+02:00 daily 1.0 https://www.novartis.com/about/novartis-and-european-union-eu/novartis-eu-public-affairs-team/vincent-vanwijnsberghe 2021-09-22T12:30:02+02:00 daily 1.0 https://www.novartis.com/about/novartis-and-european-union-eu/novartis-eu-public-affairs-team/sarah-moundir 2024-02-13T13:57:56+01:00 daily 1.0 https://www.novartis.com/about/executive-committee/rob-kowalski 2024-01-25T08:53:44+01:00 daily 1.0 https://www.novartis.com/about/board-directors/daniel-hochstrasser 2024-01-25T13:56:05+01:00 daily 1.0 https://www.novartis.com/about/board-directors/ana-de-pro-gonzalo 2024-01-24T15:48:27+01:00 daily 1.0 https://www.novartis.com/about/executive-committee/victor-bulto 2024-01-25T08:51:57+01:00 daily 1.0 https://www.novartis.com/about/executive-committee/kees-roks 2024-01-25T09:09:43+01:00 daily 1.0 https://www.novartis.com/about/executive-committee/shreeram-aradhye 2024-01-25T08:49:29+01:00 daily 1.0 https://www.novartis.com/about/executive-committee/aharon-ronny-gal-phd 2024-01-25T09:05:28+01:00 daily 1.0 https://www.novartis.com/about/executive-committee/fiona-marshall 2024-01-25T09:08:43+01:00 daily 1.0 https://www.novartis.com/about/board-directors/john-d-young 2024-01-25T13:13:57+01:00 daily 1.0 https://www.novartis.com/about/executive-committee/michelle-weese 2024-05-01T18:03:47+02:00 daily 1.0 https://www.novartis.com/about/executive-committee/patrick-horber-md 2024-01-25T09:07:54+01:00 daily 1.0 https://www.novartis.com/clinicaltrials/study/nct04597411 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct03872778 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04174157 2024-06-18T16:39:10+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06142383 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06142357 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06121349 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06042478 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06031844 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06019637 2024-06-19T16:44:26+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06004661 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06004453 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05996835 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05985915 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05983198 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05977322 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05976243 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05976230 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05948943 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05943522 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05921994 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05900141 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05888493 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05885555 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05870579 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05853458 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05849298 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05838768 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05803941 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05798117 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05776888 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05767034 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05755386 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05750628 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05739383 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05726838 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05703516 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05697146 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05682378 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05678959 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05677451 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05666804 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05653349 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05653219 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05648968 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05639114 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05634967 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05631795 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05626257 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05624749 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05622708 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05621733 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05592990 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05576792 2024-06-18T16:39:10+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05562466 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05552469 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05548062 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05544929 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05541341 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05524051 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05513001 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05462873 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05456191 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05432388 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05429502 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05415072 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05399992 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05397496 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05384587 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05380453 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05362903 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05360446 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05358249 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05349214 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05344469 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05335876 2024-06-18T16:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05304949 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05301907 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05294289 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05293470 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05285904 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05275868 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05274425 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05268289 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05266495 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05266469 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05252585 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05230537 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05222529 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05217810 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05201066 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05161195 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05156281 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05147220 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05142696 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05126277 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05110196 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05109728 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05090371 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05090033 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05073120 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05038735 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05022342 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04985487 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04967248 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04961619 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04943497 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04933552 2024-06-19T16:44:26+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04926818 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04925479 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04903197 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04889430 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04886258 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04877522 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04857372 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04817618 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04797000 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04788615 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04747613 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04712721 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04699188 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04675931 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04666272 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04657822 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04641442 2024-06-19T16:44:26+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04638647 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04589650 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04557462 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04546633 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04480853 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04230148 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04094311 2024-06-19T16:44:26+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04058756 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct03975829 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct03960840 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct03955445 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct03876769 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct03827798 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct03650114 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct03591510 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct03474965 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct03340506 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct03040973 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct02934568 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct02445222 2024-06-18T16:39:10+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct02386800 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct01892722 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct01285479 2024-06-18T16:39:10+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06262919 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06097663 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05329623 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06251986 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06157086 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05809986 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06053801 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06130540 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05646381 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06275724 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05939414 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05842954 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06148506 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06240741 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05935215 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06092879 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05868629 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06236061 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06331312 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06075758 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05739942 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05114746 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04623216 2024-06-28T08:43:39+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06133972 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04066244 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct06155500 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct05795140 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/clinicaltrials/study/nct04645589 2024-06-28T08:00:06+02:00 0.5 https://www.novartis.com/news/media-library/manufacturing-facility-stein-ch 2021-10-11T09:11:49+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-production-and-manufacturing-b-roll-video 2022-10-25T06:14:34+02:00 daily 1.0 https://www.novartis.com/news/media-library/karen-l-hale 2022-04-04T07:08:03+02:00 daily 1.0 https://www.novartis.com/news/media-library/what-non-alcoholic-steatohepatitis-nash 2021-08-16T07:56:01+02:00 daily 1.0 https://www.novartis.com/news/media-library/access-fact-sheet 2021-08-16T09:06:09+02:00 daily 1.0 https://www.novartis.com/news/media-library/healthy-family-fact-sheet 2021-08-16T09:09:08+02:00 daily 1.0 https://www.novartis.com/news/media-library/thalassemia-backgrounder 2021-08-16T07:59:01+02:00 daily 1.0 https://www.novartis.com/news/media-library/sickle-cell-disease-backgrounder 2021-08-16T08:02:11+02:00 daily 1.0 https://www.novartis.com/news/media-library/chronic-iron-overload-backgrounder 2021-08-16T08:04:21+02:00 daily 1.0 https://www.novartis.com/news/media-library/myelodysplastic-syndromes-mds-backgrounder 2021-08-16T08:06:45+02:00 daily 1.0 https://www.novartis.com/news/media-library/anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-interactive-media-guide 2021-08-16T08:09:04+02:00 daily 1.0 https://www.novartis.com/news/media-library/neuroendocrine-tumors-expert-media-guide 2021-08-16T08:11:30+02:00 daily 1.0 https://www.novartis.com/news/media-library/leprosy 2021-08-16T08:13:18+02:00 daily 1.0 https://www.novartis.com/news/media-library/reimagining-management-sickle-cell-disease-africa 2021-08-16T08:14:54+02:00 daily 1.0 https://www.novartis.com/news/media-library/malaria 2022-03-15T09:27:38+01:00 daily 1.0 https://www.novartis.com/news/media-library/chagas-disease 2021-08-16T08:18:29+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-access-fact-sheet 2021-08-03T20:09:53+02:00 daily 1.0 https://www.novartis.com/news/media-library/chronic-myeloid-leukemia-today-and-tomorrow-visual-fact-sheet 2021-08-10T19:47:12+02:00 daily 1.0 https://www.novartis.com/news/media-library/renal-cell-carcinoma-rcc-fact-sheet 2021-08-10T19:48:06+02:00 daily 1.0 https://www.novartis.com/news/media-library/early-versus-advanced-breast-cancer-list 2021-08-10T19:49:03+02:00 daily 1.0 https://www.novartis.com/news/media-library/frontal-view-gehry-building 2021-08-16T09:15:42+02:00 daily 1.0 https://www.novartis.com/news/media-library/gehry-building-from-distance 2021-08-16T09:17:04+02:00 daily 1.0 https://www.novartis.com/news/media-library/tables-and-chairs-next-green-space 2021-08-16T09:19:39+02:00 daily 1.0 https://www.novartis.com/news/media-library/steffen-lang-phd 2023-03-16T09:44:41+01:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-logo 2021-10-19T15:46:43+02:00 daily 1.0 https://www.novartis.com/news/media-library/frans-van-houten 2021-08-16T10:14:04+02:00 daily 1.0 https://www.novartis.com/news/media-library/charlotte-pamer-wieser-phd 2021-08-16T10:16:06+02:00 daily 1.0 https://www.novartis.com/news/media-library/william-t-winters 2021-08-16T10:25:10+02:00 daily 1.0 https://www.novartis.com/news/media-library/charles-l-sawyers-md 2021-08-16T10:26:47+02:00 daily 1.0 https://www.novartis.com/news/media-library/elizabeth-liz-doherty 2021-08-16T10:31:06+02:00 daily 1.0 https://www.novartis.com/news/media-library/ton-buechner 2021-08-16T10:33:29+02:00 daily 1.0 https://www.novartis.com/news/media-library/nancy-c-andrews-md-phd 2021-08-16T10:35:02+02:00 daily 1.0 https://www.novartis.com/news/media-library/joerg-reinhardt-phd 2021-08-16T10:38:44+02:00 daily 1.0 https://www.novartis.com/news/media-library/vasant-vas-narasimhan-md 2022-04-04T07:02:47+02:00 daily 1.0 https://www.novartis.com/news/media-library/trees-casting-shadows-along-fabrikstrasse 2021-08-13T07:10:42+02:00 daily 1.0 https://www.novartis.com/news/media-library/harry-kirsch 2022-04-04T07:07:49+02:00 daily 1.0 https://www.novartis.com/news/media-library/antimalarial-pills 2021-08-16T10:49:45+02:00 daily 1.0 https://www.novartis.com/news/media-library/antimalarial-raw-material 2021-08-16T10:51:23+02:00 daily 1.0 https://www.novartis.com/news/media-library/artemisinin-combination-therapy-act 2021-08-16T10:54:29+02:00 daily 1.0 https://www.novartis.com/news/media-library/artemisinin-extraction 2021-08-16T10:58:31+02:00 daily 1.0 https://www.novartis.com/news/media-library/farmer-harvesting-artemisia-annua 2021-08-16T11:01:56+02:00 daily 1.0 https://www.novartis.com/news/media-library/malaria-diagnostic-test 2023-03-16T09:47:10+01:00 daily 1.0 https://www.novartis.com/news/media-library/malaria-prevention 2023-03-16T09:46:49+01:00 daily 1.0 https://www.novartis.com/news/media-library/malaria-researchers-nairobi-kenya 2021-08-16T11:13:03+02:00 daily 1.0 https://www.novartis.com/news/media-library/mode-action-cgrp-receptor-blocker 2021-08-16T11:28:31+02:00 daily 1.0 https://www.novartis.com/news/media-library/patients-frozen-t-cells 2021-08-16T11:39:02+02:00 daily 1.0 https://www.novartis.com/news/media-library/sms-life 2021-08-16T13:19:23+02:00 daily 1.0 https://www.novartis.com/news/media-library/sms-life-training-session 2021-08-16T13:22:00+02:00 daily 1.0 https://www.novartis.com/news/media-library/t-cell-arrival-novartis-manufacturing-facility 2021-08-16T13:23:31+02:00 daily 1.0 https://www.novartis.com/news/media-library/view-fabrikstrasse-novartis-hq 2021-08-16T13:24:57+02:00 daily 1.0 https://www.novartis.com/news/media-library/worldwide-distribution-center-novartis-antimalarial-basel-switzerland 2021-08-16T13:30:21+02:00 daily 1.0 https://www.novartis.com/news/media-library/young-malaria-patient 2023-03-16T09:45:27+01:00 daily 1.0 https://www.novartis.com/news/media-library/cancer-2030-growing-global-crisis 2021-08-16T13:35:05+02:00 daily 1.0 https://www.novartis.com/news/media-library/sickle-cell-world-assessment-survey-sway-results 2021-08-16T13:35:58+02:00 daily 1.0 https://www.novartis.com/news/media-library/new-era-medicine 2021-08-16T13:37:09+02:00 daily 1.0 https://www.novartis.com/news/media-library/cell-and-gene-key-focus-areas 2021-08-16T13:40:35+02:00 daily 1.0 https://www.novartis.com/news/media-library/introduction-cell-and-gene-therapy 2021-08-16T13:42:42+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-financial-results-q3-2018-infographic 2021-08-16T13:44:09+02:00 daily 1.0 https://www.novartis.com/news/media-library/klaus-moosmayer-phd 2022-04-04T07:07:06+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-financial-results-q2-2018-infographic 2021-08-12T06:34:21+02:00 daily 1.0 https://www.novartis.com/news/media-library/impact-migraine 2021-08-12T06:51:56+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-financial-results-q1-2018-infographic 2021-08-12T07:26:12+02:00 daily 1.0 https://www.novartis.com/news/media-library/spinal-muscular-atrophy-sma-infographic 2021-08-13T13:21:00+02:00 daily 1.0 https://www.novartis.com/news/media-library/inflammation-and-cardiovascular-risk 2021-08-12T07:45:54+02:00 daily 1.0 https://www.novartis.com/news/media-library/measuring-inflammation-and-role-hscrp 2021-08-16T07:42:14+02:00 daily 1.0 https://www.novartis.com/news/media-library/chimeric-antigen-receptor-t-cell-car-t-therapy 2021-08-16T13:45:57+02:00 daily 1.0 https://www.novartis.com/news/media-library/chronic-iron-overload-infographic 2021-08-12T07:55:14+02:00 daily 1.0 https://www.novartis.com/news/media-library/chronic-myleoid-leukemia-meet-milestones-matter-one-pager 2021-08-12T07:57:02+02:00 daily 1.0 https://www.novartis.com/news/media-library/facts-about-melanoma-infographic 2021-08-12T08:03:57+02:00 daily 1.0 https://www.novartis.com/news/media-library/chronic-iron-overload-complications-infographic 2021-08-12T08:04:00+02:00 daily 1.0 https://www.novartis.com/news/media-library/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-disease-state-infographic 2021-08-12T08:09:48+02:00 daily 1.0 https://www.novartis.com/news/media-library/about-noncommunicable-diseases-infographic 2021-08-12T08:15:02+02:00 daily 1.0 https://www.novartis.com/news/media-library/access-ncd-treatment-infographic 2021-08-12T08:16:03+02:00 daily 1.0 https://www.novartis.com/news/media-library/understanding-chronic-myeloid-leukemia-infographic 2021-08-12T08:19:53+02:00 daily 1.0 https://www.novartis.com/news/media-library/gastrointestinal-neuroendocrine-tumors-infographic 2021-08-12T08:27:54+02:00 daily 1.0 https://www.novartis.com/news/media-library/pancreatic-neuroendocrine-tumors-infographic 2021-08-12T08:36:26+02:00 daily 1.0 https://www.novartis.com/news/media-library/lung-neuroendocrine-tumors-infographic 2021-08-12T08:44:12+02:00 daily 1.0 https://www.novartis.com/news/media-library/tuberous-sclerosis-complex-patient-journey-infographic 2021-08-12T08:52:12+02:00 daily 1.0 https://www.novartis.com/news/media-library/advanced-soft-tissue-sarcoma-infographic 2021-08-12T08:52:41+02:00 daily 1.0 https://www.novartis.com/news/media-library/tuberous-sclerosis-complex-common-threads-infographic 2021-08-12T09:04:26+02:00 daily 1.0 https://www.novartis.com/news/media-library/renal-cell-carcinoma-infographic 2021-08-12T09:06:05+02:00 daily 1.0 https://www.novartis.com/news/media-library/embarking-young-adulthood-tsc-monitoring-manifestations-over-time 2021-08-12T09:06:40+02:00 daily 1.0 https://www.novartis.com/news/media-library/psychological-social-impact-advanced-breast-cancer 2021-08-12T09:12:17+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-society-us-report-2020 2021-08-12T09:14:45+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-society-esg-report-2020 2021-08-12T09:28:05+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-annual-report-2020 2021-08-12T09:30:15+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-annual-report-2019 2021-08-16T08:35:26+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-society-us-report-2019 2021-08-12T09:53:11+02:00 daily 1.0 https://www.novartis.com/news/media-library/malaria-futures-central-africa 2021-08-12T09:58:22+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-society-esg-report-2019 2021-08-12T10:03:08+02:00 daily 1.0 https://www.novartis.com/news/media-library/malaria-futures-asia 2021-08-12T10:23:17+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-social-business-report-2018 2021-08-12T10:29:05+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-society-us-report-2018 2021-08-12T10:35:50+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-society-report-2018 2022-02-01T18:02:31+01:00 daily 1.0 https://www.novartis.com/news/media-library/malaria-futures-africa 2021-08-12T10:46:32+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-annual-report-2018 2021-08-12T10:50:03+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-annual-report-2017 2021-08-12T10:50:20+02:00 daily 1.0 https://www.novartis.com/news/media-library/healthy-family-10-year-report 2021-08-12T10:54:45+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-access-two-year-report 2021-08-12T10:59:27+02:00 daily 1.0 https://www.novartis.com/news/media-library/corporate-responsibility-report-2017 2021-08-12T10:59:36+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-access-one-year-report 2021-08-12T11:08:28+02:00 daily 1.0 https://www.novartis.com/news/media-library/building-trust-society-our-priorities 2021-08-16T09:02:11+02:00 daily 1.0 https://www.novartis.com/news/media-library/strengthening-our-global-health-corporate-responsibility-function 2021-08-13T08:18:24+02:00 daily 1.0 https://www.novartis.com/news/media-library/spinal-muscular-atrophy-sma-factsheet 2021-08-13T08:51:52+02:00 daily 1.0 https://www.novartis.com/news/media-library/heart-failure-hospitalization-why-moment-matters 2021-08-13T08:46:29+02:00 daily 1.0 https://www.novartis.com/news/media-library/about-migraine 2021-08-13T08:55:50+02:00 daily 1.0 https://www.novartis.com/news/media-library/diffuse-large-b-cell-lymphoma-dlbcl 2021-08-13T09:01:52+02:00 daily 1.0 https://www.novartis.com/news/media-library/acute-lymphoblastic-leukemia-all 2021-08-13T09:46:11+02:00 daily 1.0 https://www.novartis.com/news/media-library/acute-lymphoblastic-leukemia-fact-sheet 2021-08-13T09:51:42+02:00 daily 1.0 https://www.novartis.com/news/media-library/advancing-global-health 2021-08-13T10:03:30+02:00 daily 1.0 https://www.novartis.com/news/media-library/chronic-myeloid-leukemia-background-fact-sheet 2021-08-12T11:55:53+02:00 daily 1.0 https://www.novartis.com/news/media-library/science-behind-car-t-cell-therapy 2023-03-16T09:47:33+01:00 daily 1.0 https://www.novartis.com/news/media-library/manufacturing-car-t-cell-therapies-novartis-approach 2021-08-12T13:13:50+02:00 daily 1.0 https://www.novartis.com/news/media-library/lutz-hegemann-md-phd 2023-08-04T10:30:21+02:00 daily 1.0 https://www.novartis.com/news/media-library/bridgette-heller 2021-08-12T14:40:41+02:00 daily 1.0 https://www.novartis.com/news/media-library/simon-moroney-dphil 2023-03-16T09:47:55+01:00 daily 1.0 https://www.novartis.com/news/media-library/bad-sackingen-novartis-stein-switzerland 2021-08-12T14:54:42+02:00 daily 1.0 https://www.novartis.com/news/media-library/operator-culture-medium-bag 2021-08-12T14:58:17+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-site-stein-switzerland 2021-08-12T15:02:35+02:00 daily 1.0 https://www.novartis.com/news/media-library/marc-boutin 2021-10-05T14:35:43+02:00 daily 1.0 https://www.novartis.com/news/media-library/operators-clean-room 2021-08-13T06:19:14+02:00 daily 1.0 https://www.novartis.com/news/media-library/operator-labels-culture-plates 2021-08-13T06:23:38+02:00 daily 1.0 https://www.novartis.com/news/media-library/operator-prepares-connecting-hose 2021-08-13T06:25:22+02:00 daily 1.0 https://www.novartis.com/news/media-library/patrice-bula 2022-03-03T10:25:30+01:00 daily 1.0 https://www.novartis.com/news/media-library/people-park 2021-08-13T06:31:31+02:00 daily 1.0 https://www.novartis.com/news/media-library/break-park 2021-08-13T06:33:14+02:00 daily 1.0 https://www.novartis.com/news/media-library/operator-performs-process-operation-biosafety-cabinet 2021-08-13T06:36:44+02:00 daily 1.0 https://www.novartis.com/news/media-library/grocery-shop-staircase 2021-08-13T06:40:11+02:00 daily 1.0 https://www.novartis.com/news/media-library/staircase-fabrikstrasse-6-peter-markli 2023-03-30T09:37:14+02:00 daily 1.0 https://www.novartis.com/news/media-library/avenue-trees-along-fabrikstrasse 2021-08-13T07:03:30+02:00 daily 1.0 https://www.novartis.com/news/media-library/view-fabrikstrasse-6-peter-markli-trees 2023-03-30T09:30:01+02:00 daily 1.0 https://www.novartis.com/news/media-library/view-staircase-gehry-building 2021-08-13T07:25:15+02:00 daily 1.0 https://www.novartis.com/news/media-library/first-results-from-global-net-survey-part-1-time-diagnosis 2021-08-13T07:51:07+02:00 daily 1.0 https://www.novartis.com/news/media-library/tackling-chronic-disease-novartis-access 2021-10-12T11:24:54+02:00 daily 1.0 https://www.novartis.com/news/media-library/results-from-first-global-net-survey-part-2-net-patient-experience 2021-08-13T08:32:41+02:00 daily 1.0 https://www.novartis.com/news/media-library/what-polycythemia-vera 2023-03-15T14:10:34+01:00 daily 1.0 https://www.novartis.com/news/media-library/how-polycythemia-vera-diagnosed 2021-08-13T07:59:25+02:00 daily 1.0 https://www.novartis.com/news/media-library/what-are-symptoms-and-complications-polycythemia-vera 2021-08-13T08:11:00+02:00 daily 1.0 https://www.novartis.com/news/media-library/tsc-common-threads-future-outlook-tsc 2021-08-13T08:18:13+02:00 daily 1.0 https://www.novartis.com/news/media-library/tsc-common-threads-grandia-family-story 2021-08-13T08:33:10+02:00 daily 1.0 https://www.novartis.com/news/media-library/tsc-talk-did-you-know 2021-08-13T08:33:26+02:00 daily 1.0 https://www.novartis.com/news/media-library/tsc-common-threads-tsc-affects-each-person-differently 2021-08-13T08:40:12+02:00 daily 1.0 https://www.novartis.com/news/media-library/tsc-common-threads-moss-family 2021-08-13T08:44:35+02:00 daily 1.0 https://www.novartis.com/news/media-library/tsc-common-threads-life-tsc 2021-08-13T08:46:09+02:00 daily 1.0 https://www.novartis.com/news/media-library/acute-myeloid-leukemia-unique-needs-patients-and-caregivers 2021-08-13T08:52:07+02:00 daily 1.0 https://www.novartis.com/news/media-library/alk-non-small-cell-lung-cancer-patient-video-anne-marie 2021-08-13T08:57:10+02:00 daily 1.0 https://www.novartis.com/news/media-library/alk-non-small-cell-lung-cancer-patient-video-miriam-joel 2021-08-13T09:06:36+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-access-how-well-expand-access-healthcare 2021-08-13T09:12:50+02:00 daily 1.0 https://www.novartis.com/news/media-library/experts-gather-explore-response-chronic-illness-poor-countries 2021-08-13T09:12:01+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-and-international-red-cross-partner-provide-medicines-syrian-refugees 2021-08-13T09:18:38+02:00 daily 1.0 https://www.novartis.com/news/media-library/museum-ms 2021-08-13T09:21:24+02:00 daily 1.0 https://www.novartis.com/news/media-library/what-do-you-know-about-noncommunicable-diseases 2021-08-13T09:27:29+02:00 daily 1.0 https://www.novartis.com/news/media-library/about-erenumab-amg-334 2021-09-09T10:48:41+02:00 daily 1.0 https://www.novartis.com/news/media-library/erenumab-amg-334-key-clinical-trials-numbers 2021-09-09T10:48:29+02:00 daily 1.0 https://www.novartis.com/news/media-library/how-does-acz885-work 2021-09-09T10:48:16+02:00 daily 1.0 https://www.novartis.com/news/media-library/juliet-clinical-trial 2021-09-09T10:48:04+02:00 daily 1.0 https://www.novartis.com/news/media-library/kymriah-tisagenlecleucel-children-and-young-adults-b-cell-all-refractory-or-relapsed-least-twice 2022-10-20T11:02:08+02:00 daily 1.0 https://www.novartis.com/news/media-library/rth258-brolucizumab-clinical-trials 2021-09-09T10:47:38+02:00 daily 1.0 https://www.novartis.com/news/media-library/kymriah-tisagenlecleucel-suspension-intravenous-infusion 2022-10-20T10:55:43+02:00 daily 1.0 https://www.novartis.com/news/media-library/interleukin-17-il-17a-inflammatory-joint-disease 2021-09-09T10:47:10+02:00 daily 1.0 https://www.novartis.com/news/media-library/interleukin-17-il-17a-psoriasis 2021-09-09T10:46:13+02:00 daily 1.0 https://www.novartis.com/news/media-library/rob-kowalski 2022-04-04T07:07:27+02:00 daily 1.0 https://www.novartis.com/news/media-library/managing-tsc-transition-adult-care 2021-10-06T09:33:37+02:00 daily 1.0 https://www.novartis.com/news/media-library/nibr-basel 2022-10-25T06:12:17+02:00 daily 1.0 https://www.novartis.com/news/media-library/nibr-cambridge-united-states 2022-10-25T06:11:34+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-animated-logo 2022-10-25T06:10:55+02:00 daily 1.0 https://www.novartis.com/news/media-library/view-forum-1-and-fabrikstrasse-novartis-campus-basel 2021-12-07T14:30:18+01:00 daily 1.0 https://www.novartis.com/news/media-library/view-fabrikstrasse-15-novartis-campus-basel 2021-12-07T10:11:08+01:00 daily 1.0 https://www.novartis.com/news/media-library/outside-meeting-space-novartis-campus-basel 2021-12-08T09:48:37+01:00 daily 1.0 https://www.novartis.com/news/media-library/view-asklepios-8-along-rhine-riverbank-novartis-campus-basel 2021-12-07T14:29:09+01:00 daily 1.0 https://www.novartis.com/news/media-library/view-towards-asklepios-8-and-dreirosenbruckebasel-novartis-campus-basel 2021-12-07T14:37:40+01:00 daily 1.0 https://www.novartis.com/news/media-library/view-banting-1-and-novartis-campus-basel 2021-12-13T10:14:35+01:00 daily 1.0 https://www.novartis.com/news/media-library/view-banting-1 2021-12-13T10:14:45+01:00 daily 1.0 https://www.novartis.com/news/media-library/view-novartis-campus-and-banting-1-basel 2021-12-13T10:14:23+01:00 daily 1.0 https://www.novartis.com/news/media-library/view-banting-1-and-fabrikstrasse-novartis-campus-basel 2022-01-26T15:09:13+01:00 daily 1.0 https://www.novartis.com/news/media-library/view-banting-1-and-fabrikstrasse-6-passing-cyclist-novartis-campus-basel 2022-01-26T15:18:29+01:00 daily 1.0 https://www.novartis.com/news/media-library/view-banting-1-and-fabrikstrasse-6-novartis-campus-basel 2022-01-26T15:18:03+01:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-annual-report-2021 2022-02-01T23:17:40+01:00 daily 1.0 https://www.novartis.com/news/media-library/ana-de-pro-gonzalo 2022-03-04T14:59:28+01:00 daily 1.0 https://www.novartis.com/news/media-library/daniel-hochstrasser 2023-03-16T09:45:06+01:00 daily 1.0 https://www.novartis.com/news/media-library/view-novartis-campus-forum-1-banting-1-and-fabrikstrasse 2022-04-05T15:44:31+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-pavillon-banting-1-background 2022-04-05T15:45:07+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-pavillon-novartis-campus-and-banting-1-background 2022-04-05T15:45:58+02:00 daily 1.0 https://www.novartis.com/news/media-library/view-from-novartis-campus-towards-novartis-pavillon-and-basel-alongside-rhine-river 2022-04-05T15:46:51+02:00 daily 1.0 https://www.novartis.com/news/media-library/view-from-novartis-campus-towards-novartis-pavillon-and-basel 2022-04-05T15:48:12+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-pavillon-located-park-south-novartis-campus 2022-04-05T15:51:10+02:00 daily 1.0 https://www.novartis.com/news/media-library/illumination-zero-energy-media-facade-novartis-pavillon-artwork-semiconductor-0 2022-04-05T15:50:05+02:00 daily 1.0 https://www.novartis.com/news/media-library/illumination-zero-energy-media-facade-novartis-pavillon-artwork-semiconductor 2022-04-05T15:52:08+02:00 daily 1.0 https://www.novartis.com/news/media-library/illumination-zero-energy-media-facade-novartis-pavillon-0 2022-04-05T15:52:45+02:00 daily 1.0 https://www.novartis.com/news/media-library/illumination-zero-energy-media-facade-novartis-pavillon 2022-04-05T15:53:35+02:00 daily 1.0 https://www.novartis.com/news/media-library/organic-solar-cell-led-core-which-builds-illuminating-skin-novartis-pavillon 2022-04-05T15:54:18+02:00 daily 1.0 https://www.novartis.com/news/media-library/schoolhub-ground-floor-novartis-pavillon 2022-04-05T15:54:52+02:00 daily 1.0 https://www.novartis.com/news/media-library/interior-view-ground-floor-novartis-pavillon 2022-04-05T15:55:19+02:00 daily 1.0 https://www.novartis.com/news/media-library/welcome-wall-and-staircase-exhibition-wonders-medicine-novartis-pavillon 2022-04-05T15:56:13+02:00 daily 1.0 https://www.novartis.com/news/media-library/welcome-wall-novartis-pavillon 2022-04-05T15:56:39+02:00 daily 1.0 https://www.novartis.com/news/media-library/content-area-fragility-life-wonders-medicine-exhibition-novartis-pavillon 2022-04-05T15:57:24+02:00 daily 1.0 https://www.novartis.com/news/media-library/victor-bulto 2023-10-04T12:01:30+02:00 daily 1.0 https://www.novartis.com/news/media-library/kees-roks 2022-05-02T11:41:28+02:00 daily 1.0 https://www.novartis.com/news/media-library/shreeram-aradhye-md 2023-10-04T12:00:45+02:00 daily 1.0 https://www.novartis.com/news/media-library/crizanlizumab-clinical-setting-from-international-managed-access-program-map 2022-06-17T12:20:56+02:00 daily 1.0 https://www.novartis.com/news/media-library/aharon-ronny-gal-phd 2022-09-12T14:17:27+02:00 daily 1.0 https://www.novartis.com/news/media-library/about-gene-therapy 2022-08-12T09:29:48+02:00 daily 1.0 https://www.novartis.com/news/media-library/gene-therapy-manufacturing-north-carolina 2022-08-12T09:34:45+02:00 daily 1.0 https://www.novartis.com/news/media-library/about-novartis-gene-therapies 2022-10-03T10:34:29+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-gene-therapies-manufacturing-process 2022-10-03T10:31:51+02:00 daily 1.0 https://www.novartis.com/news/media-library/screen-unseen-newborn-screening-sma 2022-08-12T09:22:53+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-aav-platform 2022-10-03T10:28:58+02:00 daily 1.0 https://www.novartis.com/news/media-library/spinal-muscular-atrophy 2022-08-12T09:33:04+02:00 daily 1.0 https://www.novartis.com/news/media-library/scientist-laboratory-banting-1-office-space-background 2022-09-05T16:45:45+02:00 daily 1.0 https://www.novartis.com/news/media-library/scientists-fermentation-hub-banting-1 2022-09-05T16:45:37+02:00 daily 1.0 https://www.novartis.com/news/media-library/fermentation-hub-banting-1-where-natural-products-and-biomolecules-can-be-produced 2022-09-05T16:45:29+02:00 daily 1.0 https://www.novartis.com/news/media-library/scientists-one-state-art-laboratories-banting-1 2022-09-05T16:45:14+02:00 daily 1.0 https://www.novartis.com/news/media-library/scientists-laboratory-banting-1-where-global-discovery-chemistry-group-based 2022-09-05T16:45:05+02:00 daily 1.0 https://www.novartis.com/news/media-library/view-asklepios-building-oscillation-bench-front 2022-10-27T11:02:48+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-pavillon-located-park-south-novartis-campus-0 2022-10-27T11:06:14+02:00 daily 1.0 https://www.novartis.com/news/media-library/park-south-novartis-campus-view-novartis-pavillon 2022-10-27T11:24:37+02:00 daily 1.0 https://www.novartis.com/news/media-library/laboratory-building-virchow-6-novartis-campus 2022-10-27T11:07:29+02:00 daily 1.0 https://www.novartis.com/news/media-library/architects-map-novartis-campus-english-version 2022-10-27T10:30:25+02:00 daily 1.0 https://www.novartis.com/news/media-library/view-gehry-building-green-and-fabrikstrasse-novartis-campus-basel 2022-10-27T11:08:06+02:00 daily 1.0 https://www.novartis.com/news/media-library/fiona-h-marshall-phd 2023-10-04T11:57:56+02:00 daily 1.0 https://www.novartis.com/news/media-library/how-novartis-contributing-fight-against-malaria 2022-11-23T07:44:14+01:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-annual-report-2022 2023-02-02T12:55:12+01:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-society-integrated-report-2022 2023-02-17T18:02:34+01:00 daily 1.0 https://www.novartis.com/news/media-library/52-week-results-cosentyx-hidradenitis-suppurativa-summary 2023-02-08T07:37:04+01:00 daily 1.0 https://www.novartis.com/news/media-library/production-process-rna-therapies-schweizerhalle-switzerland 2023-02-16T15:31:34+01:00 daily 1.0 https://www.novartis.com/news/media-library/view-rna-production-schweizerhalle-switzerland 2023-02-16T15:31:52+01:00 daily 1.0 https://www.novartis.com/news/media-library/manufacturing-rna-therapies-schweizerhalle-switzerland 2023-02-16T15:31:43+01:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-society-integrierter-geschaftsbericht-2022 2023-02-17T18:02:26+01:00 daily 1.0 https://www.novartis.com/news/media-library/john-d-young 2023-03-07T12:21:40+01:00 daily 1.0 https://www.novartis.com/news/media-library/main-entrance-novartis-pavillon 2023-03-30T09:27:34+02:00 daily 1.0 https://www.novartis.com/news/media-library/birds-eye-view-novartis-pavillon 2023-03-30T09:28:12+02:00 daily 1.0 https://www.novartis.com/news/media-library/view-from-kleinbasel-towards-novartis-campus-basel 2023-03-30T09:32:11+02:00 daily 1.0 https://www.novartis.com/news/media-library/view-novartis-pavillon-towards-dreirosenbrucke-and-city-center 2023-03-30T09:27:40+02:00 daily 1.0 https://www.novartis.com/news/media-library/view-from-hohlweg-passing-under-novartis-pavillon 2023-03-30T09:28:05+02:00 daily 1.0 https://www.novartis.com/news/media-library/wonders-medicine-exhibition-novartis-pavillon 2023-03-30T09:28:27+02:00 daily 1.0 https://www.novartis.com/news/media-library/wonders-medicine-exhibition-from-lab-patient-novartis-pavillon 2023-03-30T09:28:34+02:00 daily 1.0 https://www.novartis.com/news/media-library/wonders-medicine-exhibition-from-lab-patient-novartis-pavillon-0 2023-03-30T09:28:41+02:00 daily 1.0 https://www.novartis.com/news/media-library/wonders-medicine-exhibition-steps-through-time-novartis-pavillon 2023-03-30T09:28:48+02:00 daily 1.0 https://www.novartis.com/news/media-library/wonders-medicine-exhibition-future-healthcare-novartis-pavillon 2023-03-30T09:28:54+02:00 daily 1.0 https://www.novartis.com/news/media-library/schoolhub-novartis-pavillon 2023-03-30T09:27:21+02:00 daily 1.0 https://www.novartis.com/news/media-library/pedestrian-path-trees-novartis-campus-basel 2023-03-30T09:29:01+02:00 daily 1.0 https://www.novartis.com/news/media-library/fabrikstrasse-4-sanaa-novartis-campus-basel 2023-03-30T09:29:07+02:00 daily 1.0 https://www.novartis.com/news/media-library/fabrikstrasse-28-tadao-ando-and-artwork-richard-serra-novartis-campus-basel 2023-03-30T09:29:15+02:00 daily 1.0 https://www.novartis.com/news/media-library/fabrikstrasse-12-vittorio-magnago-lampugnani-novartis-campus-basel 2023-03-30T09:29:22+02:00 daily 1.0 https://www.novartis.com/news/media-library/banting-1-and-artwork-structure-life-claudia-comte-novartis-campus-basel 2023-03-30T09:29:30+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-campus-basel-switzerland 2023-06-05T15:07:42+02:00 daily 1.0 https://www.novartis.com/news/media-library/michelle-weese 2024-05-01T18:15:21+02:00 daily 1.0 https://www.novartis.com/news/media-library/cardiovascular-disease-victorion-media-summary 2023-09-12T16:34:03+02:00 daily 1.0 https://www.novartis.com/news/media-library/cardiovascular-disease-numbers 2023-09-12T16:34:25+02:00 daily 1.0 https://www.novartis.com/news/media-library/cardiovascular-disease-orion-8-media-summary 2023-09-12T16:33:45+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-logo-banting-1-building-novartis-campus-basel-vertical 2023-10-23T13:22:46+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-logo-banting-1-building-from-main-gate-novartis-campus-basel-vertical 2023-10-23T13:20:28+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-logo-banting-1-building-from-park-south-novartis-campus-basel-vertical 2023-10-23T13:41:25+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-logo-banting-1-building-novartis-campus-basel-vertical-0 2023-10-23T13:43:21+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-logo-banting-1-building-novartis-campus-basel-vertical-1 2023-10-23T13:45:14+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-logo-banting-1-building-novartis-campus-basel-horizontal 2023-10-23T13:46:50+02:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-logo-through-colorful-facade-forum-3-novartis-campus-basel-vertical 2023-10-23T13:50:02+02:00 daily 1.0 https://www.novartis.com/news/media-library/access-medicines-eu-member-states 2023-11-23T11:49:50+01:00 daily 1.0 https://www.novartis.com/news/media-library/intellectual-property-including-regulatory-data-protection-rdp 2023-11-23T11:50:00+01:00 daily 1.0 https://www.novartis.com/news/media-library/regulatory-ema 2023-11-23T11:50:11+01:00 daily 1.0 https://www.novartis.com/news/media-library/orphan-medicinal-products-pediatrics 2023-11-23T11:50:21+01:00 daily 1.0 https://www.novartis.com/news/media-library/security-supply 2023-11-23T11:50:31+01:00 daily 1.0 https://www.novartis.com/news/media-library/vasant-vas-narasimhan-md-0 2023-11-28T15:42:41+01:00 daily 1.0 https://www.novartis.com/news/media-library/vasant-vas-narasimhan-md-1 2023-11-28T15:42:21+01:00 daily 1.0 https://www.novartis.com/news/media-library/fiona-h-marshall-phd-0 2023-11-28T11:24:41+01:00 daily 1.0 https://www.novartis.com/news/media-library/fiona-h-marshall-phd-1 2023-11-28T15:39:29+01:00 daily 1.0 https://www.novartis.com/news/media-library/harry-kirsch-0 2023-11-28T15:38:25+01:00 daily 1.0 https://www.novartis.com/news/media-library/harry-kirsch-1 2023-11-28T15:38:02+01:00 daily 1.0 https://www.novartis.com/news/media-library/aharon-ronny-gal-phd-0 2023-11-28T15:37:39+01:00 daily 1.0 https://www.novartis.com/news/media-library/aharon-ronny-gal-phd-1 2023-11-28T15:37:17+01:00 daily 1.0 https://www.novartis.com/news/media-library/rob-kowalski-0 2023-11-28T15:36:48+01:00 daily 1.0 https://www.novartis.com/news/media-library/rob-kowalski-1 2023-11-28T15:36:26+01:00 daily 1.0 https://www.novartis.com/news/media-library/shreeram-aradhye-md-0 2023-11-28T15:36:01+01:00 daily 1.0 https://www.novartis.com/news/media-library/shreeram-aradhye-md-1 2023-11-28T15:35:37+01:00 daily 1.0 https://www.novartis.com/news/media-library/victor-bulto-0 2023-11-28T15:34:45+01:00 daily 1.0 https://www.novartis.com/news/media-library/victor-bulto-1 2023-11-28T15:35:09+01:00 daily 1.0 https://www.novartis.com/news/media-library/steffen-lang-phd-0 2023-11-28T15:34:12+01:00 daily 1.0 https://www.novartis.com/news/media-library/steffen-lang-phd-1 2023-11-28T14:36:26+01:00 daily 1.0 https://www.novartis.com/news/media-library/klaus-moosmayer-phd-0 2023-11-28T14:56:56+01:00 daily 1.0 https://www.novartis.com/news/media-library/klaus-moosmayer-phd-1 2023-11-28T14:58:31+01:00 daily 1.0 https://www.novartis.com/news/media-library/lutz-hegemann-md-phd-0 2023-11-28T15:05:54+01:00 daily 1.0 https://www.novartis.com/news/media-library/lutz-hegemann-md-phd-1 2023-11-28T15:07:29+01:00 daily 1.0 https://www.novartis.com/news/media-library/kees-roks-0 2023-11-28T15:13:38+01:00 daily 1.0 https://www.novartis.com/news/media-library/kees-roks-1 2023-11-28T15:15:12+01:00 daily 1.0 https://www.novartis.com/news/media-library/karen-l-hale-0 2023-11-28T15:24:55+01:00 daily 1.0 https://www.novartis.com/news/media-library/karen-l-hale-1 2023-11-28T15:26:33+01:00 daily 1.0 https://www.novartis.com/news/media-library/karen-l-hale-2 2023-11-28T15:28:19+01:00 daily 1.0 https://www.novartis.com/news/media-library/michelle-weese-0 2024-05-01T18:05:02+02:00 daily 1.0 https://www.novartis.com/news/media-library/patrick-horber-md 2023-11-30T13:24:01+01:00 daily 1.0 https://www.novartis.com/news/media-library/patrick-horber-md-0 2023-12-05T08:22:40+01:00 daily 1.0 https://www.novartis.com/news/media-library/patrick-horber-md-1 2023-12-05T08:23:08+01:00 daily 1.0 https://www.novartis.com/news/media-library/patrick-horber-md-2 2023-12-05T08:23:25+01:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-society-integrated-report-2023 2024-01-30T18:26:35+01:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-annual-report-2023 2024-01-30T18:24:37+01:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-radioligand-therapy-rlt-manufacturing 2024-02-13T08:47:54+01:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-society-integrierter-geschaftsbericht-2023 2024-02-16T14:10:26+01:00 daily 1.0 https://www.novartis.com/news/media-library/quality-control-environmental-monitoring-radioligand-therapy-rlt-manufacturing 2024-03-13T08:52:33+01:00 daily 1.0 https://www.novartis.com/news/media-library/specialized-equipment-manufacture-radioligand-therapy-rlt 2024-03-13T08:53:34+01:00 daily 1.0 https://www.novartis.com/news/media-library/refrigeration-room-novartis-radioligand-therapy-rlt-manufacturing-facility 2024-03-13T08:54:18+01:00 daily 1.0 https://www.novartis.com/news/media-library/radioligand-therapy-rlt-production-line 2024-03-13T08:54:58+01:00 daily 1.0 https://www.novartis.com/news/media-library/novartis-radioligand-therapy-rlt-manufacturing-facility 2024-03-13T08:55:44+01:00 daily 1.0 https://www.novartis.com/news/in-the-news/pandemic-has-been-reset-pharmas-reputation 2021-09-10T11:48:12+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/moving-towards-next-normal 2021-09-21T06:27:55+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/enabling-stable-supply-medicines-during-covid-19 2021-09-21T06:31:00+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/overcoming-manufacturing-challenges 2021-09-21T06:32:37+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/proactive-scenario-planning-and-supply-risk-management 2021-09-21T06:34:17+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/supply-chain-organization-during-covid-19-pandemic 2021-09-21T06:41:10+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/coronavirus-giving-health-and-pharma-companies-chance-woo-tech-talent 2021-09-21T06:45:22+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/pharmas-pandemic-response-could-help-attract-tech-talent 2021-09-21T06:46:39+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/new-era-healthcare-innovation 2021-09-21T07:06:57+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/developing-drugs-during-pandemic 2021-09-21T07:18:38+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/breaking-through-glass-ceiling-spring-women-artificial-intelligence 2021-09-21T07:22:02+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/curious-advantage-curiosity-ceo-and-chief-people-and-organization-officer-perspective 2021-09-21T08:04:19+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-pharmaceuticals-head-chief-marie-france-tschudin-rethinking-drug-launch-formula 2021-09-21T08:06:23+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-ceo-vasant-narasimhan-building-trust-society 2021-09-21T08:13:48+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/how-be-boss-unbossed-company 2021-09-21T08:19:04+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/medicines-and-transformative-effect 2021-09-21T08:21:17+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/its-time-pivot-towards-transformational-innovation 2021-09-21T08:24:03+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-flipping-pyramid-explains-steven-baert 2021-09-21T08:35:41+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/fortunes-most-admired-pharmaceutical-companies-2019 2021-09-21T08:38:15+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/science-and-business-innovative-medicines 2021-09-21T08:40:12+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/how-long-till-final-world-malaria-day 2021-09-21T08:49:00+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-access-and-government-cameroon-sign-agreement-fight-chronic-diseases 2021-09-21T08:51:03+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/changing-world 2021-09-21T08:53:08+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/increasing-access-ncd-treatments-uganda 2021-09-21T08:54:55+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-access-and-government-pakistan-sign-memorandum-understanding 2021-09-21T08:56:49+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-access-perspective-key-fighting-chronic-disease-south-east-asia-young-people 2021-09-21T09:20:52+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-access-perspective-how-smart-partnerships-can-help-us-fight-chronic-disease-africa 2021-09-21T09:22:24+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/what-really-driving-malaria-control-personal-accountability-and-passion-community-health-workers 2021-09-21T09:29:59+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/juncture-malaria-eradication 2021-09-21T09:37:46+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/world-malaria-report-2016-keeping-momentum 2021-09-21T09:39:51+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-access-perspectives-pharma-partners-african-countries-chronic-diseases 2021-09-21T09:56:36+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/confronting-next-global-health-challenge 2021-09-21T11:30:46+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/new-strategies-improving-access-lower-income-countries 2021-09-21T11:32:26+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/tackling-chronic-disease-novartis-access 2021-09-21T11:33:48+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/price-drugs-should-reflect-value-they-deliver 2021-09-21T11:44:56+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-access-perspectives-making-medicines-affordable-worlds-poorest-people 2021-09-21T11:53:19+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/reigniting-passion-science 2021-09-21T12:11:48+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-access-perspectives-how-new-business-models-can-help-fight-chronic-diseases 2021-09-21T12:27:19+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-access-perspectives-kenyas-new-health-care-battle 2021-09-21T12:34:39+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/perfecting-access-through-embedded-sustainability-pooling-resources-and-consolidating-expertise 2021-09-21T12:41:10+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/expanding-access-healthcare-what-will-it-really-take 2021-09-21T13:21:30+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/malarias-deadly-comeback 2021-09-21T13:23:04+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-access-perspectives-expanding-access-healthcare-what-will-it-really-take 2021-09-21T13:27:15+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-access-hosts-second-stakeholder-dialogue 2021-09-21T13:29:32+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-access-perspectives-fighting-africas-future-epidemics 2021-09-21T13:33:33+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/beautiful-medicine-rediscover-power-natures-exquisite-complexity 2021-09-21T13:34:45+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/crispr-genome-editing-fuels-cancer-drug-discovery 2021-09-21T13:36:04+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-access-perspectives-tailoring-tactics-tackle-chronic-disease-low-income-countries 2021-09-29T12:08:07+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/joe-jimenez-how-improve-healthcare 2021-09-21T13:44:51+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-access-one-year-report 2021-09-29T10:40:29+02:00 daily 1.0 https://www.novartis.com/news/in-the-news/novartis-ceo-outlines-how-improve-pandemic-preparedness-warns-another-one-bound-happen 2021-10-04T16:58:46+02:00 daily 1.0 https://www.novartis.com/terms-use 2021-09-29T14:31:30+02:00 daily 1.0 https://www.novartis.com/privacy 2022-05-04T13:35:49+02:00 daily 1.0 https://www.novartis.com/home 2024-06-06T09:33:38+02:00 daily 1.0 https://www.novartis.com/page-not-found 2024-01-08T09:58:45+01:00 daily 1.0 https://www.novartis.com/careers 2024-05-27T08:11:32+02:00 daily 1.0 https://www.novartis.com/news/news-archive 2024-03-25T09:24:59+01:00 daily 1.0 https://www.novartis.com/investors/event-calendar 2024-06-28T10:13:22+02:00 daily 1.0 https://www.novartis.com/investors/financial-data 2024-06-14T14:42:51+02:00 daily 1.0 https://www.novartis.com/investors/shareholder-information 2024-04-23T09:45:54+02:00 daily 1.0 https://www.novartis.com/about/board-directors 2023-03-07T12:23:01+01:00 daily 1.0 https://www.novartis.com/about/executive-committee 2024-06-24T15:30:19+02:00 daily 1.0 https://www.novartis.com/contacts 2023-10-23T11:49:28+02:00 daily 1.0 https://www.novartis.com/clinicaltrials/about-clinical-trials 2022-01-11T11:57:49+01:00 daily 1.0 https://www.novartis.com/clinicaltrials/glossary-clinical-trial-terms 2022-11-23T17:53:29+01:00 daily 1.0 https://www.novartis.com/healthcare-professionals/medical-congresses-and-events 2024-06-05T09:20:22+02:00 daily 1.0 https://www.novartis.com/research-and-development/research-disease-areas 2024-02-08T17:44:14+01:00 daily 1.0 https://www.novartis.com/careers/early-careers/us-biomedical-research-internship-programs 2024-02-08T18:12:55+01:00 daily 1.0 https://www.novartis.com/about/awards-and-recognition 2024-04-10T09:20:18+02:00 daily 1.0 https://www.novartis.com/investors/company-overview/corporate-governance 2024-03-14T09:32:24+01:00 daily 1.0 https://www.novartis.com/investors/share-data-analysis/share-overview 2024-02-09T10:17:48+01:00 daily 1.0 https://www.novartis.com/investors/share-data-analysis/share-ownership 2024-02-09T10:17:20+01:00 daily 1.0 https://www.novartis.com/investors/share-data-analysis/return-investment-calculator 2024-02-09T10:18:39+01:00 daily 1.0 https://www.novartis.com/investors/share-data-analysis/dividend-information 2024-03-05T14:53:54+01:00 daily 1.0 https://www.novartis.com/investors/shareholder-information/share-buy-back 2024-04-23T10:02:05+02:00 daily 1.0 https://www.novartis.com/investors/financial-data/annual-results 2024-03-19T14:31:24+01:00 daily 1.0 https://www.novartis.com/investors/financial-data/quarterly-results 2024-05-07T10:24:25+02:00 daily 1.0 https://www.novartis.com/investors/share-data-analysis/share-monitor 2024-02-09T10:16:21+01:00 daily 1.0 https://www.novartis.com/investors/financial-data/sec-filings 2024-04-11T10:12:45+02:00 daily 1.0 https://www.novartis.com/investors/financial-data/product-sales 2024-04-23T10:06:16+02:00 daily 1.0 https://www.novartis.com/investors/financial-data/expected-currency-impact 2024-06-14T14:39:42+02:00 daily 1.0 https://www.novartis.com/investors/shareholder-information/american-depositary-receipts-adr 2024-03-12T16:10:33+01:00 daily 1.0 https://www.novartis.com/investors/financial-data/quarterly-results/2021-q2-transcript 2021-09-22T17:04:14+02:00 daily 1.0 https://www.novartis.com/about/novartis-and-european-union-eu/eucancerplan 2021-09-30T10:53:39+02:00 daily 1.0 https://www.novartis.com/about/novartis-and-european-union-eu/novartis-eu-public-affairs-team 2023-10-24T09:35:22+02:00 daily 1.0 https://www.novartis.com/about/25-years-novartis-more-250-years-innovation 2021-10-19T11:08:15+02:00 daily 1.0 https://www.novartis.com/healthcare-professionals/investigator-initiated-trials-studies-clinical-and-investigator-initiated-research-non-clinical 2024-06-12T11:39:22+02:00 daily 1.0 https://www.novartis.com/esg/environmental-sustainability/waste 2024-01-25T13:53:47+01:00 daily 1.0 https://www.novartis.com/healthcare-professionals/novartis-external-funding 2024-02-08T17:28:59+01:00 daily 1.0 https://www.novartis.com/research-development/chemical-biology-biomedical-research 2023-10-04T14:08:36+02:00 daily 1.0 https://www.novartis.com/healthcare-professionals/healthcare-professional-resources-country 2024-02-08T17:29:57+01:00 daily 1.0 https://www.novartis.com/patients-and-caregivers/novartis-commitment-patients-and-caregivers 2024-02-14T07:41:04+01:00 daily 1.0 https://www.novartis.com/esg/environmental-sustainability/climate 2024-01-25T13:53:39+01:00 daily 1.0 https://www.novartis.com/esg/environmental-sustainability/climate/case-study-breezhaler-carbon-footprint 2022-05-13T08:50:15+02:00 daily 1.0 https://www.novartis.com/esg/environmental-sustainability/water 2024-01-25T14:48:44+01:00 daily 1.0 https://www.novartis.com/research-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-healthcare-professionals/science-car-t-cell-therapy 2021-10-07T18:50:25+02:00 daily 1.0 https://www.novartis.com/research-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-healthcare-professionals/process-car-t-cell-therapy 2021-10-07T18:50:39+02:00 daily 1.0 https://www.novartis.com/diseases/malaria 2024-05-27T08:50:44+02:00 daily 1.0 https://www.novartis.com/diseases/sickle-cell-disease 2024-02-08T17:59:20+01:00 daily 1.0 https://www.novartis.com/news/stay-up-to-date/subscribed 2021-11-03T15:55:34+01:00 daily 1.0 https://www.novartis.com/news/stay-date/subscription-cancelled 2021-09-15T13:46:29+02:00 daily 1.0 https://www.novartis.com/diseases/chagas-disease 2023-01-30T11:01:37+01:00 daily 1.0 https://www.novartis.com/diseases/leprosy 2023-01-31T09:20:50+01:00 daily 1.0 https://www.novartis.com/research-development/translational-medicine-research-novartis 2022-07-13T18:03:40+02:00 daily 1.0 https://www.novartis.com/investors/reporting-and-transparency-hub/patient-organization-funding 2024-06-25T10:46:33+02:00 daily 1.0 https://www.novartis.com/investors/reporting-and-transparency-hub/payments-healthcare-professionals 2024-06-27T11:12:19+02:00 daily 1.0 https://www.novartis.com/investors/reporting-and-transparency-hub/living-wage 2024-01-29T13:50:07+01:00 daily 1.0 https://www.novartis.com/about/people-and-culture/we-are-inspiring-our-people 2024-01-30T15:39:43+01:00 daily 1.0 https://www.novartis.com/about/people-and-culture/we-are-instilling-curiosity 2024-01-30T15:56:46+01:00 daily 1.0 https://www.novartis.com/about/people-and-culture/we-create-unbossed-environment 2024-01-30T15:59:59+01:00 daily 1.0 https://www.novartis.com/investors/reporting-and-transparency-hub/public-policy 2024-06-13T10:59:35+02:00 daily 1.0 https://www.novartis.com/investors/reporting-and-transparency-hub/safe-workplace 2024-01-23T15:33:38+01:00 daily 1.0 https://www.novartis.com/investors/reporting-and-transparency-hub/animal-research 2024-02-02T10:01:04+01:00 daily 1.0 https://www.novartis.com/coronavirus/patients-and-caregivers-covid-19-information 2021-10-08T16:13:49+02:00 daily 1.0 https://www.novartis.com/research-and-development/research-collaborations/novartis-global-scholars-program 2024-02-13T13:55:24+01:00 daily 1.0 https://www.novartis.com/about/diversity-equity-and-inclusion/equity 2024-03-08T09:12:47+01:00 daily 1.0 https://www.novartis.com/coronavirus/can-covid-clinical-trial 2021-10-07T16:42:01+02:00 daily 1.0 https://www.novartis.com/about/diversity-equity-and-inclusion/equity/our-equal-pay-international-coalition-epic-commitments 2024-03-08T09:06:41+01:00 daily 1.0 https://www.novartis.com/about/diversity-equity-and-inclusion/equity/lgbtqi-equity 2024-06-05T16:39:05+02:00 daily 1.0 https://www.novartis.com/about/diversity-equity-inclusion/inclusivity 2024-02-02T11:59:24+01:00 daily 1.0 https://www.novartis.com/about/diversity-equity-and-inclusion/parental-leave 2024-02-08T17:05:25+01:00 daily 1.0 https://www.novartis.com/esg/access/novartis-access-principles 2024-02-08T17:54:29+01:00 daily 1.0 https://www.novartis.com/esg/access/novartis-access-principles/research-development 2024-06-19T12:19:52+02:00 daily 1.0 https://www.novartis.com/esg/access/novartis-access-principles/affordability 2023-01-24T11:37:54+01:00 daily 1.0 https://www.novartis.com/esg/access/novartis-access-principles/strengthening-healthcare-systems 2023-01-30T17:46:32+01:00 daily 1.0 https://www.novartis.com/environmental-social-and-governance 2021-09-21T14:04:39+02:00 daily 1.0 https://www.novartis.com/esg/access/patents-and-licensing 2024-02-08T17:55:07+01:00 daily 1.0 https://www.novartis.com/esg/access/donations 2024-03-14T13:59:33+01:00 daily 1.0 https://www.novartis.com/privacy/privacy-policy 2022-05-04T13:45:56+02:00 daily 1.0 https://www.novartis.com/partnering/partnering-opportunities 2023-11-17T17:09:08+01:00 daily 1.0 https://www.novartis.com/privacy/novartis-binding-corporate-rules-bcr 2022-05-04T13:36:21+02:00 daily 1.0 https://www.novartis.com/investors/shareholder-information/frequently-asked-questions 2024-05-01T13:57:54+02:00 daily 1.0 https://www.novartis.com/privacy/general-privacy-notice-external-stakeholders 2022-05-04T13:46:52+02:00 daily 1.0 https://www.novartis.com/healthcare-professionals/managed-access-programs 2024-02-08T17:27:14+01:00 daily 1.0 https://www.novartis.com/investors/shareholder-information/general-meetings 2024-03-25T15:33:15+01:00 daily 1.0 https://www.novartis.com/novartis-directory 2023-10-04T10:13:19+02:00 daily 1.0 https://www.novartis.com/partnering/our-approach-partnering 2024-06-27T09:41:55+02:00 daily 1.0 https://www.novartis.com/partnering/partnering-leadership-team 2024-06-27T09:00:47+02:00 daily 1.0 https://www.novartis.com/esg/access/creating-sustainable-business-models 2023-01-31T08:58:42+01:00 daily 1.0 https://www.novartis.com/esg/access/creating-sustainable-business-models/novartis-access 2023-01-31T08:59:28+01:00 daily 1.0 https://www.novartis.com/esg/access/creating-sustainable-business-models/healthy-family-programs 2023-01-27T09:48:44+01:00 daily 1.0 https://www.novartis.com/guidelines/novartis-facebook-community-guidelines 2021-09-24T09:05:18+02:00 daily 1.0 https://www.novartis.com/guidelines/novartis-instagram-community-guidelines 2021-09-24T09:11:35+02:00 daily 1.0 https://www.novartis.com/guidelines/novartis-linkedin-community-guidelines 2024-04-23T09:04:38+02:00 daily 1.0 https://www.novartis.com/guidelines/novartis-X-twitter-community-guidelines 2024-04-23T09:02:55+02:00 daily 1.0 https://www.novartis.com/guidelines/novartis-youtube-community-guidelines 2021-09-24T09:17:28+02:00 daily 1.0 https://www.novartis.com/investors/financial-data/fixed-income-securities 2024-06-18T10:35:08+02:00 daily 1.0 https://www.novartis.com/clinicaltrials/clinical-trials-faqs 2021-10-11T12:46:59+02:00 daily 1.0 https://www.novartis.com/clinicaltrials/patients-and-caregivers 2022-01-11T12:01:01+01:00 daily 1.0 https://www.novartis.com/about/novartis-gene-therapies/what-cell-and-gene-therapy 2023-10-04T06:38:16+02:00 daily 1.0 https://www.novartis.com/about/novartis-gene-therapies/cell-and-gene-therapy-explained-vox-creative 2023-10-04T06:35:53+02:00 daily 1.0 https://www.novartis.com/research-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-healthcare-professionals 2021-10-07T18:50:01+02:00 daily 1.0 https://www.novartis.com/clinicaltrials/transparency 2024-02-12T16:33:36+01:00 daily 1.0 https://www.novartis.com/clinicaltrials/ethics-clinical-trials 2022-02-11T09:12:17+01:00 daily 1.0 https://www.novartis.com/about/diversity-equity-inclusion/society 2024-01-30T15:29:39+01:00 daily 1.0 https://www.novartis.com/investors/financial-data/fixed-income-securities/disclaimer 2021-09-28T10:59:10+02:00 daily 1.0 https://www.novartis.com/esg/access/novartis-oncology-access 2024-02-08T17:54:48+01:00 daily 1.0 https://www.novartis.com/investors/financial-data/fixed-income-securities/sustainability-linked-bond-documents 2021-09-28T10:54:14+02:00 daily 1.0 https://www.novartis.com/investors/reporting-and-transparency-hub/reporting-archive 2024-02-09T10:23:13+01:00 daily 1.0 https://www.novartis.com/investors/reporting-and-transparency-hub/targets 2024-02-05T08:37:30+01:00 daily 1.0 https://www.novartis.com/research-development/research-disease-areas/global-health-disease-area-research-novartis 2023-05-25T16:04:21+02:00 daily 1.0 https://www.novartis.com/research-development/collaborations 2023-11-24T15:00:25+01:00 daily 1.0 https://www.novartis.com/contacts/media-contacts 2024-05-13T11:41:40+02:00 daily 1.0 https://www.novartis.com/contacts/investor-contacts 2024-04-03T13:15:51+02:00 daily 1.0 https://www.novartis.com/careers/early-careers/community-exploration-and-learning-lab-cell 2024-02-08T18:13:30+01:00 daily 1.0 https://www.novartis.com/about-novartis 2021-09-29T18:00:05+02:00 daily 1.0 https://www.novartis.com/esg/ethics-risk-and-compliance/ethical-behavior/code-ethics 2023-08-20T16:33:18+02:00 daily 1.0 https://www.novartis.com/esg/ethics-risk-and-compliance/ethical-behavior/speakup 2024-01-12T09:56:31+01:00 daily 1.0 https://www.novartis.com/esg/ethics-risk-and-compliance/ethical-behavior 2024-02-08T17:55:42+01:00 daily 1.0 https://www.novartis.com/esg/ethics-risk-and-compliance/compliance 2023-12-07T13:02:35+01:00 daily 1.0 https://www.novartis.com/esg/ethics-risk-and-compliance/compliance/anti-bribery-report 2024-01-30T15:46:33+01:00 daily 1.0 https://www.novartis.com/esg/ethics-risk-and-compliance/compliance/doing-business-ethically 2023-10-31T15:48:09+01:00 daily 1.0 https://www.novartis.com/esg/ethics-risk-and-compliance/risk-management 2024-01-09T10:11:46+01:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/chemistry-postdoc-mentors/bing-wang-phd 2021-10-20T02:14:04+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/immunology-postdoc-mentors/daniela-cipolletta-phd 2021-10-11T10:53:25+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/immunology-postdoc-mentors/frederic-bornancin-phd 2021-10-11T10:57:00+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/cancer-biology-postdoc-mentors/carlotta-costa-phd 2021-10-01T08:34:43+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/cancer-biology-postdoc-mentors/david-kodack-phd 2021-10-01T12:13:05+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/cancer-biology-postdoc-mentors/giorgio-g-galli-phd 2021-10-01T13:36:25+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/cancer-biology-postdoc-mentors/tobias-schmelzle-phd 2021-10-01T14:38:31+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/cancer-biology-postdoc-mentors/xiaomo-jiang-phd 2021-10-01T14:48:51+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/cancer-biology-postdoc-mentors/tony-dalessio-phd 2021-10-01T14:44:17+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/immunology-postdoc-mentors/martin-alexander-schneider-phd 2021-10-11T11:14:40+02:00 daily 1.0 https://www.novartis.com/about/people-and-culture/giving-volunteering 2023-11-16T14:00:22+01:00 daily 1.0 https://www.novartis.com/about/novartis-gene-therapies/about-novartis-gene-therapies 2023-10-04T06:35:20+02:00 daily 1.0 https://www.novartis.com/about/novartis-gene-therapies/gene-therapy-manufacturing 2023-10-04T06:37:34+02:00 daily 1.0 https://www.novartis.com/about/novartis-gene-therapies/resources-rare-disorders-patient-community 2023-10-04T06:38:03+02:00 daily 1.0 https://www.novartis.com/esg/ethics-risk-and-compliance/human-rights 2024-05-23T17:31:07+02:00 daily 1.0 https://www.novartis.com/esg/ethics-risk-and-compliance/learning-and-engagement 2024-02-08T17:57:42+01:00 daily 1.0 https://www.novartis.com/diseases/heart-failure 2021-10-11T11:04:22+02:00 daily 1.0 https://www.novartis.com/diseases/acute-myeloid-leukemia-aml 2021-10-11T13:00:35+02:00 daily 1.0 https://www.novartis.com/diseases/chronic-myeloid-leukemia 2023-07-24T14:54:21+02:00 daily 1.0 https://www.novartis.com/diseases/multiple-myeloma 2023-07-03T14:38:47+02:00 daily 1.0 https://www.novartis.com/diseases/advanced-melanoma 2021-10-05T15:16:37+02:00 daily 1.0 https://www.novartis.com/esg/access/value-based-pricing 2024-02-08T17:54:05+01:00 daily 1.0 https://www.novartis.com/investors/reporting-and-transparency-hub/esg-rating-performance 2024-04-10T10:44:48+02:00 daily 1.0 https://www.novartis.com/esg/ethics-risk-and-compliance/risk-management/external-partner-risk-management-eprm 2024-01-09T10:10:52+01:00 daily 1.0 https://www.novartis.com/research-development/research-disease-areas/oncology-research-novartis 2023-08-18T14:23:25+02:00 daily 1.0 https://www.novartis.com/research-development/research-disease-areas/cardiovascular-and-metabolic-disease-research-novartis 2021-10-19T11:06:15+02:00 daily 1.0 https://www.novartis.com/research-development/research-disease-areas/immunology-disease-research-novartis 2024-01-18T16:45:24+01:00 daily 1.0 https://www.novartis.com/esg/ethics-risk-and-compliance/risk-management/enterprise-risk-management 2023-12-14T15:09:39+01:00 daily 1.0 https://www.novartis.com/research-development/research-disease-areas/ophthalmology-research-novartis 2023-08-30T19:15:30+02:00 daily 1.0 https://www.novartis.com/about/quality/audit-program 2023-05-03T15:45:33+02:00 daily 1.0 https://www.novartis.com/about/quality/novartis-quality-management-system-qms 2024-02-08T17:06:31+01:00 daily 1.0 https://www.novartis.com/about/quality/product-and-patient-safety-training 2022-02-01T12:25:39+01:00 daily 1.0 https://www.novartis.com/about/quality/regulatory-inspections 2023-05-08T15:24:42+02:00 daily 1.0 https://www.novartis.com/about/quality/product-recalls 2024-02-02T13:00:16+01:00 daily 1.0 https://www.novartis.com/about/quality/third-party-suppliers 2022-02-01T12:23:19+01:00 daily 1.0 https://www.novartis.com/healthcare-professionals/managed-access-programs/novartis-gene-therapies-managed-access-program 2024-02-08T17:28:27+01:00 daily 1.0 https://www.novartis.com/research-development/collaborations/academic-partnerships-and-external-innovation 2023-11-30T12:16:32+01:00 daily 1.0 https://www.novartis.com/about/novartis-gene-therapies/novartis-gene-therapies-request-funding 2023-10-04T06:37:52+02:00 daily 1.0 https://www.novartis.com/research-development/research-disease-areas/neuroscience-research-novartis 2023-04-20T10:57:11+02:00 daily 1.0 https://www.novartis.com/diseases/spinal-muscular-atrophy-sma 2023-08-14T09:18:17+02:00 daily 1.0 https://www.novartis.com/healthcare-professionals/medical-congresses-and-events/abstract-summaries-eular 2022-03-10T14:21:41+01:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-program-leadership/darrin-stuart-phd 2021-10-06T22:36:03+02:00 daily 1.0 https://www.novartis.com/research-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-cell-therapy-pioneering-cancer-therapy 2022-03-11T09:21:14+01:00 daily 1.0 https://www.novartis.com/research-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-healthcare-professionals/treatment-landscape-haematologic-malignancies 2021-10-11T10:46:49+02:00 daily 1.0 https://www.novartis.com/esg/compliance/our-commitment-ethical-and-responsible-use-ai 2023-12-07T13:01:11+01:00 daily 1.0 https://www.novartis.com/healthcare-professionals/medical-congresses-and-events/abstract-summaries-acr 2021-10-07T07:54:38+02:00 daily 1.0 https://www.novartis.com/diseases/spinal-muscular-atrophy-sma/newborn-screening-spinal-muscular-atrophy-sma 2023-07-06T11:08:49+02:00 daily 1.0 https://www.novartis.com/research-development/biomedical-research/collaborations/biomedical-research-business-development-licensing 2023-10-04T14:12:25+02:00 daily 1.0 https://www.novartis.com/research-development/research-disease-areas/dax-exploratory-disease-research-novartis 2023-04-03T08:22:11+02:00 daily 1.0 https://www.novartis.com/research-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-healthcare-professionals/pioneers-car-t-cell-and-gene-therapy 2023-11-06T08:34:50+01:00 daily 1.0 https://www.novartis.com/research-development/open-source-science 2023-10-13T16:27:30+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/chemistry-postdoc-mentors/cara-brocklehurst-phd 2021-10-29T01:55:29+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/chemistry-postdoc-mentors/folkert-reck-phd 2021-10-29T02:13:09+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/chemistry-postdoc-mentors/frederic-berst-phd 2021-10-29T02:15:49+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/chemistry-postdoc-mentors/jay-larrow-phd 2021-10-29T21:09:12+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/chemistry-postdoc-mentors/tejas-pathak-phd 2021-10-29T21:26:30+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/computational-sciences-postdoc-mentors/florian-nigsch-phd 2021-10-28T23:25:21+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/computational-sciences-postdoc-mentors/hanneke-jansen-phd 2021-10-28T23:48:19+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/computational-sciences-postdoc-mentors/nicole-renaud-phd 2021-10-20T04:08:59+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/musculoskeletal-postdoc-mentors/mara-fornaro-phd 2021-10-28T14:42:08+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/musculoskeletal-postdoc-mentors/olivier-leupin-phd 2021-10-28T14:43:39+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/musculoskeletal-postdoc-mentors/valerie-salazar-phd 2021-10-28T14:44:44+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/pathways-biology-postdoc-mentors/david-rowlands-phd 2021-10-20T03:46:55+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/pathways-biology-postdoc-mentors/feng-cong-phd 2021-10-20T03:56:09+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/pathways-biology-postdoc-mentors/john-koschwanez-phd 2021-10-20T04:04:36+02:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/pathways-biology-postdoc-mentors/robert-esterberg-phd 2021-10-20T04:18:26+02:00 daily 1.0 https://www.novartis.com/careers/early-careers 2024-02-08T18:09:37+01:00 daily 1.0 https://www.novartis.com/esg/access/sub-saharan-africa 2023-01-27T09:22:57+01:00 daily 1.0 https://www.novartis.com/careers/career-search/notice-all-applicants-us-job-openings 2021-10-25T15:40:57+02:00 daily 1.0 https://www.novartis.com/open-source 2024-03-26T14:28:35+01:00 daily 1.0 https://www.novartis.com/investors/financial-data/quarterly-results/2021-q3-transcript 2022-02-01T22:49:15+01:00 daily 1.0 https://www.novartis.com/art-collection 2023-09-05T14:45:56+02:00 daily 1.0 https://www.novartis.com/diseases/prostate-cancer 2023-07-03T14:54:29+02:00 daily 1.0 https://www.novartis.com/research-development/technology-platforms/cell-therapy/charging-towards-next-generation-car-t 2023-11-06T08:36:19+01:00 daily 1.0 https://www.novartis.com/diseases/multiplesclerosis 2021-12-16T11:26:56+01:00 daily 1.0 https://www.novartis.com/diseases/multiplesclerosis/types-ms-and-ms-progression 2021-12-16T08:30:07+01:00 daily 1.0 https://www.novartis.com/diseases/multiplesclerosis/ms-tools 2024-03-18T08:34:00+01:00 daily 1.0 https://www.novartis.com/diseases/multiplesclerosis/ms-treatment-options 2021-12-16T08:33:26+01:00 daily 1.0 https://www.novartis.com/diseases/migraine 2021-12-16T08:24:30+01:00 daily 1.0 https://www.novartis.com/diseases/migraine/types-migraine 2021-12-16T10:58:41+01:00 daily 1.0 https://www.novartis.com/diseases/migraine/migraine-treatment-options 2021-12-16T08:18:35+01:00 daily 1.0 https://www.novartis.com/diseases/migraine/migraine-tools 2023-06-29T16:09:50+02:00 daily 1.0 https://www.novartis.com/investors/financial-data/quarterly-results/2021-q4-and-full-year-results-transcript 2022-02-08T11:40:24+01:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/pathways-biology-postdoc-mentors/joanne-wong-phd 2022-02-23T17:06:45+01:00 daily 1.0 https://www.novartis.com/careers/postdoc-program/postdoc-research-themes/cancer-biology-postdoc-mentors/anke-bill-phd 2022-03-01T23:54:41+01:00 daily 1.0 https://www.novartis.com/diseases/rare-kidney-diseases 2024-05-02T10:38:23+02:00 daily 1.0 https://www.novartis.com/patients-and-caregivers/diseases/kidney-disease/complement-mediated-kidney-diseases-and-their-impact 2022-03-09T07:17:19+01:00 daily 1.0 https://www.novartis.com/healthcare-professionals/novartis-medical-information 2024-02-08T17:31:51+01:00 daily 1.0 https://www.novartis.com/diseases/dry-eye-disease 2022-03-28T14:59:19+02:00 daily 1.0 https://www.novartis.com/privacy/privacy-notice-pharmacovigilance 2022-05-04T13:46:57+02:00 daily 1.0 https://www.novartis.com/esg/global-health/avoidable-blindness 2024-02-08T17:58:34+01:00 daily 1.0 https://www.novartis.com/investors/financial-data/quarterly-results/2022-q1-transcript 2023-06-14T10:31:19+02:00 daily 1.0 https://www.novartis.com/privacy/general-privacy-notice-business-partners 2022-05-04T13:46:12+02:00 daily 1.0 https://www.novartis.com/privacy/general-privacy-notice-third-parties 2022-05-04T13:46:46+02:00 daily 1.0 https://www.novartis.com/diseases/elevated-lipoproteina 2022-05-24T11:49:54+02:00 daily 1.0 https://www.novartis.com/esg/global-health/pandemic-preparedness 2024-02-08T17:58:12+01:00 daily 1.0 https://www.novartis.com/esg/index/access-medicines 2024-02-01T10:10:57+01:00 daily 1.0 https://www.novartis.com/esg/index/governance 2024-02-01T10:12:15+01:00 daily 1.0 https://www.novartis.com/esg/index/environmental-sustainability 2024-02-05T10:23:11+01:00 daily 1.0 https://www.novartis.com/esg/index/ethical-business-practices 2024-05-13T09:31:53+02:00 daily 1.0 https://www.novartis.com/esg/index/human-capital 2024-02-01T10:11:08+01:00 daily 1.0 https://www.novartis.com/esg/index/innovation 2024-02-01T10:10:46+01:00 daily 1.0 https://www.novartis.com/esg/index/quality 2024-02-01T10:12:05+01:00 daily 1.0 https://www.novartis.com/esg/index/supply-chain-sourcing 2024-02-01T10:11:46+01:00 daily 1.0 https://www.novartis.com/privacy/scc-c2p 2022-05-24T12:08:51+02:00 daily 1.0 https://www.novartis.com/privacy/scc-c2c 2022-05-24T12:08:50+02:00 daily 1.0 https://www.novartis.com/esg/index/other 2024-02-01T10:12:26+01:00 daily 1.0 https://www.novartis.com/esg/index 2024-02-08T17:52:51+01:00 daily 1.0 https://www.novartis.com/research-and-development/research-collaborations 2024-02-08T17:45:25+01:00 daily 1.0 https://www.novartis.com/investors/financial-data/quarterly-results/2022-q2-transcript 2023-06-14T10:31:52+02:00 daily 1.0 https://www.novartis.com/supplier-portal/sourcing-and-procurement 2023-01-17T11:19:14+01:00 daily 1.0 https://www.novartis.com/supplier-portal/supplier-onboarding 2024-06-04T14:35:27+02:00 daily 1.0 https://www.novartis.com/supplier-portal/invoicing-novartis 2024-06-27T10:09:40+02:00 daily 1.0 https://www.novartis.com/supplier-portal/simple-invoice-checking 2023-10-04T13:55:08+02:00 daily 1.0 https://www.novartis.com/supplier-portal/documentation 2023-08-04T16:12:06+02:00 daily 1.0 https://www.novartis.com/supplier-portal/tr/sourcing-and-procurement 2023-01-16T14:20:20+01:00 daily 1.0 https://www.novartis.com/supplier-portal/tr/supplier-onboarding 2024-06-06T14:01:49+02:00 daily 1.0 https://www.novartis.com/supplier-portal/tr/invoicing-novartis 2022-09-16T15:08:56+02:00 daily 1.0 https://www.novartis.com/supplier-portal/fr/sourcing-and-procurement 2023-01-16T14:12:59+01:00 daily 1.0 https://www.novartis.com/supplier-portal/fr/supplier-onboarding 2024-06-06T13:59:58+02:00 daily 1.0 https://www.novartis.com/diseases/lung-cancer 2023-06-12T09:16:49+02:00 daily 1.0 https://www.novartis.com/supplier-portal/es/sourcing-and-procurement 2023-01-16T14:15:34+01:00 daily 1.0 https://www.novartis.com/supplier-portal/es/supplier-onboarding 2024-06-06T13:57:23+02:00 daily 1.0 https://www.novartis.com/supplier-portal/es/invoicing-novartis 2022-12-16T16:42:21+01:00 daily 1.0 https://www.novartis.com/supplier-portal/fr/simple-invoice-checking 2023-10-04T13:56:40+02:00 daily 1.0 https://www.novartis.com/supplier-portal/es/simple-invoice-checking 2023-10-04T13:57:31+02:00 daily 1.0 https://www.novartis.com/supplier-portal/tr/simple-invoice-checking 2023-10-04T13:57:05+02:00 daily 1.0 https://www.novartis.com/diseases/lung-cancer/sound-up 2023-06-29T16:05:03+02:00 daily 1.0 https://www.novartis.com/supplier-portal/fr/invoicing-novartis 2022-12-16T16:43:35+01:00 daily 1.0 https://www.novartis.com/news/sandoz-spinoff 2023-10-04T07:10:18+02:00 daily 1.0 https://www.novartis.com/privacy/general-privacy-notice-clinical-trial-site-personnel 2022-09-01T09:51:52+02:00 daily 1.0 https://www.novartis.com/investors/financial-data/quarterly-results/2022-q3-transcript 2023-06-14T10:32:29+02:00 daily 1.0 https://www.novartis.com/about/therapeutic-areas/oncology/hematology 2023-11-14T09:39:03+01:00 daily 1.0 https://www.novartis.com/diseases/breast-cancer 2022-12-06T15:09:15+01:00 daily 1.0 https://www.novartis.com/supplier-portal/de/sourcing-and-procurement 2023-03-24T22:22:41+01:00 daily 1.0 https://www.novartis.com/supplier-portal/de/supplier-onboarding 2024-06-06T13:56:43+02:00 daily 1.0 https://www.novartis.com/supplier-portal/de/invoicing-novartis 2023-03-24T22:22:53+01:00 daily 1.0 https://www.novartis.com/supplier-portal/cn/sourcing-and-procurement 2023-03-24T22:24:29+01:00 daily 1.0 https://www.novartis.com/supplier-portal/cn/supplier-onboarding 2024-06-06T14:02:34+02:00 daily 1.0 https://www.novartis.com/supplier-portal/cn/invoicing-novartis 2023-03-24T22:24:37+01:00 daily 1.0 https://www.novartis.com/supplier-portal/jp/sourcing-and-procurement 2023-04-11T16:15:31+02:00 daily 1.0 https://www.novartis.com/diseases/spinal-muscular-atrophy-sma/see-unseen-newborn-screening-spinal-muscular-atrophy 2023-01-18T20:05:01+01:00 daily 1.0 https://www.novartis.com/supplier-portal/it/sourcing-and-procurement 2023-03-24T22:23:18+01:00 daily 1.0 https://www.novartis.com/supplier-portal/jp/supplier-onboarding 2024-06-06T14:03:22+02:00 daily 1.0 https://www.novartis.com/supplier-portal/jp/invoicing-novartis 2023-03-24T22:25:10+01:00 daily 1.0 https://www.novartis.com/supplier-portal/it/supplier-onboarding 2024-06-06T14:00:30+02:00 daily 1.0 https://www.novartis.com/supplier-portal/it/invoicing-novartis 2023-03-24T22:23:31+01:00 daily 1.0 https://www.novartis.com/supplier-portal/pt/sourcing-and-procurement 2023-03-24T22:23:54+01:00 daily 1.0 https://www.novartis.com/supplier-portal/pt/supplier-onboarding 2024-06-06T14:01:05+02:00 daily 1.0 https://www.novartis.com/supplier-portal/pt/invoicing-novartis 2023-03-24T22:24:09+01:00 daily 1.0 https://www.novartis.com/supplier-portal/cn/simple-invoice-checking 2023-10-04T13:58:54+02:00 daily 1.0 https://www.novartis.com/supplier-portal/de/simple-invoice-checking 2023-10-04T13:59:11+02:00 daily 1.0 https://www.novartis.com/supplier-portal/it/simple-invoice-checking 2023-10-04T13:59:35+02:00 daily 1.0 https://www.novartis.com/supplier-portal/jp/simple-invoice-checking 2023-10-04T13:59:55+02:00 daily 1.0 https://www.novartis.com/supplier-portal/pt/simple-invoice-checking 2023-10-04T14:00:14+02:00 daily 1.0 https://www.novartis.com/supplier-portal/ru/sourcing-and-procurement 2023-03-24T22:25:31+01:00 daily 1.0 https://www.novartis.com/supplier-portal/ru/supplier-onboarding 2024-06-06T13:55:59+02:00 daily 1.0 https://www.novartis.com/supplier-portal/ru/invoicing-novartis 2023-03-24T22:25:39+01:00 daily 1.0 https://www.novartis.com/supplier-portal/ru/simple-invoice-checking 2023-03-24T22:25:43+01:00 daily 1.0 https://www.novartis.com/news/world-economic-forum-2023/health-systems-building-through-disruption 2023-01-18T17:37:17+01:00 daily 1.0 https://www.novartis.com/investors/financial-data/quarterly-results/2022-q4-and-full-year-results-transcript 2023-06-19T11:22:19+02:00 daily 1.0 https://www.novartis.com/diseases/neuroendocrine-tumors-nets 2023-02-28T11:19:27+01:00 daily 1.0 https://www.novartis.com/careers/our-business-functions/careers-operations 2024-02-08T18:11:16+01:00 daily 1.0 https://www.novartis.com/careers/our-business-functions/careers-global-functions 2023-12-01T17:07:37+01:00 daily 1.0 https://www.novartis.com/careers/benefits-rewards 2024-01-26T10:46:50+01:00 daily 1.0 https://www.novartis.com/careers/our-business-functions/careers-research-and-development 2024-02-08T18:10:44+01:00 daily 1.0 https://www.novartis.com/investors/financial-data/quarterly-results/2023-q1-transcript 2024-05-07T11:50:39+02:00 daily 1.0 https://www.novartis.com/partnering/partnering-event-calendar 2024-02-09T14:38:42+01:00 daily 1.0 https://www.novartis.com/healthcare-professionals/medical-congresses-and-events/asco-annual-meeting/asco-2023 2023-06-05T10:37:29+02:00 daily 1.0 https://www.novartis.com/about/therapeutic-areas/neuroscience 2024-05-24T07:11:27+02:00 daily 1.0 https://www.novartis.com/about/therapeutic-areas/immunology 2024-02-05T13:48:01+01:00 daily 1.0 https://www.novartis.com/diseases/chronic-myeloid-leukemia/innovation-cml-novartis 2023-11-17T17:24:18+01:00 daily 1.0 https://www.novartis.com/investors/financial-data/quarterly-results/2023-q2-transcript 2024-05-07T11:48:50+02:00 daily 1.0 https://www.novartis.com/careers/linkedin-workday 2023-07-26T09:33:06+02:00 daily 1.0 https://www.novartis.com/careers/early-careers/students 2023-12-15T09:53:53+01:00 daily 1.0 https://www.novartis.com/careers/early-careers/graduates 2024-05-15T14:49:18+02:00 daily 1.0 https://www.novartis.com/diseases/paroxysmal-nocturnal-hemoglobinuria-pnh 2023-11-27T16:47:53+01:00 daily 1.0 https://www.novartis.com/about/people-and-culture/giving-volunteering/non-profit-partnering-positive-sustainable-social-change 2024-03-19T14:28:38+01:00 daily 1.0 https://www.novartis.com/research-development/technology-platforms/radioligand-therapy/radioligand-therapy-delivering-now-building-future 2024-01-08T09:21:29+01:00 daily 1.0 https://www.novartis.com/about/therapeutic-areas/cardiovascular-renal-and-metabolic 2024-05-02T10:34:56+02:00 daily 1.0 https://www.novartis.com/about/therapeutic-areas/oncology 2024-02-05T13:21:33+01:00 daily 1.0 https://www.novartis.com/clinical-trials/transparency/leadership 2024-02-13T11:05:41+01:00 daily 1.0 https://www.novartis.com/investors/morphosys-acquisition 2024-06-20T08:57:39+02:00 daily 1.0 https://www.novartis.com/privacy/scc-p2c 2024-02-07T09:28:18+01:00 daily 1.0 https://www.novartis.com/privacy/scc-p2p 2024-02-07T09:28:31+01:00 daily 1.0 https://www.novartis.com/investors/financial-data/quarterly-results/2023-q4-and-full-year-results-transcript 2024-05-07T10:18:39+02:00 daily 1.0 https://www.novartis.com/about/manufacturing/contract-manufacturing/derisk-your-mrna-program-ebook 2024-03-22T14:37:52+01:00 daily 1.0 https://www.novartis.com/diseases/iga-nephropathy 2024-04-09T16:42:16+02:00 daily 1.0 https://www.novartis.com/investors/financial-data/quarterly-results/2024-q1-transcript 2024-05-07T11:34:00+02:00 daily 1.0 https://www.novartis.com/diseases/c3-glomerulopathy 2024-05-02T10:28:13+02:00 daily 1.0 https://www.novartis.com/report 2024-05-28T15:12:02+02:00 daily 1.0 https://www.novartis.com/healthcare-professionals/medical-congresses-and-events/asco-annual-meeting/asco-2024 2024-06-04T20:42:56+02:00 daily 1.0 https://www.novartis.com/investors/morphosys-acquisition/voluntary-public-takeover-offer 2024-06-20T14:39:10+02:00 daily 1.0 https://www.novartis.com/investors/morphosys-acquisition/delisting-purchase-offer 2024-06-20T08:32:52+02:00 daily 1.0 https://www.novartis.com/investors 2024-06-28T10:14:39+02:00 daily 1.0 https://www.novartis.com/investors/share-data-analysis 2024-04-09T11:30:01+02:00 daily 1.0 https://www.novartis.com/about 2024-02-21T20:38:48+01:00 daily 1.0 https://www.novartis.com/patients-and-caregivers 2024-03-12T09:40:15+01:00 daily 1.0 https://www.novartis.com/clinicaltrials 2024-02-08T17:15:03+01:00 daily 1.0 https://www.novartis.com/healthcare-professionals 2024-02-08T17:19:04+01:00 daily 1.0 https://www.novartis.com/research-and-development 2024-02-08T17:14:22+01:00 daily 1.0 https://www.novartis.com/research-and-development/technology-platforms 2024-02-08T17:43:40+01:00 daily 1.0 https://www.novartis.com/diseases/coronavirus 2023-10-31T10:31:24+01:00 daily 1.0 https://www.novartis.com/esg 2024-05-02T11:06:16+02:00 daily 1.0 https://www.novartis.com/news 2024-06-05T09:19:52+02:00 daily 1.0 https://www.novartis.com/investors/company-overview 2024-03-19T14:00:34+01:00 daily 1.0 https://www.novartis.com/esg/environmental-sustainability 2024-02-02T08:43:04+01:00 daily 1.0 https://www.novartis.com/about/novartis-and-european-union 2024-02-15T09:44:46+01:00 daily 1.0 https://www.novartis.com/esg/global-health 2024-02-08T17:52:18+01:00 daily 1.0 https://www.novartis.com/partnering 2024-02-09T08:18:10+01:00 daily 1.0 https://www.novartis.com/esg/access 2024-05-31T15:12:10+02:00 daily 1.0 https://www.novartis.com/about/diversity-equity-and-inclusion 2024-06-06T10:07:12+02:00 daily 1.0 https://www.novartis.com/about/people-and-culture 2024-06-06T11:58:20+02:00 daily 1.0 https://www.novartis.com/about/novartis-gene-therapies 2023-11-17T17:46:11+01:00 daily 1.0 https://www.novartis.com/research-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond 2023-11-17T17:03:13+01:00 daily 1.0 https://www.novartis.com/about/quality 2024-02-02T11:51:13+01:00 daily 1.0 https://www.novartis.com/esg/ethics-risk-and-compliance 2024-02-08T17:51:44+01:00 daily 1.0 https://www.novartis.com/diseases 2024-05-02T10:31:16+02:00 daily 1.0 https://www.novartis.com/research-and-development/technology-platforms/radioligand-therapy 2024-06-26T11:16:20+02:00 daily 1.0 https://www.novartis.com/research-development/technology-platforms/gene-therapy 2023-11-17T17:01:02+01:00 daily 1.0 https://www.novartis.com/supplier-portal 2024-06-25T15:55:51+02:00 daily 1.0 https://www.novartis.com/research-development/technology-platforms/cell-therapy 2023-11-17T17:03:43+01:00 daily 1.0 https://www.novartis.com/about/manufacturing/contract-manufacturing 2024-04-01T07:51:12+02:00 daily 1.0 https://www.novartis.com/about/manufacturing/global-biotech-cooperations/what-we-do/microbial-manufacturing 2023-10-31T11:36:39+01:00 daily 1.0 https://www.novartis.com/about/manufacturing/global-biotech-cooperations/what-we-do/quality-regulatory 2023-10-31T11:42:52+01:00 daily 1.0 https://www.novartis.com/about/manufacturing 2024-03-12T11:17:30+01:00 daily 1.0 https://www.novartis.com/clinicaltrials/healthcare-professionals-researchers 2023-11-02T09:07:46+01:00 daily 1.0 https://www.novartis.com/clinicaltrials/patients 2023-12-04T06:49:19+01:00 daily 1.0 https://www.novartis.com/clinicaltrials/novartis-trials 2023-11-17T17:27:42+01:00 daily 1.0 https://www.novartis.com/clinicaltrials/NCT05089656 2022-09-22T15:02:42+02:00 daily 1.0 https://www.novartis.com/about/therapeutic-areas 2024-02-01T10:19:37+01:00 daily 1.0 https://www.novartis.com/healthcare-professionals/medical-congresses-and-events/asco-annual-meeting 2024-05-31T14:21:20+02:00 daily 1.0 https://www.novartis.com/careers/why-novartis 2023-12-01T17:06:05+01:00 daily 1.0 https://www.novartis.com/careers/our-business-functions/careers-commercial-and-sales 2024-05-06T20:12:16+02:00 daily 1.0 https://www.novartis.com/careers/our-business-functions 2023-12-01T17:01:36+01:00 daily 1.0 https://www.novartis.com/careers/career-hub 2024-04-03T15:12:50+02:00 daily 1.0 https://www.novartis.com/about/therapeutic-areas/oncology/my-cancer-my-words 2024-03-19T17:13:29+01:00 daily 1.0 https://www.novartis.com/investors/reporting-and-transparency-hub 2024-05-31T12:50:19+02:00 daily 1.0 https://www.novartis.com/investors/reporting-and-transparency-hub/novartis-society-integrated-report 2024-01-31T07:36:57+01:00 daily 1.0 https://www.novartis.com/news/media-releases/novartis-drug-afinitor-significantly-improves-progression-free-survival-advanced-nonfunctional-gastrointestinal-and-lung-net 2021-10-05T11:51:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-new-heart-failure-medicine-entrestotm-recommended-chmp-eu-approval 2021-10-05T11:51:22+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-appoints-james-e-bradner-md-president-novartis-institutes-biomedical-research-mark-fishman-retires 2022-04-08T11:39:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-nomme-le-dr-james-e-bradner-president-des-instituts-novartis-pour-la-recherche-biomedicale-suite-au-prochain-depart-la-retraite-de-mark-fishman 2021-10-05T11:51:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-ernennt-dr-james-e-bradner-zum-prasidenten-der-novartis-institutes-biomedical-research-da-mark-fishman-den-ruhestand-tritt 2021-10-05T11:51:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-launches-novartis-access-portfolio-affordable-medicines-treat-chronic-diseases-lower-income-countries 2021-10-05T11:51:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-lance-novartis-access-une-gamme-de-medicaments-prix-abordables-pour-lutter-contre-les-maladies-chroniques-dans-les-pays-faible-revenu 2021-10-05T11:51:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-lanciert-novartis-access-ein-portfolio-von-erschwinglichen-medikamenten-zur-behandlung-von-chronischen-erkrankungen-landern-mit-niedrigen-einkommen 2021-10-05T11:51:27+02:00 daily 0.5 https://www.novartis.com/news/media-releases/swissmedic-approves-novartis-new-heart-failure-medicine-entrestotm 2021-10-05T11:51:27+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-foundation-healthcare-models-and-disease-elimination-programs-showcased-ectmih 2021-10-05T11:51:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-farydak-first-its-class-anticancer-agents-approved-patients-multiple-myeloma 2021-10-05T11:51:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-launches-zarxiotm-filgrastim-sndz-first-biosimilar-united-states 2021-10-05T11:51:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-new-revolade-use-first-class-therapy-patients-severe-aplastic-anemia 2021-10-05T11:51:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-global-partnership-amgen-develop-and-commercialize-pioneering-neuroscience-treatments 2021-10-05T11:51:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-setzt-sich-weiter-fur-die-endgultige-ausrottung-von-lepra-ein 2021-10-05T11:51:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-renouvelle-son-engagement-lapproche-de-la-derniere-ligne-droite-dans-la-lutte-visant-eradiquer-la-lepre 2021-10-05T11:51:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-tafinlar-and-mekinist-first-combination-approved-patients-aggressive-form-melanoma 2021-10-05T11:51:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-continues-commitment-go-last-mile-effort-eliminate-leprosy 2021-10-05T11:51:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/das-novartis-international-biocamp-zeigt-wie-zusammenarbeit-und-vielfalt-innovationen-fordern-und-inspiriert-kunftige-wissenschaftliche-fuhrungskrafte 2021-10-05T11:51:39+02:00 daily 0.5 https://www.novartis.com/news/media-releases/le-novartis-international-biocamp-souligne-le-role-de-la-collaboration-et-de-la-diversite-pour-stimuler-linnovation-et-inspirer-les-futurs-leaders-scientifiques 2021-10-05T11:51:39+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-international-biocamp-highlights-how-collaboration-and-diversity-drive-innovation-and-inspires-future-science-leaders 2021-10-05T11:51:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-expands-use-novartis-drug-promacta-include-treatment-children-ages-1-and-older-chronic-immune-thrombocytopenia 2021-10-05T11:51:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-acquires-all-remaining-rights-gsks-ofatumumab-develop-treatments-ms-and-other-autoimmune-indications 2021-10-05T11:51:43+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-odomzo-gains-eu-approval-locally-advanced-basal-cell-carcinoma-providing-new-non-invasive-therapy-patients 2021-10-05T11:51:43+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-completes-divestiture-influenza-vaccines-business-csl-limited-usd-275-million 2021-10-05T11:51:45+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-partners-phase-4-partners-and-institutional-investors-help-create-mereo-biopharma-group-ltd 2021-10-05T11:51:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-foundation-confirms-new-members-its-board-trustees-including-new-chairman-dr-joerg-reinhardt 2021-10-05T11:51:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-approves-novartis-drug-odomzo-sonidegib-locally-advanced-basal-cell-carcinoma-labcc-form-skin-cancer 2021-10-05T11:51:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-combination-therapy-tafinlar-and-mekinist-achieves-important-eu-and-us-regulatory-milestones 2021-10-05T11:51:51+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-revolade-recommended-chmp-eu-approval-treat-patients-severe-aplastic-anemia-serious-blood-disorder 2021-10-05T11:51:51+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-solid-performance-second-quarter-strong-innovation-and-progress-new-launches 2021-10-05T11:51:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-solide-performance-au-deuxieme-trimestre-grace-la-force-de-linnovation-et-aux-progres-des-nouveaux-lancements 2021-10-05T11:51:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-im-zweiten-quartal-eine-solide-performance-mit-starken-innovationen-und-fortschritten-bei-neueinfuhrungen 2021-10-05T11:51:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-malaria-treatment-coartem-80480mg-receives-who-prequalification-enabling-greater-access-patients 2021-10-05T11:51:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-new-heart-failure-medicine-lcz696-now-called-entrestotm-approved-fda-reduce-risk-cardiovascular-death-and-heart-failure-hospitalization 2021-10-05T11:52:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-receives-european-approval-pre-loaded-intraocular-lens-delivery-system-treat-patients-undergoing-cataract-surgery 2021-10-05T11:52:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-pharmaceuticals-launches-first-app-visually-impaired-people-use-apple-watch-and-other-smart-watches 2021-10-05T11:52:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-deepens-its-industry-leading-pipeline-acquisition-spinifex-pharmaceuticals-inc 2021-10-05T11:52:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-publication-lancet-showing-sustained-efficacy-secukinumab-over-one-year-psoriatic-arthritis-patients 2021-10-05T11:52:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-farydak-recommended-chmp-eu-approval-treat-multiple-myeloma-providing-patients-new-mechanism-action 2021-10-05T11:52:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-us-launch-glatopatm-first-generic-competitor-copaxone-20mg 2021-10-05T11:52:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-strong-innovation-momentum-its-second-meet-novartis-management-investor-day 2021-10-05T11:52:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-receives-european-approval-new-trifocal-presbyopia-correcting-intraocular-lens-patients-undergoing-cataract-surgery 2021-10-05T11:52:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-data-from-large-european-study-reinforcing-benefit-first-line-tasigna-newly-diagnosed-patients-cml 2021-10-05T11:52:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-data-show-majority-patients-polycythemia-vera-treated-jakavi-achieved-long-term-disease-control 2021-10-05T11:52:12+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-eha-show-increased-pfs-benefit-farydak-new-subgroup-patients-previously-treated-multiple-myeloma 2021-10-05T11:52:12+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-arzerra-improved-median-progression-free-survival-54-patients-relapsed-chronic-lymphocytic-leukemia 2021-10-05T11:52:14+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-reports-new-analysis-showing-xolair-improving-quality-life-78-chronic-spontaneous-urticaria-patients 2021-10-05T11:52:14+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-gains-fda-approval-promacta-providing-new-option-children-ages-6-and-older-chronic-itp-rare-blood-disorder 2021-10-05T11:52:16+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-data-wcd-demonstrating-significant-efficacy-cosentyx-patients-psoriasis-nails-palms-and-soles 2021-10-05T11:52:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-new-one-year-results-demonstrating-sustained-secukinumab-efficacy-ankylosing-spondylitis-patients 2021-10-05T11:52:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-ctl019-data-showing-its-potential-treatment-specific-types-hard-treat-non-hodgkin-lymphoma 2021-10-05T11:52:18+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-data-asco-zykadia-and-combination-tafinlar-and-mekinist-certain-nsclc-patients-unmet-needs 2021-10-05T11:52:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/combination-novartis-drugs-tafinlar-and-mekinist-shows-significant-survival-benefit-patients-metastatic-melanoma 2021-10-05T11:52:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-data-21-medicines-and-11-investigational-compounds-asco-and-eha 2021-10-05T11:52:22+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-afinitor-extended-progression-free-survival-phase-iii-trial-advanced-gastrointestinal-or-lung-neuroendocrine-tumors 2021-10-05T11:52:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-two-positive-us-phase-iii-programs-copd-qva149-and-nva237 2021-10-05T11:52:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-lung-cancer-drug-zykadia-gains-eu-approval-providing-new-therapy-certain-patients-alk-nsclc 2021-10-05T11:52:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-phase-iii-study-arzerra-met-primary-endpoint-improved-progression-free-survival-patients-relapsed-cll 2021-10-05T11:52:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-sales-growth-cc-significant-margin-expansion-cc-and-strong-innovation-q11-now-more-focused-portfolio 2021-10-05T11:52:27+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-affiche-au-t11-une-forte-progression-de-ses-ventes-tcc-une-hausse-importante-de-sa-marge-tcc-et-une-innovation-tres-dynamique-avec-un-portefeuille-desormais-mieux-cible 2021-10-05T11:52:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-im-ersten-quartal1-umsatzsteigerungen-kwk-deutlich-hohere-margen-kwk-und-beachtliche-innovationen-jetzt-mit-einem-starker-fokussierten-portfolio 2021-10-05T11:52:30+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-celebrates-19th-annual-community-partnership-day-more-27000-associates-volunteering-their-local-communities 2021-10-05T11:52:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/data-aan-showed-gilenya-high-efficacy-achieving-no-evidence-disease-activity-previously-treated-highly-active-ms-patients 2021-10-05T11:52:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-fda-approval-glatopatm-first-generic-competitor-ms-therapy-copaxone-20mg 2021-10-05T11:52:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-receives-fda-approval-new-multifocal-intraocular-lens-treat-cataract-patients-united-states 2021-10-05T11:52:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/data-lancet-show-novartis-drug-arzerra-plus-chlorambucil-improved-median-progression-free-survival-71-cll-patients 2021-10-05T11:52:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/gilenya-data-aan-highlight-novartis-leadership-innovation-new-ms-assessment-methods-benefit-patients-and-physicians 2021-10-05T11:52:36+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-jadenutm-simplify-treatment-administration-patients-chronic-iron-overload 2021-10-05T11:52:38+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-accelerates-cancer-immunotherapy-efforts-aduro-biotech-alliance-and-launch-new-immuno-oncology-research-group 2021-10-05T11:52:38+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyxtm-two-year-data-shows-sustained-effect-and-favorable-safety-profile-psoriasis-patients 2021-10-05T11:52:40+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-data-shows-cosentyxtm-significantly-superior-stelara-and-clears-skin-pasi-90-nearly-80-psoriasis-patients 2021-10-05T11:52:40+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-jakavi-polycythemia-vera-first-targeted-therapy-approved-patients-rare-blood-cancer 2021-10-05T11:52:42+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-present-new-late-breaking-cosentyxtm-data-aad-2015-showing-significant-patient-benefit-achieving-clear-skin 2021-10-05T11:52:43+02:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-approves-first-biosimilar-zarxiotm-filgrastim-sndz-from-sandoz 2021-10-05T11:52:45+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-completion-transactions-gsk 2021-10-05T11:52:46+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-gibt-abschluss-von-transaktionen-mit-gsk-bekannt 2021-10-05T11:52:48+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-annonce-la-conclusion-des-transactions-avec-gsk 2021-10-05T11:52:48+02:00 daily 0.5 https://www.novartis.com/news/media-releases/positive-phase-ii-data-highlights-benefits-alcons-rth258-patients-neovascular-wet-age-related-macular-degeneration 2021-10-05T11:52:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-novartis-board-directors 2021-10-05T11:52:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration 2021-10-05T11:52:51+02:00 daily 0.5 https://www.novartis.com/news/media-releases/aktionare-genehmigen-alle-antrage-des-verwaltungsrats-von-novartis 2021-10-05T11:52:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-lung-cancer-drug-zykadia-recommended-eu-approval-patients-alk-nsclc-previously-treated-crizotinib 2021-10-05T11:52:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-farydak-first-hdac-inhibitor-patients-multiple-myeloma 2021-10-05T11:52:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-heart-failure-medicine-lcz696-granted-fda-priority-review 2021-10-05T11:52:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-receives-fda-approval-pazeotm-solution-ocular-allergy-itch-relief 2021-10-05T11:52:57+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-study-nejm-showing-jakavi-was-superior-standard-therapy-rare-blood-cancer-polycythemia-vera 2021-10-05T11:52:57+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-solid-sales-growth-margin-expansion-and-pipeline-progress-2014-portfolio-transformation-will-focus-company-leading-businesses 2021-10-05T11:52:59+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-enregistre-en-2014-une-forte-augmentation-de-ses-ventes-sa-marge-et-progres-de-son-pipeline-la-transformation-du-portefeuille-concentrera-lentreprise-sur-ses-principales-activites 2021-10-05T11:53:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-2014-solide-umsatzsteigerungen-hohere-margen-und-fortschritte-der-pipeline-mit-der-umgestaltung-des-portfolios-fokussiert-sich-das-unternehmen-auf-fuhrende-geschaftsbereiche 2021-10-05T11:53:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-bexsero-vaccine-approved-fda-prevention-meningitis-b-leading-cause-bacterial-meningitis-us 2021-10-05T11:53:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-jakavi-recommended-chmp-eu-approval-treat-adults-rare-blood-cancer-polycythemia-vera 2021-10-05T11:53:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab-moderate-severe-plaque-psoriasis-patients 2021-10-05T11:53:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyxtm-first-il-17-inhibitor-receive-eu-approval-first-line-treatment-moderate-severe-psoriasis-patients 2021-10-05T11:53:09+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-pharmaceuticals-announces-joint-investment-company-qualcomm-leading-innovation-digital-medicines-physicians-and-patients 2021-10-05T11:53:11+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-robust-phase-iii-results-qva149-and-nva237-and-submits-regulatory-applications-us-fda 2021-10-05T11:53:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-biosimilar-filgrastim-recommended-approval-fda-oncologic-drugs-advisory-committee 2021-10-05T11:53:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-collaborates-intellia-therapeutics-and-caribou-biosciences-explore-making-medicines-and-drug-discovery-tools-crispr-genome-editing-technology 2021-10-05T11:53:15+02:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-approves-sandoz-erelzitm-treat-multiple-inflammatory-diseases 2021-10-05T12:04:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-convenes-experts-discuss-new-technologies-healthcare-novartis-international-biocamp 2021-10-05T12:04:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/experten-diskutieren-am-novartis-international-biocamp-neue-technologien-im-gesundheitsbereich 2021-10-05T12:04:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-convie-plusieurs-experts-au-novartis-international-biocamp-afin-de-discuter-des-nouvelles-technologies-en-matiere-de-sante 2021-10-05T12:04:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-positive-phase-iii-results-showing-efficacy-baf312-patients-secondary-progressive-ms 2021-10-05T12:04:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/six-leading-scientists-receive-prestigious-novartis-prizes-immunology-16th-international-congress-immunology 2021-10-05T12:04:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cdk46-inhibitor-lee011-ribociclib-receives-fda-breakthrough-therapy-designation-first-line-treatment-hrher2-advanced-breast-cancer 2021-10-05T12:04:34+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-achieves-us-approval-cypass-micro-stent-micro-invasive-surgical-device-treat-glaucoma 2021-10-05T12:04:34+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-solid-q2-despite-full-quarter-us-gleevec-generic-impact-significant-positive-innovation-news-strengthens-future-growth-prospects 2021-10-05T12:04:36+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-realise-un-2eme-trimestre-solide-malgre-limpact-sur-le-trimestre-du-generique-de-gleevec-aux-us-nouvelles-positives-importantes-de-linnovation-renforcent-les-perspectives-de-croissance 2021-10-05T12:04:38+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-im-2-quartal-solide-ergebnisse-trotz-us-generikakonkurrenz-fur-gleevec-im-gesamten-quartal-wichtige-positive-neuigkeiten-zu-innovationen-starken-zukunftige-wachstumsperspektiven 2021-10-05T12:04:38+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-launches-dailies-total1-multifocal-contact-lenses-first-and-only-water-gradient-lenses-designed-people-presbyopia 2021-10-05T12:04:40+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-biosimilar-etanercept-recommended-fda-advisory-committee-approval-treat-multiple-inflammatory-diseases 2021-10-05T12:04:40+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-data-shows-sandoz-biosimilar-etanercept-candidate-has-equivalent-efficacy-originator-product 2021-10-05T12:04:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-pkc412-midostaurin-pivotal-data-published-nejm-show-60-response-rate-advanced-systemic-mastocytosis-sm 2021-10-05T12:04:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/largest-global-psoriasis-survey-shows-84-people-face-discrimination-and-humiliation-because-their-skin 2021-10-05T12:04:43+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-adds-bispecific-antibodies-its-growing-immuno-oncology-portfolio-through-collaboration-and-licensing-agreement-xencor 2021-10-05T12:04:43+02:00 daily 0.5 https://www.novartis.com/news/media-releases/timely-use-novartis-entresto-could-prevent-or-postpone-over-28000-us-deaths-year-among-hfref-patients-according-expert-analysis-jama-cardiology 2021-10-05T12:04:45+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-expands-partnership-medicines-malaria-venture-develop-next-generation-antimalarial-treatment 2021-10-05T12:04:45+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erweitert-partnerschaft-mit-medicines-malaria-venture-zur-entwicklung-von-malariamedikamenten-der-nachsten-generation 2021-10-05T12:04:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-etend-son-partenariat-avec-medicines-malaria-venture-pour-developper-la-prochaine-generation-de-traitement-antipaludeen 2021-10-05T12:04:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-long-term-safety-data-revolade-adults-chronic-immune-thrombocytopenia-rare-blood-disorder 2021-10-05T12:04:48+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-data-showing-jakavi-superior-best-available-therapy-patients-less-advanced-polycythemia-vera-pv 2021-10-05T12:04:48+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-data-demonstrates-sandoz-etanercept-and-rituximab-biosimilar-candidates-bioequivalent-originator-products 2021-10-05T12:04:50+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-amg-334-significantly-reduces-patients-monthly-migraine-days-phase-ii-study-chronic-migraine-prevention 2021-10-05T12:04:50+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-scientific-evidence-cosentyx-ankylosing-spondylitis-and-psoriatic-arthritis-patients-eular-2016 2021-10-05T12:04:51+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-combination-therapy-tafinlar-mekinist-demonstrates-overall-survival-benefit-three-year-follow-patients-advanced-melanoma 2021-10-05T12:04:51+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-pivotal-data-tafinlar-mekinist-demonstrated-63-percent-overall-response-rate-treating-rare-form-lung-cancer 2021-10-05T12:04:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-show-more-50-percent-eligible-ph-cml-patients-maintain-treatment-free-remission-tfr-after-stopping-tasigna 2021-10-05T12:04:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-afinitor-receives-eu-approval-treat-certain-types-advanced-gastrointestinal-gi-and-lung-neuroendocrine-tumors-net 2021-10-05T12:04:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-its-strong-foundation-long-term-sustainable-growth-third-meet-novartis-management-event 2021-10-05T12:04:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-biosimilar-rituximab-regulatory-submission-accepted-european-medicines-agency 2021-10-05T12:04:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-entresto-given-strong-class-i-recommendation-both-us-and-eu-heart-failure-guidelines-less-year-after-regulatory-approvals 2021-10-05T12:04:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-investment-fortihfy-clinical-program-entresto-and-heart-failure 2021-10-05T12:04:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-present-pivotal-data-hematologic-and-solid-tumor-cancers-2016-asco-annual-meeting 2021-10-05T12:04:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/monaleesa-2-trial-novartis-lee011-ribociclib-stopped-due-positive-efficacy-results-interim-analysis-hrher2-advanced-breast-cancer 2021-10-05T12:05:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-focuses-pharmaceuticals-division-creating-two-business-units-novartis-pharmaceuticals-and-novartis-oncology-appoints-leaders-executive-committee-novartis 2021-10-05T12:05:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-renforce-la-division-pharmaceuticals-par-la-creation-de-deux-unites-daffaires-novartis-pharmaceuticals-et-novartis-oncology-et-nomme-de-nouveaux-dirigeants-son-comite-de-direction 2021-10-05T12:05:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-fokussiert-ihre-division-pharmaceuticals-durch-schaffung-der-geschaftseinheiten-novartis-pharmaceuticals-und-novartis-oncology-und-beruft-deren-leiter-die-geschaftsleitung-von-novartis 2021-10-05T12:05:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-foundation-and-partners-launch-innovative-hypertension-program-vietnam 2021-10-05T12:05:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/major-study-published-nejm-confirms-novartis-ultibro-breezhaler-superiority-over-seretide-preventing-copd-exacerbations 2021-10-05T12:05:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-afinitor-recommended-chmp-european-union-approval-treat-select-gi-and-lung-neuroendocrine-tumors 2021-10-05T12:05:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-three-fda-breakthrough-therapy-designations-ilaris-treat-rare-types-periodic-fever-syndromes 2021-10-05T12:05:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-solid-q1-despite-gleevec-loss-exclusivity-investing-behind-new-launches-long-term-growth 2021-10-05T12:05:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-im-ersten-quartal-trotz-verlust-der-exklusivrechte-gleevec-solide-ergebnisse-und-investiert-neueinfuhrungen-zugunsten-langfristigen-wachstums 2021-10-05T12:05:09+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-enregistre-un-premier-trimestre-solide-malgre-la-perte-dexclusivite-de-gleevec-et-investi-dans-de-nouveaux-lancements-pour-soutenir-la-croissance-long-terme 2021-10-05T12:05:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-afinitor-significantly-reduces-seizures-phase-iii-study-patients-tuberous-sclerosis-complex 2021-10-05T12:05:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-ec-approval-subcutaneous-route-administration-biosimilar-binocrits-nephrology-indication 2021-10-05T12:05:12+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-revolade-first-class-therapy-children-aged-1-year-and-above-chronic-itp 2021-10-05T12:05:12+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-analyses-show-novartis-entrestotm-reduced-cardiovascular-death-or-hospitalization-heart-failure-consistently-benefitting-patients-reduced-ejection-fraction-regardless 2021-10-05T12:05:14+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-publishes-updated-2015-segment-financials-reflecting-new-division-structure 2021-10-05T12:05:16+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-superior-stelara-delivering-long-lasting-skin-clearance-pasi-90-psoriasis-patients-52-weeks 2021-10-05T12:05:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-approves-new-indication-novartis-drug-afinitor-progressive-nonfunctional-gi-and-lung-neuroendocrine-tumors-net 2021-10-05T12:05:18+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors 2021-10-05T12:05:18+02:00 daily 0.5 https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-0 2021-10-05T12:05:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-aktionare-genehmigen-alle-antrage-des-verwaltungsrats 2021-10-05T12:05:22+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-pkc412-midostaurin-receives-breakthrough-therapy-designation-from-fda-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml 2021-10-05T12:05:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-expands-leadership-position-treating-glaucoma-through-acquisition-transcend-medical-inc 2021-10-05T12:05:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-strengthens-its-biosimilars-portfolio-acquisition-pfizers-biosimilar-infliximab-eea 2021-10-05T12:05:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-advances-its-biosimilars-program-ema-acceptance-regulatory-submission-biosimilar-pegfilgrastim 2021-10-05T12:05:26+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-foundation-commemorates-world-leprosy-day-its-continued-efforts-go-last-mile-toward-elimination 2021-10-05T12:05:26+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-strong-sales-growth-and-core-margin-expansion-cc1-2015-announces-plans-accelerate-growth-alcon-streamline-group-operations 2021-10-05T12:05:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-enregistre-en-2015-une-forte-croissance-des-ventes-et-une-hausse-de-sa-marge-core-tcc1-et-annonce-des-plans-pour-accelerer-la-croissance-dalcon-et-rationaliser-les-operations-du-groupe 2021-10-05T12:05:30+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-2015-eine-kraftige-steigerung-des-umsatzes-und-der-kern-gewinnmarge-kwk1-plane-zur-wachstumsbeschleunigung-bei-alcon-und-zur-straffung-der-konzernaktivitaten-bekannt-gegeben 2021-10-05T12:05:32+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-two-new-fda-approvals-cosentyx-treat-patients-ankylosing-spondylitis-and-psoriatic-arthritis-us 2021-10-05T12:05:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-continues-grow-immuno-oncology-pipeline-through-collaboration-and-licensing-agreement-surface-oncology 2021-10-05T12:05:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-pharmaceuticals-collaborates-qualcomm-digital-innovation-breezhalertm-inhaler-device-treat-copd 2021-10-05T12:05:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-two-major-trials-showing-significant-efficacy-cosentyx-ankylosing-spondylitis-patients 2021-10-05T12:05:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/300-million-child-friendly-antimalarial-treatments-supplied-without-profit-novartis 2021-10-05T12:05:38+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-advances-its-biosimilars-program-european-medicines-agency-ema-acceptance-regulatory-submission-biosimilar-etanercept 2021-10-05T12:05:40+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-new-ctl019-phase-ii-data-demonstrating-93-complete-remission-pediatric-patients-rr-all 2021-10-05T12:05:40+02:00 daily 0.5 https://www.novartis.com/news/media-releases/phase-iii-data-shows-sandoz-proposed-biosimilar-pegfilgrastim-has-similar-safety-and-efficacy-reference-product 2021-10-05T12:05:42+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-pkc412-midostaurin-improves-overall-survival-23-global-phase-iii-study-aml-patients-flt3-mutations 2021-10-05T12:05:43+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-new-ctl019-study-data-demonstrating-overall-response-adult-patients-certain-types-lymphoma 2021-10-05T12:05:43+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-phase-iii-studies-jakavi-show-disease-improvement-patients-myelofibrosis-and-polycythemia-vera 2021-10-05T12:05:45+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-data-targeted-combination-therapy-sabcs-reinforcing-commitment-breast-cancer-patients 2021-10-05T12:05:45+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-clinical-advances-ash-2015-underscoring-leadership-hematology-research 2021-10-05T12:05:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-heart-failure-medicine-entrestotm-receives-eu-approval 2021-10-05T12:05:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-two-landmark-european-approvals-cosentyx-treat-patients-ankylosing-spondylitis-and-psoriatic-arthritis 2021-10-05T12:05:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-pharmaceuticals-corporation-finalizes-settlement-agreement-resolving-civil-suit-filed-us-attorneys-office-southern-district-new-york 2021-10-05T12:05:51+02:00 daily 0.5 https://www.novartis.com/news/media-releases/regulatory-submission-sandoz-proposed-biosimilar-pegfilgrastim-accepted-fda 2021-10-05T12:05:52+02:00 daily 0.5 https://www.novartis.com/news/media-releases/flame-study-shows-superiority-novartis-ultibro-breezhaler-over-seretide-reducing-copd-exacerbations 2021-10-05T12:05:52+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-introduces-contoura-vision-first-personalized-lasik-procedure-american-academy-ophthalmology-annual-meeting 2021-10-05T12:05:54+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-two-year-data-cosentyx-showing-no-progression-joint-damage-84-psoriatic-arthritis-patients 2021-10-05T12:05:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-two-year-data-novartis-cosentyx-show-sustained-response-and-no-progression-spinal-damage-shown-x-ray-80-patients-ankylosing-spondylitis 2021-10-05T12:05:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-nominating-elizabeth-doherty-and-ton-buechner-board-directors 2021-10-05T12:05:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-foundation-and-partners-launch-new-hypertension-program-ghana 2021-10-05T12:05:59+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-strong-core-margin-expansion-cc-and-continued-strengthen-pipeline-q3-track-full-year-guidance 2021-10-05T12:06:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-realise-au-troisieme-trimestre-une-forte-hausse-de-sa-marge-core-tcc-et-continue-de-renforcer-son-pipeline-confirmant-ainsi-ses-previsions-pour-lexercice 2021-10-05T12:06:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-steigert-die-kerngewinnmarge-kwk-im-dritten-quartal-kraftig-starkt-erneut-die-pipeline-und-ist-auf-kurs-fur-die-jahresprognose 2021-10-05T12:06:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-first-il-17a-inhibitor-cosentyxtm-treat-ankylosing-spondylitis-and-psoriatic-arthritis 2021-10-05T12:06:06+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-broadens-immuno-oncology-pipeline-acquisition-admune-therapeutics-and-licensing-agreements-xoma-and-palobiofarma 2021-10-05T12:06:06+02:00 daily 0.5 https://www.novartis.com/news/media-releases/kenya-first-country-launch-novartis-access-expanding-affordable-treatment-options-against-chronic-diseases 2021-10-05T12:06:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-data-showing-majority-patients-are-able-maintain-clear-or-almost-clear-skin-cosentyx-across-3-years 2021-10-05T12:06:09+02:00 daily 0.5 https://www.novartis.com/news/media-releases/long-term-efficacy-gilenya-reinforced-new-no-evidence-disease-activity-neda-4-analysis-ms-patients-over-seven-years 2021-10-05T12:06:11+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-receives-fda-approval-pre-loaded-intraocular-lens-delivery-system-treat-patients-undergoing-cataract-surgery 2021-10-05T12:06:11+02:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-accepts-sandoz-regulatory-submission-proposed-biosimilar-etanercept 2021-10-05T12:06:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-secukinumab-phase-iii-data-confirming-significant-efficacy-patients-psoriatic-arthritis 2021-10-05T12:06:15+02:00 daily 0.5 https://www.novartis.com/news/media-releases/patients-aggressive-form-melanoma-lived-more-two-years-average-when-taking-novartis-therapies-tafinlar-mekinist 2021-10-05T12:06:18+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-next-generation-car-t-cell-therapy-ctl119-combined-ibrutinib-shows-high-rate-responses-cll-patients 2021-10-05T12:08:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-expanded-use-zykadia-first-line-alk-positive-metastatic-non-small-cell-lung-cancer-nsclc 2021-10-05T12:08:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-new-analyses-reinforce-potential-ultibro-breezhaler-copd-patients-historically-treated-steroids 2021-10-05T12:08:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-first-line-use-zykadia-alk-positive-advanced-non-small-cell-lung-cancer-nsclc 2021-10-05T12:08:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-asco-icml-and-eha-meetings-demonstrate-meaningful-advancements-cancer-care 2021-10-05T12:08:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-foundation-and-partners-launch-initiative-tackle-hypertension-and-its-root-causes-low-income-urban-communities 2021-10-05T12:08:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-celebrates-21st-annual-community-partnership-day-over-24500-associates-volunteering-their-local-communities 2021-10-05T12:08:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-exercises-exclusive-option-agreement-conatus-treatment-nash 2021-10-05T12:08:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-rydapt-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml-and-three-types-systemic-mastocytosis-sm 2021-10-05T12:08:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-announces-eu-launch-cypass-micro-stent-micro-invasive-glaucoma-surgical-device-lower-intraocular-pressure-iop-patients-primary-open-angle-glaucoma 2021-10-05T12:08:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-sales-growth-across-all-divisions-cc1-growth-drivers-including-cosentyx-and-entresto-more-offset-generic-erosion-innovation-momentum-continued 2021-10-05T12:08:12+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-ventes-en-progression-tcc1-dans-toutes-ses-divisions-les-moteurs-de-croissance-cosentyx-et-entresto-inclus-compensent-lerosion-due-aux-generiques-linnovation-toujours-en-plein-essor 2021-10-05T12:08:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-umsatzsteigerungen-allen-divisionen-kwk1-wobei-wachstumstreiber-wie-cosentyx-und-entresto-die-einbussen-durch-generika-mehr-als-wettmachen-innovationsdynamik-setzt-sich-fort 2021-10-05T12:08:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-expands-global-collaboration-amgen-commercialize-first-class-amg-334-erenumab-program-migraine-prevention-us-and-canada 2021-10-05T12:08:15+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-real-world-data-aan-confirms-benefit-gilenya-four-key-measures-disease-activity-relapsing-ms 2021-10-05T12:08:15+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilars-rituximab-and-etanercept-recommended-approval-europe 2021-10-05T12:08:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/nih-study-nejm-shows-novartis-drug-eltrombopag-first-line-therapy-standard-treatment-improves-responses-severe-aplastic-anemia 2021-10-05T12:08:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-expands-development-programs-nash-through-clinical-collaboration-allergan 2021-10-05T12:08:18+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation-treatment-adult-patients-rr-dlbcl 2021-10-05T12:08:18+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-strengthen-rd-pipeline-licensing-ecf843-ophthalmic-indications 2021-10-05T12:08:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-combination-tafinlar-mekinist-receives-eu-approval-braf-v600-positive-advanced-non-small-cell-lung-cancer-nsclc 2021-10-05T12:08:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-first-car-t-cell-therapy-bla-pediatric-and-young-adult-patients-rr-b-cell-all-granted-fda-priority-review 2021-10-05T12:08:22+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-receives-us-fda-approval-new-acrysof-iq-restor-25-multifocal-toric-iol-activefocustm-design-uncompromised-distance-vision-and-presbyopia-correction 2021-10-05T12:08:22+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-rlx030-serelaxin-patients-acute-heart-failure 2021-10-05T12:08:24+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-first-and-only-il-17a-inhibitor-potentially-modify-course-psoriasis 2021-10-05T12:08:24+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-analysis-shows-novartis-entresto-improves-glycemic-control-reduced-ejection-fraction-heart-failure-patients-diabetes 2021-10-05T12:08:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-ribociclib-lee011-receives-fda-approval-first-line-treatment-hrher2-metastatic-breast-cancer-combination-any-aromatase-inhibitor 2021-10-05T12:08:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-winners-inaugural-healthcare-access-challenge-sandoz-hack 2021-10-05T12:08:27+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-almost-all-psoriasis-patients-rapidly-regain-skin-clearance-following-treatment-pause 2021-10-05T12:08:27+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-data-demonstrate-sandoz-proposed-biosimilar-adalimumab-has-equivalent-efficacy-reference-medicine 2021-10-05T12:08:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-aktionare-genehmigen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats 2021-10-05T12:08:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting 2021-10-05T12:08:30+02:00 daily 0.5 https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-annuelle 2021-10-05T12:08:32+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-tafinlar-mekinist-braf-positive-non-small-cell-lung-cancer-nsclc-patients 2021-10-05T12:08:32+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-zykadia-receives-fda-priority-review-first-line-use-patients-alk-metastatic-nsclc 2021-10-05T12:08:34+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-pharmaceuticals-ag-recu-la-certification-top-employer-suisse-2017 2021-10-05T12:08:34+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-pharmaceuticals-ag-als-top-arbeitgeber-schweiz-2017-ausgezeichnet 2021-10-05T12:08:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-votubia-receives-eu-approval-treat-refractory-partial-onset-seizures-patients-tsc 2021-10-05T12:08:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-progress-towards-access-and-environmental-goals-2016-corporate-responsibility-performance-report 2021-10-05T12:08:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-launches-new-trifocal-toric-intraocular-lens-patients-astigmatism-undergoing-cataract-surgery 2021-10-05T12:08:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-solid-2016-performance-growth-products1-absorbing-gleevec-us-loe-innovation-momentum-continued-announces-share-buyback 2021-10-05T12:08:39+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-solide-performance-en-2016-les-produits-de-croissance1-absorbant-la-perte-dexclusivite-de-gleevec-aux-usa-dynamique-continue-dinnovation-rachat-dactions-annonce 2021-10-05T12:08:40+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-2016-solide-ergebnisse-wobei-die-wachstumsprodukte1-den-verlust-der-exklusivrechte-fur-gleevec-den-usa-wettmachen-innovationsdynamik-halt-aktienruckkauf-angekundigt 2021-10-05T12:08:42+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-invests-next-generation-therapies-reduce-cardiovascular-risk-patients-underlying-lipid-disorders 2021-10-05T12:08:42+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-bolsters-ophthalmology-pipeline-through-acquisition-encore-vision-inc 2021-10-05T12:08:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-exclusive-option-collaboration-and-license-agreement-conatus-develop-new-oral-treatments-chronic-liver-diseases 2021-10-05T12:08:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-recommendation-ilaris-treat-rare-diseases-adults-and-children-called-periodic-fever-syndromes 2021-10-05T12:08:46+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-votubia-recommended-chmp-eu-approval-treat-refractory-partial-onset-seizures-patients-tsc 2021-10-05T12:08:46+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-bolsters-innovative-dermatology-portfolio-through-acquisition-ziarco-group-limited 2021-10-05T12:08:48+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-launches-sms-life-20-nigeria-help-improve-access-essential-medicines 2021-10-05T12:08:48+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-lance-sms-life-20-au-nigeria-pour-aider-ameliorer-lacces-aux-medicaments-essentiels 2021-10-05T12:08:50+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-fuhrt-sms-life-20-nigeria-ein-um-den-zugang-zu-unentbehrlichen-arzneimitteln-zu-verbessern 2021-10-05T12:08:50+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-pegpleranib-phase-iii-clinical-trial-program-patients-neovascular-age-related-macular-degeneration-namd-or-wet-amd 2021-10-05T12:08:52+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-lee011-ribociclib-plus-letrozole-analyses-show-superior-pfs-across-broad-spectrum-patients-first-line-hrher2-advanced-breast-cancer-versus-letrozole 2021-10-05T12:08:52+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-ultibro-breezhaler-improved-lung-function-and-copd-symptoms-after-direct-switch-from-previous-treatment 2021-10-05T12:08:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-lucentis-received-eu-approval-new-indication-lucentis-only-treatment-available-wide-range-cnv-conditions 2021-10-05T12:08:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-zykadia-first-line-study-results-showing-166-month-progression-free-survival-patients-alk-advanced-nsclc 2021-10-05T12:08:57+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-shows-treatment-free-remission-rates-are-consistently-above-50-regardless-reason-switch-tasigna-from-glivec 2021-10-05T12:09:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-survey-uncovers-real-world-burden-myeloproliferative-neoplasms-rare-blood-cancers-daily-activity-and-ability-work 2021-10-05T12:09:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-interim-data-demonstrate-sandoz-proposed-biosimilar-rituximab-has-equivalent-efficacy-reference-product 2021-10-05T12:09:06+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-results-from-first-global-registration-trial-ctl019-pediatric-and-young-adult-patients-rr-b-all 2021-10-05T12:09:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-seg101-crizanlizumab-formerly-selg1-significantly-reduces-frequency-sickle-cell-pain-crises-phase-ii-study 2021-10-05T12:09:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-access-communique-son-bilan-un-et-annonce-la-signature-dun-protocole-daccord-avec-le-rwanda 2021-10-05T12:09:11+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-access-shares-one-year-learnings-and-announces-memorandum-understanding-rwanda 2021-10-05T12:09:11+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-access-informiert-uber-erfahrungen-im-ersten-jahr-und-gibt-memorandum-understanding-mit-ruanda-bekannt 2021-10-05T12:09:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-acquires-selexys-pharmaceuticals-corporation-and-selg1-antibody-reduction-pain-crises-sickle-cell-disease-scd 2021-10-05T12:09:16+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-commends-publication-major-report-which-recommends-broad-use-dual-bronchodilators-treat-copd 2021-10-05T12:09:16+02:00 daily 0.5 https://www.novartis.com/news/media-releases/innovative-study-three-treatment-switches-confirms-sandoz-biosimilar-etanercept-has-equivalent-efficacy-originator 2021-10-05T12:09:19+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-amg-334-significantly-reduces-monthly-migraine-days-second-pivotal-phase-iii-episodic-migraine-study 2021-10-05T12:09:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-ash-and-sabcs-showcase-latest-innovations-development-patients-blood-disorders-and-breast-cancer 2021-10-05T12:09:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-analysis-novartis-entresto-data-shows-long-term-benefits-heart-failure-readmissions-and-total-cardiovascular-deaths 2021-10-05T12:09:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-pkc412-midostaurin-granted-fda-priority-review-newly-diagnosed-flt3-mutated-aml-and-advanced-systemic-mastocytosis 2021-10-05T12:09:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-cosentyx-data-showing-long-lasting-efficacy-psoriatic-arthritis-over-3-years-including-patient-reported-pain 2021-10-05T12:09:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-improves-ranking-2016-access-medicine-index 2021-10-05T12:09:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-lee011-ribociclib-granted-fda-priority-review-first-line-treatment-hrher2-advanced-breast-cancer 2021-10-05T12:09:32+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-wins-two-prestigious-prix-galien-foundation-awards-gleevec-recognized-discovery-decade-best-pharmaceutical-product-cosentyx-best-biotechnology-product 2021-10-05T12:09:34+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-solid-third-quarter-growth-products1-offsetting-gleevec-patent-expiration-several-positive-readouts-potential-blockbusters 2021-10-05T12:09:36+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-im-dritten-quartal-solide-ergebnisse-wobei-die-wachstumsprodukte1-den-verlust-des-patents-fur-gleevec-wettmachen-mehrere-positive-daten-fur-potenzielle-blockbuster 2021-10-05T12:09:38+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-realise-un-troisieme-trimestre-solide-les-produits-de-croissance1-ayant-compense-lexpiration-du-brevet-de-glivec-plusieurs-resultats-positifs-concernant-des-blockbusters-potentiels 2021-10-05T12:09:40+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-launches-cypass-micro-stent-american-academy-ophthalmology-aao-2016-annual-meeting 2021-10-05T12:09:46+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-alk-metastatic-nsclc-therapy-zykadia-extends-progression-free-survival-beyond-18-months-phase-ii-study 2021-10-05T12:09:48+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-tafinlar-dabrafenib-mekinist-trametinib-demonstrate-superior-overall-survival-benefit-advanced-melanoma-patients-three-year-follow 2021-10-05T12:09:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-breakthrough-therapy-lee011-plus-letrozole-demonstrates-superior-progression-free-survival-first-line-treatment-hrher2-advanced-breast-cancer-compared-standard-care 2021-10-05T12:09:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-reports-over-half-psoriasis-patients-do-not-reach-achievable-treatment-goal-clear-skin-largest-global-survey 2021-10-05T12:09:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-late-breaking-data-show-cosentyx-delivers-high-and-long-lasting-skin-clearance-over-4-years-psoriasis-patients 2021-10-05T12:09:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-phase-iii-study-shows-amg-334-significantly-reduces-monthly-migraine-days-people-episodic-migraine 2021-10-05T12:09:59+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-invites-young-entrepreneurs-enter-sandoz-hack-global-competition-help-solve-healthcare-access-challenges 2021-10-05T12:10:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-three-new-fda-approvals-expanded-use-ilaris-treating-rare-periodic-fever-syndrome-conditions 2021-10-05T12:10:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-positive-top-line-results-from-ascend-4-phase-iii-trial-zykadia-untreated-adult-alk-nsclc-patients 2021-10-05T12:10:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novel-novartis-malaria-compound-shows-potential-be-effective-against-infections-resistant-all-currently-available-antimalarial-drugs 2021-10-05T12:10:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/important-new-analysis-shows-novartis-entresto-associated-higher-relative-health-related-quality-life-scores-among-hfref-patients 2021-10-05T12:10:06+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-baf312-reduces-risk-disability-progression-pivotal-phase-iii-study-secondary-progressive-ms-patients 2021-10-05T12:10:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-data-presented-ectrims-show-benefit-gilenya-patient-disability-progression-10-years 2021-10-05T12:10:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-positive-data-ehmtic-showing-amg-334-significantly-reduces-monthly-migraine-days-chronic-migraine 2021-10-05T12:10:16+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-foundation-showcases-progress-leprosy-elimination-programs-19th-international-leprosy-congress 2021-10-05T12:10:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-point-care-nijitm-system-may-provide-earlier-diagnosis-severe-allergic-asthma-and-faster-treatment-decisions 2021-10-05T12:10:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-launches-ngenuity-3d-visualization-system-designed-further-enhance-retinal-surgeon-experience 2021-10-05T12:10:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-ultibro-breezhaler-consistently-more-effective-seretide-reducing-copd-flare-ups-across-different-patient-groups 2021-10-05T12:10:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/airflusal-forspiro-showed-superiority-12-months-over-seretide-diskus1-persistence-treatment 2021-10-05T12:10:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-new-data-reinforces-superiority-cosentyx-versus-stelara-achieving-skin-clearance-psoriasis-patients 2021-10-05T12:36:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-regulatory-submission-proposed-biosimilar-adalimumab-accepted-fda 2021-10-05T12:36:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-appoints-elizabeth-barrett-oncology-head 2021-10-05T12:36:19+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-ernennt-elizabeth-barrett-zur-chefin-onkologie 2021-10-05T12:36:19+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-advances-head-head-superiority-trials-cosentyx-versus-humira-and-proposed-biosimilar-adalimumab 2021-10-05T12:36:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-promacta-receives-fda-breakthrough-therapy-designation-first-line-use-severe-aplastic-anemia-saa 2021-10-05T12:36:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-received-fda-breakthrough-therapy-designation-initial-endocrine-based-treatment-premenopausal-women-hrher2-advanced-breast-cancer 2021-10-05T12:36:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-tasigna-approved-fda-first-and-only-cml-therapy-treatment-free-remission-data-its-label 2021-10-05T12:36:24+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-combination-therapy-tafinlar-mekinist-granted-fda-priority-review-adjuvant-treatment-stage-iii-braf-v600-mutation-positive-melanoma 2021-10-05T12:36:24+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-oncology-head-retire 2021-10-05T12:36:26+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-gibt-rucktritt-des-onkologie-chefs-bekannt 2021-10-05T12:36:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-crizanlizumab-shown-prolong-time-patients-first-sickle-cell-pain-crisis-subgroup-analysis-sustain-study 2021-10-05T12:36:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/primary-analysis-results-from-novartis-pivotal-juliet-trial-show-kymriahtm-tisagenlecleucel-sustained-complete-responses-six-months-adults-rr-dlbcl-difficult-treat-cancer 2021-10-05T12:36:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-new-phase-i-data-showing-proposed-biosimilar-pegfilgrastim-matches-reference-medicine 2021-10-05T12:36:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-tender-offer-advanced-accelerator-applications-commences 2021-10-05T12:36:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/kisqali-first-and-only-cdk46-inhibitor-show-superior-efficacy-vs-oral-endocrine-therapy-1l-treatment-randomized-phase-iii-trial-premenopausal-women-hrher2-advanced-breast-cancer 2021-10-05T12:36:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-first-biologic-show-long-term-efficacy-nail-and-palmoplantar-psoriasis-which-can-impact-90-psoriasis-patients 2021-10-05T12:36:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-phase-iii-strive-data-published-nejm-demonstrating-significant-and-sustained-efficacy-erenumab-amg334-migraine-prevention 2021-10-05T12:36:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-ultibro-breezhaler-significantly-improved-copd-patients-lung-function-after-direct-switch-from-seretide 2021-10-05T12:36:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-tasigna-nilotinib-secures-eu-approval-first-and-second-line-treatment-ph-cml-cp-children 2021-10-05T12:36:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-ascp-and-acs-join-forces-fight-cancer-ethiopia-uganda-and-tanzania 2021-10-05T12:36:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-data-sabcs-across-broad-range-breast-cancer-patient-populations-combination-treatments-and-lines-therapy 2021-10-05T12:36:38+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-data-reinforces-clinical-basis-switching-sandoz-biosimilar-medicines 2021-10-05T12:36:38+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-canakinumab-acz885-reduced-cardiovascular-risk-25-subgroup-cantos-phase-iii-trial-participants 2021-10-05T12:36:40+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-its-differentiated-late-stage-pipeline-rd-update-and-investor-event 2021-10-05T12:36:40+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-entresto-real-world-evidence-data-shows-beneficial-impact-quality-life-people-living-heart-failure 2021-10-05T12:36:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/punjab-province-pakistan-signs-agreement-novartis-access-against-chronic-diseases 2021-10-05T12:36:52+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-brolucizumab-rth258-demonstrates-superiority-versus-aflibercept-key-secondary-endpoint-measures-disease-activity-namd-leading-cause-blindness 2021-10-05T12:36:52+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-reports-positive-results-from-phase-iii-trial-kisqali-ribociclib-combination-therapy-premenopausal-women-hrher2-advanced-or-metastatic-breast-cancer 2021-10-05T12:36:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-study-data-demonstrating-cosentyx-reduced-signs-and-symptoms-psoriatic-arthritis-while-inhibiting-progression-joint-structural-damage 2021-10-05T12:36:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-seeks-leadership-cosentyx-showing-no-radiographic-progression-ankylosing-spondylitis-4-years 2021-10-05T12:36:57+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-reaches-another-regulatory-milestone-ctl019-tisagenlecleucel-submission-its-maa-ema-children-young-adults-rr-b-cell-all-and-adult-patients-rr-dlbcl 2021-10-05T12:36:57+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-expanded-collaboration-banner-alzheimers-institute-pioneering-prevention-program 2021-10-05T12:36:59+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-data-ash-patients-serious-blood-disorders-lymphoma-leukemia-and-sickle-cell-disease 2021-10-05T12:37:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-submits-application-fda-kymriahtm-tisagenlecleucel-adult-patients-rr-dlbcl-seeking-second-indication-first-ever-fda-approved-car-t-therapy 2021-10-05T12:37:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-present-first-its-kind-evidence-cosentyx-potential-maintain-mobility-patients-and-psa 2021-10-05T12:37:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-advanced-accelerator-applications-strengthen-oncology-portfolio 2021-10-05T12:37:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-paradigms-data-show-children-and-adolescents-ms-had-82-lower-relapse-rate-gilenya-vs-interferon-beta-1a 2021-10-05T12:37:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilar-pegfilgrastim-accepted-ema-regulatory-review 2021-10-05T12:37:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-confirms-leadership-multiple-sclerosis-ms-scientific-advancements-and-new-data-presented-ectrims 2021-10-05T12:37:09+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-growth-top-and-bottom-line-all-divisions-q3 2021-10-05T12:37:09+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-au-troisieme-trimestre-croissance-du-chiffre-daffaires-et-du-resultat-dans-toutes-les-divisions 2021-10-05T12:37:11+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-steigert-im-dritten-quartal-umsatz-und-gewinn-allen-divisionen 2021-10-05T12:37:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-combination-adjuvant-therapy-tafinlar-mekinist-receives-fda-breakthrough-therapy-designation-stage-iii-braf-v600-mutation-positive-melanoma-patients 2021-10-05T12:37:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-revolade-shows-long-term-disease-control-chronicpersistent-immune-thrombocytopenia-itp 2021-10-05T12:37:16+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-receives-ce-mark-first-its-kind-autonometm-preloaded-intraocular-lens-iol-delivery-system-clareon-iol 2021-10-05T12:37:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-introduces-new-innovations-cataract-surgery-european-society-cataract-refractive-surgeons-2017-annual-congress 2021-10-05T12:37:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-uc-berkeley-collaborate-tackle-undruggable-disease-targets 2021-10-05T12:37:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-max-foundation-transform-pioneering-cancer-access-program-people-lower-income-countries 2021-10-05T12:37:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-rydapt-midostaurin-receives-eu-approval-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml-and-three-types-advanced-systemic-mastocytosis-sm 2021-10-05T12:37:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-xolair-confirms-re-treatment-efficacy-chronic-spontaneous-urticaria-patients-after-treatment-interruption 2021-10-05T12:37:27+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilar-adalimumab-matches-reference-biologic-terms-efficacy-and-safety-long-term-study 2021-10-05T12:37:27+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-sets-new-benchmark-psoriasis-robust-5-year-sustained-phase-iii-efficacy-and-safety-data 2021-10-05T12:37:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilar-rituximab-accepted-review-fda 2021-10-05T12:37:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-phase-iii-study-demonstrates-adjuvant-tafinlar-mekinist-reduced-risk-disease-recurrence-53-patients-resected-braf-v600-mutation-positive-melanoma 2021-10-05T12:37:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-analysis-demonstrating-amg-334-erenumab-significantly-reduced-monthly-migraine-days-patients-who-failed-previous-preventive-therapies 2021-10-05T12:37:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-landmark-phase-iii-trial-shows-fingolimod-significantly-reduces-relapses-children-and-adolescents-ms 2021-10-05T12:37:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-ceo-joseph-jimenez-retire-from-novartis-2018-vasant-narasimhan-appointed-ceo-effective-february-1-2018 2021-10-05T12:37:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019-children-and-young-adults-b-cell-all-refractory-or-has-relapsed-least-twice 2021-10-05T12:37:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-analysis-published-lancet-showing-acz885-reduced-lung-cancer-mortality-77-cantos-study-further-studies-planned 2021-10-05T12:37:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-phase-iii-cantos-study-demonstrates-targeting-inflammation-acz885-reduces-cardiovascular-risk 2021-10-05T12:37:42+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-appoints-bertrand-bodson-chief-digital-officer 2021-10-05T12:37:42+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-ribociclib-receives-eu-approval-first-line-treatment-hrher2-locally-advanced-or-metastatic-breast-cancer-combination-any-aromatase-inhibitor 2021-10-05T12:37:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-et-medicines-malaria-venture-lancent-une-etude-clinique-en-afrique-pour-kaf156-un-candidat-medicament-novateur-contre-le-paludisme-multiresistant 2021-10-05T12:37:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-launch-patient-trial-africa-kaf156-novel-compound-against-multidrug-resistant-malaria 2021-10-05T12:37:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-und-medicines-malaria-venture-starten-afrika-eine-patientenstudie-mit-kaf156-einem-neuartigen-wirkstoff-gegen-multiresistente-malaria 2021-10-05T12:37:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-expands-partnership-world-child-cancer-help-children-access-treatment-four-developing-countries 2021-10-05T12:37:50+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-rydapt-midostaurin-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml-and-three-types-advanced-systemic-mastocytosis-sm 2021-10-05T12:37:54+02:00 daily 0.5 https://www.novartis.com/news/media-releases/die-ergebnisse-im-zweiten-quartal-bestatigen-die-jahresprognosen-starke-forschungs-und-entwicklungsresultate-untermauern-das-potenzial-einiger-hoch-innovativer-produkte 2021-10-05T12:37:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/les-resultats-du-t2-confirment-les-previsions-de-lexercice-2017-les-tres-bons-resultats-du-pipeline-etayent-le-potentiel-de-plusieurs-produits-hautement-novateurs 2021-10-05T12:37:57+02:00 daily 0.5 https://www.novartis.com/news/media-releases/q2-results-confirm-full-year-guidance-strong-pipeline-results-underpin-potential-several-highly-innovative-products 2021-10-05T12:37:59+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-confirms-5-year-data-first-and-only-fully-human-il-17a-inhibitor-cosentyx-reinforcing-sustained-efficacy-and-safety-profile-psoriasis 2021-10-05T12:37:59+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-unanimously-10-0-recommended-approval-fda-advisory-committee-treat-pediatric-young-adult-rr-b-cell-all 2021-10-05T12:38:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-approval-eu-cosentyx-label-update-includes-long-term-superiority-data-versus-stelara-psoriasis 2021-10-05T12:38:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-first-line-use-zykadia-alk-positive-advanced-non-small-cell-lung-cancer-nsclc 2021-10-05T12:38:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-approval-europe-erelzi-biosimilar-etanercept-treat-multiple-inflammatory-diseases 2021-10-05T12:38:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/nejm-publishes-full-analysis-rydapt-midostaurin-phase-iii-ratify-trial-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml 2021-10-05T12:38:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-ribociclib-receives-positive-chmp-opinion-first-line-treatment-hrher2-locally-advanced-or-metastatic-breast-cancer-combination-any-aromatase-inhibitor 2021-10-05T12:38:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-shows-half-eligible-ph-cml-cp-patients-remain-treatment-free-remission-nearly-two-years-after-stopping-tasigna 2021-10-05T12:38:09+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-pivotal-ctl019-6-month-follow-data-show-durable-remission-rates-children-young-adults-rr-b-cell-all 2021-10-05T12:38:09+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-combination-targeted-therapy-tafinlar-mekinist-receives-fda-approval-braf-v600e-mutant-metastatic-non-small-cell-lung-cancer-nsclc 2021-10-05T12:38:11+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-phase-iii-study-shows-acz885-canakinumab-reduces-cardiovascular-risk-people-who-survived-heart-attack 2021-10-05T12:38:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-achieves-important-regulatory-milestone-amg-334-erenumab-migraine-prevention-ema-filing-acceptance 2021-10-05T12:38:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-rth258-brolucizumab-demonstrates-robust-visual-gains-namd-patients-majority-12-week-injection-interval 2021-10-05T12:38:14+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-real-world-study-shows-almost-half-chronic-urticaria-patients-are-not-receiving-any-treatment-despite-significant-disease-burden 2021-10-05T12:38:16+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-approval-europe-rixathon-biosimilar-rituximab-treat-blood-cancers-and-immunological-diseases 2021-10-05T12:38:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-international-ag-new-patient-survey-highlights-need-more-action-help-severe-asthma-patients-gain-control-their-disease 2021-10-05T12:38:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-accepts-sandoz-regulatory-submission-generic-version-advair-diskus 2021-10-05T12:38:19+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-sustained-improvements-signs-and-symptoms-both-and-psa-80-patients-3-years 2021-10-05T12:38:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-data-demonstrating-efficacy-amg-334-erenumab-migraine-prevention-american-headache-society-annual-meeting 2021-10-05T12:38:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-interim-results-from-global-pivotal-ctl019-trial-show-durable-complete-responses-adults-rr-dlbcl 2021-10-05T12:38:22+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-tasigna-receives-eu-approval-inclusion-treatment-free-remission-tfr-data-product-label 2021-10-05T12:38:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-clinical-collaboration-bristol-myers-squibb-evaluate-potential-treatments-metastatic-colorectal-cancer 2021-10-05T12:38:27+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-ground-breaking-collaboration-ibm-watson-health-outcomes-based-care-advanced-breast-cancer 2021-10-05T12:38:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-landmark-study-tafinlar-mekinist-demonstrates-durable-survival-benefit-five-years-patients-braf-mutation-positive-metastatic-melanoma 2021-10-05T12:38:32+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-updated-data-reinforce-efficacy-and-safety-kisqali-ribociclib-plus-letrozole-first-line-option-hrher2-advanced-or-metastatic-breast-cancer 2021-10-05T12:38:32+02:00 daily 0.5 https://www.novartis.com/news/media-releases/progress-reported-global-fight-against-diarrheal-disease-cryptosporidiosis 2021-10-05T12:38:34+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilars-adalimumab-and-infliximab-accepted-regulatory-review-european-medicines-agency 2021-10-05T12:38:36+02:00 daily 0.5 https://www.novartis.com/news/media-releases/meet-novartis-management-investor-event-novartis-highlights-focus-innovation-and-productivity-expects-next-growth-phase-begin-2018 2021-10-05T12:38:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-ernennt-dr-klaus-moosmayer-zum-chief-ethics-risk-and-compliance-officer 2021-10-05T12:39:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-marks-new-era-migraine-patients-eu-approval-aimovig-first-its-kind-treatment-specifically-designed-migraine-prevention 2021-10-05T12:39:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-european-commission-approval-biosimilar-hyrimoz-adalimumab 2021-10-05T12:39:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-combination-tafinlar-mekinist-receives-positive-chmp-opinion-adjuvant-treatment-braf-v600-mutation-positive-melanoma 2021-10-05T12:39:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-renews-drug-donation-egaten-triclabendazole-until-2022-reaffirming-its-commitment-fight-against-liver-fluke 2021-10-05T12:39:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-demonstrates-commitment-lead-immuno-dermatology-licensing-il-17c-compound-atopic-dermatitis 2021-10-05T12:39:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-now-first-and-only-cdk46-inhibitor-indicated-us-first-line-therapy-specifically-premenopausal-women-and-initial-therapy-fulvestrant-postmenopausal-women 2021-10-05T12:39:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivers-solid-growth-second-quarter-and-continues-transformation-focused-medicines-company 2021-10-05T12:39:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-realise-une-solide-croissance-au-deuxieme-trimestre-et-poursuit-sa-transformation-en-une-entreprise-axee-sur-les-medicaments 2021-10-05T12:39:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-im-zweiten-quartal-ein-solides-wachstum-und-setzt-die-transformation-zu-einem-fokussierten-arzneimittelunternehmen-fort 2021-10-05T12:39:38+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-kymriah-treating-two-aggressive-blood-cancers-marking-important-medical-advance-patients-europe 2021-10-05T12:39:40+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erhalt-positive-chmp-stellungnahme-fur-kymriah-zur-behandlung-zweier-aggressiver-blutkrebsarten-ein-wichtiger-medizinischer-fortschritt-fur-patientinnen-und-patienten-europa 2021-10-05T12:39:42+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-intention-seek-shareholder-approval-100-spinoff-alcon-eye-care-devices-business-initiates-share-buyback-usd-5-bn 2021-10-05T12:39:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-gibt-absicht-bekannt-die-genehmigung-der-aktionare-fur-einen-100igen-spin-des-geschafts-mit-ophthalmologischen-produkten-von-alcon-einzuholen-und-leitet-gleichzeitig-einen-aktienruck 2021-10-05T12:39:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-annonce-son-intention-de-solliciter-lapprobation-des-actionnaires-pour-la-scission-100-dalcon-sa-division-de-produits-ophtalmologiques-et-initie-un-rachat-dactions-hauteur-dusd 2021-10-05T12:39:46+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-data-demonstrating-long-term-efficacy-safety-and-tolerability-aimovig-erenumab-patients-chronic-and-episodic-migraine 2021-10-05T12:39:46+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-international-ag-global-study-novartis-and-european-migraine-and-headache-alliance-reveals-60-employed-people-severe-migraine-miss-average-week-work-month 2021-10-05T12:39:48+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-clear-about-psoriasis-survey-data-highlights-challenges-psoriasis-patients-face-achieve-goal-clear-skin 2021-10-05T12:39:48+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-international-ag-alcon-acrysof-iq-panoptix-trifocal-intraocular-lens-shows-superior-visual-performance-head-head-trial-post-cataract-surgery 2021-10-05T12:39:50+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-juliet-trial-kymriah-demonstrates-more-one-year-durability-responses-adults-relapsed-or-refractory-dlbcl 2021-10-05T12:39:50+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-survey-uncovers-real-world-impact-immune-thrombocytopenia-or-itp-rare-blood-disease-patients-quality-life 2021-10-05T12:39:52+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-study-real-world-data-concludes-jakavi-associated-reduction-risk-death-and-dangerous-blood-clots-patients-rare-blood-cancer 2021-10-05T12:39:52+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-presents-new-long-term-and-switching-data-biosimilars-zessly-infliximab-and-erelzi-etanercept-rheumatoid-arthritis 2021-10-05T12:39:54+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-data-advance-understanding-role-il-17a-and-reinforce-cosentyx-leadership-spondyloarthritis 2021-10-05T12:39:54+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-jco-publication-lutathera-netter-1-data-showing-significantly-longer-time-deterioration-key-quality-life-measures-patients-progressive-midgut-nets 2021-10-05T12:39:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-schullabor-empfangt-hunderttausendsten-besucher 2021-10-05T12:39:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/third-novartis-phase-iii-trial-shows-kisqali-combination-therapy-significantly-improves-pfs-hrher2-advanced-breast-cancer 2021-10-05T12:39:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-data-presented-asco-find-nearly-half-cml-patients-treated-tasigna-remain-remission-almost-three-years-after-stopping-therapy 2021-10-05T12:39:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-completes-sale-stake-consumer-healthcare-joint-venture-gsk-usd130-billion 2021-10-05T12:40:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-adalimumab 2021-10-05T12:40:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-aimovig-erenumab-prevention-migraine 2021-10-05T12:40:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-expedites-review-novartis-drug-promacta-first-line-severe-aplastic-anemia-saa 2021-10-05T12:40:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-international-ag-patient-reported-outcomes-tool-revealed-significant-improvement-symptom-frequency-and-quality-life-domains-entresto 2021-10-05T12:40:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-european-commission-approval-zessly-infliximab-gastroenterological-rheumatological-and-dermatological-diseases 2021-10-05T12:40:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-fda-approval-aimovigtm-erenumab-novel-treatment-developed-specifically-migraine-prevention 2021-10-05T12:40:06+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-asco-and-eha-reinforce-companys-commitment-reimagining-cancer 2021-10-05T12:40:06+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kundigt-veranderungen-der-geschaftsleitung 2021-10-05T12:40:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/meet-novartis-management-investor-event-novartis-highlights-strategy-focus-company-and-drive-sustainable-growth 2021-10-05T12:40:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-changes-executive-committee 2021-10-05T12:40:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avexis-inc 2021-10-05T12:40:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-arrow-trial-assess-mechanistic-superiority-direct-il-17a-inhibition-cosentyx-over-il-23-inhibition-tremfya 2021-10-05T12:40:12+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-completes-tender-offer-all-outstanding-shares-avexis-inc 2021-10-05T12:40:12+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-gilenya-first-disease-modifying-therapy-pediatric-relapsing-multiple-sclerosis 2021-10-05T12:40:14+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-cares-project-100-commits-reducing-cataract-blindness-globally 2021-10-05T12:40:14+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-complete-response-letter-from-us-fda-proposed-biosimilar-rituximab 2021-10-05T12:40:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/kymriah-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma 2021-10-05T12:40:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-proposed-acquisition-avexis 2021-10-05T12:40:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-tafinlar-mekinist-adjuvant-treatment-braf-v600-mutant-melanoma 2021-10-05T12:40:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-phase-iii-data-brolucizumab-demonstrate-reliability-12-week-treatment-interval 2021-10-05T12:40:22+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-launches-focalview-app-providing-opportunity-patients-participate-ophthalmology-clinical-trials-from-home 2021-10-05T12:40:24+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-analyses-aan-show-siponimods-efficacy-disability-and-cognition-secondary-progressive-ms-patients 2021-10-05T12:40:24+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-appoints-john-tsai-head-global-drug-development-and-chief-medical-officer 2021-10-05T12:40:26+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-strong-first-quarter-and-acted-become-more-focused-medicines-company 2021-10-05T12:40:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-realise-une-bonne-performance-au-premier-trimestre-et-agi-pour-devenir-une-entreprise-plus-centree-sur-les-medicaments 2021-10-05T12:40:30+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-verzeichnet-ein-starkes-erstes-quartal-und-ergreift-schritte-um-ein-starker-fokussiertes-arzneimittelunternehmen-zu-werden 2021-10-05T12:40:32+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-signs-agreement-pear-therapeutics-develop-and-commercialize-prescription-digital-therapeutics-patients-substance-use-disorder-and-opioid-use-disorders 2021-10-05T12:40:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-first-its-kind-evidence-aan-reinforcing-robust-and-consistent-efficacy-aimovigtm-erenumab-migraine-patients-multiple-treatment-failures 2021-10-05T12:40:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-renews-commitment-malaria-elimination-investing-usd-100-million-research-and-develop-next-generation-antimalarials 2021-10-05T12:40:38+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-bekraftigt-engagement-zur-eliminierung-von-malaria-und-investiert-usd-100-millionen-die-erforschung-und-entwicklung-der-nachsten-generation-von-malariamedikamenten 2021-10-05T12:40:38+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-renouvelle-son-engagement-afin-deliminer-le-paludisme-en-investissant-100-millions-de-dollars-dans-la-recherche-et-le-developpement-dantipaludiques-de-nouvelle-generation 2021-10-05T12:40:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-tender-offer-avexis-commences 2021-10-05T12:40:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-new-analysis-demonstrating-entresto-helped-preserve-kidney-function-patients-chronic-heart-failure-especially-those-diabetes 2021-10-05T12:40:45+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-enters-agreement-acquire-avexis-inc-usd-87-bn-transform-care-sma-and-expand-position-gene-therapy-and-neuroscience-leader 2021-10-05T12:40:45+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-schliesst-vereinbarung-zum-erwerb-von-avexis-inc-fur-usd-87-mrd-ab-um-therapie-der-sma-zu-transformieren-und-position-als-fuhrendes-gentherapie-und-neuroscience-unternehmen-auszubauen 2021-10-05T12:40:48+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-outlines-plans-next-healthcare-access-challenge-hack-support-local-digital-innovation 2021-10-05T12:40:48+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-jama-cardiology-publication-data-showing-entresto-improves-physical-and-social-activity-hfref-patients-versus-enalapril 2021-10-05T12:40:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-present-predictability-data-brolucizumab-namd-from-pivotal-hawk-and-harrier-trials-arvo 2021-10-05T12:40:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-sell-stake-consumer-healthcare-joint-venture-gsk-usd130-billion-focus-strategic-priorities 2021-10-05T12:40:51+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-verkauft-beteiligung-consumer-healthcare-joint-venture-fur-usd-13-milliarden-gsk-um-sich-auf-strategische-prioritaten-zu-konzentrieren 2021-10-05T12:40:51+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-infliximab 2021-10-05T12:40:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/phase-iii-data-lancet-show-novartis-siponimod-significantly-improves-outcomes-patients-secondary-progressive-ms 2021-10-05T12:40:54+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-drug-tasigna-approved-fda-treat-children-rare-form-leukemia 2021-10-05T12:40:54+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-teams-harvard-develop-next-generation-biomaterial-systems-deliver-immunotherapies 2021-10-05T12:40:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-changes-executive-committee-support-strategic-priorities 2021-10-05T12:40:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kundigt-veranderungen-der-geschaftsleitung-zur-unterstutzung-strategischer-prioritaten 2021-10-05T12:40:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-annonce-des-changements-au-sein-de-son-comite-de-direction-afin-de-soutenir-ses-priorites-strategiques 2021-10-05T12:41:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-expands-alliance-science-37-advance-virtual-clinical-trials-program 2021-10-05T12:41:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-xolair-recommended-new-global-chronic-urticaria-guideline 2021-10-05T12:41:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-0 2021-10-05T12:41:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale 2021-10-05T12:41:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-aktionare-genehmigen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats-0 2021-10-05T12:41:09+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-pear-therapeutics-develop-digital-therapeutics-patients-schizophrenia-and-multiple-sclerosis 2021-10-05T12:41:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/treatment-novartis-ultibro-breezhaler-improved-cardiac-function-copd-patients-lung-hyperinflation 2021-10-05T12:41:14+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-new-data-show-cosentyx-improved-quality-life-over-5-years-two-thirds-patients-moderate-severe-plaque-psoriasis 2021-10-05T12:41:16+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-new-cosentyx-data-confirms-robust-efficacy-and-quality-life-improvements-scalp-psoriasis 2021-10-05T12:41:18+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-forms-alliance-develop-medicines-treating-infectious-diarrheal-disease 2021-10-05T12:41:18+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-us-fda-approval-and-launch-glatopa-40-mgml-three-times-week-generic-option-relapsing-forms-multiple-sclerosis 2021-10-05T12:41:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-cosentyx-label-update-include-moderate-severe-scalp-psoriasis 2021-10-05T12:41:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-completes-subsequent-offering-period-tender-offer-advanced-accelerator-applications-sa 2021-10-05T12:41:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-updated-analysis-from-eliana-trial-showing-longer-term-durable-remissions-kymriahtm-children-young-adults-rr-all 2021-10-05T12:41:26+02:00 daily 0.5 https://www.novartis.com/news/media-releases/advanced-accelerator-applications-receives-fda-approval-lutathera-treatment-gastroenteropancreatic-neuroendocrine-tumors 2021-10-05T12:41:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-exclusively-licenses-first-ophthalmology-gene-therapy-all-markets-outside-us-milestone-patients-rare-inherited-vision-loss 2021-10-05T12:41:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-good-operational-performance-and-landmark-innovation-2017-entering-our-next-growth-phase 2021-10-05T12:41:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-enregistre-en-2017-une-belle-performance-operationnelle-et-des-innovations-majeures-entrant-ainsi-dans-une-nouvelle-phase-de-croissance 2021-10-05T12:41:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-2017-eine-gute-operative-performance-sowie-wegweisende-innovationen-und-ist-gut-gerustet-fur-die-nachste-wachstumsphase 2021-10-05T12:41:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-reports-erenumab-met-all-primary-and-secondary-endpoints-unique-phase-iiib-study-episodic-migraine-patients-who-have-failed-multiple-prior-preventive-treatments 2021-10-05T12:41:43+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-completes-tender-offer-advanced-accelerator-applications-sa-and-announces-commencement-subsequent-offering-period 2021-10-05T12:41:45+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-exclusive-global-collaboration-biocon-next-generation-biosimilars 2021-10-05T12:41:45+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-granted-us-fda-priority-review-kymriahtm-tisagenlecleucel-formerly-ctl019-adults-rr-dlbcl 2021-10-05T12:41:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/europe-africa-partnership-spearheads-development-next-generation-antimalarial-drug 2023-07-03T16:44:54+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-drives-differentiated-portfolio-deal-commercialize-new-treatment-opioid-induced-constipation-key-european-countries 2021-10-05T12:42:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-continues-transformation-leading-medicines-company-completion-alcon-spin 2021-10-05T12:42:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-updates-migraine-collaboration-amgen 2021-10-05T12:42:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-resubmits-biosimilar-pegfilgrastim-application-us-fda 2021-10-05T12:42:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-first-class-cosentyx-approved-china-psoriasis-patients 2021-10-05T12:42:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-expands-world-leading-gene-therapy-manufacturing-capacity-purchase-advanced-biologics-therapy-manufacturing-campus-longmont-colorado 2021-10-05T12:42:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-adds-clinical-and-preclinical-anti-inflammatory-programs-portfolio-acquisition-ifm-tre 2021-10-05T12:42:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary-progressive-ms-active-disease 2021-10-05T12:42:59+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-plans-alcon-spin-april-9-2019 2021-10-05T12:43:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-announces-acquisition-powervision-inc 2021-10-05T12:43:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-joins-global-chagas-disease-coalition-and-also-announces-first-multinational-prospective-randomized-study-people-chronic-chagas-cardiomyopathy 2021-10-05T12:43:06+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-change-sandoz-leadership 2021-10-05T12:43:06+02:00 daily 0.5 https://www.novartis.com/news/media-releases/three-winners-2019-sandoz-healthcare-access-challenge-hack-are-announced-sxsw 2021-10-05T12:43:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-superior-improvements-psoriasis-patients-quality-life-versus-janssens-il-23-stelara 2021-10-05T12:43:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-confirm-rapid-response-and-high-efficacy-cosentyx-psoriasis-patients-first-time-china 2021-10-05T12:43:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-1 2021-10-05T12:43:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/die-aktionare-von-novartis-heissen-der-generalversammlung-alle-antrage-des-verwaltungsrates-gut 2021-10-05T12:43:12+02:00 daily 0.5 https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-0 2021-10-05T12:43:12+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-issues-summary-financial-information-alcon-eye-care-business-ahead-shareholder-vote-proposed-spin 2021-10-05T12:43:14+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-pursue-transformational-therapy-reduce-risk-cardiovascular-disease-people-living-elevated-levels-inherited-lipoproteina 2021-10-05T12:43:14+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-egaten-treatment-fascioliasis-neglected-tropical-disease 2021-10-05T12:43:18+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-strong-sales-growth-core-margin-expansion-built-leading-advanced-therapy-platforms-and-focused-company-2018 2021-10-05T12:43:18+02:00 daily 0.5 https://www.novartis.com/news/media-releases/en-2018-novartis-enregistre-une-forte-croissance-de-ses-ventes-avec-une-expansion-de-sa-marge-core-developpe-des-plates-formes-leaders-de-traitements-de-pointe-et-recentre-lentreprise 2021-10-05T12:43:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-2018-ein-kraftiges-umsatzwachstum-bei-gleichzeitiger-steigerung-der-kerngewinnmarge-baut-wegweisende-therapieplattformen-auf-und-fokussiert-das-unternehmen 2021-10-05T12:43:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-investigational-therapy-crizanlizumab-seg101-receives-fda-breakthrough-therapy-designation-prevention-vaso-occlusive-crises-sickle-cell-disease 2021-10-05T12:43:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-and-pear-therapeutics-announce-us-launch-reset-otm-help-treat-opioid-use-disorder 2021-10-05T12:43:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-endocyte 2021-10-05T12:43:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-european-commission-ec-approval-expanded-indication-kisqali-ribociclib 2021-10-05T12:43:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-offer-acquire-cellforcure-expand-manufacturing-capacity-innovative-cell-and-gene-therapies 2021-10-05T12:43:43+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-new-ceo-oncology-business-unit 2021-10-05T12:43:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-enters-commercialization-and-supply-agreement-insulin-biosimilars-anticipating-growing-demand-diabetes-burden-rises 2021-10-05T12:43:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-announces-acquisition-tear-film-innovations-inc 2021-10-05T12:43:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-self-administration-xolair-across-all-indications 2021-10-05T12:43:54+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-inc-and-pear-therapeutics-obtain-fda-clearance-reset-otm-treat-opioid-use-disorder 2021-10-05T12:43:54+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-demonstrates-consistent-efficacy-and-tolerability-kisqali-combination-therapy-hrher2-advanced-breast-cancer-patients-difficult-treat-visceral-disease 2021-10-05T12:43:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-investigational-byl719-alpelisib-plus-fulvestrant-consistently-improved-pfs-patients-pik3ca-mutated-hrher2-advanced-breast-cancer-new-solar-1-analyses 2021-10-05T12:43:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-advances-ligelizumab-qge031-urticaria-phase-iii-basis-strong-phase-ii-head-head-data 2021-10-05T12:43:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-fda-filing-acceptance-and-priority-review-avxs-101-one-time-treatment-designed-address-genetic-root-cause-sma-type-1 2021-10-05T12:44:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/real-world-data-show-novartis-drug-revolade-improves-outcomes-itp-patients-compared-other-second-line-therapies 2021-10-05T12:44:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-longer-term-analyses-from-pivotal-kymriah-trials-showed-durable-responses-are-maintained-patients-advanced-blood-cancers 2021-10-05T12:44:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-new-crizanlizumab-seg101-data-analysis-sickle-cell-disease-and-investment-sentry-clinical-program 2021-10-05T12:44:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-eu-approval-gilenya-children-and-adolescents-ms-making-it-first-and-only-oral-disease-modifying-treatment-these-patients-europe 2021-10-05T12:44:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-eighth-european-commission-approval-biosimilar-ziextenzo-pegfilgrastim 2021-10-05T12:44:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-highlight-its-vision-strategy-and-benefits-standalone-company-investors-and-analysts-new-york-and-london 2021-10-05T12:44:09+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-landmark-eu-approval-one-time-gene-therapy-luxturna-restore-vision-people-rare-inherited-retinal-disease 2021-10-05T12:44:11+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-rises-second-place-2018-access-medicine-index 2021-10-05T12:44:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-and-pear-therapeutics-announce-launch-reset-treatment-patients-substance-use-disorder 2021-10-05T12:44:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-approves-novartis-drug-promacta-first-line-saa-and-grants-breakthrough-therapy-designation-additional-new-indication 2021-10-05T12:44:15+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-expand-kisqali-combination-therapy-all-women-hrher2-locally-advanced-or-metastatic-breast-cancer 2021-10-05T12:44:22+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-files-initial-form-20-f-registration-statement-sec-proposed-spinoff-plans-investor-days-new-york-and-london 2021-10-05T12:44:22+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-study-supports-entresto-foundational-hfref-therapy-and-hospital-initiation-appropriate-stabilized-heart-failure-patients 2021-10-05T12:44:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-rd-update-highlights-industry-leading-development-pipeline-including-potential-blockbusters-and-advanced-therapy-platforms 2021-10-05T12:44:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-decides-not-pursue-us-biosimilar-rituximab-will-focus-robust-biosimilar-portfolio-unmet-access-and-sustainability-needs 2021-10-05T12:44:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-ash-and-sabcs-show-strength-pipeline-and-portfolio-hematology-and-oncology 2021-10-05T12:44:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-biosimilar-hyrimoztm-adalimumab-adaz 2021-10-05T12:44:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-clinical-collaboration-pfizer-advance-treatment-nash 2021-10-05T12:44:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/two-year-data-novartis-brolucizumab-reaffirm-superiority-versus-aflibercept-reducing-retinal-fluid-patients-namd 2021-10-05T12:44:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-approval-cosentyx-label-update-europe-include-dosing-flexibility-psoriatic-arthritis 2021-10-05T12:44:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-develop-smart-suite-digital-health-platform-cataract-surgery 2021-10-05T12:44:39+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-lancet-publication-pioneering-study-migraine-prevention-showing-efficacy-aimovig-where-other-treatments-have-failed 2021-10-05T12:44:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-combi-ad-study-tafinlar-mekinist-continues-demonstrate-relapse-free-survival-benefit-patients-braf-v600-mutant-stage-iii-melanoma 2021-10-05T12:44:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-investigational-byl719-alpelisib-plus-fulvestrant-nearly-doubles-median-pfs-patients-pik3ca-mutated-hrher2-advanced-breast-cancer-compared-fulvestrant-alone 2021-10-05T12:44:43+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-phase-ii-geometry-mono-1-trial-investigational-medicine-capmatinib-inc280-shows-positive-results-patients-met-mutated-advanced-nsclc 2021-10-05T12:44:43+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-presentation-new-lutathera-netter-1-data-esmo-demonstrating-significant-improvement-pfs-regardless-baseline-liver-tumor-burden 2021-10-05T12:44:45+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-endocyte-expand-expertise-radiopharmaceuticals-and-build-commitment-transformational-therapeutic-platforms 2021-10-05T12:44:45+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-strong-growth-and-innovation-during-third-quarter-including-progressing-advanced-therapy-platforms-drive-future-growth 2021-10-05T12:44:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-enregistre-au-troisieme-trimestre-une-forte-croissance-et-fait-preuve-dune-innovation-dynamique-incluant-des-plateformes-therapeutiques-avancees-pour-soutenir-la-croissance-future 2021-10-05T12:44:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-im-dritten-quartal-starkes-wachstum-und-treibt-innovationen-wie-fortschrittliche-therapieplattformen-voran-um-das-zukunftige-wachstum-zu-beschleunigen 2021-10-05T12:44:51+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-5-year-data-psoriatic-arthritis-and-ankylosing-spondylitis-reinforces-cosentyx-leadership-spondyloarthritis 2021-10-05T12:44:51+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-global-resolution-biosimilar-adalimumab-patent-disputes-securing-patient-access 2021-10-05T12:44:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-new-data-from-first-direct-head-head-trial-demonstrate-superior-efficacy-gilenya-over-copaxone-patients-relapsing-remitting-multiple-sclerosis 2021-10-05T12:44:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/breadth-data-ectrims-underpins-novartis-relentless-commitment-decoding-science-multiple-sclerosis-ms-and-decreasing-patient-burden 2021-10-05T12:44:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-analysis-shows-crizanlizumab-seg101-increased-number-patients-free-sickle-cell-pain-crises-vs-placebo-during-sustain-study 2021-10-05T12:44:57+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-fda-and-ema-filing-acceptance-siponimod-first-and-only-drug-shown-meaningfully-delay-disability-progression-typical-spms-patients 2021-10-05T12:44:57+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-healthcare-access-challenge-hack-returns-seeking-digital-solutions-local-healthcare-access-challenges 2021-10-05T12:44:59+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-licenses-three-novel-anti-infective-programs-boston-pharmaceuticals 2021-10-05T12:44:59+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-five-grant-recipients-excellence-ophthalmology-vision-award-xova-nonprofit-sustainable-eye-health-initiatives 2021-10-05T12:45:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-file-new-lucentis-ranibizumab-indication-retinopathy-prematurity-rop-rare-disease-premature-infants-often-leads-blindness 2021-10-05T12:45:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-analysis-novartis-phase-iii-brolucizumab-rth258-data-reinforces-superior-reduction-retinal-fluid-key-marker-disease-activity-namd 2021-10-05T12:45:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-pegfilgrastim 2021-10-05T12:45:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-gilenya-treatment-children-and-adolescents-ms-marking-major-medical-advance-young-ms-patients-europe 2021-10-05T12:45:06+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-positive-chmp-opinion-one-time-gene-therapy-luxturna-treat-children-and-adults-rare-inherited-retinal-disease 2021-10-05T12:45:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/worlds-largest-alzheimers-survey-reveals-most-adults-believe-cure-will-be-developed-their-lifetime 2021-10-05T12:45:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/launch-alcon-experience-academy-reinforces-commitment-training-and-education-eye-care-professionals 2021-10-05T12:45:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-real-world-evidence-confirms-efficacy-and-safety-benefits-cosentyx-daily-life-psoriasis-patients 2021-10-05T12:45:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-landmark-paradigms-study-demonstrating-significant-benefit-gilenya-children-and-adolescents-ms 2021-10-05T12:45:12+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-survey-shows-psoriasis-patients-want-treatment-effect-beyond-clear-skin 2021-10-05T12:45:12+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-confirms-commitment-switzerland-ahead-proposed-spinoff-from-novartis 2021-10-05T12:45:14+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-bestatigt-vor-dem-vorgeschlagenen-spin-von-novartis-das-engagement-der-schweiz 2021-10-05T12:45:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-confirme-son-engagement-envers-la-suisse-en-perspective-de-la-scission-proposee-avec-novartis 2021-10-05T12:45:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-divest-sandoz-us-dermatology-business-and-generic-us-oral-solids-portfolio-aurobindo 2021-10-05T12:45:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/european-commission-approves-novartis-combination-therapy-tafinlar-mekinist-adjuvant-treatment-braf-v600-mutation-positive-melanoma 2021-10-05T12:45:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/alcon-announces-voluntary-global-market-withdrawal-cypass-micro-stent-surgical-glaucoma 2021-10-05T12:45:24+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-its-car-t-cell-therapy-kymriah-tisagenlecleucel 2021-10-05T12:45:26+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erhalt-die-zulassung-fur-seine-car-t-zell-therapie-kymriah-tisagenlecleucel-von-der-europaischen-kommission 2021-10-05T12:45:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-new-data-show-entresto-sacubitrilvalsartan-can-be-initiated-early-safely-hospitalized-patients-after-acute-heart-failure-episode 2021-10-05T12:45:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/solar-1-trial-novartis-investigational-alpha-specific-pi3k-inhibitor-byl719-alpelisib-meets-primary-endpoint-hrher2-advanced-breast-cancer-pik3ca-mutation 2021-10-05T12:45:32+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-appoints-dr-klaus-moosmayer-chief-ethics-risk-and-compliance-officer 2021-10-05T12:45:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-breadth-data-2019-ash-demonstrates-commitment-reimagining-medicine-hematology-through-innovative-therapeutic-platforms 2021-10-05T12:50:26+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-acquire-medicines-company-usd-97-bn-adding-inclisiran-potentially-transformational-investigational-cholesterol-lowering-therapy-address-leading-global-cause-death 2021-10-05T12:50:26+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-launches-innovation-prize-assistive-tech-encourage-new-technologies-address-unmet-needs-multiple-sclerosis-community 2021-10-05T12:50:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-paragon-hf-analyses-suggest-entresto-benefit-beyond-hfref 2021-10-05T12:50:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-medicine-adakveo-crizanlizumab-approved-fda-reduce-frequency-pain-crises-individuals-living-sickle-cell-disease 2021-10-05T12:50:30+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-mayzent-siponimod-treatment-adult-patients-active-secondary-progressive-multiple-sclerosis-spms 2021-10-05T12:50:30+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-new-strategy-provide-innovative-medicines-more-patients-sub-saharan-africa 2021-10-05T12:50:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-presents-real-world-data-showing-effectiveness-erelzi-etanercept-szzs-rheumatic-disease-treatment 2021-10-05T12:50:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-prevent-data-show-cosentyx-delivers-early-relief-axial-spondyloarthritis 2021-10-05T12:50:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-show-tropifexor-ljn452-significantly-improves-several-key-biomarkers-nash-patients-moderate-severe-fibrosis 2021-10-05T12:50:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-agreement-acquire-aspens-japanese-operations-and-associated-assets-strengthening-position-worlds-third-largest-generics-market 2021-10-05T12:50:34+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-long-acting-oncology-supportive-care-biosimilar-ziextenzotm-pegfilgrastim-bmez 2021-10-05T12:50:34+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-encouraging-results-versus-humira-from-first-its-kind-head-head-trial-psoriatic-arthritis 2021-10-05T12:50:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-avxs-101-intrathecal-study-update 2021-10-05T12:50:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-approval-cosentyx-label-update-europe-include-dosing-flexibility-ankylosing-spondylitis 2021-10-05T12:50:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-another-strong-quarter-double-digit-sales-growth-and-core1-margin-expansion-2019-sales-and-profit-guidance-raised-beovu-launched-us 2021-10-05T12:50:39+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-verzeichnet-ein-weiteres-starkes-quartal-mit-zweistelligem-umsatz-wachstum-und-hoherer-kerngewinnmarge1-umsatz-und-gewinnerwartung-fur-2019-angehoben-us-einfuhrung-von-beovu 2021-10-05T12:50:39+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-encore-un-fort-trimestre-croissance-deux-chiffres-des-ventes-et-expansion-de-la-marge-core1-hausse-des-previsions-de-chiffre-daffaires-et-de-resultat-en-2019-beovu-lance-aux-usa 2021-10-05T12:50:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-jakavi-ruxolitinib-meets-primary-endpoint-phase-iii-study-acute-graft-versus-host-disease 2021-10-05T12:50:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-show-cosentyx-treatment-results-rapid-and-sustained-resolution-signs-and-symptoms-psoriatic-arthritis-patients-and-without-enthesitis 2021-10-05T12:50:42+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-real-world-evidence-confirms-high-efficacy-long-term-response-and-favorable-safety-profile-cosentyx-clinical-practice 2021-10-05T12:50:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-show-more-patients-are-completely-symptom-free-from-chronic-spontaneous-urticaria-ligelizumab-qge031-xolair-300-mg 2021-10-05T12:50:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept 2021-10-05T12:50:45+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-presents-updated-strong-data-wms 2021-10-05T12:50:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-positive-52-week-prevent-data-confirm-cosentyx-efficacy-addressing-entire-axspa-spectrum 2021-10-05T12:50:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-microsoft-announce-collaboration-transform-medicine-artificial-intelligence 2021-10-05T12:50:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iii-palladium-study-inhaled-combination-qmf149-patients-uncontrolled-asthma 2021-10-05T12:50:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iii-iridium-study-inhaled-combination-qvm149-patients-uncontrolled-asthma 2021-10-05T12:50:51+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-delivers-consistently-superior-overall-survival-monaleesa-3-trial-demonstrates-more-life-postmenopausal-hrher2-advanced-breast-cancer-patients 2021-10-05T12:50:51+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-presents-new-data-epns-continuing-show-significant-therapeutic-benefit-zolgensma-prolonging-event-free-survival-now-5-years-age-patients-spinal-muscular-atrophy-sma-type-1 2021-10-05T12:50:52+02:00 daily 0.5 https://www.novartis.com/news/media-releases/positive-results-from-novartis-five-year-verify-study-type-2-diabetes-demonstrate-long-term-clinical-benefits-early-combination-treatment-galvus-and-metformin 2021-10-05T12:50:52+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-positive-16-week-prevent-results-advance-potential-new-indication-patients-axial-spondyloarthritis 2021-10-05T12:50:54+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-phase-iii-asclepios-trials-demonstrate-robust-efficacy-ofatumumab-patients-relapsing-multiple-sclerosis 2021-10-05T12:50:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-data-show-neuronal-and-glial-filaments-biomarkers-disease-activity-have-potential-support-decision-making-management-multiple-sclerosis-ms-patient 2021-10-05T12:50:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-data-show-mayzent-can-help-preserve-mobility-longer-patients-secondary-progressive-multiple-sclerosis-spms 2021-10-05T12:50:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-ectrims-highlight-innovative-approach-reimagining-care-people-living-multiple-sclerosis-ms 2021-10-05T12:50:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-confirm-long-term-efficacy-and-safety-aimovig-majority-patients-episodic-migraine 2021-10-05T12:50:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-investigational-lung-cancer-therapy-capmatinib-inc280-granted-fda-breakthrough-therapy-designation-patients-met-mutated-advanced-non-small-cell-lung-cancer 2021-10-05T12:50:59+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-study-shows-migraine-support-workplace-can-improve-employee-quality-life 2021-10-05T12:50:59+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-global-deal-commercialize-proposed-biosimilar-natalizumab-key-multiple-sclerosis-medicine 2021-10-05T12:51:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/entresto-improved-measures-heart-structure-and-function-hfref-patients-new-novartis-study-additional-data-complement-findings 2021-10-05T12:51:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-paragon-hf-trial-suggests-entresto-benefit-hfpef-patients-narrowly-misses-primary-endpoint 2021-10-05T12:51:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-ofatumumab-demonstrates-superiority-versus-aubagio-two-head-head-phase-iii-multiple-sclerosis-studies 2021-10-05T12:51:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-present-new-entresto-hfpef-and-hfref-data-esc-congress-2019 2021-10-05T12:51:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-will-appeal-district-court-new-jersey-ruling-biosimilar-erelzi-etanercept-szzs-us-patent-case 2021-10-05T12:51:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-stands-behind-zolgensma-onasemnogene-abeparvovec-xioi-treatment-children-less-2-years-age-spinal-muscular-atrophy 2021-10-05T12:51:06+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-significantly-prolongs-life-women-hrher2-advanced-breast-cancer-now-two-distinct-phase-iii-trials 2021-10-05T12:51:06+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-paragon-hf-trial-heart-failure-patients-preserved-ejection-fraction-hfpef 2021-10-05T12:51:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-lucentis-treatment-preterm-infants-retinopathy-prematurity-rop-disease-causing-visual-impairment-and-blindness 2021-10-05T12:51:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-first-patient-enrolled-clinical-study-proposed-biosimilar-denosumab-osteoporosis 2021-10-05T12:51:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-key-multiple-sclerosis-product-gilenya-approved-china 2021-10-05T12:51:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivers-strong-sales-double-digit-core-operating-income-growth-and-launches-zolgensma-and-piqray-second-quarter-sales-and-profit-guidance-increased 2021-10-05T12:51:11+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-au-2e-trimestre-fortes-ventes-croissance-deux-chiffres-du-resultat-operationnel-core-et-lancements-de-zolgensma-et-de-piqray-prevision-des-ventes-et-du-resultat-revue-la-hausse 2021-10-05T12:51:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-im-zweiten-quartal-starke-umsatze-eine-zweistellige-steigerung-des-operativen-kernergebnisses-und-lanciert-zolgensma-und-piqray-anhebung-der-umsatz-und-gewinnerwartung 2021-10-05T12:51:14+02:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-accepts-file-and-accelerates-review-novartis-sickle-cell-disease-medicine-crizanlizumab-seg101 2021-10-05T12:51:18+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-amgen-and-banner-alzheimers-institute-discontinue-clinical-program-bace-inhibitor-cnp520-alzheimers-prevention 2021-10-05T12:51:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-launches-oncology-generic-gefitinib-13-eu-countries-loss-market-exclusivity-expanding-access-essential-medicine 2021-10-05T12:51:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-cognition-data-secondary-progressive-multiple-sclerosis-spms 2021-10-05T12:51:22+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-xiidra-bolstering-ophthalmic-portfolio 2021-10-05T12:51:22+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-show-aimovig-cuts-acute-migraine-medication-days-half-patients-who-failed-prior-preventive-therapies 2021-10-05T12:51:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-underpin-long-term-efficacy-aimovig-where-other-treatments-have-failed 2021-10-05T12:51:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-new-publication-showing-il-17a-antibody-cosentyx-improves-inflammation-and-rapidly-suppresses-il-23-plaque-psoriasis 2021-10-05T12:51:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-phase-2b-encore-lf-trial-nash-cirrhosis 2021-10-05T12:51:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-analysis-novartis-data-confirms-cosentyx-demonstrates-durable-comprehensive-treatment-across-psoriatic-disease 2021-10-05T12:51:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-sandoz-biosimilar-adalimumab-data-confirms-switching-from-reference-biologic-has-no-impact-safety-or-efficacy 2021-10-05T12:51:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-continues-innovate-cml-long-term-treatment-free-remission-results-following-tasigna-use-and-promising-combination-data-investigational-compound-asciminib-abl001 2021-10-05T12:51:31+02:00 daily 0.5 https://www.novartis.com/news/media-releases/three-quarters-people-living-axial-spondyloarthritis-struggle-find-job-imas-survey-shows 2021-10-05T12:51:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/cosentyx-provides-long-lasting-inhibition-radiographic-progression-psoriatic-arthritis-new-novartis-data-show 2021-10-05T12:51:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-first-show-efficacy-all-key-manifestations-psoriatic-arthritis 2021-10-05T12:51:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-new-leader-pharmaceuticals-business-unit 2021-10-05T12:51:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-stellt-neue-leiterin-der-pharmaceuticals-business-unit-vor 2021-10-05T12:51:39+02:00 daily 0.5 https://www.novartis.com/news/media-releases/advanced-accelerator-applications-receives-positive-chmp-opinion-lysakare 2021-10-05T12:51:39+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-first-its-kind-histology-data-iscalimab-cfz533-suggesting-extended-survival-transplanted-organs-may-be-possible 2021-10-05T12:51:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/long-term-survival-benefit-shown-metastatic-melanoma-patients-treated-novartis-tafinlar-mekinist 2021-10-05T12:51:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-shows-growing-strength-lung-cancer-innovation-new-capmatinib-investigational-data-and-novel-canakinumab-clinical-trials 2021-10-05T12:51:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/xolair-omalizumab-significantly-reduced-nasal-polyps-and-congestion-symptoms-adults-chronic-rhinosinusitis-nasal-polyps-two-phase-iii-studies 2021-10-05T12:51:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-significantly-extends-life-women-hrher2-advanced-breast-cancer-monaleesa-7-trial 2021-10-05T12:51:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-phase-iii-quartz-study-new-investigational-inhaled-combination-treatment-qmf149-meets-primary-and-key-secondary-endpoints-patients-inadequately-controlled-asthma 2021-10-05T12:51:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-approves-novartis-piqray-first-and-only-treatment-specifically-patients-pik3ca-mutation-hrher2-advanced-breast-cancer 2021-10-05T12:51:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-announces-innovative-zolgensma-gene-therapy-access-programs-us-payers-and-families 2021-10-05T12:51:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-receives-fda-approval-zolgensma-first-and-only-gene-therapy-pediatric-patients-spinal-muscular-atrophy-sma 2021-10-05T12:51:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-company-transformation-catalyst-rich-pipeline-and-strong-progress-strategy-meet-novartis-management-investor-event 2021-10-05T12:51:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-phase-ii-data-new-inhaled-combination-treatment-qvm149-demonstrates-significant-improvements-over-current-standard-care-inhaled-treatment 2021-10-05T12:51:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-asco-and-eha-demonstrate-novel-approaches-reimagining-medicine-cancer-and-serious-blood-disorders 2021-10-05T12:51:57+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-aan-show-gilenya-first-and-only-disease-modifying-therapy-proven-superiority-versus-glatiramer-acetate-relapsing-remitting-ms 2021-10-05T12:51:57+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-demonstrates-strategic-focus-china-first-kind-generic-approval-under-quality-consistency-evaluation-system 2021-10-05T12:51:59+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-acquire-xiidra-expanding-front-eye-portfolio-and-strengthening-leadership-eye-care 2021-10-05T12:51:59+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-aan-show-mayzents-positive-impact-cognitive-processing-speed-core-element-cognitive-function-people-living-secondary-progressive-ms 2021-10-05T12:52:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-avexis-data-aan-showed-long-term-durability-zolgensma-patients-spinal-muscular-atrophy-sma-type-1 2021-10-05T12:52:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-first-its-kind-algorithm-based-tool-help-ms-patients-and-physicians-evaluate-and-discuss-early-signs-progression-secondary-progressive-ms 2021-10-05T12:52:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-presented-robust-data-aan-demonstrating-efficacy-zolgensma-broad-spectrum-spinal-muscular-atrophy-sma-patients 2021-10-05T12:52:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlight-extensive-long-term-safety-and-efficacy-data-aimovig-across-spectrum-migraine-aan 2021-10-05T12:52:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-data-aan-reinforce-novartis-commitment-transforming-lives-people-all-ages-who-live-neurological-conditions 2021-10-05T12:52:09+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-enters-agreement-proposed-trastuzumab-biosimilar-currently-phase-iii-development-treat-selected-her2-positive-cancer-tumors 2021-10-05T12:52:09+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-starts-2019-strong-sales-and-double-digit-core1-operating-income-growth-mayzent-launch-and-alcon-spin-profit-guidance-upgraded 2021-10-05T12:52:11+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-entame-2019-avec-une-forte-croissance-des-ventes-et-une-hausse-deux-chiffres-du-resultat-operationnel-core1-le-lancement-de-mayzent-et-le-spin-dalcon-profit-annuel-revu-la-hausse 2021-10-05T12:52:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-startet-2019-mit-starken-umsatzen-und-einer-zweistelligen-steigerung-des-operativen-kernergebnisses1-einfuhrung-von-mayzent-sowie-abspaltung-von-alcon-gewinnprognose-angehoben 2021-10-05T12:52:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-data-reinforce-effectiveness-zolgensma-treating-spinal-muscular-atrophy-sma-type-1 2021-10-05T12:52:15+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-fda-filing-acceptance-and-priority-review-brolucizumab-rth258-patients-wet-amd 2021-10-05T12:52:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-post-hoc-analysis-shows-high-dose-enerzair-breezhaler-reduces-asthma-exacerbations-versus-medium-dose-complementing-key-pivotal-iridium-study-findings 2021-10-05T14:27:18+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-pivotal-study-tabrectatm-patients-metex14-metastatic-non-small-cell-lung-cancer 2021-10-05T14:27:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-collaboration-between-novartis-and-africa-medical-supplies-platform-facilitate-supply-covid-19-related-medicines 2021-10-05T14:27:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-ambitious-esg-targets-increase-access-medicines-and-achieve-full-carbon-neutrality 2021-10-05T14:27:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-new-analysis-shows-high-consistency-lowering-ldl-c-individual-response-investigational-inclisiran 2021-10-05T14:27:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-ii-study-lnp023-patients-paroxysmal-nocturnal-hemoglobinuria-pnh 2021-10-05T14:27:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-investigational-novel-stamp-inhibitor-asciminib-abl001-meets-primary-endpoint-phase-iii-chronic-myeloid-leukemia-study 2021-10-05T14:27:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-evaluating-investigational-spartalizumab-pdr001-combination-tafinlar-mekinist-advanced-melanoma 2021-10-05T14:27:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-approves-novartis-kesimpta-ofatumumab-first-and-only-self-administered-targeted-b-cell-therapy-patients-relapsing-multiple-sclerosis 2021-10-05T14:27:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-us-district-court-district-delaware-upholds-validity-gilenya-fingolimod-dosage-regimen-patent 2021-10-05T14:27:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-ec-approval-new-xolair-indication-treat-severe-chronic-rhinosinusitis-nasal-polyps 2021-10-05T14:27:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-phase-iii-asclepios-trials-demonstrating-superior-efficacy-ofatumumab-patients-relapsing-multiple-sclerosis 2021-10-05T14:27:30+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-kymriah-meets-primary-endpoint-interim-analysis-pivotal-study-follicular-lymphoma 2021-10-05T14:27:32+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-eu-approval-first-line-systemic-treatment-pediatric-psoriasis 2021-10-05T14:27:32+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-piqray-approval-europe-first-and-only-targeted-medicine-hrher2-advanced-breast-cancer-pik3ca-mutation 2021-10-05T14:27:34+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-plans-joint-investment-help-strengthen-future-antibiotics-manufacturing-europe 2021-10-05T14:27:36+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-analysis-shows-wet-amd-patients-achieved-sustained-fluid-control-faster-beovu-versus-aflibercept 2021-10-05T14:27:36+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-adakveo-receives-positive-chmp-opinion-prevention-recurrent-vaso-occlusive-crises-patients-sickle-cell-disease 2021-10-05T14:27:40+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-phase-iii-study-jakavi-chronic-graft-versus-host-disease-met-primary-and-key-secondary-endpoints 2021-10-05T14:27:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-strong-h1-performance-fy-2020-guidance-confirmed-higher-end-core-operating-income-and-lower-end-sales 2021-10-05T14:27:43+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielte-im-ersten-halbjahr-eine-starke-performance-die-jahresprognose-2020-fur-das-operative-kernergebnis-bzw-den-umsatz-wurde-am-oberen-bzw-unteren-ende-fruherer-voraussagen-bestatigt 2021-10-05T14:27:45+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-realise-une-excellente-performance-au-s1-previsions-pour-2020-confirmees-dans-le-haut-de-la-fourchette-pour-le-resultat-operationnel-core-et-dans-le-bas-pour-le-chiffre-daffaires 2021-10-05T14:27:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-launches-first-its-kind-not-profit-portfolio-medicines-symptomatic-treatment-covid-19 2021-10-05T14:27:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-phase-iii-iridium-data-lancet-respiratory-medicine-show-benefit-enerzair-breezhaler-qvm149-first-class-inhaled-labalamaics-combination-uncontrolled-asthma 2021-10-05T14:27:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-ec-approval-enerzair-breezhaler-including-first-digital-companion-sensor-and-app-can-be-prescribed-alongside-treatment-uncontrolled-asthma-eu 2021-10-05T14:27:52+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-resolves-legacy-litigation-matters-finalizing-settlement-speaker-program-litigation-government-us-and-positioning-company-future-fully-scaling-its-next-generation-digital-engagement-technologies 2021-10-05T14:27:52+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-reviewing-options-after-federal-circuit-upholds-lower-court-ruling-biosimilar-erelzi-case 2021-10-05T14:27:54+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-met-inhibitor-tabrectatm-approved-japan-advanced-non-small-cell-lung-cancer-metex14 2021-10-05T14:27:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-simultaneous-approval-five-new-products-from-japanese-ministry-health-labour-and-welfare-offering-japanese-patients-broad-range-novel-treatment-options 2021-10-05T14:27:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-positive-chmp-opinion-pediatric-psoriasis-reinforcing-established-efficacy-and-safety-profile 2021-10-05T14:27:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-new-xolair-indication-treat-severe-chronic-rhinosinusitis-nasal-polyps 2021-10-05T14:27:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-resolves-legacy-fcpa-investigations 2021-10-05T14:28:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-winners-innovation-prize-assistive-tech-rewarding-new-technologies-could-improve-mobility-and-independence-people-living-multiple-sclerosis 2021-10-05T14:28:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-research-shows-technology-talent-increasingly-drawn-pharma-industry-covid-19-solve-healthcare-challenges 2021-10-05T14:28:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-discontinues-hydroxychloroquine-clinical-trial-based-slow-enrollment-remains-committed-pandemic-research-efforts 2021-10-05T14:28:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-expands-africa-sickle-cell-disease-program-uganda-and-tanzania 2021-10-05T14:28:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-new-indication-treat-active-non-radiographic-axial-spondyloarthritis 2021-10-05T14:28:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/us-fda-approves-updated-novartis-beovu-label-include-additional-safety-information 2021-10-05T14:28:11+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-phase-iiib-argon-study-meets-primary-endpoint-comparison-enerzair-breezhaler-qvm149-versus-free-combination-two-existing-inhaled-treatments-uncontrolled-asthma 2021-10-05T14:28:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-prevent-data-show-cosentyx-helps-patients-realize-early-and-lasting-relief-axial-spondyloarthritis 2021-10-05T14:28:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-fda-review-ofatumumab-self-administered-targeted-b-cell-therapy-patients-relapsing-multiple-sclerosis 2021-10-05T14:28:15+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-long-term-relapse-free-survival-benefit-high-risk-stage-iii-melanoma-patients-treated-tafinlar-mekinist-following-surgery 2021-10-05T14:28:15+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-piqray-receives-positive-chmp-opinion-treat-hrher2-advanced-breast-cancer-pik3ca-mutation 2021-10-05T14:28:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-highlight-benefit-early-treatment-initiation-patients-secondary-progressive-multiple-sclerosis-spms 2021-10-05T14:28:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-shows-overall-survival-benefit-hrher2-advanced-breast-cancer-consistent-findings-patients-more-aggressive-disease 2021-10-05T14:28:19+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-new-late-breaking-ofatumumab-data-ean-demonstrating-robust-efficacy-and-safety-treatment-relapsing-forms-multiple-sclerosis-rms 2021-10-05T14:28:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-study-reveals-migraine-support-workspace-can-significantly-decrease-impact-disease-affected-employees 2021-10-05T14:28:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-receives-ec-approval-and-activates-day-one-access-program-zolgensma-only-gene-therapy-spinal-muscular-atrophy-sma 2021-10-05T14:28:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-asco-and-eha-showcase-bold-approaches-reimagine-cancer-and-blood-disorders-through-multiple-therapeutic-platforms 2021-10-05T14:28:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-met-inhibitor-tabrectatm-metastatic-non-small-cell-lung-cancer-metex14 2021-10-05T14:28:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-chmp-positive-opinion-enerzair-breezhaler-qvm149-potential-first-class-inhaled-labalamaics-combination-uncontrolled-asthma 2021-10-05T14:28:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-fourth-indication-eu-first-class-approval-axial-spondyloarthritis-spectrum 2021-10-05T14:28:30+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-maintains-strong-operational-performance-q1-confirms-fy-2020-guidance-time-and-advances-broad-range-efforts-support-global-response-covid-19 2021-10-05T14:28:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-setzt-im-1-quartal-die-starke-operative-performance-fort-bestatigt-derzeit-die-prognose-2020-und-fordert-verschiedenste-aktivitaten-um-globale-massnahmen-gegen-covid-19-zu-unterstutzen 2021-10-05T14:28:34+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-conserve-une-forte-performance-operationnelle-au-1er-trimestre-confirme-ce-stade-les-previsions-pour-2020-et-fournit-de-grands-efforts-pour-contribuer-la-reponse-mondiale-au-covid-19 2021-10-05T14:28:36+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-data-showing-jakavi-ruxolitinib-more-effective-best-available-therapy-acute-graft-versus-host-disease 2021-10-05T14:28:39+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kymriah-receives-fda-regenerative-medicine-advanced-therapy-designation-follicular-lymphoma 2021-10-05T14:28:40+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-new-mayzent-siponimod-data-show-sustained-effect-delaying-disability-five-years-patients-secondary-progressive-multiple-sclerosis-spms 2021-10-05T14:28:42+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-sponsor-large-clinical-trial-hydroxychloroquine-hospitalized-covid-19-patients 2021-10-05T14:28:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-acquires-amblyotech-pursuing-novel-digital-therapy-children-and-adult-patients-lazy-eye 2021-10-05T14:28:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-data-neurology-reinforcing-real-world-and-long-term-effectiveness-and-safety-aimovig-preventive-treatment-across-full-spectrum-migraine 2021-10-05T14:28:46+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-plan-initiate-clinical-study-jakavi-severe-covid-19-patients-and-establish-international-compassionate-use-program 2021-10-05T14:28:46+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-mutual-agreement-terminate-sale-sandoz-us-generic-oral-solids-dermatology-portfolio-aurobindo 2021-10-05T14:28:48+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-new-analysis-further-shows-durable-and-potent-ldl-c-reduction-inclisiran-investigational-first-class-sirna-cholesterol-lowering-treatment 2021-10-05T14:28:48+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-positive-chmp-opinion-new-indication-axial-spondyloarthritis-spectrum 2021-10-05T14:28:51+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-receives-positive-chmp-opinion-zolgensma-only-gene-therapy-spinal-muscular-atrophy-sma 2021-10-05T14:28:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-life-sciences-companies-commit-expertise-and-assets-fight-against-covid-19-pandemic-alongside-bill-melinda-gates-foundation 2021-10-05T14:28:53+02:00 daily 0.5 https://www.novartis.com/news/media-releases/zolgensma-data-shows-rapid-significant-clinically-meaningful-benefit-sma-including-prolonged-event-free-survival-motor-milestone-achievement-and-durability-now-5-years-post-dosing 2021-10-05T14:28:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-presents-avxs-101-it-data-demonstrating-remarkable-increases-hfmse-scores-and-consistent-clinically-meaningful-response-older-patients-sma-type-2 2021-10-05T14:28:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-commits-donate-130-million-doses-hydroxychloroquine-support-global-covid-19-pandemic-response 2021-10-05T14:29:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-approval-from-japanese-ministry-health-labour-and-welfare-zolgensma-only-gene-therapy-patients-spinal-muscular-atrophy-sma 2021-10-05T14:29:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-three-pivotal-trials-showing-durable-and-potent-efficacy-inclisiran-investigational-first-class-sirna-cholesterol-lowering-therapy 2021-10-05T14:29:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-broad-range-initiatives-respond-covid-19-pandemic-creates-usd-20-million-global-fund-support-impacted-communities 2021-10-05T14:29:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/international-research-partnership-and-edctp-invest-eu44m-next-generation-antimalarials-combat-drug-resistant-malaria-africa 2021-10-05T14:29:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-resolves-generic-drug-antitrust-investigation-us 2021-10-05T14:29:06+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-2 2021-10-05T14:29:06+02:00 daily 0.5 https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lassemblee-generale-annuelle 2021-10-05T14:29:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-dndi-collaborate-development-new-oral-drug-treat-visceral-leishmaniasis 2021-10-05T14:29:12+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-fda-and-ema-filing-acceptance-ofatumumab-novel-b-cell-therapy-patients-relapsing-forms-multiple-sclerosis-rms 2021-10-05T14:29:12+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-ec-approval-beovu-next-generation-anti-vegf-treatment-wet-amd-leading-cause-blindness-worldwide 2021-10-05T14:29:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-met-inhibitor-capmatinib-inc280-first-potential-treatment-metex14-mutated-advanced-non-small-cell-lung-cancer-granted-priority-fda-review 2021-10-05T14:29:15+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-completes-acquisition-aspens-japanese-operations-strengthening-its-position-worlds-third-largest-market-generics-and-patent-medicines 2021-10-05T14:29:15+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-builds-its-axspa-leadership-us-label-update-dosing-flexibility-ankylosing-spondylitis 2021-10-05T14:29:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-strong-sales-growth-margin-expansion-and-breakthrough-innovation-launching-five-nmes-2019 2021-10-05T14:29:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-2019-ein-starkes-umsatzwachstum-margen-steigerungen-und-bahnbrechende-innovationen-mit-der-markteinfuhrung-funf-neuer-wirkstoffe 2021-10-05T14:29:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-realise-en-2019-une-forte-croissance-de-son-chiffre-daffaires-une-augmentation-de-sa-marge-et-une-percee-dans-linnovation-en-lancant-cinq-nouvelles-entites-moleculaires 2021-10-05T14:29:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-eu-approval-mayzent-siponimod-adult-patients-secondary-progressive-multiple-sclerosis-spms-active-disease 2021-10-05T14:29:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-ligelizumab-qge031-more-effective-xolair-inhibiting-immunoglobulin-e-pathway-responsible-chronic-spontaneous-urticaria 2021-10-05T14:29:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-medicines-company-adding-potentially-first-class-investigational-cholesterol-lowering-therapy-inclisiran 2021-10-05T14:29:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-completes-tender-offer-all-outstanding-shares-medicines-company 2021-10-05T14:29:27+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-luster-phase-iii-studies-patients-uncontrolled-gina-45-asthma 2021-10-05T14:29:29+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-beovu-brolucizumab-treatment-wet-amd 2021-10-05T14:29:30+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-data-show-superior-overall-survival-compared-fulvestrant-and-consistent-efficacy-across-advanced-breast-cancer-patient-subgroups-monaleesa-3 2021-10-05T14:29:30+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kymriah-demonstrates-consistent-efficacy-and-safety-outcomes-us-patients-when-used-real-world-setting 2021-10-05T14:29:32+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-global-survey-uncovers-profound-and-often-under-reported-effects-sickle-cell-disease-patients 2021-10-05T14:29:33+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-phase-iii-data-new-inhaled-dual-combination-qmf149-show-significant-improvement-across-key-asthma-outcomes-versus-monotherapy 2021-10-05T14:29:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-tender-offer-medicines-company-commences 2021-10-05T14:29:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-investigational-oral-therapy-iptacopan-lnp023-shows-benefit-monotherapy-treatment-naive-patients-rare-and-life-threatening-blood-disorder-paroxysmal-nocturnal-hemoglobinuria 2021-10-05T14:32:11+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-new-interim-analysis-phase-ii-data-iptacopan-rare-kidney-disease-c3-glomerulopathy-c3g 2021-10-05T14:32:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-iptacopan-met-phase-ii-study-primary-endpoint-rare-kidney-disease-iga-nephropathy-igan 2021-10-05T14:32:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-tabrecta-first-published-overall-survival-and-updated-overall-response-data-patients-metex14-metastatic-nsclc 2021-10-05T14:32:15+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-investigational-checkpoint-inhibitor-tislelizumab-met-primary-endpoint-overall-survival-pivotal-phase-iii-trial-esophageal-cancer-after-systemic-therapy 2021-10-05T14:32:15+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-reports-clinically-relevant-improvement-median-overall-survival-data-final-analysis-pivotal-netter-1-study-targeted-radioligand-therapy-lutathera 2021-10-05T14:32:16+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-177lu-psma-617-significantly-improves-overall-survival-and-radiographic-progression-free-survival-men-metastatic-castration-resistant-prostate-cancer-phase-iii-vision-study 2021-10-05T14:32:18+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kymriah-pivotal-trial-demonstrates-strong-response-rates-and-remarkable-safety-profile-relapsed-or-refractory-follicular-lymphoma 2021-10-05T14:32:18+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-reports-longest-median-overall-survival-postmenopausal-hrher2-metastatic-breast-cancer-patients 2021-10-05T14:32:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-positive-phase-iii-results-from-junipera-study-supporting-cosentyx-potential-treatment-jia-population-eular-2021 2021-10-05T14:32:20+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-moderate-severe-plaque-psoriasis 2021-10-05T14:32:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-reports-one-year-results-phase-iii-merlin-study-evaluating-beovu-every-four-week-dosing-and-provides-update-beovu-clinical-program 2021-10-05T14:32:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-molecular-partners-announce-start-empathy-clinical-trial-ensovibep-treatment-covid-19 2021-10-05T14:32:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-unveil-new-data-asco-and-eha-from-its-robust-portfolio-including-overall-survival-prostate-and-breast-cancer 2021-10-05T14:32:23+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-plans-further-strengthen-its-antibiotics-manufacturing-setup-europe 2021-10-05T14:32:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-reaches-milestone-delivery-1-billion-courses-antimalarial-treatment 2021-10-05T14:32:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/us-supreme-court-denies-sandoz-petition-review-biosimilar-erelzi-etanercept-szzs-case 2021-10-05T14:32:26+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-confirms-late-stage-clinical-development-plans-proposed-biosimilar-aflibercept-key-ophthalmology-medicine 2021-10-05T14:32:26+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-phase-iii-beovu-data-show-potential-fluid-resolution-more-diabetic-macular-edema-patients-fewer-injections-versus-aflibercept 2021-10-05T14:32:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-key-growth-drivers-and-launches-continue-momentum-q1-maintaining-confidence-growth-group-guidance-fy-2021-confirmed 2021-10-05T14:32:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-moteurs-cles-de-la-croissance-et-lancements-poursuivent-leur-essor-au-1er-trimestre-maintenant-la-confiance-dans-la-croissance-confirmation-des-previsions-pour-le-groupe-pour-2021 2021-10-05T14:32:30+02:00 daily 0.5 https://www.novartis.com/news/media-releases/wichtige-wachstumstreiber-und-neueinfuhrungen-von-novartis-setzen-ihre-dynamik-im-ersten-quartal-fort-und-erhalten-das-vertrauen-das-wachstum-konzernprognose-fur-2021-bestatigt 2021-10-05T14:32:34+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-initiate-smart-phase-3b-global-study-zolgensma-children-21-kg-building-real-world-experience 2021-10-05T14:32:34+02:00 daily 0.5 https://www.novartis.com/news/media-releases/kesimpta-ofatumumab-data-aan-showed-reduction-disability-progression-independent-relapse-activity-newly-diagnosed-patients-rms 2021-10-05T14:32:36+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-signs-initial-agreement-reserve-capacity-and-implement-technology-transfer-production-active-pharmaceutical-ingredient-roches-actemraroactemra 2021-10-05T14:32:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-kesimpta-ofatumumab-first-and-only-self-administered-targeted-b-cell-therapy-adult-patients-relapsing-multiple-sclerosis 2021-10-05T14:32:37+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-expands-targeted-radioligand-therapy-pipeline-license-compounds-targeting-fibroblast-activation-protein-fap 2021-10-05T14:32:39+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-positive-result-phase-iii-study-radioligand-therapy-177lu-psma-617-patients-advanced-prostate-cancer 2021-10-05T14:32:39+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-appoints-karen-hale-chief-legal-officer 2021-10-05T14:32:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-zolgensma-data-demonstrate-age-appropriate-development-when-used-early-real-world-benefit-older-children-and-durability-5-years-post-treatment 2021-10-05T14:32:41+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-evaluating-canakinumab-acz885-second-or-third-line-treatment-combination-chemotherapy-non-small-cell-lung-cancer 2021-10-05T14:32:42+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-change-executive-committee 2021-10-05T14:32:42+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-signs-initial-agreement-curevac-manufacture-covid-19-vaccine-candidate 2021-10-05T14:32:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-3 2021-10-05T14:32:44+02:00 daily 0.5 https://www.novartis.com/news/media-releases/die-aktionare-von-novartis-heissen-der-generalversammlung-alle-antrage-des-verwaltungsrats-gut 2021-10-05T14:32:46+02:00 daily 0.5 https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-annuelle-0 2021-10-05T14:32:46+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-strengthens-oncology-pipeline-successful-closing-tislelizumab-licensing 2021-10-05T14:32:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-eu-label-update-first-its-kind-maximise-data-axial-manifestations-psoriatic-arthritis 2021-10-05T14:32:47+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-bill-melinda-gates-foundation-collaborate-discover-and-develop-accessible-vivo-gene-therapy-sickle-cell-disease 2021-10-05T14:32:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-entresto-granted-expanded-indication-chronic-heart-failure-fda 2021-10-05T14:32:49+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-show-multiple-sclerosis-patients-and-nurses-prefer-kesimpta-ofatumumab-sensoready-autoinjector-pen 2021-10-05T14:32:50+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-agreement-acquire-gsks-cephalosporin-antibiotics-business-reinforcing-its-leading-global-position-antibiotics 2021-10-05T14:32:50+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-fda-breakthrough-therapy-designations-investigational-stamp-inhibitor-asciminib-abl001-chronic-myeloid-leukemia 2021-10-05T14:32:52+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-kesimpta-ofatumumab-self-administered-treatment-adult-patients-relapsing-multiple-sclerosis 2021-10-05T14:32:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-signs-initial-agreement-provide-manufacturing-capacity-pfizer-biontech-covid-19-vaccine 2021-10-05T14:32:55+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-renews-who-medicine-donation-pledge-aim-ending-leprosy 2021-10-05T14:32:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-sales-growth-and-margin-expansion-continued-progress-its-next-wave-medicines-2020 2021-10-05T14:32:56+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-hat-2020-umsatz-und-margen-gesteigert-und-die-nachste-welle-von-medikamenten-weiter-vorangetrieben 2021-10-05T14:32:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/en-2020-novartis-enregistre-une-croissance-de-son-chiffre-daffaires-et-de-sa-marge-il-continue-de-faire-progresser-sa-prochaine-vague-de-medicaments 2021-10-05T14:33:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-gsk-announce-collaboration-support-scientific-research-genetic-diversity-africa 2021-10-05T14:33:01+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-ligelizumab-qge031-receives-fda-breakthrough-therapy-designation-patients-chronic-spontaneous-urticaria-csu 2021-10-05T14:33:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-expands-oncology-pipeline-licensing-tislelizumab-from-beigene 2021-10-05T14:33:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-complete-response-letter-from-us-fda-inclisiran 2021-10-05T14:33:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-builds-commitment-addressing-need-neuropsychiatric-disorders-cadent-therapeutics-acquisition 2021-10-05T14:33:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-investigational-oral-therapy-iptacopan-lnp023-receives-fda-breakthrough-therapy-designation-pnh-and-rare-pediatric-disease-designation-c3g 2021-10-05T14:33:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-positive-fda-advisory-committee-recommendation-use-entresto-treat-patients-hfpef 2021-10-05T14:33:09+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-reports-positive-topline-results-from-second-phase-iii-trial-beovu-patients-diabetic-macular-edema 2021-10-05T14:33:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-ruxcovid-study-ruxolitinib-hospitalized-patients-covid-19 2021-10-05T14:33:12+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-leqvio-inclisiran-first-class-sirna-lower-cholesterol-two-doses-year 2021-10-05T14:33:14+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-data-demonstrate-superior-benefit-across-main-intrinsic-subtypes-metastatic-breast-cancer 2021-10-05T14:33:15+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-demonstrates-nearly-five-years-median-overall-survival-metastatic-breast-cancer 2021-10-05T14:33:15+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-investigational-stamp-inhibitor-asciminib-abl001-shows-superior-mmr-rate-bosulif-chronic-myeloid-leukemia-trial 2021-10-05T14:33:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-analyses-confirm-benefit-kymriah-clinically-meaningful-rates-complete-response-seen-patients-certain-advanced-lymphomas 2021-10-05T14:33:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-first-data-from-reach3-trial-showing-jakavi-ruxolitinib-significantly-improved-outcomes-patients-steroid-resistantdependent-chronic-gvhd 2021-10-05T14:33:19+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-confidence-growing-sales-margin-expansion-fueled-market-brands-and-rich-pipeline-annual-meet-management-investor-event 2021-10-05T14:33:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-secures-exclusive-rights-potential-acute-respiratory-distress-syndrome-cell-therapy 2021-10-05T14:33:22+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-data-ash-reinforce-breadth-novartis-hematology-portfolio-across-multiple-blood-cancers-and-serious-hematologic-diseases 2021-10-05T14:33:22+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-set-achieve-100-renewable-electricity-its-european-operations 2021-10-05T14:33:24+02:00 daily 0.5 https://www.novartis.com/news/media-releases/results-from-real-world-data-and-post-hoc-analysis-novartis-beovu-pivotal-trials-presented-aao-2020 2021-10-05T14:33:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-analyses-investigational-inclisiran-demonstrate-consistently-effective-and-sustained-ldl-c-reduction-month-17-regardless-age-and-gender 2021-10-05T14:33:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-can-covid-trial-hospitalized-patients-covid-19-pneumonia-and-cytokine-release-syndrome-crs 2021-10-05T14:33:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-early-synovitis-reduction-patients-psoriatic-arthritis-first-its-kind-study 2021-10-05T14:33:28+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iv-study-showing-superior-tolerability-and-efficacy-aimovig-erenumab-compared-topiramate-migraine-prevention 2021-10-05T14:33:30+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-sickle-cell-medicine-adakveo-approved-europe-prevent-recurrent-vaso-occlusive-crises 2021-10-05T14:33:30+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-expands-kymriah-manufacturing-footprint-first-ever-approved-site-commercial-car-t-cell-therapy-manufacturing-asia 2021-10-05T14:33:32+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-latest-phase-iii-data-reinforcing-cosentyx-first-line-systemic-treatment-pediatric-psoriasis 2021-10-05T14:33:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-acquires-vedere-bio-adding-novel-optogenetic-gene-therapy-technology-treating-blindness 2021-10-05T14:33:35+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-collaboration-molecular-partners-develop-two-darpin-therapies-designed-potential-use-against-covid-19 2021-10-05T14:33:36+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivers-solid-q3-performance-11-core-operating-income-growth-net-sales-line-prior-year-strong-pipeline-progression-upgrades-full-year-core-operating-income-guidance 2021-10-05T14:33:38+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-im-3-qu-mit-solider-performance-operatives-kernergebnis-steigt-um-11-nettoumsatz-auf-vorjahresniveau-starke-pipeline-fortschritte-jahresprognose-fur-operatives-kernergebnis-angehoben 2021-10-05T14:33:39+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-au-t3-performance-solide-croissance-de-11-du-resultat-operationnel-core-chiffre-daffaires-net-proche-de-lan-dernier-pipeline-en-fort-progres-hausse-du-resultat-operationnel-core-prevu 2021-10-05T14:33:51+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-promising-interim-phase-ii-data-potential-first-class-oral-therapy-iptacopan-lnp023-rare-renal-disease-c3-glomerulopathy-c3g 2021-10-05T14:33:59+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-european-medicines-agency-ema-has-granted-orphan-drug-designation-iptacopan-lnp023-iga-nephropathy-igan 2021-10-05T14:34:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-us-food-and-drug-administration-fda-orphan-drug-designation-branaplam-lmi070-huntingtons-disease-hd 2021-10-05T14:34:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-leqvio-inclisiran-potential-first-class-sirna-treatment-high-cholesterol 2021-10-05T14:34:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-received-european-medicines-agency-ema-prime-designation-iptacopan-lnp-c3-glomerulopathy-c3g 2021-10-05T14:34:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-phase-iii-analysis-demonstrates-novartis-beovu-showed-improvement-best-corrected-visual-acuity-wet-amd-patients-early-persistent-fluid 2021-10-05T14:34:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/zolgensma-data-including-patients-more-severe-sma-baseline-further-demonstrate-therapeutic-benefit-including-prolonged-event-free-survival-increased-motor-function-and-milestone-achievement 2021-10-05T14:34:06+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-avxs-101-intrathecal-clinical-development-program 2021-10-05T14:34:08+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-receives-highest-rating-any-cdk46-inhibitor-esmo-magnitude-clinical-benefit-scale 2021-10-05T14:34:10+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-piqray-data-show-survival-benefit-patients-hrher2-advanced-breast-cancer-pik3ca-mutation 2021-10-05T14:34:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-reports-late-breaking-data-from-phase-iii-combi-i-trial-spartalizumab-pdr001-tafinlar-and-mekinist-advanced-melanoma 2021-10-05T14:34:13+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-tafinlar-mekinist-demonstrates-long-term-relapse-free-survival-benefit-high-risk-stage-iii-melanoma-patients-study-published-nejm 2021-10-05T14:34:16+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-reinforces-commitment-patient-access-pricing-eur-185-billion-sustainability-linked-bond 2021-10-05T14:34:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/european-medicines-agency-ema-approves-safety-label-update-novartis-beovu 2021-10-05T14:34:17+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-reports-positive-topline-results-from-first-phase-iii-trial-beovu-versus-aflibercept-patients-diabetic-macular-edema-dme 2021-10-05T14:34:19+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-show-early-treatment-mayzent-siponimod-delays-disability-progression-and-show-benefits-cognitive-performance-patients-secondary-progressive-multiple-sclerosis-spms 2021-10-05T14:34:21+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-data-actrims-ectrims-kesimpta-ofatumumab-newly-diagnosed-treatment-naive-adults-relapsing-multiple-sclerosis 2021-10-05T14:34:22+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-actrims-ectrims-highlight-strength-leading-multiple-sclerosis-ms-portfolio-life-changing-therapies-people-across-ms-spectrum 2021-10-05T14:34:24+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-community-statement-global-managed-access-program-avxs-101 2021-10-06T12:17:57+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-community-statement-coronavirus-disease-covid-19 2021-10-06T12:17:57+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-community-statement-global-managed-access-program-avxs-101-0 2021-10-06T12:17:57+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-statement-changes-senior-leadership-team 2021-10-06T12:17:57+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-statement-access-zolgensma-onasemnogene-abeparvovec-xioi 2021-10-06T12:17:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-reports-first-quarter-2018-financial-and-operating-results 2021-10-06T12:17:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-announces-first-patient-dosed-phase-3-trial-avxs-101-pre-symptomatic-sma-types-1-2-and-3 2021-10-06T12:17:58+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-presents-initial-data-from-pivotal-us-trial-sma-type-1-and-24-month-follow-data-from-phase-1-trial-avxs-101-sma-type-1-annual-meeting-american-academy-neurology 2021-10-06T12:18:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-present-avxs-101-data-annual-meeting-american-academy-neurology 2021-10-06T12:18:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-gene-therapy-awarded-sakigake-designation-spinal-muscular-atrophy-type-1 2021-10-06T12:18:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-enters-licensing-agreement-genethon 2021-10-06T12:18:00+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-reports-fourth-quarter-and-full-year-2017-financial-and-operating-results 2021-10-06T12:18:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-report-fourth-quarter-and-full-year-2017-financial-and-operating-results 2021-10-06T12:18:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-initiate-screening-remaining-patients-pivotal-trial-avxs-101-sma-type-1-following-review-preliminary-data-from-first-three-patients 2021-10-06T12:18:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-announces-closing-public-offering-common-stock-and-full-exercise-underwriters-option-purchase-additional-shares 2021-10-06T12:18:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-announces-pricing-public-offering-common-stock 2021-10-06T12:18:04+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-announces-proposed-public-offering-common-stock 2021-10-06T12:18:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-announces-expanded-clinical-development-program-avxs-101-spinal-muscular-atrophy 2021-10-06T12:18:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/regenxbio-and-avexis-announce-expansion-relationship-through-amended-license-agreement-development-and-commercialization-treatments-spinal-muscular-atrophy 2021-10-06T12:18:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/avexis-announces-alignment-fda-next-steps-toward-bla-submission-avxs-101-sma-type-1 2021-10-06T12:18:07+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-expects-sustain-long-term-growth-robust-pipeline-25-potential-blockbusters-highlighted-rd-day 2021-10-06T17:07:25+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-present-broad-range-portfolio-data-ectrims-reinforcing-long-standing-commitment-people-living-multiple-sclerosis 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-resolves-legacy-federal-government-civil-investigation-us-regarding-generic-drugs 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-show-rapid-and-effective-disease-activity-control-remibrutinib-lou064-patients-chronic-spontaneous-urticaria 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-accelerates-efforts-toward-esg-targets-increase-access-medicines-improve-health-equity-and-achieve-net-zero-carbon-emissions 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-report-positive-results-phase-2b-study-novel-ganaplacidelumefantrine-combination-children-malaria 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/new-data-reinforce-efficacy-and-convenience-novartis-cosentyx-secukinumab-300-mg-autoinjector-adults-psoriasis 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-show-achieving-complete-control-chronic-spontaneous-urticaria-csu-improves-overall-quality-life-reported-patients 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-acquires-arctos-medical-expanding-optogenetics-portfolio-bring-gene-therapies-patients-severe-vision-loss 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-acquiert-arctos-medical-elargissant-ainsi-son-portefeuille-doptogenetique-afin-de-proposer-des-therapies-geniques-aux-patients-souffrant-dune-severe-perte-de-la-vision 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-ubernimmt-arctos-medical-und-erweitert-damit-ihr-optogenetik-portfolio-um-patientinnen-und-patienten-mit-einem-schwerem-verlust-des-sehvermogens-gentherapien-anbieten-zu-konnen 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-collaboration-harmonia-phase-iii-head-head-trial-evaluating-kisqali-vs-ibrance-patients-hrher2-advanced-breast-cancer 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-kisqali-data-showing-longest-median-overall-survival-ever-reported-hrher2-advanced-breast-cancer 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-findings-from-real-world-study-alpelisib-demonstrating-clinical-benefit-people-pik3ca-related-overgrowth-spectrum-pros 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-reports-positive-health-related-quality-life-data-177lu-psma-617-radioligand-therapy-patients-advanced-prostate-cancer-esmo-2021 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-first-fda-filing-acceptance-anti-pd-1-antibody-tislelizumab-people-esophageal-cancer 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-strengthens-pipeline-entering-agreement-biosimilar-bevacizumab-key-oncology-medicine 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-findings-ers-reinforcing-efficacy-enerzair-breezhaler-highlighting-its-digital-companion-well-showcasing-commitment-low-carbon-footprint-asthma-solutions 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/world-first-agreement-between-novartis-and-nhs-enables-broad-and-rapid-access-first-class-cholesterol-lowering-medicine-leqvio-vinclisiran 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-leqvio-inclisiran-analyses-show-effective-and-sustained-ldl-c-reduction-two-sub-populations-patients-ascvd 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-important-overall-survival-and-quality-life-results-across-solid-tumor-portfolio-among-other-key-data-esmo 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-belinda-study-investigating-kymriah-second-line-treatment-aggressive-b-cell-non-hodgkin-lymphoma 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-secures-new-approval-china-cosentyx-secukinumab-pediatric-psoriasis 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iii-trials-beovu-diabetic-macular-edema-including-dosing-intervals-16-weeks 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-lift-partial-clinical-trial-hold-and-plans-initiate-new-pivotal-phase-3-study-intrathecal-oav-101-older-patients-sma 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivered-strong-q2-performance-driven-momentum-key-growth-brands-fy-2021-guidance-unchanged 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-forte-performance-au-deuxieme-trimestre-soutenue-par-la-dynamique-des-marques-cles-de-croissance-previsions-pour-lexercice-2021-inchangees 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-hat-im-zweiten-quartal-dank-der-dynamik-wichtiger-wachstums-marken-eine-starke-performance-erzielt-prognose-fur-2021-unverandert 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-pledges-10-year-commitment-morehouse-school-medicine-26-historically-black-colleges-universities-medical-schools-and-other-leading-organizations-co-create-effective-measurable-solutions-health-equity 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-positive-phase-iii-reach3-data-jakavi-chronic-gvhd 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-appoints-rob-kowalski-chief-people-organization-officer 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-eu-launch-ready-dilute-generic-pemetrexed-treat-most-prevalent-form-lung-cancer 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/positive-survival-data-novartis-investigational-radioligand-therapy-177lu-psma-617-published-new-england-journal-medicine 2021-12-02T12:33:04+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-hewlett-packard-enterprise-join-forces-advance-novartis-global-health-efforts 2021-12-02T18:33:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/kesimpta-ofatumumab-data-show-long-term-preservation-iggigm-levels-and-no-increased-risk-serious-infections-people-living-multiple-sclerosis 2021-12-03T22:33:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/new-zolgensma-data-demonstrate-age-appropriate-development-when-used-presymptomatically-and-rapid-clinically-meaningful-efficacy-symptomatic-children-even-those-severe-sma-baseline 2021-12-04T11:03:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-completes-acquisition-gsks-cephalosporin-business-reinforcing-leading-global-position-antibiotics 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-fda-and-ema-filing-acceptances-beovu-patients-diabetic-macular-edema 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/kesimpta-ofatumumab-data-ectrims-highlights-preservation-igg-levels-and-safety-experience-over-extended-exposure-35-years-people-living-relapsing-multiple-sclerosis 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/global-heart-hub-and-novartis-partner-tackle-ascvd-global-health-crisis-and-worlds-1-killer 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-signs-new-initial-agreement-biontech-support-fill-and-finish-mrna-pfizer-biontech-covid-19-vaccine 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-top-line-results-canopy-1-phase-iii-study-support-further-evaluation-canakinumab-lung-cancer 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivers-solid-q3-results-strong-growth-innovative-medicines-announces-strategic-review-sandoz 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-realise-de-solides-resultats-au-3e-trimestre-avec-une-forte-croissance-dinnovative-medicines-et-annonce-un-examen-strategique-de-sandoz 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-im-dritten-quartal-solide-ergebnisse-mit-starkem-wachstum-bei-innovative-medicines-das-unternehmen-kundigt-eine-strategische-uberprufung-von-sandoz 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-priority-review-us-fda-and-filing-acceptance-ema-kymriah-treat-patients-relapsed-or-refractory-follicular-lymphoma 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-approves-novartis-scemblix-asciminib-novel-mechanism-action-treatment-chronic-myeloid-leukemia 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-sell-its-roche-stake-bilateral-transaction-roche 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-verkauft-ihre-roche-beteiligung-einer-bilateralen-transaktion-roche 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/new-data-ash-spotlight-novartis-recently-approved-scemblix-next-generation-car-t-platform-and-expanding-hematology-portfolio 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-iptacopan-meets-primary-endpoints-phase-ii-study-rare-kidney-disease-c3-glomerulopathy-c3g 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/leqvio-inclisiran-reduced-ldl-c-people-who-are-overweight-or-obese 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-new-publication-cephalalgia-data-showcasing-superior-tolerability-and-efficacy-aimovig-erenumab-compared-topiramate-migraine-prevention 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-positive-phase-iii-results-cosentyx-children-active-enthesitis-related-arthritis-era-and-juvenile-psoriatic-arthritis-jpsa-acr-2021 2021-12-02T12:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-rd-day-spotlights-attractive-growth-profile-underpinned-strong-market-brands-20-potential-high-value-pipeline-assets-and-technology-platforms 2021-12-06T17:48:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/bilateral-transaction-between-novartis-and-roche-successfully-closed 2021-12-06T17:48:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/new-kisqali-data-shows-consistent-overall-survival-benefit-across-genomic-and-clinical-subtypes-interest-hrher2-metastatic-breast-cancer 2021-12-08T15:33:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-year-two-phase-iii-trial-beovu-diabetic-macular-edema 2021-12-09T16:48:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-highlight-efficacy-piqray-hrher2-metastatic-breast-cancer-pik3ca-driver-mutation-immediately-post-cdk46i 2021-12-10T14:03:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kymriah-demonstrates-strong-responses-high-risk-patients-relapsed-or-refractory-follicular-lymphoma-extended-study-follow 2021-12-11T18:03:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-scemblix-demonstrates-sustained-response-rate-48-week-follow-patients-chronic-myeloid-leukemia 2021-12-11T22:03:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-t-chargetm-next-generation-car-t-platform-first-human-data-ash-2021 2021-12-13T20:48:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-initiates-new-usd-15-billion-share-buyback-highlighting-confidence-growth-and-pipeline 2021-12-16T07:03:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-ligelizumab-qge031-studies-chronic-spontaneous-urticaria-csu 2021-12-20T07:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-strengthens-immunotherapy-pipeline-option-collaboration-and-license-agreement-beigene-tigit-inhibitor-ociperlimab 2021-12-20T12:18:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-submits-biologics-license-application-proposed-biosimilar-trastuzumab-us-fda 2021-12-20T22:18:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-submits-marketing-authorization-application-proposed-biosimilar-trastuzumab-ema 2021-12-22T07:18:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-acquire-gyroscope-therapeutics-adding-one-time-gene-therapy-could-transform-care-geographic-atrophy-leading-cause-blindness 2021-12-22T08:03:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-approves-novartis-leqvio-inclisiran-first-class-sirna-lower-cholesterol-and-keep-it-low-two-doses-year 2021-12-22T22:18:04+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-enthesitis-related-arthritis-and-psoriatic-arthritis 2021-12-23T00:03:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-4 2022-03-03T13:19:05+01:00 daily 0.5 https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-annuelle-1 2022-03-03T13:19:05+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-entresto-granted-expanded-indication-chronic-heart-failure-fda-0 2022-03-03T13:19:05+01:00 daily 0.5 https://www.novartis.com/news/media-releases/new-peer-reviewed-research-shows-no-increased-risk-serious-covid-19-infections-kesimpta-ofatumumab-treated-adults-multiple-sclerosis 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-targets-growth-opportunities-respiratory-and-complex-generics-through-acquisition-respiratory-device-company-coalesce 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-again-demonstrate-age-appropriate-development-when-zolgensma-used-presymptomatically-and-post-hoc-data-reveal-sma-type-1-patients-could-speak-swallow-and-maintain-airway-protection 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-signs-initial-agreement-carisma-therapeutics-manufacturing-her-2-targeted-car-m-cell-therapy 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/nejm-publication-novartis-kisqali-data-shows-longest-median-overall-survival-ever-reported-hrher2-advanced-breast-cancer 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-voyager-therapeutics-reach-license-option-agreement-next-generation-gene-therapy-vectors-neurological-diseases 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-5 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-ordinaire 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-heissen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats-gut 2022-06-29T02:04:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-peer-reviewed-safety-and-tolerability-data-further-strengthens-kesimptas-ofatumumab-favorable-benefit-risk-profile-patients-relapsing-multiple-sclerosis 2022-06-30T00:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-launches-generic-lenalidomide-19-countries-across-europe-expanding-access-essential-oncology-medicine 2022-06-30T00:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivers-mid-single-digit-sales-growth-margin-expansion-and-advancement-robust-pipeline-2021 2022-06-30T00:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-enregistre-en-2021-une-croissance-du-chiffre-daffaires-net-un-chiffre-dans-le-milieu-de-la-fourchette-une-expansion-de-la-marge-et-une-avancee-du-robuste-pipeline 2022-06-30T00:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-2021-ein-umsatzwachstum-im-mittleren-einstelligen-bereich-verbessert-die-margen-und-treibt-die-solide-pipeline-voran 2022-06-30T00:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-molecular-partners-report-positive-topline-data-from-phase-2-study-ensovibep-mp0420-darpin-antiviral-therapeutic-covid-19 2022-06-30T00:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-collaboration-alnylam-explore-targeted-therapy-restore-liver-function 2022-06-30T00:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-us-court-appeals-federal-circuit-cafc-upholds-validity-gilenya-fingolimod-dosage-regimen-patent 2022-06-30T00:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-jakavi-treat-acute-and-chronic-graft-versus-host-disease 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-kymriah-car-t-cell-therapy-adult-patients-relapsed-or-refractory-follicular-lymphoma-europe 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-european-commission-approval-beovu-people-living-diabetic-macular-edema 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-new-organizational-structure-accelerate-growth-strengthen-pipeline-and-increase-productivity 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-gibt-neue-organisationsstruktur-bekannt-fur-schnelleres-wachstum-eine-starkere-pipeline-und-hohere-produktivitat 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-four-year-data-efficacy-and-safety-kesimpta-ofatumumab-people-living-relapsing-multiple-sclerosis 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-expands-zolgensma-manufacturing-capacity-approval-multi-product-north-carolina-facility 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-approves-novartis-vijoice-alpelisib-first-and-only-treatment-select-patients-pik3ca-related-overgrowth-spectrum-pros 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-extends-collaboration-agreement-drive-cutting-edge-digital-solutions-global-fight-against-antimicrobial-resistance-amr 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-anti-pd-1-tislelizumab-accepted-ema-regulatory-review-esophageal-and-lung-cancers 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-early-clinical-data-unique-krasg12c-inhibitor-american-association-cancer-research-annual-meeting 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-launches-generic-brimonidine-tartratetimolol-maleate-eyedrop-us-patients-ocular-hypertension-expanding-leading-ophthalmic-portfolio 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-tabrecta-patients-metex14-advanced-non-small-cell-lung-cancer 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivers-solid-sales-and-profit-growth-strong-performance-market-brands-supports-confidence-mid-term-growth-outlook 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-solide-croissance-du-chiffre-daffaires-et-du-benefice-la-forte-performance-des-marques-existantes-soutient-la-confiance-dans-les-previsions-de-croissance-moyen-terme 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-ein-solides-umsatz-und-gewinnwachstum-die-starke-performance-auf-dem-markt-befindlicher-marken-stutzt-das-vertrauen-die-mittelfristigen-wachstumsaussichten 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-tislelizumab-plus-chemotherapy-significantly-improved-overall-survival-first-line-treatment-advanced-esophageal-cancer-phase-iii-study 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kymriah-receives-ec-approval-first-car-t-cell-therapy-adults-relapsed-or-refractory-follicular-lymphoma 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-data-demonstrate-only-kisqali-offers-more-life-first-line-setting-postmenopausal-hrher2-advanced-breast-cancer-patients 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-jakavi-be-first-post-steroid-treatment-acute-and-chronic-graft-versus-host-disease 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-production-radioligand-therapy-medicines 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-asco-and-eha-showcase-latest-oncology-research-and-innovation-including-breast-and-prostate-cancer 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-secukinumab-receives-positive-chmp-opinion-expanded-use-childhood-arthritic-conditions 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-appoints-new-board-representative-global-amr-industry-alliance 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-approves-novartis-kymriah-car-t-cell-therapy-adult-patients-relapsed-or-refractory-follicular-lymphoma 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-new-global-act4biosimilars-initiative-improve-patient-access-and-increase-adoption-least-30-30-countries-2030 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-partnership-american-society-hematology-fight-sickle-cell-disease-sub-saharan-africa 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-cdk46i-data-asco-reinforce-novartis-kisqali-only-drug-class-consistently-proven-overall-survival-benefit-hrher2-metastatic-breast-cancer 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-data-show-piqray-effectiveness-across-key-biomarkers-patients-hrher2-metastatic-breast-cancer 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-tafinlar-dabrafenib-mekinist-trametinib-demonstrates-unprecedented-efficacy-pediatric-patients-braf-v600-low-grade-gliomas-phase-iiiii-study 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-scemblix-novel-mechanism-action-shows-superior-long-term-efficacy-and-consistent-tolerability-96-week-follow-chronic-myeloid-leukemia-trial 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-five-year-kymriah-data-show-durable-remission-and-long-term-survival-maintained-children-and-young-adults-advanced-b-cell-all 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-research-reveals-critical-actions-needed-ensure-covid-19-driven-surge-virtual-health-and-care-drives-health-access-and-equity 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-application-proposed-biosimilar-adalimumabs-high-concentration-formulation-accepted-ema 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-nature-medicine-publication-zolgensma-data-demonstrating-age-appropriate-milestones-when-treating-children-sma-presymptomatically 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-plans-petition-us-court-appeals-federal-circuit-further-review-uphold-validity-gilenya-fingolimod-dosing-regimen-patent 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-tabrecta-treatment-metex14-skipping-advanced-non-small-cell-lung-cancer 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-tafinlar-mekinist-receives-fda-approval-first-tumor-agnostic-indication-braf-v600e-solid-tumors 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-renews-commitment-neglected-tropical-disease-and-malaria-elimination-investing-usd-250-million-over-five-years-research-and-develop-new-treatments 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-scemblix-novel-treatment-adult-patients-chronic-myeloid-leukemia 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-extension-phase-data-show-nearly-80-rms-patients-treated-kesimpta-ofatumumab-had-no-evidence-disease-activity-neda-3 2022-06-30T07:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/cosentyx-secukinumab-receives-expanded-approvals-eu-use-childhood-arthritic-conditions 2022-06-28T21:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-maintains-growth-momentum-and-confirms-fy22-group-guidance 2022-12-05T17:19:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-investigational-oral-monotherapy-iptacopan-demonstrates-clinically-meaningful-superiority-over-anti-c5-treatment-phase-iii-apply-pnh-study 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-pluvicto-patients-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-unveils-new-focused-strategy-underpinned-eight-potential-multi-billion-dollar-peak-sales-brands-deep-pipeline-meet-management-event 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-plans-petition-us-supreme-court-uphold-validity-gilenya-fingolimod-dosing-regimen-patent 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-further-progress-its-biosimilar-pipeline-release-positive-results-denosumab-integrated-phase-iiii-clinical-trial 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-statement-regarding-competition-authority-investigation-assertion-patent 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-invests-early-technical-development-capabilities-next-generation-biotherapeutics 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-tislelizumab-demonstrated-efficacy-and-tolerability-first-line-advanced-liver-cancer-phase-iii-trial 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-clinically-meaningful-symptom-improvements-patients-hidradenitis-suppurativa-pivotal-phase-iii-trials 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-adds-one-more-year-survival-benefit-broadest-set-patients-including-those-aggressive-hrher2-advanced-breast-cancer 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-depth-immunology-pipeline-novel-data-key-upcoming-international-congresses 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-appoints-fiona-marshall-phd-president-novartis-institutes-biomedical-research-jay-bradner-md-steps-down-from-executive-committee-novartis 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-data-breast-and-prostate-cancer-esmo 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-scemblix-novel-mechanism-action-approved-european-commission-adult-patients-chronic-myeloid-leukemia 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-intention-separate-sandoz-business-create-standalone-company-way-100-spin 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-canopy-study-evaluating-canakinumab-adjuvant-treatment-non-small-cell-lung-cancer 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/applications-proposed-first-kind-multiple-sclerosis-biosimilar-natalizumab-accepted-us-fda-and-ema 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-supplemental-biologics-license-application-accepted-us-fda-biosimilar-hyrimoz-adalimumab-adaz-high-concentration-formulation-hcf 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivers-continued-strong-momentum-key-growth-brands-progress-strategic-initiatives-and-confirms-fy22-group-guidance 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/new-phase-iii-data-show-novartis-tislelizumab-significantly-extended-median-overall-survival-more-6-months-first-line-advanced-esophageal-cancer-combination-chemotherapy 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-resumes-production-and-delivery-radioligand-therapy-medicines-ahead-schedule 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-further-investment-key-manufacturing-facility-austria-support-increased-global-demand-essential-antibiotics 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/new-long-term-leqvio-inclisiran-data-from-novartis-show-sustained-efficacy-and-safety-over-four-years 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-scientific-advances-kisqali-iptacopan-scemblix-and-ytb323-data-sabcs-and-ash 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-announce-decision-move-phase-3-study-novel-ganaplacidelumefantrine-sdf-combination-adults-and-children-malaria 2022-12-05T17:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-setzt-die-wachstumsdynamik-fort-und-bestatigt-die-konzernprognose-fur-das-geschaftsjahr-2022 2023-01-18T11:07:06+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-will-das-sandoz-geschaft-durch-eine-hundertprozentige-ausgliederung-als-eigenstandiges-unternehmen-abspalten 2023-01-18T11:07:09+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-eine-anhaltend-starke-dynamik-der-wichtigsten-wachstumsmarken-sowie-fortschritte-bei-strategischen-initiativen-und-bestatigt-die-konzernprognose-fur-das-geschaftsjahr-2022 2023-01-18T11:07:11+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-maintient-sa-dynamique-de-croissance-et-confirme-les-previsions-de-lexercice-2022-pour-le-groupe 2023-01-18T11:07:14+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-continue-le-fort-elan-des-principales-marques-de-croissance-progresse-dans-ses-initiatives-strategiques-et-confirme-les-previsions-de-lexercice-2022-pour-le-groupe 2023-01-18T11:07:16+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-announces-appointment-chairman-designate-sandoz-board-directors 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-biologics-license-application-proposed-biosimilar-denosumab-accepted-us-fda 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/patients-hidradenitis-suppurativa-experienced-sustained-efficacy-and-symptom-improvement-one-year-when-treated-novartis-cosentyx 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-continues-grow-further-core-margin-expansion-and-achieves-important-innovation-milestones 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-poursuit-sa-croissance-avec-une-nouvelle-expansion-de-sa-marge-core-et-franchit-des-etapes-importantes-dans-linnovation 2023-06-02T01:34:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-setzt-wachstumskurs-mit-weiterer-steigerung-der-kerngewinnmarge-fort-und-erreicht-wichtige-innovations-meilensteine 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-citrate-free-high-concentration-formulation-adalimumab-biosimilar 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-agreement-acquire-leading-antifungal-agent-mycamine-from-astellas-reinforcing-hospital-offering-and-leading-anti-infectives-portfolio 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-pivotal-phase-iii-apply-pnh-data-ash-demonstrating-investigational-oral-monotherapy-iptacopan-superiority-over-anti-c5 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-pluvicto-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-investigational-iptacopan-provides-clinically-meaningful-increases-hemoglobin-levels-complement-inhibitor-naive-patients-pnh 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-prolonged-pfs-benefit-pre-and-perimenopausal-patients-aggressive-hrher2-metastatic-breast-cancer-compared-chemotherapy 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-pluvictotm-shows-statistically-significant-and-clinically-meaningful-radiographic-progression-free-survival-benefit-patients-psma-positive-metastatic-castration-resistant-prostate-cancer 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-6 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-ordinaire-0 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-heissen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats-gut-0 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-signs-memorandum-understanding-build-new-biologics-production-plant-slovenia-support-increasing-global-demand-biosimilar-medicines 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-tafinlar-mekinist-approved-fda-pediatric-patients-braf-v600e-low-grade-glioma-most-common-pediatric-brain-cancer 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-shares-zolgensma-long-term-data-demonstrating-sustained-durability-75-years-post-dosing-100-achievement-all-assessed-milestones-children-treated-prior-sma-symptom-onset 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-biosimilar-hyrimoz-adalimumab-adaz-high-concentration-formulation 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-phase-iii-natalee-trial-meets-primary-endpoint-interim-analysis-demonstrating-clinically-meaningful-benefit-broad-population-patients-early-breast-cancer 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-entresto-receives-positive-chmp-opinion-pediatric-heart-failure 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-approval-european-commission-hyrimoz-adalimumab-high-concentration-formulation 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-five-year-data-disability-outcomes-and-safety-kesimpta-ofatumumab-people-living-relapsing-multiple-sclerosis 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivers-strong-sales-growth-robust-margin-expansion-and-major-innovation-milestones-raises-fy-guidance 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-realise-une-croissance-forte-de-son-chiffre-daffaires-une-expansion-robuste-de-sa-marge-des-etapes-majeures-de-linnovation-et-rehausse-ses-previsions-pour-lexercice-2023 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-kraftige-umsatzsteigerungen-eine-robuste-margenerhohung-und-wichtige-innovationsmeilensteine-erhohung-der-jahresprognose 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-phase-iii-appoint-pnh-trial-shows-investigational-oral-monotherapy-iptacopan-improves-hemoglobin-near-normal-levels-leading-transfusion-independence-all-treatment-naive-pnh-patients 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-present-new-data-across-oncology-portfolio-including-kisqali-phase-iii-natalee-trial-early-breast-cancer-asco 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-positive-chmp-opinion-hidradenitis-suppurativa 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-exclusively-commercialize-six-products-us-reinforcing-global-leadership-position-patent-medicines 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-strengthens-pipeline-expansion-through-partnership-develop-and-manufacture-multiple-biosimilars 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-feature-new-pnh-and-cml-scientific-data-from-broad-hematology-portfolio-european-hematology-association-annual-meeting 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-sandoz-board-directors-appointed 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-marketing-authorization-applications-proposed-biosimilar-denosumab-accepted-ema 2023-06-01T07:49:05+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-european-approval-cosentyx-first-and-only-il-17a-inhibitor-hidradenitis-suppurativa 2023-12-03T09:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-plans-move-new-central-basel-headquarters-mid-2024-following-proposed-spin-standalone-company 2023-12-12T09:19:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-significantly-reduced-risk-recurrence-25-across-broad-population-patients-early-breast-cancer-clinically-meaningful-benefit-was-consistent-across-subgroups 2023-12-03T09:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-presents-compelling-investment-proposition-standalone-company-capital-markets-day 2023-12-03T09:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-unveils-results-from-global-patient-and-physician-survey-disrupting-notion-cml-solved-disease 2023-12-03T09:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-bolsters-innovative-medicines-strategy-and-renal-pipeline-agreement-acquire-chinook-therapeutics-usd-32bn-upfront-usd-40-share 2023-12-03T09:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-introduces-act4biosimilars-action-plan-accelerate-patient-access-biosimilar-medicines 2023-12-03T09:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-signs-agreement-divest-front-eye-ophthalmology-assets-line-focused-strategy 2023-12-03T09:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-publishes-new-five-year-efficacy-data-kesimpta-ofatumumab-treatment-relapsing-multiple-sclerosis 2023-12-13T14:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-launch-hyrimoz-adalimumab-adaz-high-concentration-formulation-marking-sandoz-entrance-us-immunology-space 2023-12-02T22:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-will-appeal-us-court-appeals-uphold-validity-entresto-combination-patent-maintains-2023-guidance-and-mid-term-outlook 2023-12-02T22:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-builds-neuroscience-pipeline-and-xrna-platform-capabilities-acquisition-dtx-pharma 2023-12-02T18:49:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivers-strong-sales-growth-robust-margin-expansion-and-raises-guidance-announces-usd-15-billion-share-buyback-and-board-endorses-sandoz-spin-off12 2023-12-02T17:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-realise-une-forte-croissance-de-son-chiffre-daffaires-et-de-sa-marge-releve-ses-previsions-et-annonce-un-rachat-dactions-dusd-15-milliards1-le-conseil-dadministration-approuve-le-spin-de-sandoz2 2023-12-02T18:49:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-kraftige-umsatz-und-margensteigerungen-und-erhoht-die-prognose-aktienruckkaufprogramm-von-usd-15-milliarden-angekundigt-der-verwaltungsrat-unterstutzt-den-spin-von-sandoz12 2023-12-02T18:49:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-plans-build-biosimilar-technical-development-center-slovenia-support-future-growth-biosimilar-pipeline 2023-12-02T17:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-multiple-sclerosis-biosimilar-natalizumab 2023-12-02T17:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-remibrutinib-phase-iii-trials-met-their-primary-endpoints-and-showed-rapid-symptom-control-chronic-spontaneous-urticaria 2023-12-02T17:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-completes-acquisition-chinook-therapeutics 2023-12-02T17:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-positive-results-from-mylight-phase-lll-study-biosimilar-aflibercept 2023-12-02T14:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-issues-egm-invitation-and-shareholder-information-brochure-sandoz-publishes-listing-prospectus-ahead-proposed-spin-vote 2023-12-02T14:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-publiziert-einladung-und-aktionarsbroschure-zur-ausserordentlichen-generalversammlung-sandoz-veroffentlicht-den-kotierungsprospekt-im-vorfeld-der-abstimmung-zum-vorgeschlagenen-spin 2023-12-02T14:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-publie-linvitation-lage-et-la-brochure-dinformation-aux-actionnaires-sandoz-publie-le-prospectus-de-cotation-avant-le-vote-sur-la-proposition-de-scission 2023-12-02T14:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-fda-approval-tyruko-natalizumab-sztn-first-and-only-fda-approved-biosimilar-relapsing-forms-multiple-sclerosis 2023-12-02T14:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-completes-acquisition-leading-antifungal-agent-mycamine-from-astellas-reinforcing-leading-global-anti-infectives-portfolio 2023-12-02T14:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-long-term-leqvio-inclisiran-data-demonstrating-consistent-efficacy-and-safety-beyond-six-years 2023-12-02T07:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-publishes-supplement-listing-prospectus-including-sandoz-h1-2023-financial-statements 2023-12-02T06:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-publie-un-supplement-au-prospectus-de-cotation-comprenant-les-etats-financiers-de-sandoz-au-premier-semestre-2023 2023-12-02T07:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-veroffentlicht-nachtrag-zum-kotierungsprospekt-einschliesslich-finanzabschluss-von-sandoz-fur-das-1-halbjahr-2023 2023-12-02T07:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-appoints-patrick-horber-md-president-international-marie-france-tschudin-president-innovative-medicines-international-and-chief-commercial-officer-steps-down-from-executive-committee-novartis 2023-12-01T23:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-ernennt-dr-patrick-horber-zum-president-international-da-marie-france-tschudin-president-innovative-medicines-international-und-chief-commercial-officer-aus-der-geschaftsleitung-von-novartis-ausscheidet 2023-12-02T06:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-nomme-patrick-horber-docteur-en-medecine-au-poste-de-president-international-alors-que-marie-france-tschudin-president-innovative-medicines-international-et-chief-commercial-officer-quitte-le-comite-executif-de-novartis 2023-12-02T06:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-announces-exclusive-deal-commercialize-biosimilar-ustekinumab-further-reinforcing-growing-pipeline-and-immunology-patient-offering 2023-12-01T23:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-reduced-risk-cancer-recurrence-while-maintaining-quality-life-patients-diagnosed-early-breast-cancer 2023-12-01T23:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-shareholders-approve-proposed-100-spin-sandoz 2023-12-01T05:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-le-projet-de-scission-100-de-sandoz 2023-12-01T08:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-stimmen-dem-geplanten-100-igen-spin-von-sandoz-zu 2023-12-01T23:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-breast-and-gastric-cancer-biosimilar-trastuzumab 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-radioligand-therapy-lutathera-demonstrated-statistically-significant-and-clinically-meaningful-progression-free-survival-first-line-advanced-gastroenteropancreatic-neuroendocrine-tumors-gep-nets 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-confirms-sandoz-spin-october-4-2023 2023-12-01T10:19:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/sandoz-receives-european-commission-approval-tyruko-natalizumab-first-and-only-biosimilar-multiple-sclerosis-europe 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-completes-divestment-front-eye-ophthalmology-assets 2023-12-01T10:19:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-investigational-iptacopan-phase-iii-study-demonstrates-clinically-meaningful-and-highly-statistically-significant-proteinuria-reduction-patients-iga-nephropathy-igan 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-executes-sandoz-spin-completing-strategic-transformation-leading-focused-innovative-medicines-company 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-present-new-oncology-data-esmo-2023-demonstrating-practice-changing-innovation-advanced-prostate-and-early-breast-cancer 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kisqali-natalee-analysis-reinforces-consistent-reduction-risk-recurrence-across-key-subgroups-patients-early-breast-cancer 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-pluvictotm-shows-clinically-meaningful-and-highly-statistically-significant-rpfs-benefit-patients-psma-positive-metastatic-castration-resistant-prostate-cancer-pre-taxane-setting 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivers-12-sales-and-21-core-operating-income-growth-from-continuing-operations-cc1-executes-sandoz-spin-achieves-important-innovation-milestones-and-raises-fy-2023-guidance 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-hausse-de-12-du-chiffre-daffaires-et-de-21-du-resultat-operationnel-core-tcc1-spin-de-sandoz-etapes-importantes-de-linnovation-hausse-des-previsions-pour-2023 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-steigert-umsatz-um-12-und-operatives-kernergebnis-um-21-fortzufuhrende-geschaftsbereiche-kwk1-sandoz-abgespalten-wichtige-innovationsmeilensteine-erreicht-und-prognose-2023-erhoht 2023-12-01T07:04:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-confirms-unconstrained-supply-pluvicto-and-continues-significantly-expand-number-treatment-centers 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-investigational-atrasentan-phase-iii-study-demonstrates-clinically-meaningful-and-highly-statistically-significant-proteinuria-reduction-patients-iga-nephropathy-igan 2023-12-01T10:19:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/fda-approves-novartis-cosentyx-first-new-biologic-treatment-option-hidradenitis-suppurativa-patients-nearly-decade 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-data-show-potential-remibrutinib-oral-treatment-chronic-spontaneous-urticaria-providing-significant-symptom-improvement-early-week-2 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-showcases-significant-data-updates-from-kisqali-iptacopan-and-scemblix-sabcs-and-ash 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-upgrades-mid-term-sales-growth-guidance-showcases-its-differentiated-innovative-medicines-strategy-and-robust-pipeline-rd-day 2023-12-01T18:34:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-investigational-iptacopan-phase-iii-study-demonstrates-clinically-meaningful-and-statistically-significant-proteinuria-reduction-patients-c3-glomerulopathy-c3g 2024-05-06T02:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-48-week-results-from-phase-iii-apply-pnh-trial-showing-sustained-efficacy-and-long-term-safety-fabhalta-iptacopan-adults-paroxysmal-nocturnal-hemoglobinuria-pnh 2024-05-06T02:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/latest-novartis-kisqali-natalee-analysis-reinforces-25-reduction-risk-recurrence-across-broad-population-patients-early-breast-cancer-supports-regulatory-submissions 2024-05-06T02:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-fabhalta-iptacopan-offering-superior-hemoglobin-improvement-absence-transfusions-first-oral-monotherapy-adults-pnh 2024-05-06T02:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-expands-production-pluvictotm-addition-its-largest-and-most-advanced-radioligand-therapy-manufacturing-facility-indianapolis 2024-05-06T02:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-scemblix-shows-superior-major-molecular-response-mmr-rates-vs-standard-care-tkis-phase-iii-trial-newly-diagnosed-patients-chronic-myeloid-leukemia 2024-05-06T02:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors 2024-04-30T22:34:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivers-strong-full-year-performance-10-net-sales-and-18-core-operating-income-growth-cc1-margin-expansion-continuing-innovation-momentum-multiple-positive-ph3-readouts 2024-05-02T17:04:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-forte-performance-en-2023-hausse-de-10-du-chiffre-daffaires-net-et-de-18-du-resultat-operationnel-core-tcc1-expansion-de-la-marge-innovation-nombreux-resultats-positifs-de-phase-iii 2024-01-31T09:27:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/starkes-jahresergebnis-novartis-steigert-den-nettoumsatz-um-10-das-operative-kernergebnis-um-18-kwk1-sowie-die-margen-weitere-innovationsdynamik-mit-mehreren-positiven-phase-3-ergebnissen 2024-02-05T22:48:49+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-strengthen-oncology-pipeline-agreement-acquire-morphosys-ag-eur-68-share-or-aggregate-eur-27bn-cash 2024-02-05T22:48:45+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-new-data-safety-and-efficacy-zolgensma-including-maintained-and-improved-motor-milestones-older-and-heavier-children-sma 2024-03-04T07:19:03+01:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-7 2024-03-05T15:34:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-ordinaire-1 2024-03-05T15:34:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-heissen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats-gut-1 2024-05-02T14:04:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-fabhalta-iptacopan-receives-positive-chmp-opinion-first-oral-monotherapy-adult-patients-paroxysmal-nocturnal-hemoglobinuria-pnh 2024-03-22T12:34:02+01:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-data-show-early-addition-twice-yearly-leqvio-inclisiran-following-maximally-tolerated-statin-therapy-significantly-reduces-ldl-c-ascvd-patients-real-world-setting 2024-05-03T14:49:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-tender-offer-morphosys-ag-commences 2024-05-04T09:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/new-novartis-fabhalta-iptacopan-data-show-clinically-meaningful-and-statistically-significant-proteinuria-reduction-383-versus-placebo-patients-iga-nephropathy-igan 2024-05-02T20:19:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-kesimpta-six-year-efficacy-data-show-substantial-benefits-recently-diagnosed-treatment-naive-people-relapsing-multiple-sclerosis 2024-04-17T14:34:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-delivers-double-digit-sales-growth-and-core-margin-expansion-q1-fy-2024-guidance-raised 2024-05-02T08:49:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-au-premier-trimestre-croissance-deux-chiffres-du-chiffre-daffaires-et-expansion-de-la-marge-core-hausse-des-previsions-pour-2024 2024-04-23T08:03:16+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-erzielt-im-ersten-quartal-ein-zweistelliges-umsatzwachstum-und-steigert-die-kerngewinnmarge-prognose-fur-das-geschaftsjahr-2024-erhoht 2024-04-23T08:03:19+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-radioligand-therapy-lutathera-fda-approved-first-medicine-specifically-pediatric-patients-gastroenteropancreatic-neuroendocrine-tumors 2024-04-23T19:49:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-enters-agreement-acquire-mariana-oncology-strengthening-radioligand-therapy-pipeline 2024-06-23T09:04:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-announce-positive-efficacy-and-safety-data-novel-treatment-babies 2024-06-18T12:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-highlights-pioneering-innovation-cml-data-from-scemblix-phase-iii-asc4first-study-newly-diagnosed-patients-asco-and-eha 2024-06-23T05:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-meets-all-tender-offer-conditions-acquire-morphosys-ag-eur-68-share-cash 2024-06-18T12:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-presents-latest-phase-iii-fabhalta-iptacopan-data-c3-glomerulopathy-c3g-showing-clinically-meaningful-and-statistically-significant-351-proteinuria-reduction-vs-placebo 2024-06-24T20:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-atrasentan-phase-iii-data-show-clinically-meaningful-proteinuria-reduction-further-advancing-companys-iga-nephropathy-igan-portfolio 2024-06-23T09:04:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-phase-iii-data-confirm-sustained-efficacy-and-long-term-safety-oral-remibrutinib-chronic-spontaneous-urticaria 2024-06-22T13:49:02+02:00 daily 0.5 https://www.novartis.com/news/media-releases/novartis-scemblix-phase-iii-data-first-show-superior-efficacy-favorable-safety-and-tolerability-profile-vs-standard-care-tkis-adults-newly-diagnosed-cml 2024-06-25T17:34:03+02:00 daily 0.5 https://www.novartis.com/news/media-releases/latest-analysis-novartis-natalee-study-shows-kisqali-reduces-risk-cancer-recurrence-early-breast-cancer-patients-high-risk-node-negative-disease 2024-06-23T09:04:02+02:00 daily 0.5 https://www.novartis.com/news/novartis-financial-results-q1-2021 2024-05-07T13:51:36+02:00 daily 1.0 https://www.novartis.com/news/novartis-inaugurates-innovative-watershed-project-india-increase-water-availability 2024-06-07T12:57:01+02:00 daily 1.0 https://www.novartis.com/news/world-cancer-day-2021 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/global-health-corporate-responsibility 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/achieving-100-renewable-electricity 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-appoints-marc-boutin-global-head-patient-engagement-advocacy 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-provides-update-use-and-safety-beovu-patients-wet-amd 2021-09-14T13:02:04+02:00 daily 1.0 https://www.novartis.com/news/avexis-data-integrity-updates 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/epis-explores-how-covid-19-shaping-future-digital-engagement-within-healthcare 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-ranks-second-2021-access-medicine-index 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/highlights-from-co-creating-impact-summit-2020 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/world-chagas-disease-day-2021 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/bold-advocates-blood-cancers-and-blood-disorders 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/blood-cancer-awareness-month-cutting-edge-innovation-hematology 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/solar-1-nejm-publication 2021-10-07T09:00:16+02:00 daily 1.0 https://www.novartis.com/news/mission-transform-planetary-health 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-announces-flexible-return-office-and-site-field-activities-starting-may-11-2020 2021-10-13T09:18:27+02:00 daily 1.0 https://www.novartis.com/news/novartis-completes-safety-review-and-initiates-update-beovu-prescribing-information-worldwide 2021-09-09T09:50:29+02:00 daily 1.0 https://www.novartis.com/news/novartis-announces-first-european-donation-hydroxychloroquine-switzerland 2021-09-09T09:51:21+02:00 daily 1.0 https://www.novartis.com/news/novartis-coronavirus-update-supply-chain-response-measures-efpia-rd-call 2021-10-14T08:01:51+02:00 daily 1.0 https://www.novartis.com/news/expanding-car-t-manufacturing-australia 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-ash 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/why-healthcares-digital-moment-now 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/avexis-renamed-novartis-gene-therapies-signifying-growing-importance-gene-therapy-novartis-corporate-strategy 2021-10-07T09:12:50+02:00 daily 1.0 https://www.novartis.com/news/ruxcovid-clinical-trial 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/study-suggests-there-may-be-two-stages-fatal-lung-disease-covid-19 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/choice-responsibility-reimagining-how-we-work 2022-12-05T08:13:49+01:00 daily 1.0 https://www.novartis.com/news/international-womens-day-2020 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/world-sight-day-2020 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/standing-racial-equity-and-justice-one-novartis 2021-09-09T09:49:34+02:00 daily 1.0 https://www.novartis.com/news/novartis-update-following-who-solidarity-trial-announcement 2021-09-09T09:49:43+02:00 daily 1.0 https://www.novartis.com/news/novartis-announces-plan-initiate-clinical-trial-canakinumab-patients-covid-19-pneumonia 2021-09-09T09:50:01+02:00 daily 1.0 https://www.novartis.com/news/leading-performance-sustainability 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/world-heart-day-2020-from-our-heart-yours 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/50-climate-leaders 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/new-report-shows-how-ai-health-critical-covid-19-response-and-recovery 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-coronavirus-update-remote-working-business-travel-restrictions 2021-09-14T13:02:17+02:00 daily 1.0 https://www.novartis.com/news/expanding-car-t-manufacturing-europe-serve-more-patients 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/committed-increasing-access 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/pride-novartis-2020-inspired-make-difference 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/world-sickle-cell-day-2020 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-asco 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/pride-novartis-2019 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/world-chagas-disease-day-2020 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-covid-19-response-fund-provides-support-healthcare-workers-and-communities 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-esmo 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/day-african-child-2020 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/world-cancer-day-2020 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-world-economic-forum-annual-meeting-davos-2020 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/sustaining-momentum-toward-universal-health-coverage-africa 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/discussing-innovative-solutions-address-unmet-healthcare-needs-asia 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-joins-accelerating-covid-19-therapeutic-interventions-and-vaccines-activ-initiative 2021-09-09T09:50:17+02:00 daily 1.0 https://www.novartis.com/news/novartis-announces-further-steps-protect-and-support-its-associates-during-covid-19-pandemic 2021-09-14T12:59:55+02:00 daily 1.0 https://www.novartis.com/news/novartis-ranks-4-patientviews-2019-corporate-reputation-survey-patient-organizations 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/behind-research-driving-our-data-medical-conferences 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/uncovering-profound-and-under-reported-effects-people-living-sickle-cell-disease 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/amazon-web-services-aws-announces-strategic-collaboration-novartis-accelerate-digital-transformation-its-business-operations 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-opens-facility-innovative-cell-and-gene-therapies-switzerland 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/world-sight-day-2019 2022-02-10T11:47:38+01:00 daily 1.0 https://www.novartis.com/news/novartis-and-microsoft-announce-collaboration-transform-medicine-artificial-intelligence 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/health-experts-explore-response-chronic-illness-poor-countries 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/world-malaria-day-2019 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/global-equal-parental-leave-policy-all-novartis-parents 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-moves-address-superbug-threat 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/celebrating-community-partnership-day 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-recognized-global-leader-sustainable-water-and-climate-management 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/biosimilar-drugs-have-potential-save-more-usd-54-billion 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-foundation-joins-global-partnership-zero-leprosy 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/world-sickle-cell-day-2019 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/exploring-future-access-healthcare-lower-income-countries 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/alcon-survey-reveals-people-are-happier-and-more-satisfied-their-lives-after-cataract-surgery 2021-08-23T10:08:22+02:00 daily 1.0 https://www.novartis.com/news/car-t-therapies-are-manufactured-each-individual-patient 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/asthma-and-exercise-why-patients-can-and-should-stay-active 2021-07-28T14:09:59+02:00 daily 1.0 https://www.novartis.com/news/beyond-pill-precision-medicine-practice 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/improving-diabetes-awareness-and-treatment-adherence-india 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/how-digital-technologies-are-creating-new-normal-people-living-copd 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/when-innovation-draws-new-future-patient-treatments 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/taking-action-psoriasis-patients-who-psoriasis-resolution 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-medikidz-and-copd-foundation-partnership-superhero-proportions 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/innovation-practice-how-we-form-partnerships-pharma 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-evolving-business-practices-better-educate-medical-community 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/medical-researchers-using-new-tools-turn-science-fiction-science-fact 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/students-take-challenges-digital-medicine 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/fighting-high-blood-pressure-vietnam 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/world-asthma-day-2021 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/nurturing-next-generation-scientists 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-and-red-cross-partner-tackle-chronic-diseases-refugee-populations 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/essential-consultants-updates 2021-10-14T09:40:24+02:00 daily 1.0 https://www.novartis.com/news/avxs-101-managed-access-program 2021-10-13T11:51:31+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q1-2020 2023-05-22T11:17:09+02:00 daily 1.0 https://www.novartis.com/news/world-malaria-day-2021 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q2-2020 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-dialogue-explore-solutions-rise-chronic-diseases-developing-world 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q3-2020 2023-12-06T10:23:10+01:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q1-2018 2024-02-01T12:01:47+01:00 daily 1.0 https://www.novartis.com/news/novartis-2020-financial-results 2023-01-31T12:03:28+01:00 daily 1.0 https://www.novartis.com/news/novartis-2017-financial-results 2023-02-01T08:45:22+01:00 daily 1.0 https://www.novartis.com/news/novartis-host-stakeholder-dialogue-ways-improve-access-healthcare-lower-income-countries 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q3-2018 2024-02-01T12:06:39+01:00 daily 1.0 https://www.novartis.com/news/european-patient-innovation-summit-recommends-increasing-impact-digital-technologies 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/alcon-becomes-separately-traded-standalone-company 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-rd-day 2022-12-15T11:16:56+01:00 daily 1.0 https://www.novartis.com/news/novartis-2018-financial-results 2024-02-01T12:10:03+01:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q1-2019 2023-01-18T11:33:52+01:00 daily 1.0 https://www.novartis.com/news/novartis-jp-morgan-2020 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-2015-financial-results 2021-10-07T15:34:53+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q2-2019 2023-06-19T14:27:07+02:00 daily 1.0 https://www.novartis.com/news/novartis-2019-financial-results 2023-04-17T16:27:05+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q3-2019 2023-06-19T14:28:41+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q2-2018 2024-02-01T12:04:02+01:00 daily 1.0 https://www.novartis.com/news/co-creating-impact-summit-society-and-planet 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-2016-financial-results 2022-02-02T08:45:07+01:00 daily 1.0 https://www.novartis.com/news/life-science-companies-and-bill-melinda-gates-foundation-joint-communique 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/european-patient-innovation-summit-publishes-call-action-ensure-greater-patient-involvement-digital-health-solution-development 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-research-shows-technology-talent-increasingly-drawn-pharma-industry-covid-19 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/world-malaria-day-2020 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/impact-measurement-and-valuation 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/ai-nurse-set-transform-standards-care-heart-failure-patients-china 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/meet-novartis-management-2020 2023-12-06T10:37:20+01:00 daily 1.0 https://www.novartis.com/news/novartis-announces-discontinuation-cirrus-1-study-cfz533-iscalimab-kidney-transplant-patients 2021-10-04T08:25:52+02:00 daily 1.0 https://www.novartis.com/news/novartis-receives-fda-fast-track-designation-lna043-osteoarthritis-knee 2021-10-04T08:28:19+02:00 daily 1.0 https://www.novartis.com/news/novartis-sabatolimab-receives-orphan-drug-designation-from-european-commission-myelodysplastic-syndromes 2021-10-14T13:31:54+02:00 daily 1.0 https://www.novartis.com/news/fda-accelerates-review-novartis-stamp-inhibitor-asciminib-abl001-patients-chronic-myeloid-leukemia-cml 2021-10-04T08:26:24+02:00 daily 1.0 https://www.novartis.com/news/novartis-receives-fda-orphan-drug-designation-nis793-pancreatic-cancer 2021-10-04T08:28:06+02:00 daily 1.0 https://www.novartis.com/news/novartis-announces-complete-response-resubmission-inclisiran-new-drug-application 2021-10-04T08:26:03+02:00 daily 1.0 https://www.novartis.com/news/novartis-receives-fda-breakthrough-therapy-designation-investigational-177lu-psma-617-patients-metastatic-castration-resistant-prostate-cancer-mcrpc 2023-04-11T16:10:26+02:00 daily 1.0 https://www.novartis.com/news/novartis-entresto-indicated-treatment-hypertension-china 2021-10-04T08:25:43+02:00 daily 1.0 https://www.novartis.com/news/novartis-receives-fda-fast-track-designation-sabatolimab-mbg453-myelodysplastic-syndromes 2021-10-04T08:28:13+02:00 daily 1.0 https://www.novartis.com/news/industry-and-academia-collaborating-innovate-patients 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/fda-grants-priority-review-investigational-targeted-radioligand-therapy-177lu-psma-617-patients-metastatic-castration-resistant-prostate-cancer-mcrpc 2021-10-14T10:02:25+02:00 daily 1.0 https://www.novartis.com/news/one-billion-antimalarial-treatments-delivered-extraordinary-partnership-journey 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/asia-pacific-patient-innovation-summit-examines-capability-building-gaps-patient-organizations 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/enabling-our-associates-work-safely-our-sites 2021-10-07T13:13:01+02:00 daily 1.0 https://www.novartis.com/news/beacon-hope-addressing-health-disparities-through-holistic-community-based-collective-action 2021-10-11T12:14:00+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q2-2021 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-hematology-relentless-pursuit-cure 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/two-decades-pioneering-innovation-cml-and-beyond 2023-03-13T10:41:16+01:00 daily 1.0 https://www.novartis.com/news/covid-19-news-archive 2023-07-03T16:14:31+02:00 daily 1.0 https://www.novartis.com/news/world-sight-day-2021 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q3-2021 2021-10-26T13:22:41+02:00 daily 1.0 https://www.novartis.com/news/sound-up 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/raising-awareness-prostate-cancer-during-movember 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-receives-fda-fast-track-designation-branaplam-lmi070-treatment-huntingtons-disease 2021-12-16T10:00:12+01:00 daily 1.0 https://www.novartis.com/news/2021-global-managed-access-program-community-update 2022-01-31T14:36:51+01:00 daily 1.0 https://www.novartis.com/news/novartis-2021-financial-results 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-co-creating-impact-summit-2021 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-announces-european-patent-office-orders-grant-european-gilenya-fingolimod-05mg-daily-dose-patent 2022-02-15T10:02:38+01:00 daily 1.0 https://www.novartis.com/news/novartis-condemns-war-ukraine-and-commits-supporting-humanitarian-efforts 2022-03-15T08:49:19+01:00 daily 1.0 https://www.novartis.com/news/novartis-expands-humanitarian-efforts-ukraine-through-donation-essential-medicines 2022-03-08T16:49:12+01:00 daily 1.0 https://www.novartis.com/news/novartis-condemns-war-ukraine-update-march-22 2022-03-22T08:11:41+01:00 daily 1.0 https://www.novartis.com/news/novartis-provides-more-usd-25-million-medical-aid-patients-ukraine-and-bordering-countries 2022-04-19T14:32:46+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q1-2022 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-asco-and-eha-2022 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-resumes-business-ukraine 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q2-2022 2022-07-28T12:22:49+02:00 daily 1.0 https://www.novartis.com/news/from-the-heart 2022-11-07T09:58:07+01:00 daily 1.0 https://www.novartis.com/news/zolgensma-acute-liver-failure-update 2022-08-16T17:30:22+02:00 daily 1.0 https://www.novartis.com/news/branaplam-vibrant-hd-study-update 2022-08-25T16:01:23+02:00 daily 1.0 https://www.novartis.com/news/novartis-hematology-working-help-ensure-patients-are-getting-access-they-need 2022-10-25T09:27:45+02:00 daily 1.0 https://www.novartis.com/news/world-sight-day-2022 2022-10-13T09:44:32+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q3-2022 2022-10-24T21:19:13+02:00 daily 1.0 https://www.novartis.com/news/creating-positive-social-change-through-volunteering 2022-11-29T13:07:09+01:00 daily 1.0 https://www.novartis.com/news/zolgensma-global-managed-access-program-2023 2023-01-09T08:36:49+01:00 daily 1.0 https://www.novartis.com/news/world-economic-forum-2023 2023-01-23T10:37:02+01:00 daily 1.0 https://www.novartis.com/news/novartis-shares-strategy-insights-and-highlights-key-pipeline-catalysts-jp-morgan-healthcare-conference-2023 2023-01-09T17:18:36+01:00 daily 1.0 https://www.novartis.com/news/novartis-2022-financial-results 2023-02-20T16:20:56+01:00 daily 1.0 https://www.novartis.com/news/novartis-provides-update-phase-iii-stand-trial-assessing-crizanlizumab 2023-02-01T12:36:05+01:00 daily 1.0 https://www.novartis.com/news/novartis-announces-support-people-affected-earthquake-turkey-and-syria 2023-02-07T19:10:01+01:00 daily 1.0 https://www.novartis.com/news/novartis-releases-emergency-funding-usd-1-million-people-turkey-and-syria-and-launches-employee-donation-and-volunteering-programs 2023-02-09T16:14:57+01:00 daily 1.0 https://www.novartis.com/news/novartis-unwavering-support-one-year-from-start-war-ukraine 2023-02-28T17:30:32+01:00 daily 1.0 https://www.novartis.com/news/novartis-completes-fda-filing-approval-millburn-facility-support-pluvicto-launch 2023-03-03T08:56:35+01:00 daily 1.0 https://www.novartis.com/news/fda-approves-novartis-millburn-facility-us-commercial-production-pluvicto 2023-04-21T17:17:29+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q1-2023 2023-04-25T06:06:47+02:00 daily 1.0 https://www.novartis.com/news/chmp-recommends-revoking-conditional-marketing-authorization-adakveo-crizanlizumab 2023-05-26T14:28:49+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q2-2023 2024-05-16T16:49:57+02:00 daily 1.0 https://www.novartis.com/news/european-commission-ec-adopts-decision-endorsing-chmp-recommendation-revoke-conditional-marketing-authorization-adakveo-crizanlizumab 2023-08-04T14:29:20+02:00 daily 1.0 https://www.novartis.com/news/novartis-statement-about-entresto-sacubitrilvalsartan-selection-medicare-drug-price-negotiation-program 2023-08-29T14:51:15+02:00 daily 1.0 https://www.novartis.com/news/novartis-statement-filing-inflation-reduction-act-lawsuit 2023-09-01T20:47:26+02:00 daily 1.0 https://www.novartis.com/news/novartis-giving-volunteering-wins-accps-2023-corporate-social-impact-team-year-award 2023-10-11T14:26:30+02:00 daily 1.0 https://www.novartis.com/news/gt005-ppy988-development-program-geographic-atrophy 2023-09-11T16:14:11+02:00 daily 1.0 https://www.novartis.com/news/novartis-provides-support-moroccan-earthquake-victims 2023-09-13T15:52:00+02:00 daily 1.0 https://www.novartis.com/news/novartis-statement-collaboration-and-license-agreement-tislelizumab-beigene-ltd 2023-09-19T14:36:00+02:00 daily 1.0 https://www.novartis.com/news/novartis-condemns-terrorist-actions-against-people-israel-and-loss-innocent-lives 2023-10-13T13:31:56+02:00 daily 1.0 https://www.novartis.com/news/violence-against-innocent-people-runs-counter-our-work-improve-human-health 2023-10-19T07:57:08+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q3-2023 2023-10-23T19:43:20+02:00 daily 1.0 https://www.novartis.com/news/our-next-era 2023-12-04T06:31:45+01:00 daily 1.0 https://www.novartis.com/news/jp-morgan-healthcare-conference-2024 2024-01-15T08:40:58+01:00 daily 1.0 https://www.novartis.com/news/novartis-shares-strategy-and-growth-update-jp-morgan-healthcare-conference-2024 2024-01-08T17:33:04+01:00 daily 1.0 https://www.novartis.com/news/novartis-2023-financial-results 2024-04-19T18:24:34+02:00 daily 1.0 https://www.novartis.com/news/novartis-appoints-sloan-simpson-global-head-investor-relations 2024-02-29T08:59:50+01:00 daily 1.0 https://www.novartis.com/news/novartis-confirms-plans-file-pluvicto-pre-taxane-label-expansion-h2-2024-based-latest-data-from-phase-iii-psmafore-study 2024-04-04T15:27:08+02:00 daily 1.0 https://www.novartis.com/news/novartis-implements-manufacturing-adjustments-ribociclib-ensure-alignment-latest-regulatory-standards-ebc-end-q2 2024-04-09T22:26:46+02:00 daily 1.0 https://www.novartis.com/news/novartis-financial-results-q1-2024 2024-04-22T21:41:58+02:00 daily 1.0 https://www.novartis.com/news/novartis-receives-fda-breakthrough-therapy-designation-scemblix-1l-cml 2024-05-10T14:58:23+02:00 daily 1.0 https://www.novartis.com/stories/artificial-intelligence-decodes-cancer-pathology-images 2022-02-10T13:40:05+01:00 daily 1.0 https://www.novartis.com/stories/african-experts-call-renewed-global-drive-beat-malaria 2021-10-12T14:51:02+02:00 daily 1.0 https://www.novartis.com/stories/10-big-questions-dissect-science-papers 2021-10-18T14:17:21+02:00 daily 1.0 https://www.novartis.com/stories/abcdes-melanoma-prevention-and-detection 2021-10-18T07:50:01+02:00 daily 1.0 https://www.novartis.com/stories/challenging-young-scientist-focus-patients 2021-10-14T07:38:35+02:00 daily 1.0 https://www.novartis.com/stories/biological-battle-bulge 2021-10-07T10:20:50+02:00 daily 1.0 https://www.novartis.com/stories/building-boot-camps-immune-cells-near-tumors 2021-10-08T14:58:49+02:00 daily 1.0 https://www.novartis.com/stories/bringing-gene-therapy-focus 2022-02-11T14:53:34+01:00 daily 1.0 https://www.novartis.com/stories/can-we-unlock-bodys-ability-regenerate-lost-hearing 2021-10-07T10:28:25+02:00 daily 1.0 https://www.novartis.com/stories/building-collaborations-fight-pandemic 2021-10-07T12:27:31+02:00 daily 1.0 https://www.novartis.com/stories/breaking-vicious-cycle-inflammation 2021-10-07T15:54:28+02:00 daily 1.0 https://www.novartis.com/stories/bringing-real-change-people 2021-10-07T12:17:22+02:00 daily 1.0 https://www.novartis.com/stories/cancer-cocktails-abl001-hitting-one-target-twice 2021-10-07T10:25:55+02:00 daily 1.0 https://www.novartis.com/stories/cancer-cocktails-come-age 2021-10-07T10:25:26+02:00 daily 1.0 https://www.novartis.com/stories/bringing-science-and-medicine-together-help-patients-cancer 2021-10-08T14:54:04+02:00 daily 1.0 https://www.novartis.com/stories/cancer-cocktails-lee011-popular-combination-partner 2021-09-14T11:23:06+02:00 daily 1.0 https://www.novartis.com/stories/cancer-cocktails-ljm716-closing-common-release-valve 2021-09-14T12:38:16+02:00 daily 1.0 https://www.novartis.com/stories/cancer-researchers-ready-aim-cures 2021-10-07T07:10:36+02:00 daily 1.0 https://www.novartis.com/stories/chan-zuckerberg-initiative-friends-novartis-scientist-mission-conquer-disease 2021-10-15T13:20:59+02:00 daily 1.0 https://www.novartis.com/stories/clinical-trial-comes-together-weeks-address-coronavirus 2021-10-15T13:51:13+02:00 daily 1.0 https://www.novartis.com/stories/cellular-drama-heart-researchers-family 2021-10-15T12:06:55+02:00 daily 1.0 https://www.novartis.com/stories/clinical-trials-make-move-toward-mice 2021-10-15T13:48:39+02:00 daily 1.0 https://www.novartis.com/stories/close-look-cryo-electron-microscopy 2021-10-15T14:00:33+02:00 daily 1.0 https://www.novartis.com/stories/collaborating-explore-new-gene-regulation-therapies 2021-10-18T14:29:32+02:00 daily 1.0 https://www.novartis.com/stories/collaborating-unlock-secrets-microbiome 2021-10-08T06:30:33+02:00 daily 1.0 https://www.novartis.com/stories/compound-designed-fight-alzheimers-disease-shows-promise-lab 2021-10-07T14:27:10+02:00 daily 1.0 https://www.novartis.com/stories/compounds-spur-insulin-producing-cells-replicate-lab 2021-10-15T15:20:55+02:00 daily 1.0 https://www.novartis.com/stories/combination-therapies-seeking-block-cancers-pathways-growth 2021-10-15T14:43:44+02:00 daily 1.0 https://www.novartis.com/stories/counting-combos-complex-liver-diseases 2022-06-08T10:16:00+02:00 daily 1.0 https://www.novartis.com/stories/confidence-led-researcher-swim-against-current 2021-10-11T11:47:55+02:00 daily 1.0 https://www.novartis.com/stories/covid-19-answering-your-top-questions 2021-10-01T06:28:14+02:00 daily 1.0 https://www.novartis.com/stories/data42-program-shows-novartis-intent-go-big-data-and-digital 2021-10-11T14:30:46+02:00 daily 1.0 https://www.novartis.com/stories/could-umbilical-cords-yield-more-stem-cells-life-saving-transplants 2021-10-15T15:31:20+02:00 daily 1.0 https://www.novartis.com/stories/digital-health-ecosystem-gets-boost-novartis-biome 2022-01-07T09:15:56+01:00 daily 1.0 https://www.novartis.com/stories/embracing-big-data-understand-complex-diseases 2021-10-18T14:31:42+02:00 daily 1.0 https://www.novartis.com/stories/decades-long-journey-blood-cancer-research 2021-10-15T15:46:52+02:00 daily 1.0 https://www.novartis.com/stories/drug-development-gets-big-data-analytics-boost 2021-10-07T10:45:05+02:00 daily 1.0 https://www.novartis.com/stories/evolution-scientist 2021-10-07T10:43:41+02:00 daily 1.0 https://www.novartis.com/stories/experimental-gene-therapy-discovered-house-enters-clinical-testing 2021-10-18T14:37:43+02:00 daily 1.0 https://www.novartis.com/stories/experimental-treatment-clears-malaria-infections-small-clinical-study 2021-10-15T16:01:23+02:00 daily 1.0 https://www.novartis.com/stories/exploring-longstanding-questions-about-heart-disease 2021-10-07T08:08:20+02:00 daily 1.0 https://www.novartis.com/stories/eye-fastest-muscle-human-body 2021-07-21T14:12:47+02:00 daily 1.0 https://www.novartis.com/stories/dna-encoded-molecules-provide-new-edge-cancer-drug-hunts 2021-10-01T06:43:44+02:00 daily 1.0 https://www.novartis.com/stories/factory-foreman-keeps-livers-line-workers-task 2021-10-07T08:39:15+02:00 daily 1.0 https://www.novartis.com/stories/eyewitness-healer-pursues-new-treatments-patients 2021-10-18T14:42:38+02:00 daily 1.0 https://www.novartis.com/stories/fresh-look-fighting-glaucoma 2021-10-07T08:40:37+02:00 daily 1.0 https://www.novartis.com/stories/from-patient-patient-advocate-how-cancer-diagnosis-fueled-new-career-path 2021-10-01T07:13:00+02:00 daily 1.0 https://www.novartis.com/stories/getting-down-roots-alzheimers-disease 2021-10-07T14:25:16+02:00 daily 1.0 https://www.novartis.com/stories/going-global-meet-local-needs-china 2021-10-15T16:50:12+02:00 daily 1.0 https://www.novartis.com/stories/how-love-sport-led-scientific-breakthrough 2021-10-07T08:59:33+02:00 daily 1.0 https://www.novartis.com/stories/heart-failure-leading-cause-hospitalizations-it-doesnt-have-be 2023-04-11T16:04:59+02:00 daily 1.0 https://www.novartis.com/stories/eye-patients-mind-innovation 2021-10-01T07:09:42+02:00 daily 1.0 https://www.novartis.com/stories/helping-clinical-trial-patients-during-lockdown 2021-10-18T09:37:02+02:00 daily 1.0 https://www.novartis.com/stories/how-scientists-aim-expand-immunotherapy-options-cancer-patients 2022-06-07T17:03:01+02:00 daily 1.0 https://www.novartis.com/stories/immuno-oncology-researchers-seek-build-smart-drug-combos 2021-10-18T14:45:39+02:00 daily 1.0 https://www.novartis.com/stories/innovating-trusted-class-antibiotics-attack-superbugs 2021-10-18T09:55:14+02:00 daily 1.0 https://www.novartis.com/stories/investigating-myopia-mystery 2022-06-21T15:35:00+02:00 daily 1.0 https://www.novartis.com/stories/it-takes-rd-village-fight-pandemic 2021-10-18T14:47:58+02:00 daily 1.0 https://www.novartis.com/stories/intractable-tumor-cells-crippled 2021-10-18T10:15:06+02:00 daily 1.0 https://www.novartis.com/stories/keeping-heart-patients-heart-everything-we-do 2023-07-04T14:59:31+02:00 daily 1.0 https://www.novartis.com/stories/let-there-be-sight 2021-10-07T09:08:43+02:00 daily 1.0 https://www.novartis.com/stories/loss-friend-liver-cancer-sharpens-focus-experimental-therapy 2021-09-29T07:49:04+02:00 daily 1.0 https://www.novartis.com/stories/killing-three-diseases-one-stone-lab 2021-09-29T08:11:16+02:00 daily 1.0 https://www.novartis.com/stories/leveraging-livers-ability-heal-scarred-tissue 2021-10-18T12:01:21+02:00 daily 1.0 https://www.novartis.com/stories/making-possible-stepping-toward-future-cell-and-gene-therapy 2022-01-14T16:58:56+01:00 daily 1.0 https://www.novartis.com/stories/meet-achim-leading-data42-program 2021-10-07T09:14:48+02:00 daily 1.0 https://www.novartis.com/stories/mutant-protein-spreads-through-neural-circuit-huntingtons-disease 2021-10-07T09:49:48+02:00 daily 1.0 https://www.novartis.com/stories/moving-from-speculation-science-during-pandemic 2021-10-01T08:06:31+02:00 daily 1.0 https://www.novartis.com/stories/not-your-grandparents-nuclear-medicine 2022-01-11T09:30:42+01:00 daily 1.0 https://www.novartis.com/stories/machine-learning-poised-accelerate-drug-discovery 2022-06-21T17:07:09+02:00 daily 1.0 https://www.novartis.com/stories/neuroscientists-restore-cell-cell-signaling-and-sociability-autism-models 2021-10-07T14:50:04+02:00 daily 1.0 https://www.novartis.com/stories/new-drug-manufacturing-tools-change-pharma-chemistry 2021-10-07T09:54:51+02:00 daily 1.0 https://www.novartis.com/stories/new-recruit-has-big-dreams-cancer-immunotherapy 2021-10-18T15:02:03+02:00 daily 1.0 https://www.novartis.com/stories/new-hope-treating-inflammatory-diseases-kidney 2022-01-11T09:27:11+01:00 daily 1.0 https://www.novartis.com/stories/novartis-and-pfizer-join-forces-upend-oncology-dogma 2021-10-18T15:13:48+02:00 daily 1.0 https://www.novartis.com/stories/novartis-cancer-researchers-advance-precision-medicine 2021-10-18T15:59:25+02:00 daily 1.0 https://www.novartis.com/stories/novartis-researches-smas-genetic-roots 2021-10-07T10:05:11+02:00 daily 1.0 https://www.novartis.com/stories/open-science-demystified 2021-10-19T08:44:12+02:00 daily 1.0 https://www.novartis.com/stories/novartis-scientists-target-resistance-threat-malaria 2021-10-07T10:09:33+02:00 daily 1.0 https://www.novartis.com/stories/organic-dealmaker-drug-discovery 2021-10-11T11:55:22+02:00 daily 1.0 https://www.novartis.com/stories/open-resources-novartis-help-drive-innovation 2022-01-14T15:56:41+01:00 daily 1.0 https://www.novartis.com/stories/physician-scientist-donald-ganem-takes-reins-infectious-disease 2021-10-07T10:21:16+02:00 daily 1.0 https://www.novartis.com/stories/potential-weight-loss-treatment-takes-shape-help-from-patients 2021-10-19T08:56:04+02:00 daily 1.0 https://www.novartis.com/stories/predictive-analytics-could-bring-medicines-patients-faster 2021-10-19T09:01:12+02:00 daily 1.0 https://www.novartis.com/stories/reaping-cancer-clues-from-blood 2021-09-28T11:25:16+02:00 daily 1.0 https://www.novartis.com/stories/rare-speed-rare-disease 2021-10-19T09:23:22+02:00 daily 1.0 https://www.novartis.com/stories/researchers-overcome-hurdles-test-experimental-malaria-drug 2021-10-07T14:36:23+02:00 daily 1.0 https://www.novartis.com/stories/researchers-aim-beat-trick-play-tumors-drug-combo 2021-10-19T09:28:15+02:00 daily 1.0 https://www.novartis.com/stories/quest-new-measure-mental-health 2021-10-19T09:04:18+02:00 daily 1.0 https://www.novartis.com/stories/researcher-races-find-new-treatment-his-progressive-disease 2021-10-18T08:18:59+02:00 daily 1.0 https://www.novartis.com/stories/researchers-phd-leads-medical-breakthrough-rare-skin-disease 2021-10-07T10:40:50+02:00 daily 1.0 https://www.novartis.com/stories/researcher-seeks-roots-plants-healing-power 2021-10-19T09:32:29+02:00 daily 1.0 https://www.novartis.com/stories/respiratory-clinical-trials-putting-patients-heart-research 2023-07-04T16:27:20+02:00 daily 1.0 https://www.novartis.com/stories/rewriting-playbook-clinical-testing-rare-disease 2021-10-07T10:42:50+02:00 daily 1.0 https://www.novartis.com/stories/saving-tumor-suppressors-from-shredder 2021-10-07T10:44:12+02:00 daily 1.0 https://www.novartis.com/stories/shaping-future-sickle-cell-disease 2021-10-07T10:46:16+02:00 daily 1.0 https://www.novartis.com/stories/search-differences-make-difference 2021-10-07T10:45:02+02:00 daily 1.0 https://www.novartis.com/stories/specter-malaria-resists-treatment 2021-10-07T10:49:09+02:00 daily 1.0 https://www.novartis.com/stories/stepping-toward-regenerative-medicine-diabetes 2021-10-18T08:21:01+02:00 daily 1.0 https://www.novartis.com/stories/small-viruses-could-accelerate-cell-and-gene-therapy-research 2021-10-18T15:24:48+02:00 daily 1.0 https://www.novartis.com/stories/stopping-alzheimers-disease-it-starts 2021-10-07T10:52:35+02:00 daily 1.0 https://www.novartis.com/stories/stifling-danger-signals-rheumatoid-arthritis 2021-10-07T10:51:16+02:00 daily 1.0 https://www.novartis.com/stories/tackling-common-denominator-liver-disease 2021-10-07T10:55:11+02:00 daily 1.0 https://www.novartis.com/stories/systematically-exposing-vulnerabilities-cancer-cells 2022-01-11T09:33:46+01:00 daily 1.0 https://www.novartis.com/stories/taking-clinical-trials-next-level-through-technology 2021-10-07T10:59:00+02:00 daily 1.0 https://www.novartis.com/stories/taking-obesity 2021-10-18T15:26:11+02:00 daily 1.0 https://www.novartis.com/stories/tracking-patients-progress-radio-signals-and-machine-learning 2021-10-07T11:30:50+02:00 daily 1.0 https://www.novartis.com/stories/talking-bruno-strigini-why-were-entering-transformative-time-cancer-care 2021-10-07T11:26:16+02:00 daily 1.0 https://www.novartis.com/stories/teaming-academia-discover-medicines 2021-10-07T11:28:03+02:00 daily 1.0 https://www.novartis.com/stories/turning-research-advances-innovative-medicines 2021-11-23T16:15:54+01:00 daily 1.0 https://www.novartis.com/stories/women-science-cathryn-clary 2021-10-19T06:42:09+02:00 daily 1.0 https://www.novartis.com/stories/visualizing-immuno-oncology-research 2023-04-11T15:58:47+02:00 daily 1.0 https://www.novartis.com/stories/women-science-kristen-harrington-smith 2021-10-07T11:42:54+02:00 daily 1.0 https://www.novartis.com/stories/women-science-annie-martin 2021-10-07T11:39:50+02:00 daily 1.0 https://www.novartis.com/stories/women-science-mimi-huizinga 2021-10-07T11:56:55+02:00 daily 1.0 https://www.novartis.com/stories/women-science-hannah-mosca 2021-10-19T06:34:41+02:00 daily 1.0 https://www.novartis.com/stories/women-science-lauren-abrey 2021-10-07T11:43:54+02:00 daily 1.0 https://www.novartis.com/stories/women-science-sandrine-piret-gerard 2021-10-07T11:58:35+02:00 daily 1.0 https://www.novartis.com/stories/women-science-renee-rodgers 2021-10-07T11:57:43+02:00 daily 1.0 https://www.novartis.com/stories/women-science-lilli-petruzzelli 2021-10-07T11:45:02+02:00 daily 1.0 https://www.novartis.com/stories/women-science-shilpa-shah-mehta 2021-09-28T12:36:21+02:00 daily 1.0 https://www.novartis.com/stories/women-science-shannon-campbell 2021-10-07T11:59:29+02:00 daily 1.0 https://www.novartis.com/stories/women-science-susanne-schaffert 2021-10-07T12:00:55+02:00 daily 1.0 https://www.novartis.com/stories/women-science-medy-attalla 2021-10-07T11:51:41+02:00 daily 1.0 https://www.novartis.com/stories/word-street-what-cell-and-gene-therapy 2021-10-07T12:03:47+02:00 daily 1.0 https://www.novartis.com/stories/women-science-tania-small 2021-10-07T12:02:01+02:00 daily 1.0 https://www.novartis.com/stories/3-d-printing-scientists-reinvent-research-tools 2021-10-07T12:05:57+02:00 daily 1.0 https://www.novartis.com/stories/women-science-virginia-lazala 2021-10-18T14:39:45+02:00 daily 1.0 https://www.novartis.com/stories/bringing-virtual-reality-lab 2022-01-11T09:54:21+01:00 daily 1.0 https://www.novartis.com/stories/brain-dish-researchers-take-neurological-disorders 2021-10-07T12:08:17+02:00 daily 1.0 https://www.novartis.com/stories/5-tips-making-smart-decisions-research-projects 2021-10-07T12:06:40+02:00 daily 1.0 https://www.novartis.com/stories/building-brain-organoids-shed-light-disease 2021-10-07T12:09:56+02:00 daily 1.0 https://www.novartis.com/stories/cancer-spies-find-drug-beating-covert-cells 2021-07-21T14:55:17+02:00 daily 1.0 https://www.novartis.com/stories/can-we-edit-our-genes-fight-disease 2021-09-13T11:20:18+02:00 daily 1.0 https://www.novartis.com/stories/chemical-genetics-sleuthing-behind-modern-drug-discovery 2021-10-07T12:14:12+02:00 daily 1.0 https://www.novartis.com/stories/could-digital-technology-drive-clinical-research-africa 2021-10-07T12:15:19+02:00 daily 1.0 https://www.novartis.com/stories/disease-pathways-key-new-drug-discovery 2021-10-07T12:18:57+02:00 daily 1.0 https://www.novartis.com/stories/electrical-brainstorms-traced-genetic-mutations 2021-10-07T12:43:58+02:00 daily 1.0 https://www.novartis.com/stories/crispr-genome-editing-fuels-cancer-drug-discovery 2021-10-18T09:44:31+02:00 daily 1.0 https://www.novartis.com/stories/countering-genome-reprogramming-cancer-cells 2021-10-18T08:26:48+02:00 daily 1.0 https://www.novartis.com/stories/eye-disease-tracked-glitch-starburst-cells 2021-10-07T12:45:00+02:00 daily 1.0 https://www.novartis.com/stories/five-things-look-scientific-mentor 2021-10-07T12:48:50+02:00 daily 1.0 https://www.novartis.com/stories/hooked-science-jay-bradner-becomes-top-researcher-novartis 2021-10-07T13:02:26+02:00 daily 1.0 https://www.novartis.com/stories/hardwiring-future 2021-10-07T13:01:34+02:00 daily 1.0 https://www.novartis.com/stories/giraffes-have-high-blood-pressure-why-dont-they-drop-dead 2021-10-07T13:00:25+02:00 daily 1.0 https://www.novartis.com/stories/fixing-whats-lost-translation 2021-10-07T12:59:32+02:00 daily 1.0 https://www.novartis.com/stories/how-address-culture-gap-between-academia-and-industry-biomedicine 2021-10-07T14:46:10+02:00 daily 1.0 https://www.novartis.com/stories/improving-science-communication-3-easy-steps 2021-10-07T13:07:35+02:00 daily 1.0 https://www.novartis.com/stories/mhealth-revolution-healthcare 2021-10-07T13:09:14+02:00 daily 1.0 https://www.novartis.com/stories/how-i-built-mini-gut-next-no-biology-training 2021-10-07T13:05:22+02:00 daily 1.0 https://www.novartis.com/stories/how-zika-infects-growing-brain 2021-10-07T13:06:08+02:00 daily 1.0 https://www.novartis.com/stories/minion-challenges-assumptions-about-genome 2021-10-07T13:10:05+02:00 daily 1.0 https://www.novartis.com/stories/molecular-glue-kills-cancer-cells-mice 2022-01-07T09:04:45+01:00 daily 1.0 https://www.novartis.com/stories/letters-my-younger-self-female-scientists-share-their-wisdom 2021-10-07T13:08:20+02:00 daily 1.0 https://www.novartis.com/stories/neuroscientists-target-alzheimers-silent-stage 2021-10-07T13:12:17+02:00 daily 1.0 https://www.novartis.com/stories/nurturing-life-science-ecosystem 2021-10-07T13:14:24+02:00 daily 1.0 https://www.novartis.com/stories/opening-chemistry-education-world 2021-10-07T13:15:17+02:00 daily 1.0 https://www.novartis.com/stories/rebuilding-blood 2021-10-07T13:16:18+02:00 daily 1.0 https://www.novartis.com/stories/rediscovering-power-natures-exquisite-complexity 2021-10-07T13:17:33+02:00 daily 1.0 https://www.novartis.com/stories/reigniting-passion-science 2021-10-07T13:17:40+02:00 daily 1.0 https://www.novartis.com/stories/reimagining-protein-sequencing 2021-10-07T13:16:50+02:00 daily 1.0 https://www.novartis.com/stories/robots-speed-pace-modern-drug-discovery 2022-01-07T08:53:12+01:00 daily 1.0 https://www.novartis.com/stories/stopping-free-radicals-their-source 2021-10-18T10:44:53+02:00 daily 1.0 https://www.novartis.com/stories/novartis-antibody-increases-muscle-growth-mice-and-human-cell-cultures 2021-10-18T08:13:19+02:00 daily 1.0 https://www.novartis.com/stories/surfing-wave-big-data-analytics 2021-10-18T15:31:43+02:00 daily 1.0 https://www.novartis.com/stories/three-lessons-ive-learned-industry-postdoc 2021-10-07T11:12:25+02:00 daily 1.0 https://www.novartis.com/stories/turning-heat-tumors 2021-10-07T11:21:04+02:00 daily 1.0 https://www.novartis.com/stories/visual-tour-scientific-strategies-combating-coronavirus 2022-01-10T09:20:55+01:00 daily 1.0 https://www.novartis.com/stories/vision-hacker 2021-10-07T11:28:09+02:00 daily 1.0 https://www.novartis.com/stories/tuning-drugs-succeed-cells-surface 2021-10-18T10:16:57+02:00 daily 1.0 https://www.novartis.com/stories/women-science-alexandra-bach-weidmuller 2021-10-07T11:46:01+02:00 daily 1.0 https://www.novartis.com/stories/what-goes-wrong-window-soul-glaucoma 2021-10-18T10:23:58+02:00 daily 1.0 https://www.novartis.com/stories/when-tiny-brains-are-best-brain-research 2021-10-07T11:33:33+02:00 daily 1.0 https://www.novartis.com/stories/women-science-jean-silveri 2021-10-07T12:43:01+02:00 daily 1.0 https://www.novartis.com/stories/women-science-cyndy-grosskreutz 2021-10-07T12:41:30+02:00 daily 1.0 https://www.novartis.com/stories/turning-power-nuclear-technology-medical-force 2021-11-25T16:08:34+01:00 daily 1.0 https://www.novartis.com/stories/women-science-jennifer-allport-anderson 2021-10-07T12:44:38+02:00 daily 1.0 https://www.novartis.com/stories/young-talent-emerging-technologies-come-together-biocamp 2021-10-07T12:52:48+02:00 daily 1.0 https://www.novartis.com/stories/2-million-kids-receive-malaria-medicine 2021-11-16T11:53:01+01:00 daily 1.0 https://www.novartis.com/stories/women-science-wendy-winckler 2021-10-11T15:39:31+02:00 daily 1.0 https://www.novartis.com/stories/women-science-marjorie-eiref 2021-10-18T08:19:57+02:00 daily 1.0 https://www.novartis.com/stories/ai-changing-face-healthcare 2021-10-07T12:57:25+02:00 daily 1.0 https://www.novartis.com/stories/asian-health-experts-call-final-push-wipe-out-deadliest-form-malaria 2023-07-03T17:16:31+02:00 daily 1.0 https://www.novartis.com/stories/bringing-chagas-disease-peoples-attention 2021-10-13T08:24:01+02:00 daily 1.0 https://www.novartis.com/stories/bringing-modern-medicine-rural-vietnam 2022-06-08T10:29:09+02:00 daily 1.0 https://www.novartis.com/stories/cancer-didnt-stop-covid-19 2021-10-18T11:08:06+02:00 daily 1.0 https://www.novartis.com/stories/collaboration-strengthening-care-chronic-illness-ethiopia 2021-10-07T13:11:18+02:00 daily 1.0 https://www.novartis.com/stories/chagas-disease-breaking-silence 2021-10-07T13:12:12+02:00 daily 1.0 https://www.novartis.com/stories/confronting-global-spread-chronic-disease 2021-10-07T13:06:03+02:00 daily 1.0 https://www.novartis.com/stories/tackling-rare-disease-working-toward-treatment-sma 2021-10-07T10:56:23+02:00 daily 1.0 https://www.novartis.com/stories/sleuths-use-hi-tech-sensors-fight-pharmaceutical-crime 2021-10-18T10:49:49+02:00 daily 1.0 https://www.novartis.com/stories/dealing-spread-chronic-disease-africa 2021-10-07T13:02:28+02:00 daily 1.0 https://www.novartis.com/stories/fighting-malaria-africa 2022-06-10T10:21:56+02:00 daily 1.0 https://www.novartis.com/stories/ensuring-medicine-supply-patients-during-covid-19 2021-10-13T09:10:15+02:00 daily 1.0 https://www.novartis.com/stories/fighting-respiratory-disease-source 2021-10-07T12:54:29+02:00 daily 1.0 https://www.novartis.com/stories/delivering-access-first-launch-kenya 2023-07-04T12:04:14+02:00 daily 1.0 https://www.novartis.com/stories/health-collaboration-russia-helped-reduce-blood-pressure-deaths 2021-10-18T11:32:58+02:00 daily 1.0 https://www.novartis.com/stories/fighting-pneumonia-biggest-killer-young-children 2021-10-07T12:55:38+02:00 daily 1.0 https://www.novartis.com/stories/kenya-confronts-chronic-diseases-building-progress-against-aids 2021-10-13T10:25:07+02:00 daily 1.0 https://www.novartis.com/stories/helping-people-sickle-cell-disease-painful-and-life-threatening-blood-disorder 2021-10-07T11:53:32+02:00 daily 1.0 https://www.novartis.com/stories/helping-syrian-refugees-manage-chronic-diseases 2021-10-07T11:52:45+02:00 daily 1.0 https://www.novartis.com/stories/improving-lives-through-community-based-care 2023-04-11T16:06:58+02:00 daily 1.0 https://www.novartis.com/stories/sight-savers-jet-rescue 2021-10-14T12:13:48+02:00 daily 1.0 https://www.novartis.com/stories/streamlining-systems-respond-covid-19 2021-10-14T12:21:47+02:00 daily 1.0 https://www.novartis.com/stories/tailoring-tactics-tackle-chronic-disease-low-income-countries 2021-10-14T12:39:12+02:00 daily 1.0 https://www.novartis.com/stories/talking-ann-aerts-head-novartis-foundation 2023-07-04T16:34:31+02:00 daily 1.0 https://www.novartis.com/stories/life-dedicated-fighting-malaria 2021-11-17T15:28:51+01:00 daily 1.0 https://www.novartis.com/stories/living-breast-cancer-uganda 2021-10-13T11:00:21+02:00 daily 1.0 https://www.novartis.com/stories/living-hypertension-cameroon-few-dollars-day 2021-09-28T14:41:19+02:00 daily 1.0 https://www.novartis.com/stories/malaria-fighter-rides-bicycle-battle-disease 2021-10-13T12:26:09+02:00 daily 1.0 https://www.novartis.com/stories/malaria-still-disrupting-lives-despite-progress 2021-10-13T13:19:02+02:00 daily 1.0 https://www.novartis.com/stories/talking-juergen-brokatzky-geiger-global-head-corporate-responsibility-novartis 2021-10-11T13:40:12+02:00 daily 1.0 https://www.novartis.com/stories/talking-patrice-matchaba-global-head-corporate-responsibility-novartis 2021-10-07T10:49:27+02:00 daily 1.0 https://www.novartis.com/stories/telemedicine-taking-health-care-worlds-far-corners 2022-05-24T16:12:47+02:00 daily 1.0 https://www.novartis.com/stories/text-messages-africa-help-fight-malaria 2021-11-18T16:25:22+01:00 daily 1.0 https://www.novartis.com/stories/treating-cataracts-leading-cause-preventable-blindness-worldwide 2021-10-07T10:46:15+02:00 daily 1.0 https://www.novartis.com/stories/women-science-fionnuala-doyle 2021-10-07T10:44:52+02:00 daily 1.0 https://www.novartis.com/stories/fighting-ms-through-innovation 2021-10-11T13:33:22+02:00 daily 1.0 https://www.novartis.com/stories/from-melanoma-survivor-front-line-nurse 2021-09-29T07:18:25+02:00 daily 1.0 https://www.novartis.com/stories/ai-nurse-evolving-heart-failure-patients-china 2021-12-14T12:32:41+01:00 daily 1.0 https://www.novartis.com/stories/body-painter-captures-anguish-those-who-suffer-from-psoriasis 2023-07-04T09:30:26+02:00 daily 1.0 https://www.novartis.com/stories/changing-landscape-cancer-treatment 2023-07-04T11:43:33+02:00 daily 1.0 https://www.novartis.com/stories/caring-someone-heart-failure 2023-07-24T13:42:04+02:00 daily 1.0 https://www.novartis.com/stories/choosing-right-care 2021-10-07T10:22:32+02:00 daily 1.0 https://www.novartis.com/stories/conversations-patient-advocates-ron-hollander-president-inca 2021-10-07T10:21:12+02:00 daily 1.0 https://www.novartis.com/stories/coping-eye-disease-and-fading-vision-late-life 2021-10-07T10:07:58+02:00 daily 1.0 https://www.novartis.com/stories/meet-manuel-cobos-transplant-surgeon-and-researcher 2021-10-13T14:51:37+02:00 daily 1.0 https://www.novartis.com/stories/creative-ways-help-kids-understand-rare-diseases 2021-10-11T13:15:33+02:00 daily 1.0 https://www.novartis.com/stories/dealing-psoriasis 2022-02-14T15:53:07+01:00 daily 1.0 https://www.novartis.com/stories/debunking-myths-about-multiple-sclerosis 2021-10-07T10:03:44+02:00 daily 1.0 https://www.novartis.com/stories/digital-innovation-looks-set-dominate-2021-healthcare-agenda 2023-07-04T12:08:30+02:00 daily 1.0 https://www.novartis.com/stories/digital-health-providing-opportunities-advocacy-groups-and-community-patients 2021-10-07T10:02:05+02:00 daily 1.0 https://www.novartis.com/stories/meet-martin-grobusch-malaria-fighter 2021-10-13T15:53:46+02:00 daily 1.0 https://www.novartis.com/stories/experts-call-new-approach-patient-and-physician-management-type-2-diabetes 2021-10-07T09:59:01+02:00 daily 1.0 https://www.novartis.com/stories/giving-small-community-big-voice 2021-10-15T15:57:22+02:00 daily 1.0 https://www.novartis.com/stories/fitness-trainer-strives-keep-his-mothers-mind-limber 2021-10-11T11:48:50+02:00 daily 1.0 https://www.novartis.com/stories/from-nurse-patient-facing-aggressive-blood-cancer 2021-10-18T06:19:36+02:00 daily 1.0 https://www.novartis.com/stories/glaucoma-silently-steals-sight 2021-10-15T15:53:20+02:00 daily 1.0 https://www.novartis.com/stories/meet-visionary-who-beat-odds-realize-his-vision-inclusive-eye-care 2023-07-04T15:38:55+02:00 daily 1.0 https://www.novartis.com/stories/groundskeeper-tackles-cancer-several-ways 2021-10-15T15:50:32+02:00 daily 1.0 https://www.novartis.com/stories/heart-failure-coping-one-worlds-biggest-killers 2021-10-15T15:45:59+02:00 daily 1.0 https://www.novartis.com/stories/importance-caregivers 2021-10-15T15:39:28+02:00 daily 1.0 https://www.novartis.com/stories/inside-cancer-diagnosis 2021-10-15T14:51:02+02:00 daily 1.0 https://www.novartis.com/stories/patients-perspective-biomarker-testing 2021-10-15T11:46:39+02:00 daily 1.0 https://www.novartis.com/stories/led-steven-taylor-sjogrens-syndrome-foundation-raising-awareness-little-known-autoimmune-disease 2021-10-08T10:39:04+02:00 daily 1.0 https://www.novartis.com/stories/lessons-from-blind-chef 2022-01-07T09:19:03+01:00 daily 1.0 https://www.novartis.com/stories/living-heart-failure 2021-10-15T11:45:48+02:00 daily 1.0 https://www.novartis.com/stories/living-hfpef-patients-story 2021-11-17T17:37:31+01:00 daily 1.0 https://www.novartis.com/stories/longevity-vitality-japanese-elders-provide-examples-healthy-aging 2021-10-15T12:09:23+02:00 daily 1.0 https://www.novartis.com/stories/lung-cancer-test-or-not-test 2021-10-14T14:28:13+02:00 daily 1.0 https://www.novartis.com/stories/meet-tj-sharpe 2023-07-04T15:36:44+02:00 daily 1.0 https://www.novartis.com/stories/most-europeans-have-limited-awareness-about-heart-failure 2022-01-07T09:11:28+01:00 daily 1.0 https://www.novartis.com/stories/migraine-one-worlds-most-common-diseases 2021-10-14T14:11:18+02:00 daily 1.0 https://www.novartis.com/stories/new-years-resolution-copd 2021-10-14T13:51:17+02:00 daily 1.0 https://www.novartis.com/stories/no-longer-living-fear 2021-10-15T12:22:53+02:00 daily 1.0 https://www.novartis.com/stories/one-boys-quest-battle-cancer 2023-07-04T16:05:46+02:00 daily 1.0 https://www.novartis.com/stories/parenting-child-rare-disease 2023-07-04T16:10:37+02:00 daily 1.0 https://www.novartis.com/stories/patient-advocacy-work-one-mans-contributions-copd-community 2021-10-14T13:01:39+02:00 daily 1.0 https://www.novartis.com/stories/psoriasis-story-hidden-condition 2021-10-11T11:09:07+02:00 daily 1.0 https://www.novartis.com/stories/putting-patients-first 2022-02-14T11:58:04+01:00 daily 1.0 https://www.novartis.com/stories/rare-every-day-experiences-challenges-and-victories-rare-disease-community 2021-09-30T09:08:16+02:00 daily 1.0 https://www.novartis.com/stories/protecting-our-tomorrows-portraits-meningococcal-disease 2021-10-14T11:41:25+02:00 daily 1.0 https://www.novartis.com/stories/realities-living-premenopausal-metastatic-breast-cancer 2021-11-17T11:46:58+01:00 daily 1.0 https://www.novartis.com/stories/reimagining-asthma-care-how-data-and-digital-could-bring-asthma-management-goals-within-reach 2023-07-04T16:15:04+02:00 daily 1.0 https://www.novartis.com/stories/surviving-heart-failure 2022-06-21T15:49:35+02:00 daily 1.0 https://www.novartis.com/stories/speaking-cml 2021-09-29T10:00:07+02:00 daily 1.0 https://www.novartis.com/stories/targeting-roots-sjogrens-syndrome 2021-09-29T10:18:29+02:00 daily 1.0 https://www.novartis.com/stories/tj-sharpe-why-clinical-trials-matter 2023-07-04T16:36:55+02:00 daily 1.0 https://www.novartis.com/stories/visionary-silke-mader-has-vision-care-premature-infants-and-their-parents 2021-10-11T10:30:01+02:00 daily 1.0 https://www.novartis.com/stories/why-research-rare-diseases-matters 2021-08-25T13:31:50+02:00 daily 1.0 https://www.novartis.com/stories/turning-sound-patient-voices-lung-cancer-research-and-development 2021-10-01T07:49:32+02:00 daily 1.0 https://www.novartis.com/stories/flexibility-novartis-ana-graf 2021-09-29T11:17:57+02:00 daily 1.0 https://www.novartis.com/stories/enabling-130000-employees-grow-organization-committed-continuous-learning 2021-09-29T10:38:57+02:00 daily 1.0 https://www.novartis.com/stories/your-genes-your-melanoma 2021-09-29T10:27:17+02:00 daily 1.0 https://www.novartis.com/stories/flexibility-novartis-deepti-mittal 2021-09-29T11:20:57+02:00 daily 1.0 https://www.novartis.com/stories/flexibility-novartis-christine-sturchler-and-aileen-wrynn 2021-10-14T07:23:16+02:00 daily 1.0 https://www.novartis.com/stories/flexibility-novartis-janneke-van-der-kamp 2021-09-29T11:22:04+02:00 daily 1.0 https://www.novartis.com/stories/flexibility-novartis-peter-canavan 2021-10-14T06:37:46+02:00 daily 1.0 https://www.novartis.com/stories/flexibility-novartis-linda-karpiak 2021-09-29T11:23:23+02:00 daily 1.0 https://www.novartis.com/stories/flexibility-novartis-robert-gschwentner-and-stefan-lackner 2021-10-14T06:27:54+02:00 daily 1.0 https://www.novartis.com/stories/going-extra-mile-keep-clinical-trials-track-during-covid-19-pandemic 2021-09-29T12:37:53+02:00 daily 1.0 https://www.novartis.com/stories/flexibility-novartis-shamsah-kazani 2021-11-16T11:15:40+01:00 daily 1.0 https://www.novartis.com/stories/novartis-social-business-careers-improving-health-lower-income-countries 2022-01-07T09:00:43+01:00 daily 1.0 https://www.novartis.com/stories/oncology-careers-life-changing-purpose 2021-09-29T12:46:25+02:00 daily 1.0 https://www.novartis.com/stories/parental-leave-novartis-alfreds-story 2022-05-24T16:23:14+02:00 daily 1.0 https://www.novartis.com/stories/parental-leave-novartis-michaels-story 2021-11-23T16:50:24+01:00 daily 1.0 https://www.novartis.com/stories/nudging-bias-out-organization 2021-09-23T11:39:01+02:00 daily 1.0 https://www.novartis.com/stories/qa-new-nibr-cio-dimitris-agrafiotis 2021-09-30T14:50:31+02:00 daily 1.0 https://www.novartis.com/stories/reimagining-cancer-workplace 2021-09-29T12:52:28+02:00 daily 1.0 https://www.novartis.com/stories/teaching-daughter-power-purpose 2021-10-14T10:09:52+02:00 daily 1.0 https://www.novartis.com/stories/two-decades-volunteering-novartis 2021-10-11T10:18:12+02:00 daily 1.0 https://www.novartis.com/stories/making-healthcare-sustainable-developing-world 2021-10-06T07:37:52+02:00 daily 1.0 https://www.novartis.com/stories/positive-gains-are-needed-accelerate-change-women-lung-disease 2021-10-01T10:03:00+02:00 daily 1.0 https://www.novartis.com/stories/new-drugs-could-offer-hope-malaria-patients 2021-10-03T16:01:27+02:00 daily 1.0 https://www.novartis.com/stories/partnering-improved-cancer-care-around-globe 2021-10-07T11:03:23+02:00 daily 1.0 https://www.novartis.com/stories/pioneering-business-approach-expands-healthcare-indian-villages 2021-10-14T11:57:33+02:00 daily 1.0 https://www.novartis.com/stories/novartis-joins-pharma-wide-effort-meet-global-demand-covid-19-vaccines 2022-05-20T15:35:45+02:00 daily 1.0 https://www.novartis.com/stories/new-orbis-flying-eye-hospital-helps-fight-blindness-china 2021-10-14T08:54:03+02:00 daily 1.0 https://www.novartis.com/stories/novartis-access-impact-evaluation-progress-update-our-work-boston-university 2021-10-01T10:07:32+02:00 daily 1.0 https://www.novartis.com/stories/novartis-invites-scrutiny-effort-improve-access-medicine 2022-06-07T17:08:17+02:00 daily 1.0 https://www.novartis.com/stories/artificial-intelligence-decodes-cancer-pathology-images-without-image-gallery 2021-08-24T11:51:26+02:00 daily 1.0 https://www.novartis.com/stories/can-data-from-heart-disease-trial-lead-potential-cancer-treatment 2021-09-30T14:48:46+02:00 daily 1.0 https://www.novartis.com/stories/cancer-research-drives-breast-cancer-treatment-forward 2021-09-30T09:47:34+02:00 daily 1.0 https://www.novartis.com/stories/discovery-gives-cystic-fibrosis-researchers-new-direction 2021-10-11T10:39:37+02:00 daily 1.0 https://www.novartis.com/stories/guidance-system-lights-path-drug-discovery 2021-10-18T09:03:23+02:00 daily 1.0 https://www.novartis.com/stories/need-new-heart-disease-medicines-drives-wave-potential-therapies 2021-09-30T11:20:32+02:00 daily 1.0 https://www.novartis.com/stories/researchers-boost-understanding-t-cell-therapy-blood-cancer 2021-09-30T11:41:44+02:00 daily 1.0 https://www.novartis.com/stories/novartis-and-uc-berkeley-take-undruggable-proteins-new-collaboration 2022-05-24T16:17:59+02:00 daily 1.0 https://www.novartis.com/stories/striving-vanquish-leukemia 2021-09-27T11:08:05+02:00 daily 1.0 https://www.novartis.com/stories/sourcing-innovation-strategically 2021-09-30T12:12:06+02:00 daily 1.0 https://www.novartis.com/stories/take-visual-tour-medicines-target-rna 2022-06-21T17:13:21+02:00 daily 1.0 https://www.novartis.com/stories/toward-improving-health-and-longevity-transplanted-organs 2021-09-30T15:13:47+02:00 daily 1.0 https://www.novartis.com/stories/using-super-resolution-microscopy-see-neurodegeneration 2021-09-30T15:30:39+02:00 daily 1.0 https://www.novartis.com/stories/visualizing-molecular-glues 2021-09-30T15:43:23+02:00 daily 1.0 https://www.novartis.com/stories/advancing-medicine-through-collaboration 2021-09-30T16:00:24+02:00 daily 1.0 https://www.novartis.com/stories/how-19th-century-technology-speeding-drug-discovery 2021-09-30T16:13:22+02:00 daily 1.0 https://www.novartis.com/stories/seeing-through-knees-quest-alleviate-osteoarthritis 2021-09-30T16:17:25+02:00 daily 1.0 https://www.novartis.com/stories/why-novartis-scouts-disruptive-technology 2021-09-30T16:30:01+02:00 daily 1.0 https://www.novartis.com/stories/future-chronic-myeloid-leukemia-evolving 2021-10-15T16:05:57+02:00 daily 1.0 https://www.novartis.com/stories/inspiring-daughter-make-her-own-path 2021-10-15T12:05:00+02:00 daily 1.0 https://www.novartis.com/stories/being-and-becoming-data-science-company 2021-09-30T14:30:36+02:00 daily 1.0 https://www.novartis.com/stories/doing-right-thing-good-business 2021-10-11T08:41:26+02:00 daily 1.0 https://www.novartis.com/stories/discover-how-inflammation-could-fan-flames-cancer 2021-10-11T10:42:18+02:00 daily 1.0 https://www.novartis.com/stories/your-neighborhood-community-based-approach-health-equity-us 2021-10-26T16:09:50+02:00 daily 1.0 https://www.novartis.com/stories/search-new-options-patients-lung-cancer 2021-10-01T12:27:18+02:00 daily 1.0 https://www.novartis.com/stories/toward-regrowing-cartilage 2023-07-04T16:46:35+02:00 daily 1.0 https://www.novartis.com/stories/blood-cancer-patients-long-road-diagnosis 2021-10-15T12:02:17+02:00 daily 1.0 https://www.novartis.com/stories/photographer-captures-patients-around-world-persevering-itp 2021-10-08T08:09:48+02:00 daily 1.0 https://www.novartis.com/stories/expanding-new-digital-healthcare-solution-across-chronic-heart-disease-management 2021-10-11T08:39:32+02:00 daily 1.0 https://www.novartis.com/stories/restoring-vision-and-hope-thousands-southeast-asia 2023-02-06T10:13:26+01:00 daily 1.0 https://www.novartis.com/stories/demystifying-science-myelodysplastic-syndromes 2023-02-06T10:13:06+01:00 daily 1.0 https://www.novartis.com/stories/breaking-down-barriers-patients-sickle-cell-disease 2023-02-06T10:12:35+01:00 daily 1.0 https://www.novartis.com/stories/make-difference-start-patients 2023-02-06T10:12:51+01:00 daily 1.0 https://www.novartis.com/stories/solving-puzzle-immunotherapy 2023-04-11T15:57:36+02:00 daily 1.0 https://www.novartis.com/stories/stopping-coronavirus-and-next-one 2023-02-06T10:11:58+01:00 daily 1.0 https://www.novartis.com/stories/art-drug-design-technological-age 2023-02-06T10:11:41+01:00 daily 1.0 https://www.novartis.com/stories/when-it-comes-cancer-theres-power-good-partner 2023-02-06T10:11:08+01:00 daily 1.0 https://www.novartis.com/stories/prioritizing-needs-patients 2023-02-06T10:10:30+01:00 daily 1.0 https://www.novartis.com/stories/understanding-hidradenitis-suppurativa-through-jasmines-eyes 2022-03-25T10:27:19+01:00 daily 1.0 https://www.novartis.com/stories/tackling-health-toll-climate-change 2022-04-06T15:38:18+02:00 daily 1.0 https://www.novartis.com/stories/staying-one-step-ahead-malaria-parasite 2022-04-19T18:16:06+02:00 daily 1.0 https://www.novartis.com/stories/boosting-access-cancer-care-where-its-needed-most 2022-06-13T09:30:28+02:00 daily 1.0 https://www.novartis.com/stories/how-emilys-act-bravery-inspired-wave-continued-innovation 2023-02-06T10:09:32+01:00 daily 1.0 https://www.novartis.com/stories/prostate-cancer-collective-commitment-serving-underserved-communities 2022-06-13T09:12:51+02:00 daily 1.0 https://www.novartis.com/stories/shared-mission-take-impossible-cancer-research 2022-06-15T08:37:00+02:00 daily 1.0 https://www.novartis.com/stories/sickle-cell-screening-urged-newborns-africa 2023-02-06T09:22:58+01:00 daily 1.0 https://www.novartis.com/stories/renewing-our-commitment-neglected-tropical-disease-and-malaria-elimination 2022-06-23T07:30:04+02:00 daily 1.0 https://www.novartis.com/stories/lets-talk-about-c-word-navigating-cancer-diagnosis-and-life-beyond-it-leanne-pero 2022-10-12T16:02:31+02:00 daily 1.0 https://www.novartis.com/stories/neuroscience-inflection-point-knowledge-and-technology 2022-10-13T22:47:12+02:00 daily 1.0 https://www.novartis.com/stories/scientist-from-start-qa-nibr-president-fiona-marshall 2022-11-01T12:41:44+01:00 daily 1.0 https://www.novartis.com/stories/prostate-cancer-and-support-care-partner-carl-and-arlenes-story 2023-02-16T15:34:10+01:00 daily 1.0 https://www.novartis.com/stories/compassionate-use-providing-access-much-needed-treatments 2023-02-06T09:19:07+01:00 daily 1.0 https://www.novartis.com/stories/when-you-think-word-cancer-what-are-first-words-spring-mind 2023-04-24T15:44:38+02:00 daily 1.0 https://www.novartis.com/stories/qa-addressing-unmet-needs-people-living-pnh-rare-and-chronic-blood-disorder 2023-08-29T14:32:50+02:00 daily 1.0 https://www.novartis.com/stories/future-medicine-here 2023-05-30T09:55:27+02:00 daily 1.0 https://www.novartis.com/stories/treatments-blood-cancers-and-serious-blood-disorders-are-advancing-rapidly-novartis-helping-lead-way 2023-09-08T15:13:36+02:00 daily 1.0 https://www.novartis.com/stories/how-i-found-my-true-purpose-novartis 2023-11-28T08:16:01+01:00 daily 1.0 https://www.novartis.com/stories/belonging-here-how-novartis-helped-me-come-out-transgender-woman 2023-11-28T08:16:49+01:00 daily 1.0 https://www.novartis.com/stories/mentoring-matters-how-we-grow-together-novartis 2023-11-28T08:14:32+01:00 daily 1.0 https://www.novartis.com/stories/beacon-hope-lights-way-more-equitable-future 2023-11-30T18:38:42+01:00 daily 1.0 https://www.novartis.com/stories/shoulder-to-shoulder 2023-12-08T17:10:45+01:00 daily 1.0 https://www.novartis.com/stories/innovation-fueled-compassion 2023-12-14T09:16:07+01:00 daily 1.0 https://www.novartis.com/stories/balancing-family-life-legal-career 2024-02-07T13:56:41+01:00 daily 1.0 https://www.novartis.com/stories/facing-fear-breast-cancer-recurrence 2024-02-05T10:04:04+01:00 daily 1.0 https://www.novartis.com/stories/partnership-against-epilepsy 2024-02-05T10:10:58+01:00 daily 1.0 https://www.novartis.com/stories/water-project-revives-rural-community-india 2024-02-05T09:59:30+01:00 daily 1.0 https://www.novartis.com/stories/giving-voice-people-misunderstood-disease 2024-02-05T10:08:14+01:00 daily 1.0 https://www.novartis.com/stories/cancer-patient-gets-new-lease-life 2024-01-29T15:21:43+01:00 daily 1.0 https://www.novartis.com/stories/empowering-next-generation-healthcare-leaders 2024-01-29T15:23:04+01:00 daily 1.0 https://www.novartis.com/stories/going-upstream-improve-heart-health-philadelphia 2024-01-26T11:32:14+01:00 daily 1.0 https://www.novartis.com/stories/colombia-researcher-works-against-devastating-disease 2024-01-26T11:32:56+01:00 daily 1.0 https://www.novartis.com/stories/how-collaboration-can-enhance-your-science-career 2024-02-08T09:23:38+01:00 daily 1.0 https://www.novartis.com/stories/listening-cml-patient-community 2024-02-14T08:13:45+01:00 daily 1.0 https://www.novartis.com/stories/drug-delivery-service-delivery-and-future-cancer-care 2024-05-06T16:40:52+02:00 daily 1.0 https://www.novartis.com/stories/from-black-holes-ai-driven-drug-discovery-collaboration-wins-day 2024-04-30T09:58:46+02:00 daily 1.0 https://www.novartis.com/stories/personal-journey-full-circle-from-curiosity-about-life-earth-transformative-therapies-novartis 2024-05-27T08:09:18+02:00 daily 1.0 https://www.novartis.com/stories/legacy-blood-cancer-innovation 2024-06-04T18:08:58+02:00 daily 1.0 https://www.novartis.com/careers/career-search/job/details/390577br-pricing-manager 2024-06-06T12:00:17+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392731br-medical-director-dermatology-translational-medicine 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392841br-hire-retire-services-expert 2024-03-29T08:01:02+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/387793br-pnh-specialist-multiple-locations-may-be-considered 2024-04-18T08:00:41+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389256br-scientist-mst-senior-fmd 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393036br-sr-product-manager 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392824br-associate-country-qa-compliance 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392825br-associate-country-qa-operations-core-products 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392849br-hire-retire-services-expert-japanese 2024-04-22T10:00:36+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389544br-ad-disease-and-clinical-specialist-raleigh-remote 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392006br-rlt-drug-product-project-leader-dppl-mfd 2024-06-19T10:00:13+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392011br-rlt-analytical-project-leader-mfd 2024-06-19T10:00:13+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392016br-rlt-analytical-expert-mfd 2024-06-19T10:00:13+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392763br-cvm-therapeutic-area-biomarker-lead 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/385749br-lead-ta-medical-specialty 2024-03-07T10:00:44+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392162br-manager-gprm-japan 2024-04-11T06:00:39+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392671br-associate-director-lan-sol-architect-cz-spain-mexico 2024-06-25T14:00:11+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/381718br-sr-prin-clinical-data-scientist-prog-data-mgr 2024-05-28T20:00:17+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392585br-praktikant-mwd-der-internen-und-externen-kommunikation 2024-06-26T14:00:11+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392618br-clinical-bio-specimen-senior-scientist 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392457br-senior-lead-early-medical 2024-05-24T08:00:16+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389444br-technicien-de-production-controle-qualite-saint-genis-pouilly-hf 2024-06-11T14:00:14+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391014br-qc-lab-analyst-i-temp 2024-03-26T10:01:08+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392164br-associate-director-solution-delivery-mfd 2024-03-28T10:01:09+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391255br-director-quantitative-safety-statistician 2024-05-29T12:00:19+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392181br-site-quality-head 2024-06-28T10:00:11+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390047br-reliability-engineer 2024-05-07T08:00:33+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392110br-director-quantitative-solutions-engineering 2024-04-18T14:00:43+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/387537br-production-support-engineer-mfd 2024-04-16T12:00:41+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391836br-qa-supplier-management-specialist-ii-mfd 2024-06-13T10:00:13+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391864br-people-organization-hr-internship-fmd 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391716br-senior-specialist-data-science-ai-ml 2024-05-15T12:00:23+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/375810br-associate-director-ddit-im-data-products 2024-05-14T16:00:24+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/382952br-global-category-head-it-outsourcing-services 2024-06-27T10:00:10+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391175br-ad-access-reimbursement-radioligand-therapy-remote-arkansas 2024-05-23T14:00:23+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391268br-senior-process-expert-fmd 2024-06-21T14:00:11+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389458br-lead-senior-lead-rwe-bio-statistics-specialist 2024-06-12T02:00:12+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389542br-ad-disease-and-clinical-specialist-mn-ia-remote 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391152br-ad-access-reimbursement-radioligand-therapy-remote-salt-lake-city 2024-06-04T18:00:15+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391149br-ad-access-reimbursement-nps-radioligand-therapy-remote-seattle-wa 2024-06-20T16:00:14+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390989br-global-procurement-head-it-infrastructure-security 2024-06-27T10:00:10+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390604br-stagiaires-chef-de-projets-meetings-congres-et-evenements 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390639br-senior-principal-scientist-computational-medicinal-chemistry 2024-06-05T18:00:16+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390522br-stage-chef-de-produit-oncologie 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390198br-research-informatics-associate-director-business-relationship-mgmt 2024-04-20T00:00:37+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390364br-stage-excellence-medicale 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/369404br-associate-director-ddit-im-data-solution-delivery 2024-06-21T16:00:12+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386248br-solutions-delivery-lead-mdm 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386247br-mdm-products-lead 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390230br-sr-digital-operation-excellence 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390043br-manufacturing-projects-engineer 2024-05-07T08:00:33+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/383978br-lead-or-senior-lead-medical-solid 2024-06-03T10:00:14+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/384282br-time-service-delivery-expert-german-speaking 2024-05-31T10:00:17+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389960br-netzwerkmanager-mwd-prostate-cancer-rheinland-pfalz-und-saarland 2024-04-19T14:00:44+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386265br-director-commercial-it-architecture-advanced-therapies 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/383462br-chef-de-projet-data-hf 2024-03-08T16:00:50+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/388923br-crm-japan-program-clinical-head 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/388168br-project-engineer-mfd 2024-05-16T14:00:23+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386267br-commercial-it-domain-architect 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/365067br-public-affairs-manager-mwd 2024-03-12T14:01:00+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/377387br-senior-public-affairs-manager-dwm 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386319br-senior-brand-manager 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386320br-senior-brand-manager 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386403br-senior-brand-manager 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/383937br-cardiologist-physician-scientist-translational-medicine 2024-03-07T20:00:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386757br-lehrling-fur-den-lehrberuf-mechatronik-fertigungstechnik-mwd 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/384820br-lehrling-fur-den-lehrberuf-pharmatechnologie-mwd 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/384822br-lehrling-fur-den-lehrberuf-mechatronik-automatisierungstechnik-mwd 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/384823br-lehrling-fur-den-lehrberuf-labortechnik-chemie-mwd 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/384824br-lehrling-fur-den-lehrberuf-elektrotechnik-mwd 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/384825br-lehrling-fur-den-lehrberuf-chemieverfahrenstechnik-mwd 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/383771br-clinical-development-medical-director 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/383772br-sr-clinical-development-medical-director 2024-02-28T11:51:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/383989br-japan-program-manager 2024-05-28T10:00:18+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/383790br-senior-accounting-specialist-audit-experience 2024-03-27T12:01:10+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/377503br-business-insights-manager-wmd 2024-05-17T10:00:20+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393000br-omnichannel-engagement-manager-mwd 2024-06-18T08:00:11+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393193br-marketing-manager 2024-02-29T10:00:48+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/385022br-principal-software-engineer 2024-04-03T12:00:42+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/370538br-sales-representive-mwd-aschaffenburg-bad-mergentheim 2024-04-11T16:00:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392700br-market-access-manager-mwd-hospital-care-radioligandentherapien 2024-06-10T10:00:17+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393350br-allergy-area-business-leader-detroit-mi-remote 2024-06-14T18:00:12+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393380br-lead-medical-science 2024-04-22T06:00:38+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393397br-senior-brand-manager 2024-03-04T08:00:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393204br-saperp-deployment-director 2024-06-12T12:00:12+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393522br-qa-officer 2024-04-11T10:00:43+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393545br-site-quality-lead-saint-genis-pouilly-01-hf 2024-06-25T14:00:11+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393561br-it-assistant-digital-workspace-et-projet-it 2024-03-05T14:01:01+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393573br-business-data-migration-expert-sales-management 2024-03-26T12:01:13+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393564br-medical-director-clinical-pharmacology 2024-03-05T18:00:54+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393655br-people-engagement-expert 2024-04-17T04:00:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/357636br-werkstudent-der-pharmazeutischen-produktion-mwd 2024-03-06T14:00:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393798br-responsable-technique-industrie-radiopharmaceutique-toulouse-hf 2024-06-12T08:00:13+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393801br-clinical-biospecimen-expert-scientist 2024-03-07T18:00:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393835br-marketing-coe-lead 2024-03-25T06:00:56+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393841br-japan-clinical-trial-lead 2024-03-08T06:00:54+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/387389br-assoc-director-scrum-master 2024-03-08T16:00:50+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393708br-applied-computational-biologist-renal-i 2024-03-08T16:00:50+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393342br-associate-director-ms-pbpk 2024-05-23T20:00:19+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393189br-chef-de-produit-rhumato-hf 2024-03-12T12:00:53+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391288br-head-health-data-insights-design 2024-03-12T22:00:52+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394166br-associate-product-manager 2024-03-13T10:00:56+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393205br-real-estate-lead-architecture-laboratories 2024-05-02T14:00:33+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394289br-lead-cx-content-creation 2024-05-27T10:00:18+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393223br-senior-regulatory-writer 2024-03-15T00:00:56+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394328br-associate-director-regulatory-writing 2024-03-15T00:00:56+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394444br-allergy-territory-account-specialist-atlanta-north-remote 2024-06-27T18:00:11+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394446br-allergy-territory-account-specialist-bowling-green-remote 2024-06-18T20:00:12+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394558br-therapy-area-medical-lead-heart-failure 2024-05-31T12:00:17+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394651br-technology-product-associate-director 2024-03-18T20:00:56+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394655br-associate-clinical-trial-leader 2024-03-18T20:00:56+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394656br-technology-product-manager 2024-03-18T20:00:56+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/364036br-cdm-migration-business-lead 2024-03-19T10:01:11+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394724br-regulatory-coordinator 2024-03-19T12:01:11+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394848br-associate-submission-manager 2024-03-20T06:00:59+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395075br-assistant-chef-de-produit-cancer-du-sein-en-stage 2024-03-21T12:01:10+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395077br-immunology-japan-program-clinical-head 2024-03-21T12:01:10+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394408br-logistics-assistant-mfd 2024-03-21T16:01:17+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393884br-clinical-document-manager-knowledge-manager 2024-03-21T18:01:09+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393885br-clinical-document-manager-learning-manager-x-3 2024-03-22T10:01:02+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391993br-sales-representative-brustkrebs-dwm-essen-mgladbach-duisburg 2024-06-19T14:00:12+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395170br-associate-director-pipeline-management 2024-04-12T04:00:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/387508br-communications-engagement-manager 2024-06-26T14:00:11+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394584br-medical-director-translational-medicine-immunology 2024-03-25T14:01:11+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395230br-ad-access-reimbursement-radioligand-therapy-remote-miami-bilingual 2024-03-28T18:01:17+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394169br-senior-global-program-regulatory-manager-immunology 2024-03-28T04:01:44+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394272br-snr-director-infrastructure-services-productivity-m365 2024-04-12T08:00:40+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393921br-clinical-data-specialist 2024-04-01T10:00:56+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395373br-lims-application-manager-qc-support 2024-04-10T18:00:43+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395374br-manufacturing-technical-mes-system-specialist 2024-05-30T16:00:19+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395401br-site-head-hse 2024-05-29T16:00:18+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393070br-clinical-program-leader-radioligand-therapy-rlt 2024-04-30T10:02:08+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/387028br-sales-representative-dwm-rheumatologiegebiet-sudhessen 2024-04-12T14:00:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/352910br-sales-representative-mwdrheumatologie-paderborn-kassel-marburg 2024-04-12T14:00:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/388653br-associate-director-director-biotherapeutics-dual-posting 2024-06-24T16:00:11+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394018br-expert-vendor-program-manager 2024-04-30T10:02:08+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394240br-senior-vendor-program-manager 2024-04-30T10:02:08+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394729br-senior-specialist-sasayama-site-it 2024-06-20T10:00:12+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000025-county-executive-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000506-ps-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000689-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000805-dm-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002027-production-operator-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000581-gaojidequjingli-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004154-customer-service-agent-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004839-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004875-senior-scientist-genetically-engineered-models-80-100-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004052-medical-scientific-liaison-manager-wmd-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004837-international-trade-expert-mwd-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002550-senior-manufacturing-system-expert-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004159-pharmaziepraktikant-mwd-im-medical-competence-center-ab-november-2024-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004170-schichtfuhrer-mwd-kundl-tirol-osterreich-de-de 2024-06-24T13:30:54+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003151-produktionsmitarbeiter-mfd-kundl-tirol-osterreich-de-de 2024-06-24T13:30:54+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005685-county-executive-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003162-schichtfuhrer-stellvertreter-mfd-kundl-tirol-osterreich-de-de 2024-06-26T13:30:48+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005639-clinical-project-manager-ii-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007189-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007252-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006640-ast-expert-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007537-medical-affairs-lead-mwd-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395252br-analyst-sfe-products-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006799-documentation-specialist-gmp-fmd-kundl-tirol-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006282-contracts-manager-ldc-solutions-design-manager-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008456-gaojidequjingli-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006284-ldc-sol-design-manager-contract-mgmt-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008960-equipment-operator-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008854-pharmareferent-dwm-ta-cardio-gebiet-bezirk-gelsenkirchen-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009328-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002888-employment-tax-manager-mwd-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007340-sales-representative-brustkrebs-dwm-hessen-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395166br-kam-strategic-lead-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009759-senioradvanced-medicalsales-representative-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009448-principal-scientist-i-toxicology-80-100-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009291-project-mgr-ddit-ies-ma-programs-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008587-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008316-associate-director-mfd-method-expert-team-80-100-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004169-equipment-specialist-mwd-kundl-tirol-osterreich-de-de 2024-06-26T14:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008942-tax-operations-specialist-teilzeit50-mwd-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009030-cell-processing-specialist-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008014-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007048-validation-lead-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010871-gaojidequjingli-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010397-data-science-innovation-fellow-structural-bioinformatics-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011293-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010212-automatiker-im-schichtbetrieb-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010158-network-manager-prostate-cancer-mwd-hannover-braunschweig-bremen-gottingen-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011128-sales-representative-dwm-ta-onkologie-niedersachsen-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011307-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011184-training-manager-mwd-sales-and-medical-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011186-field-excellence-manager-mwd-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008900-scientific-education-manager-mwd-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006045-pharmareferent-mwd-hematology-gebiet-essen-nrw-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001911-pharmareferentin-onkologie-brustkrebs-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010920-senior-buyer-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011464-project-manager-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000993-operational-tax-manager-mwd-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010980-post-graduate-qc-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006264-quality-team-leader-qc-fmd-schaftenau-austria-de-de 2024-06-27T11:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012245-senior-mr-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010464-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012312-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012301-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009452-labortechniker-qc-analyst-ii-mwd-schaftenau-tirol-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011946-life-cycle-program-manager-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011995-gaojidequjingli-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012873-senior-mr-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004904-trainee-marketing-mwd-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008859-sample-management-and-logistics-specialist-mfd-de-de 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000025-county-executive-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000689-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000805-dm-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000581-gaojidequjingli-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002705-technical-accounting-manager-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004088-ldc-commercial-adopt-manager-revenue-management-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004089-ldc-commercial-adopt-manager-order-cash-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004839-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004087-ldc-commercial-adopt-process-manager-pricing-contracting-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004922-procure-pay-senior-specialist-mr11-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005685-county-executive-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005451-accounting-sr-specialist-projects-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005639-clinical-project-manager-ii-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005638-clinical-project-manager-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007189-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007252-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003277-eu-rlt-drug-product-compliance-lead-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395252br-analyst-sfe-products-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005164-clinical-operations-specialist-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008456-gaojidequjingli-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008854-pharmareferent-dwm-ta-cardio-gebiet-bezirk-gelsenkirchen-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009328-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008993-order-management-specialist-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395166br-kam-strategic-lead-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009907-order-cash-and-treasury-cash-management-manager-acc-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009759-senioradvanced-medicalsales-representative-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009904-quality-operations-specialist-supplier-quality-management-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008587-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009688-pc-lab-analyst-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001229-ast-analyst-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008014-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007751-csv-and-data-management-analyst-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010871-gaojidequjingli-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011293-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004925-qa-specialist-apqr-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011307-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002347-adopt-cutover-hypercare-business-lead-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006668-medical-science-liaison-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009656-p2p-service-delivery-sd-lead-ngsc-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010234-treasury-cash-manegement-senior-payment-specialist-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011969-patient-safety-specialist-es-es 2024-06-26T15:30:48+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006355-global-finance-master-data-senior-specialist-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011837-payroll-analyst-mexico-temporary-role-6-moths-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012245-senior-mr-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010464-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012312-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012301-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011120-invoicing-analyst-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011685-complaints-management-specialist-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011995-gaojidequjingli-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011645-strategy-hss-sr-manager-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011965-kam-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012873-senior-mr-es-es 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009920-head-payeurs-du-secteur-prive-fr-ca 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012355-specialiste-affaires-reglementaires-fr-ca 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012519-regulatory-affairs-specialist-fr-ca 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000025-county-executive-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000689-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000805-dm-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001440-apprenti-specialiste-process-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001285-apprenti-ingenieur-genie-climatique-fr-fr 2024-06-28T10:30:29+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000581-gaojidequjingli-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002600-delegue-hospitalier-dermato-ra-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002890-delegue-hospitalier-fr-fr 2024-06-25T13:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003203-msl-tumeurs-solides-nord-est-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004839-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004591-apprenti-specialiste-process-fh-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000783-delegue-hospitalier-neuro-ile-de-france-hf-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005685-county-executive-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001000-responsable-maintenance-fh-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005639-clinical-project-manager-ii-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005106-early-market-acces-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001188-apprenti-chef-de-produit-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007189-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007252-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007325-technicien-de-production-centrale-de-pesee-hf-cdd-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002607-apprenti-expert-automation-1-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006829-delegue-hospitalier-neuro-rhone-alpes-hf-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005103-alternant-market-acces-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004844-alternant-market-acces-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005104-alternant-market-acces-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007713-alternant-controle-de-gestion-bpa-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395252br-analyst-sfe-products-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002854-apprenti-technicien-de-production-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002582-apprenti-technicien-de-production-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007364-alternant-expert-en-developpement-des-competences-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007939-alternant-medical-advisor-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007745-alternant-ingenieur-data-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007141-technicien-de-laboratoire-cq-hf-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007134-technicien-cq-support-equipements-hf-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008456-gaojidequjingli-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008546-alternant-chef-de-projet-maladie-de-verneuilurticaire-chronique-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008854-pharmareferent-dwm-ta-cardio-gebiet-bezirk-gelsenkirchen-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009328-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007928-alternant-strategy-and-operations-coordinator-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005334-cdd-assistante-hf-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002020-sap-expert-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003184-apprentie-coordinateur-formation-hf-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003177-apprentie-coordinateur-formation-hf-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003174-medical-head-radioligand-therapy-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009974-alternant-chef-de-projet-rse-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395166br-kam-strategic-lead-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009759-senioradvanced-medicalsales-representative-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008587-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010306-analyste-strategique-hf-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008195-responsable-aq-compliance-qa-compliance-lead-hf-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008014-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010032-gestionnaire-adv-cdd-hf-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010871-gaojidequjingli-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007888-apprentie-animateur-sse-hf-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011293-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010011-responsable-relations-sociales-hf-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011307-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009266-chargee-bonnes-pratiques-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010303-alternant-specialiste-process-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006918-apprenti-affaires-reglementaires-bon-usage-du-medicament-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012245-senior-mr-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010464-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012312-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012301-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011995-gaojidequjingli-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012873-senior-mr-fr-fr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012363-msl-neuro-est-fr-fr 2024-06-27T11:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000025-county-executive-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000689-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000805-dm-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000581-gaojidequjingli-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004839-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005685-county-executive-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005639-clinical-project-manager-ii-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007189-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007252-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395252br-analyst-sfe-products-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008456-gaojidequjingli-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008854-pharmareferent-dwm-ta-cardio-gebiet-bezirk-gelsenkirchen-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009328-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395166br-kam-strategic-lead-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009759-senioradvanced-medicalsales-representative-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008587-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008014-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010871-gaojidequjingli-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011293-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011307-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012245-senior-mr-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010464-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012312-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012301-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011995-gaojidequjingli-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012873-senior-mr-it-it 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000025-county-executive-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000689-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000805-dm-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000581-gaojidequjingli-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004839-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005685-county-executive-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005639-clinical-project-manager-ii-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007189-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007252-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006599-senior-lead-ecosystem-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395252br-analyst-sfe-products-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004442-lead-ta-medical-general-medicines-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004284-lead-integrated-insights-planningshichangdiaozha-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008456-gaojidequjingli-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008169-senior-lead-ta-medicalgeneral-medicines-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008854-pharmareferent-dwm-ta-cardio-gebiet-bezirk-gelsenkirchen-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009328-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007993-leadassociate-field-access-management-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006590-leadassociate-medical-science-1-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395166br-kam-strategic-lead-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008026-senior-lead-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009759-senioradvanced-medicalsales-representative-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008587-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003913-manager-center-excellence-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008014-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010257-japan-program-head-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010466-manager-financial-control-compliance-fcc-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010871-gaojidequjingli-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008876-associatemanager-msl-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011293-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011307-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012245-senior-mr-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010464-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012312-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012301-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010893-clinical-biospecimen-senior-scientist-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012195-associatemanager-hybrid-mslneuroscience-gene-therapy-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011995-gaojidequjingli-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012395-value-access-wholesaler-kam-wholesaler-strategic-planning-lead-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012873-senior-mr-ja-jp 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000025-county-executive-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000689-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000805-dm-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000581-gaojidequjingli-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004839-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005685-county-executive-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005639-clinical-project-manager-ii-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007189-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007252-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395252br-analyst-sfe-products-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008456-gaojidequjingli-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008854-pharmareferent-dwm-ta-cardio-gebiet-bezirk-gelsenkirchen-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009328-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395166br-kam-strategic-lead-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009759-senioradvanced-medicalsales-representative-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008587-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008014-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010871-gaojidequjingli-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011293-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011307-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009376-qc-analyst-ii-temp-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012245-senior-mr-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010464-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012312-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012301-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011995-gaojidequjingli-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012873-senior-mr-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012533-msl-cardiovascular-west-netherlands-nl-nl 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004957-access-and-heor-lead-pt-br 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000025-county-executive-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000689-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000805-dm-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000581-gaojidequjingli-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004223-medical-advisor-rheumatology-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004839-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005295-specialist-po-organizacii-meropriyatiy-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005685-county-executive-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005639-clinical-project-manager-ii-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003725-territory-market-access-manager-moscow-central-region-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005564-specialist-po-serializacii-i-agregacii-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007189-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007252-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395252br-analyst-sfe-products-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005513-key-account-manager-irkutsk-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008189-medical-science-liaison-immuno-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008456-gaojidequjingli-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009057-key-account-manager-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007737-specialist-po-obespecheniyu-kachestva-na-proizvodstve-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008854-pharmareferent-dwm-ta-cardio-gebiet-bezirk-gelsenkirchen-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009328-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395166br-kam-strategic-lead-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009759-senioradvanced-medicalsales-representative-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008587-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008014-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010871-gaojidequjingli-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011293-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011307-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011348-analyst-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012245-senior-mr-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010464-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012312-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012301-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011118-key-account-manager-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012161-treasury-manager-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011995-gaojidequjingli-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012873-senior-mr-ru-ru 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000025-county-executive-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000689-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000805-dm-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000581-gaojidequjingli-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004839-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005685-county-executive-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005639-clinical-project-manager-ii-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007189-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007252-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395252br-analyst-sfe-products-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008456-gaojidequjingli-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008854-pharmareferent-dwm-ta-cardio-gebiet-bezirk-gelsenkirchen-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009328-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395166br-kam-strategic-lead-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009759-senioradvanced-medicalsales-representative-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008587-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008014-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010871-gaojidequjingli-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011293-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011307-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012245-senior-mr-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010464-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012312-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012301-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011995-gaojidequjingli-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012873-senior-mr-sl-si 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000025-county-executive-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000689-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000805-dm-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000581-gaojidequjingli-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004839-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005685-county-executive-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005771-medical-scientific-liaison-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005639-clinical-project-manager-ii-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007189-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007252-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395252br-analyst-sfe-products-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008456-gaojidequjingli-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008854-pharmareferent-dwm-ta-cardio-gebiet-bezirk-gelsenkirchen-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009328-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395166br-kam-strategic-lead-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009759-senioradvanced-medicalsales-representative-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008587-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008014-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010871-gaojidequjingli-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011293-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011307-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012245-senior-mr-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010464-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012312-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012301-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011995-gaojidequjingli-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012873-senior-mr-tr-tr 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000025-county-executive-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000135-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000130-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000526-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000584-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000689-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000805-dm-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000038-milling-specialistexpert-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001882-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001847-gaojiyiyaodaibiao-zishenchanpinzhuguan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000581-gaojidequjingli-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003019-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003003-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004447-manufacturing-specialist-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003533-xianyuzhurenzhuguan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004691-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004839-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004822-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004096-senior-medical-advisor-oncology-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005685-county-executive-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006017-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004095-xianyuzhurenzhuguan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005639-clinical-project-manager-ii-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004449-senior-public-affairs-manager-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007135-msl-manager-hematology-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007170-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007189-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007252-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007783-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008053-mr-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395252br-analyst-sfe-products-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008122-senior-mr-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008073-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000905-maintenance-engineer-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008210-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008208-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007064-gaojidequjingli-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008456-gaojidequjingli-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008460-gaojidequjingli-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008854-pharmareferent-dwm-ta-cardio-gebiet-bezirk-gelsenkirchen-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009089-mr-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009328-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007782-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009343-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009249-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009364-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010118-po-managerpeople-partner-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395166br-kam-strategic-lead-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010075-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009759-senioradvanced-medicalsales-representative-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010361-xianyuzhurenxianyuzhuguan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010455-district-manager-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008587-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009779-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010135-msl-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010459-expert-science-technology-zh-cn 2024-06-28T11:30:53+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010672-contracting-specialist-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008014-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010813-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010871-gaojidequjingli-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010458-local-gcppv-auditor-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007529-mr-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011294-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011293-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010924-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008092-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010914-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010898-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011307-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011345-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011481-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011482-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011682-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010302-equipment-operator-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004694-senior-medical-sciences-liaison-bc-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003865-senior-medical-sciences-liaison-bc-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010870-senior-mr-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011860-msl-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010721-contracting-specialist-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012245-senior-mr-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010464-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012312-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012301-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012403-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012399-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004125-new-product-launch-lead-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012442-first-line-manager-district-manager-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012804-zongjianzhuli-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012430-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011856-market-access-specialist-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012819-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011995-gaojidequjingli-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012616-clinical-trial-associate-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012873-senior-mr-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012798-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012934-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-26T07:30:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012725-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-24T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013029-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-25T10:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003823-technicien-de-production-specialise-cdi-fr-fr 2024-06-24T16:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003811-cra-zh-cn 2024-06-25T03:30:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012975-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-25T03:30:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012444-xianyuzhurenxianyuzhuguan-zh-cn 2024-06-25T03:30:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000005-cra-zh-cn 2024-06-25T03:30:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013060-xianyuzhurenxianyuzhuguan-zh-cn 2024-06-26T10:30:48+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013050-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-25T10:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003278-mitarbeiter-pilotanlage-mwd-kundl-tirol-de-de 2024-06-25T08:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007067-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-25T08:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007067-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-25T08:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007067-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-25T08:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007067-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-25T08:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007067-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-25T08:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007067-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-25T08:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007067-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-25T08:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007067-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-25T08:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007067-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-25T08:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007067-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-25T08:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012493-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-25T10:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012493-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-25T10:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012493-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-25T10:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012493-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-25T10:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012493-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-25T10:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012493-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-25T10:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012493-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-25T10:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012493-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-25T10:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012493-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-25T10:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012493-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-25T10:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013172-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-27T09:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013177-hta-statistician-mwd-de-de 2024-06-25T13:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003364-content-design-manager-mwd-de-de 2024-06-25T14:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008952-sr-field-medical-lead-gene-therapy-pt-br 2024-06-25T20:30:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008384-consultor-tecnico-especialidades-sr-crm-pt-br 2024-06-25T22:30:52+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013220-xianyuzhurenxianyuzhuguan-de-de 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011027-ns-therapeutic-area-biomarker-lead-associate-director-de-de 2024-06-26T05:30:50+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013220-xianyuzhurenxianyuzhuguan-es-es 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013220-xianyuzhurenxianyuzhuguan-fr-fr 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013220-xianyuzhurenxianyuzhuguan-it-it 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013220-xianyuzhurenxianyuzhuguan-ja-jp 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013220-xianyuzhurenxianyuzhuguan-nl-nl 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013220-xianyuzhurenxianyuzhuguan-ru-ru 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013220-xianyuzhurenxianyuzhuguan-sl-si 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013220-xianyuzhurenxianyuzhuguan-tr-tr 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013220-xianyuzhurenxianyuzhuguan-zh-cn 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009638-senior-district-manager-zh-cn 2024-06-26T07:30:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008976-spec-ddit-isc-qnova-de-de 2024-06-26T09:30:58+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008976-spec-ddit-isc-qnova-es-es 2024-06-26T09:30:58+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008976-spec-ddit-isc-qnova-fr-fr 2024-06-26T09:30:58+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008976-spec-ddit-isc-qnova-it-it 2024-06-26T09:30:58+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008976-spec-ddit-isc-qnova-ja-jp 2024-06-26T09:30:58+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008976-spec-ddit-isc-qnova-nl-nl 2024-06-26T09:30:58+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008976-spec-ddit-isc-qnova-ru-ru 2024-06-26T09:30:58+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008976-spec-ddit-isc-qnova-sl-si 2024-06-26T09:30:58+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008976-spec-ddit-isc-qnova-tr-tr 2024-06-26T09:30:58+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008976-spec-ddit-isc-qnova-zh-cn 2024-06-26T09:30:58+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013148-associate-record-report-ja-jp 2024-06-26T10:30:48+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013361-medical-science-liaison-hemato-saint-petersburg-ru-ru 2024-06-26T12:30:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013377-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-26T11:30:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013039-qc-analyst-ja-jp 2024-06-26T12:30:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008887-scm-sourcing-officer-fmd-temporary-role-2-years-de-de 2024-06-26T14:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011824-pharmacien-enregistrement-hf-fr-fr 2024-06-26T14:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011982-clinical-project-manager-pt-br 2024-06-26T19:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011215-payroll-services-expert-pt-br 2024-06-26T21:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013501-gaojidequjingli-zh-cn 2024-06-28T04:30:28+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013437-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-27T03:30:50+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013465-gaojiyiyaodaibiao-zishenchanpinzhuguan-zh-cn 2024-06-27T11:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013037-gaojidequjingli-de-de 2024-06-27T05:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013037-gaojidequjingli-es-es 2024-06-27T05:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013037-gaojidequjingli-fr-fr 2024-06-27T05:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013037-gaojidequjingli-it-it 2024-06-27T05:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013037-gaojidequjingli-ja-jp 2024-06-27T05:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013037-gaojidequjingli-nl-nl 2024-06-27T05:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013037-gaojidequjingli-ru-ru 2024-06-27T05:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013037-gaojidequjingli-sl-si 2024-06-27T05:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013037-gaojidequjingli-tr-tr 2024-06-27T05:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013037-gaojidequjingli-zh-cn 2024-06-27T05:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013448-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-27T07:30:48+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013528-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-27T09:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013532-xianyuzhurenxianyuzhuguan-de-de 2024-06-27T11:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013532-xianyuzhurenxianyuzhuguan-es-es 2024-06-27T11:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013532-xianyuzhurenxianyuzhuguan-fr-fr 2024-06-27T11:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013532-xianyuzhurenxianyuzhuguan-it-it 2024-06-27T11:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013532-xianyuzhurenxianyuzhuguan-ja-jp 2024-06-27T11:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013532-xianyuzhurenxianyuzhuguan-nl-nl 2024-06-27T11:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010637-analista-contabil-pleno-global-functions-sp-pt-br 2024-06-27T11:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013532-xianyuzhurenxianyuzhuguan-ru-ru 2024-06-27T11:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013532-xianyuzhurenxianyuzhuguan-sl-si 2024-06-27T11:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013532-xianyuzhurenxianyuzhuguan-tr-tr 2024-06-27T11:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013532-xianyuzhurenxianyuzhuguan-zh-cn 2024-06-27T11:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013589-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-28T04:30:28+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013590-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013589-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-28T04:30:28+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013590-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013589-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-28T04:30:28+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013590-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013589-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-28T04:30:28+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013590-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013589-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-28T04:30:28+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013590-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013589-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-28T04:30:28+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013590-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013589-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-28T04:30:28+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013590-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013589-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-28T04:30:28+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013590-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013589-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-28T04:30:28+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013590-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013589-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-28T04:30:28+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013590-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-27T12:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012952-ethics-risk-compliance-sr-manager-mexico-international-es-es 2024-06-27T22:30:50+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007293-medical-science-liaison-multiple-sclerosis-nl-nl 2024-06-27T22:30:50+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010645-medical-science-liaison-rare-diseases-nl-nl 2024-06-27T22:30:50+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013547-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-28T04:30:28+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008639-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-de-de 2024-06-28T09:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008639-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-es-es 2024-06-28T09:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008639-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-fr-fr 2024-06-28T09:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008639-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-it-it 2024-06-28T09:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008639-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ja-jp 2024-06-28T09:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008639-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-nl-nl 2024-06-28T09:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008639-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-ru-ru 2024-06-28T09:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008639-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-sl-si 2024-06-28T09:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008639-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-tr-tr 2024-06-28T09:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013598-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-28T09:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008639-gaojiyiyaodaibiao-zishenchanpinzhuanyuan-zh-cn 2024-06-28T09:30:55+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009820-method-expert-analytical-sciences-mfd-80-100-de-de 2024-06-28T19:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013705-county-executive-zh-cn 2024-06-28T10:30:29+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012734-portfolio-strategy-management-analytical-development-rd-biologics-cell-and-gene-therapies-mfd-de-de 2024-06-28T14:30:47+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011173-senior-quality-assurance-engineer-es-es 2024-06-28T18:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013363-medical-science-liaison-hemato-siberia-ru-ru 2024-06-28T18:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012359-method-expert-analytical-sciences-mfd-fixed-term-contract-de-de 2024-06-28T19:30:49+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013309-consultor-tecnico-especialidades-sr-onco-pt-br 2024-06-28T21:30:46+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000025-county-executive 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000361-medical-representative-can-tho 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000689-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000460-associate-director-global-security-investigator 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000472-site-equipment-cqv-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001445-qa-operations-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001466-medical-science-liaison-msl-solid-tumor-oncology-upper-manhattan-bronx 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001236-senior-study-leader 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000805-dm 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392998br-territory-commercial-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393468br-therapy-area-lead-oncohema-nsimm 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393467br-customer-experience-content-partner-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394280br-office-administrator-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393470br-new-products-strategic-pricing-partner-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393466br-patient-access-lead-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386815br-medical-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001032-principal-software-engineer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393685br-junior-mass-spectrometry-expert-mfd-analytical-characterization-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393784br-senior-mass-spectrometry-expert-analytical-characterisation-mfd-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001507-medical-science-liaison-cardio-renal-metabolic 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393064br-territory-business-executive-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393217br-manager-erp-bpm-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394113br-associate-director-ddit-ma-deal-enablement-asset-mgmt 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001635-sr-spec-ddit-ies-netsec-engg 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001018-sr-spec-ddit-ies-cloud-engineering 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002232-senior-brand-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394168br-assoc-dir-ddit-isc-ent-arch-digit-sec-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394178br-medical-representative-disease-area-specialist-south-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393086br-assoc-dir-ddit-isc-endpoint-data-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002313-patient-engagement-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002475-novartis-turkiye-summer-internship-2024-head-office 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/388900br-assoc-dir-ddit-isc-vulnsvcs-role-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393453br-sr-bus-analyst-ddit-usi-cpm-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001321-team-lead-data-governance 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392477br-sr-spec-ddit-isc-secops-iam-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391564br-assoc-dir-funct-security-architect-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391695br-associate-director-kinaxis-rr-business-process-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001792-customer-experience-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001103-clinical-research-associate 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000581-gaojidequjingli 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000272-chemielabortechniker-qc-analyst-ii-mwd-kundl-tirol 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002322-senior-expert-biologics-analytical-operations-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002323-senior-expert-biologics-analytical-operations-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386105br-senior-patient-access-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386304br-customer-engagement-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000927-scm-lead-rlt-sasayama 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392187br-senior-patient-access-lead-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/388901br-healthcare-solutions-lead-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002815-medical-science-liaison-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001653-life-cycle-manager-eso-lm 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391118br-executive-assistant-ecc 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394165br-customer-experience-partner 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/388061br-primary-market-research-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002671-sr-abl-rlt 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002986-msl-manager-rlt 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392536br-snr-spec-platform-analytics-ai 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391345br-snr-specialistappian-low-code-bpm-automation-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392042br-associate-directorsap-mdg-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390770br-snr-spec-apd-platform-analytics-aws 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002089-care-navigator-2-11-am-8-pm-est-multiple-positions 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393955br-mgr-ddit-svcmgt-china-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394166br-associate-product-manager-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393869br-sr-mgr-ddit-svcmgt-cn-data-platf-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393875br-sr-mgr-ddit-soldel-china-data-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002981-rlt-medical-launch-liaison 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393973br-equipment-specialist-1 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002988-rlt-medical-launch-liaison 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002980-rlt-medical-launch-liaison 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003236-medical-representative 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391126br-international-trade-analyst-dwm-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392904br-sachkundige-person-radiopharmazie-dwm-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003392-qualification-maintenance-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000231-global-procurement-category-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000175-sr-spec-ddit-ies-nw-engineering 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002811-senior-analyst-ffo-analytics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391900br-snrspec-ddit-apd-sol-del-visualization 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394054br-sr-specialist-ddit-apd-erp-platformtech 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003109-bip-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003638-therapeutic-area-partner-kuwait 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003582-health-safety-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390368br-senior-medical-information-manager-2 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393585br-qa-operations-expert-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001213-associate-clinical-development-medical-director 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002911-medical-science-liaison-prostate-radioligand-therapies-southeast-territory 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002637-global-program-associate-director 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003761-global-gcppv-senior-auditor 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392248br-innovation-manager-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392168br-gl-quality-analytics-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002650-bmd-lead-and-senior-principal-scientist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003000-spec-ddit-ies-cloud-engineering 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002651-principal-scientist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002652-senior-scientist-ii 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393710br-applied-computational-biologist-renal-ii 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394015br-clinical-development-medical-director-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001511-sr-manager-it-bp-finance-china 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003791-bpa-head 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003615-senior-ta-strategy-lead-specialty 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001928-senior-expert-science-technology-mfd-drug-product-development 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001786-snr-specialist-mdm-master-data-management-implementation-using-reltio 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003964-medical-science-liaison-allergy-derm-mn-wi-nd-sd-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386345br-senior-expert-biologics-visual-inspection-mfd-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393361br-executive-director-us-patient-advocacy-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001855-senior-method-expert-mfd-analytical-sciences-80-100 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000145-senior-method-expert-mfd-analytical-sciences 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002668-head-quality 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390669br-medical-science-liaison-msl-allergy-derm-ky-sw-oh-remote-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003476-senior-study-start-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003631-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003591-project-site-procurement-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003845-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003693-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003855-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004670-brand-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000885-senior-brand-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002321-principal-scientist-pathology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004671-brand-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004667-brand-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393036br-product-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000059-associate-director-opx-portfolio-management-cz-spain-india 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389179br-senior-expert-science-technology-ii 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/383889br-senior-consultant-ma-post-merger-integrations-separations 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392996br-senior-consultant 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004425-maintenance-calibration-technician-2nd-shift 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001342-assoc-dir-ddit-opx-planning 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004428-oncology-specialist-rlt-portland-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004749-director-scientific-governance-pks 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390414br-medical-directorsenior-medical-director-radiopharmaceuticals-rlt-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001462-director-data-science 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/382621br-clinical-development-medical-director 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004686-area-marketing-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004839-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004819-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004684-area-marketing-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386810br-mr 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004524-inzenir-tehnicnih-storitev-podrocje-gmp-medijev-mzd-ts-engineer-gmp-media-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004697-area-marketing-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004687-gaojiquyushichangjingli 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/379140br-cybersecurity-solutions-architect-global-drug-development-team-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392534br-medical-lead-medical-advisor-hemato-myeloide-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/384321br-assoc-dir-ddit-usi-awb-products 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/384322br-snr-spec-ddit-im-da-operations 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004479-research-scientist-discovery-translational-pharmacology-80-100 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005079-analytics-and-data-driven-insights-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393483br-abl-rlt 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004943-commissioning-qualification-cq-engineering-lead-rlt-carlsbad 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004486-principal-scientist-discovery-translational-pharmacology-80-100 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392270br-data-scientist-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394217br-python-developer-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001508-mst-expansion-lead-rlt-sasayama 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004652-senior-automation-engineer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392683br-associate-process-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003224-senior-specialistpython-and-aws 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386700br-technical-systems-lead-facility-rlt-sasayama 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386692br-rlt-sasayamafinance-manager-business-planning-and-analysis-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005078-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004585-product-manager-hematology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002149-external-analytical-operations-manager-fmd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392797br-regional-commercial-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394848br-associate-submission-manager-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393363br-executive-director-us-corporate-communication 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005402-process-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003290-sr-process-team-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393040br-senior-analyst-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005596-patient-safety-specialist-temporary-18-months-1 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394730br-senior-expert-device-project-analyst-fmd-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395398br-external-analytical-operations-manager-fmd-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393316br-clinical-research-medical-advisor-oncology-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393421br-clinical-research-medical-advisor-haemato-oncology-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002050-senior-clinical-research-associate-western-region 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005685-county-executive 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004696-area-marketing-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393532br-senior-legal-counsel-operations-china-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393079br-director-public-affairs-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/385543br-region-workplace-lead-apcj-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004470-information-specialist-literature-intelligence 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391248br-technicien-services-techniques-utilites-hf-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392265br-head-medical-affairs-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005703-sso-study-start-team-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/388827br-process-engineer-mfd-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005500-snr-specialist-sap-fico-operations 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391893br-sr-specialist-mdm-operations 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/379770br-medical-science-liaison-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005028-brand-manager-cardiology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000078-assoc-dir-ddit-opx-portfolio-management-czech-rep-spain-india 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/376203br-senior-specialist-automation-iam-isc-cybertools-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005878-principal-scientist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393921br-clinical-data-specialist-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006000-product-manager-cardiology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/387667br-production-head-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005475-dermatology-territory-account-specialist-kansas-citywichita-ks-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394227br-sr-spec-ddit-isc-secops-cyber-tools-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006001-principal-scientist-preclinical-safety 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389413br-inzenir-zagonov-kvalifikacij-mzd-cq-engineer-ii-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001856-spec-ddit-ies-cloud-engineering 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005639-clinical-project-manager-ii 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389449br-senior-analyst-apld-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005615-associate-director-scrum-master 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005995-expert-science-technology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/384003br-global-procurement-head-category-warehousing-distribution-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005507-ldc-adopt-operations-mgrsupply-planning 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006266-customer-engagement-solution-partner 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390898br-research-informatics-product-growth-manager-x3-us-or-switzerland 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005657-engineering-maintenance-cmms-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005910-senior-clinical-research-associate 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005260-head-isotopes-manufacturing-and-supply 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389750br-tehnolog-proizvodnega-inzeniringa-lokacije-kljucni-uporabnik-sap-mzd-engineer-multidiscipline-sap-key-user-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002575-sr-spec-ddit-ies-cloud-engineering 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005272-sr-spec-ddit-ies-cloud-engineering 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005829-clinical-project-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006265-knowledge-management-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003332-data-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005232-associate-directorsap-sd-s4hana 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005233-assoc-director-sap-vistex-s4-hana 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392340br-maintenance-technician-instrumentation-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005254-rheumatology-territory-account-specialist-cleveland-west-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005793-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391878br-exec-director-process-development-cell-therapy 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393360br-executive-director-public-affairs-lacan-region 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/388658br-senior-clinical-development-medical-director 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391150br-assoc-dir-ddit-apd-erp-platformtech-se 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006524-regulatory-affairs-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386838br-associate-scm-planner-rlt-sasayama 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006005-director-ddit-im-jp-apma-analyst-patient 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005673-supply-chain-management-head 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391324br-ekspert-tehnologije-izdelkov-mzd-product-steward-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/385758br-vodja-validacij-mzd-validation-lead-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004914-medical-science-liaison-msl-neuroscience-cleveland-columbus-oh-western-pa-morgantown-wv-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004964-disease-area-partner-heart-failure-dakahliadamietta 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005214-disease-area-partner-heart-failure-giza 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/387664br-real-world-evidence-team-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392420br-senior-specialist-information-security-awareness 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386479br-real-estate-lead-data-technology-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005526-ekspert-uvedbe-ldc-operacij-nacrtovanje-proizvodnje-materiala-ldc-adopt-operations-mgr-production-and-material-planning-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392958br-ldc-solution-design-manager-tendering-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005525-ekspert-uvedbe-ldc-operacij-logistika-ldc-adopt-operations-mgr-logistics-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005992-healthcare-partnership-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392392br-regional-hospital-access-head-east 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004255-qc-specialist-ii-mwd-schaftenau-tirol 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003387-senior-specialist-audit-mgmnt-office 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391465br-snr-spec-ddit-isc-ies-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005786-senior-analyst-commercial-design-advisory 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006463-key-account-manager-oncology-therapy-area 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393950br-quality-assurance-systems-and-compliance-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006954-principal-scientist-ii-drug-discovery-kidney-diseases-80-100 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006951-principal-scientist-kidney-diseases-nephrology-80-100 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005588-business-data-migration-expert-manufacturing 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389471br-principal-rwe-research-analyst-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007189-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006965-therapeutic-area-head-hematology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005404-associate-expert-operational-excellence 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007252-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006733-marketing-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006732-brand-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006734-brand-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006731-senior-marketing-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006952-principal-scientist-ii-drug-discovery-kidney-diseases 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391716br-sr-specialist-ai-comp-sci 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/388561br-customer-experience-manager-st 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006950-principal-scientist-i-drug-discovery-kidney-diseases 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005406-associate-director-publication-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001167-principal-scientific-writer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001160-scientific-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006172-head-ddit-ies-infrastructure-solutions 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005158-associate-director-pharmacokinetic-sciences-pks 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005255-regional-director-msls-cvm-midwest-territory-chicago 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007422-head-customer-strategy-operations 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004451-channel-strategy-excellence-head 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006204-global-program-clinical-head-dermatology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004930-medical-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006290-healthcare-manager-cardiology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007211-neuroscience-territory-account-specialist-west-texas-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006558-clinical-laboratory-scientist-generalist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006315-senior-investigator-pharmacokinetics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003737-manager-advanced-analytics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006522-microsoft-365-solution-architect 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005781-senior-gl-financial-reporting-and-accounting-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007855-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395207br-cell-processing-specialist-cgt-2-years-novartis-contract 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007132-analytical-project-lead-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389522br-inzenir-tehnicnih-storitev-za-scada-sisteme-mzd-ts-engineer-scada-systemsmfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/383853br-senior-clinical-project-manager-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/382684br-strategic-materials-lifecycle-manager-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007781-state-government-affairs-partnerships-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007787-state-government-affairs-partnerships-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005049-key-account-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392841br-hire-retire-services-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390029br-document-quality-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006425-senior-manager-bip 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006270-analyst-patient-oriented-programs 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007443-salesforce-marketing-cloud-architect 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392868br-associate-supply-chain-performance-mngr 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006009-senior-analyst-data-science 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395252br-analyst-sfe-products 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393678br-ldc-solution-design-expert-direct-tax-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004506-associate-director-data-science 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006554-principal-senior-principal-scientist-pks-oncology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006745-assoc-director-medical-science-liaison-cvm-detroit-michigan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006246-preclinical-pipeline-lead-data42 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008015-clinical-label-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392790br-senior-vendor-program-manager-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/381169br-senior-clinical-development-medical-director-rheumatology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006374-data-scientist-senior-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003569-senior-analyst-data-science 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005560-sr-spec-ddit-isc-ies 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005381-specialist-supply-operations 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007088-senior-accounting-specialist-switzerland 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007289-senior-analyst-deployment-services 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007341-specialist-qa-ops-manufacturing-mgmt 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395121br-fcc-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389957br-maintenance-technician-mechatronics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007910-oncology-specialist-nm-hematology-peoria-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007294-manager-deployment-services 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004658-clinical-development-director-cdd-cardio-renal-metabolism 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/387596br-document-quality-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005423-external-material-planner 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/383772br-clinical-development-medical-director-cardio-renal-metabolism 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003727-clinical-science-data-and-ai-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005200-fra-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007110-disease-area-partner-hematology-cairo 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386088br-disease-area-strategist-oncology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392425br-senior-analyst-data-products 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007897-expert-scientific-writer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007899-expert-scientific-writer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/383281br-hse-facilities-maintenances-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002654-supervisor-quality-control-nights 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003747-clinical-development-medical-director 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004700-gaojiquyushichangjingli 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005168-associate-clinical-research-medical-director-immunology-rheumatology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007648-visji-skrbnik-osnovnih-podatkov-materialov-senior-site-master-data-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004699-gaojiquyushichangjingli 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394626br-global-digital-fra-operations-lead-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008683-center-operation-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008682-center-operation-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007253-medical-lead-multiple-sclerosis-and-immunology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008677-center-operation-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008680-center-operation-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008674-center-operation-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008758-diseases-area-specialist-oncology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386440br-associate-director-cloud-security-architect-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006871-financial-control-compliance-fcc-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008350-computational-chemist-protein-protein-interactions 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008377-snr-spec-platform-analytics-ai 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395010br-us-paralegal-site-head-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007464-medical-information-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000646-expert-medical-information-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005065-director-enterprise-architect-apd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008547-tax-operations-senior-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007248-project-manager-automation-robotics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002681-project-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007249-project-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007973-care-navigator-2-1100-am-800-pm-est-shift-multiple-positionseast-hanover-nj 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/387343br-country-hr-head 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008262-site-sr-hse-business-partner 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009010-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006976-global-clinical-publishing-associate 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008107-tehnolog-proizvodnih-procesov-i-zmdprocess-expert-i-fmd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006999-lead-associate-integrated-insights-planningmarket-excellence 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390150br-senior-business-analyst-ddit-usi-jpapm-japanese-speaker 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008933-engineering-technician 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008734-gcppv-auditor 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008486-end-end-supply-network-planning-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005127-senior-employee-benefits-accounting-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006304-clinical-bioanalysis-monitor-pk-sciences-principal-scientist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008456-gaojidequjingli 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008671-territory-account-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007503-marketing-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008877-regional-head-pv-qa 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004374-senior-molecular-imaging-expert-senior-principal-scientist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007534-clinical-project-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008932-sr-principal-clin-data-stds-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008885-senior-expert-science-technology-analytical-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008879-senior-expert-drug-supply-process-chemist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392849br-hire-retire-services-specialist-japan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009009-ast-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007565-customer-services-coordinator-temporary 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006777-director-data-management 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392911br-director-market-access-strategy-remote-1-2-roles 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009011-msl-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008854-pharmareferent-dwm-ta-cardio-gebiet-bezirk-gelsenkirchen 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008999-dd-it-project-managerscrum-master-americas 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008983-senior-specialist-master-batch-record-mbr-design 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006357-therapeutic-area-biomarker-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007726-reimbursement-specialist-i-10-am-7-pm-est-multiple-positions 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007205-salesforce-health-cloud-regional-program-director-patient-experience 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009328-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000550-fra-technical-accounting-special-projects-apma 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007975-director-us-market-access-ta-strategy-hematology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003966-director-pilot-plant-rlt 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/387829br-expert-electricite-hf-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392639br-time-management-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004571-associate-director-general-management-strategy-business-planning-analysis 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008105-spec-platform-svcs-edls-ops 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005729-payroll-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008108-knowledge-management-solutions-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008665-expert-analytical-instrumentation-engineering 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009312-senior-expert-data-science 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009086-sr-integrated-insights-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392113br-senior-cluster-procurement-manager-belgium-and-italy 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004508-bssoldelivery 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394338br-associate-external-operations-manager-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392928br-data-steward-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008472-statutory-accounting-and-reporting-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393548br-clinical-development-medical-director-renal-80-100 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007655-senior-qa-operations-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001600-seniorglobal-program-clinical-head-renal-80-100 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007912-tehnolog-proizvodnega-inzeniringa-lokacije-avtomatizacija-mzd-engineer-multidiscipline-automation-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008278-tax-team-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006730-assoc-dir-ddit-isc-secops-vulnsvcs 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009414-associate-directoragile-transformation-scrum-master 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005514-ekspert-uvedbe-ldc-operacij-ic-upravljanje-narocil-ldc-adopt-opr-mgr-ic-order-mngt-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005908-clinical-development-director-crm-80-100 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393258br-associate-scientist-pm-shift 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002893-senior-study-start-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392117br-dir-congress-strat-orchestration-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004820-ra-cmc-associate-manager-ii 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009698-senior-specialistexpert-qa-ops-lifecycle-management 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009757-clinical-development-medical-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391263br-medical-evidence-and-execution-manager-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008002-people-engagement-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003584-team-lead-advanced-analytics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008167-p2p-te-specialist-arabic-speaker 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009506-principal-scientific-writer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008281-process-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006081-senior-statistical-programmer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391189br-disease-area-partner-heart-failure-sharkia-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393476br-disease-area-partner-ascvd-alexandria-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393377br-administrative-assistant-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/370991br-senior-statistical-programmer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/384282br-time-service-delivery-expert-german-speaking-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008636-corporate-tax-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006078-senior-principal-statistical-programmer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009957-qualityteamleaderqa-ops-mfg-mgtqa-sf 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004976-qc-specialist-i 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009621-generative-ai-architect 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008759-operativni-vodja-oskrbe-nphsoperations-lead-supply-chain-nphs 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006588-s4hana-abap-technical-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008997-bioprocess-engineer-i 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005798-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009172-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391542br-dir-integrated-insights-gep-net-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009177-senior-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009940-specialist-representative 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008705-senior-analyst-international 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393648br-lead-consultant-management-consulting 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005166-sr-specialist-process-mining 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008761-ldc-security-manager-1 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004394-director-innovation-lab-mava-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006471-senior-data-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006497-manager-ffo-analytics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393114br-cash-management-bank-reconciliation-ma 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394770br-technicien-laboratoire-prelevement-microbiologie-hf 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009299-maintenance-technician-mechatronics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009648-maintenance-planner 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395166br-kam-strategic-lead-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394254br-lead-capability-learning-solutions-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009829-supply-chain-project-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009920-head-private-payers 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010071-senior-process-engineer-multidiscipline 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009889-change-control-coordinator 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008126-talent-acquisition-business-partner 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008967-associate-director-global-security-investigator 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009062-rewards-excellence-partner 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009021-talent-acquisition-business-partner 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394060br-sourcing-manager-rd-drug-development-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010160-scientific-writing-project-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008830-qc-analyst-iii-analytical 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007430-tehnik-inzeniringa-lokacije-i-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008908-ekspert-tehnologije-izdelkov-iii-product-steward-iii 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009943-senior-consultant-pmpmo 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009759-senioradvanced-medicalsales-representative 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005670-qc-specialist-ii-analytical 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391528br-site-quality-assurance-head-drug-product 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005017-financial-reporting-accounting-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009215-vendor-startup-manager-vsm 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003497-manager-us-federal-and-state-tax-reporting-east-hanover-nj 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005052-senior-medical-information-manager-ii 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004414-medical-director-hematology-franchise 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003207-enterprise-architecture-and-integration-director-commercial-areas 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010081-director-psc-program-and-systems-training 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002591-ad-operational-reporting-analytics-insights 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002717-associate-director-chemical-pharmaceutical-profiling-cpp-project-leader 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/386694br-associate-hse-health-safety-environment 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010519-sales-representative-cv 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008072-p2p-te-specialist-japanese-speaker 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008587-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008890-r2r-specialist-inventory 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007095-product-consultant 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002234-senior-consultant-management-consulting 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/374104br-solution-architect-corporate-functions 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009482-ekspert-mednarodne-trgovineinternational-trade-expert-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009479-ekspert-mednarodne-trgovineinternational-trade-expert-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008187-manager-forecasting 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010499-sr-specialistitil-itsm-innovation 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010502-takticni-planertactical-planner-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009289-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009758-cyber-threat-intelligence-researcher 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009292-senior-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009101-quality-manager-trd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010260-associate-director-renal-clinical-education-mid-atlantic-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010262-associate-director-renal-clinical-education-new-england-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010264-associate-director-renal-clinical-education-northwest-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010259-associate-director-renal-clinical-education-gulf-coast-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010258-associate-director-renal-clinical-education-great-lakes-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001453-medical-science-liaison-msl-solid-tumor-oncology-seattle-wa-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009114-energiemanager-hvac-und-tga-dsk-kundl-mwd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007743-director-financial-controls-compliance-us 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010265-associate-director-renal-clinical-education-south-central-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010267-associate-director-renal-clinical-education-southwest-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009647-congress-planner 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390301br-medical-science-liaison-onc-prostate-radioligand-therapies-dfw-or-north 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010233-medical-science-liaison-msl-hematology-vadcmdde-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009909-medical-science-liaison-msl-onc-radioligand-therapy-no-florida-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010225-data-engineering-manager-data-services 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007326-senior-manager-graphic-design 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009732-data-steward 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009843-qc-chemistry-specialist-1 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009354-data-engineering-manager-data-services 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007152-national-kol-manager-network-manager-solid-tumors-dfm 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002507-shift-lead-ii-ointments 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007397-business-excellence-execution-medical-governance-lead-limited-contract 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010282-key-account-manager-rheumatology-bucharest 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391125br-responsable-grands-comptes-onco-region-centre-limousin-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389390br-principal-rwe-research-analyst-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010436-senior-automation-engineer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010570-business-information-security-manager-usi 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009676-manager-medicaid-contracting-rebate-administration 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008014-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010056-vice-president-integrated-insights-ta-1-2-roles 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010055-executive-director-integrated-insights-ns 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009972-spec-ddit-ies-cis-governance 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002722-senior-expert-materials-science-project-leader 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007715-manager-video-and-post-production 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010749-engineering-technician-1 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006550-clinical-development-medical-director 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002193-principal-scientist-protein-analysis-80-100 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010294-application-development-expert-crm-salesforce-veeva 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010209-validation-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009569-associate-director-parenteral-packaging-delivery-systems 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010501-senior-fra-specialist-gl-inventory 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009821-enterprise-security-architect-data-protection 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009678-director-policy-communications-advocacy-and-media-relations 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010054-head-ta-integrated-insights-portfolio-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392630br-renal-rare-area-business-leader-mid-atlantic-remote-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003524-manager-data-science 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010421-vice-president-global-head-oncology-data-science 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009749-techops-finance-head-us 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011054-associate-clinical-trial-leader 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010871-gaojidequjingli 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393693br-regional-category-manager-indirect-apac-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006972-pnh-field-medical-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000782-procurement-administrative-specialist-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010815-equipment-specialist-i 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393894br-manager-commercial-analytics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/387779br-technical-transfer-lead-medical-device-fmd-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011154-millenial-discovery-program-extended-trainee-program 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010821-scientific-coordinator-radioligand-therapy-vivo-oncology-labs-80-100 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011130-patient-safety-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011065-associate-manager-master-data-management 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008765-safety-assessment-expert-associate-director 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004347-part-time-qa-manager-responsible-person 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009680-associate-director-region-policy-communications-media-relations 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395072br-oc-analyst-ii 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009554-tehnicni-projektni-vodja-director-tppm-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008103-associate-dir-platform-services-messaging 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008957-assoc-director-qa-engineer-leadsalesforce 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007906-manager-ddit-ies-simplify-it-exp 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008085-snr-spec-platform-analytics-hpc-devops 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009555-operativni-tehnicni-projektni-vodja-associate-director-tppm-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003480-manager-state-local-tax-east-hanover-nj 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010839-senior-scientist-discovery-translational-pharmacology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010643-logistic-analyst-afternoon-shift 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393695br-regional-sourcing-manager-apac-indirect-japanese-speaker-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011029-customer-engagement-and-trade-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009609-assoc-dir-ddit-apd-erp-commercials-and-cross-functional 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011041-medical-science-liaison-neuroscience-alberta-bc 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010449-product-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010717-head-business-operations-execution 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008929-associate-director-isc-apd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001800-procurement-manager-wd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009421-senior-clinical-data-scientist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009431-dermatology-medical-science-liaison-immunology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009975-spec-ddit-ies-cis-governance 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010964-recent-master-graduate 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011293-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011264-medical-scientific-liaison 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007772-ta-strategy-director-immunology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009946-senior-consultant-pmo 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007303-sr-integrated-insights-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008056-specialist-laboratorijske-opreme-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393292br-elektrotechniker-mfd-kundl-tirol 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004036-audit-and-compliance-professional 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009113-prozessingenieur-mwd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010495-principal-scientist-radioligand-therapy-80-100 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389584br-sales-representative-dwm-ta-onkologie-bremen 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010842-associate-director-director-developmental-and-reproductive-toxicology-dual-posting 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390562br-principal-scientist-drug-discovery-glomerulonephritis-80-100-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010579-study-start-director 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/388626br-senior-scientist-i-vitro-oncology-drug-discovery-radioligand-therapy-80-100 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395156br-senior-principal-scientistassociate-director-translational-research-immunology-80-100 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011200-ed-ce-comms-and-meeting-engagement 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010858-global-program-clinical-head-market-brands 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010594-senior-analyst-patient-analytics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010987-scientist-analytical-science-and-technology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011202-manager-field-communications 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011204-director-hcp-customer-execution 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011197-manager-field-enablement 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011203-ed-field-insights-analytics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009424-commercial-medical-field-excellence-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006027-sr-sales-executive-oph 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011307-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007543-senior-operations-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394835br-rwe-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003822-tehnik-ii-process-specialist-ii 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008842-sr-sales-executive-crm-ha-team 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003807-solution-delivery-sap-sme-btp-cpi 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005062-lead-consultant-pmo-service 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007036-tehnik-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011137-associate-director-specialty-parenteral 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010912-laboratorijski-analitik-v-bioanalitskem-laboratoriju-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011339-associate-manager-master-data-management 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011535-medical-engagement-partner 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010938-gaojidequjingli 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010465-scm-associate-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009651-clin-ops-prog-dir-feasibility 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009550-associate-technical-project-leader-fmd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010751-p2p-te-business-partner-japanese-speaker 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009667-manager-us-oncology-communications 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010065-manager-us-channel-operations-publishing 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011367-assoc-dir-ddit-ies-cloud-engineering 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011271-regulatory-affairs-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005498-elect-instt-engineering-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011686-global-program-regulatory-manager-lcm 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006006-electrical-instrumentation-engineering-senior-executive 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009965-treasury-cash-management-team-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395273br-director-product-manager-site-lead-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009818-manager-us-immunology-communications 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007190-ed-product-strategy-lead-multiple-sclerosis 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010374-associate-director-order-management-supply-chain-pomocnik-direktorja-dobavne-verige-za-upravljanje-narocil 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011506-business-data-migration-expert-material-master 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009045-regional-access-and-solutions-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391932br-assoc-dir-ddit-ies-nw-telephony-svcs-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010584-automation-engineer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007986-oncology-disease-area-lead-womens-breast-cancer-san-francisco 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009870-director-us-policy-issues-communications 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007118-nf-director-precision-health 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009874-manager-us-people-culture 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009876-manager-us-reputation-corporate-storytelling 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009872-manager-us-policy-issues-communications 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011485-key-account-executive-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010172-senior-expert-data-science-immunology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394053br-principal-rwe-scientific-data-analyst-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006146-head-cd-pediatric-coe 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010934-sourcing-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004707-senior-msl 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011053-territory-business-executive 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005134-r2r-senior-specialist-gl-reporting 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391382br-aussendienstmitarbeiter-mwd-cardio-wurzburg 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010562-associate-director-data-architect-corporate-functions 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011765-specialist-quality-operations 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010926-analyst-im-international 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011709-ecompliance-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003535-sr-spec-ddit-ies-nw-engg 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005663-ad-access-reimbursement-lancaster-pa 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011157-oncology-medical-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011147-pipeline-medical-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390891br-customer-engagement-manager-dermatology-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011719-business-data-migration-expert-commercial-customer-master 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009570-senior-expert-engineering 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011728-business-data-migration-expert-commercial-contractspricing 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010936-customer-engagement-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001136-site-engineering-head 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007944-head-clinical-development-pediatric-coe 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002177-digital-workplace-services-client-engineer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011700-executive-assistant-country-president 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010216-lead-clinical-supply-austria 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010078-director-case-management-3-openings 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010635-senior-contract-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006941-clinical-program-leader 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010613-associate-director-reverification 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010229-director-transfer-pricing-east-hanover-nj 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009842-associate-director-paid-social 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005139-associate-director-peer-peer-marketing-delivery 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010799-team-guide-patient-support-center-east-hanover-nj-or-tempe-az 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011051-qc-senior-specialist-mwd-kundl-tirol 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011657-area-sales-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012008-mst-asia-projects-expansions-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011393-customer-engagement-manager-therapeutic-area-lead-belgrade 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008184-spec-ddit-ies-cloud-engineering 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008165-spec-ddit-ies-automation 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008158-spec-ddit-ies-automation 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011387-customer-engagement-manager-oncology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008069-spec-ddit-ies-cloud-engineering 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007073-senior-accounting-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001630-projektni-inzenir-mzd-project-engineer-ii-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009574-znanstveni-svetovalec-mzd-senior-expert-science-technology-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390889br-tactical-planner-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011085-znanstveni-svetovalec-ekspert-zmd-associate-director-science-technology-fmd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011450-analyst-digital-marketing 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007470-director-nps-experience-design 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011164-neuroscience-territory-account-specialist-youngstown-oh-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009790-specialist-upravljanja-kakovosti-za-podporo-laboratorijem-mzd-quality-assurance-specialist-laboratory-support-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007472-ad-nps-experience-design 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008203-senior-manager-paid-social 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008088-specialist-upravljanja-kakovosti-za-podrocje-upravljanja-kakovosti-prostorov-opreme-hvac-sistemov-medijev-mzd-quality-specialist-premises-equipment-hvac-systems-and-media-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011666-associate-clinical-research-medical-director-oncology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010895-process-engineer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010896-technical-system-lead-qualification 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010844-business-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001509-project-engineer-design-phaserlt-sasayama 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395169br-senior-buyer-indirect-techops-japanese-speaker-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011372-knowledge-management-pmo-senior-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008666-manager-post-production-video-services 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010161-scientific-writing-project-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009105-assoc-dir-solution-delivery 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010892-project-engineer-construction-phase 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004194-senior-principal-analyst-data-operations 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004199-analyst-data-operations 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000946-dir-ddit-isc-enterprise-architecture-appsec 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006099-sr-spec-ddit-ies-infra-services 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391590br-assoc-dir-ddit-ies-cloud-engineering-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011228-senior-principal-pharmacometrics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010769-executive-assistant 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006615-assoc-dir-ddit-isc-secops-pam 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006613-assoc-dir-ddit-isc-secops-pam 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010487-sr-spec-ddit-ies-db-mw-services-ies-cloud-platform-svcs 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006617-sr-spec-ddit-secops-iam 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/384418br-snr-spec-ddit-isc-secops-iam 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009528-technical-steward-mfd-ekspert-procesnih-tehnologij-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009207-customer-service-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009028-sr-spec-ddit-ies-cis-security 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392697br-sr-spec-ddit-ies-cloud-engineering-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011912-principal-scientific-writer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009351-analitik-v-racunovodstvu-mzd-financial-reporting-and-accounting-analyst-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011227-senior-administrative-assistant 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009346-laboratorijski-analitik-v-analitski-znanosti-tehnologiji-ast-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011332-po-workday-product-expert-compensation 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008735-expert-st-ipc-laboratory-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011334-po-workday-product-expert-absence 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008821-country-head-medical-affairs 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011335-po-workday-product-expert-hcm 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011333-po-workday-product-expert-recruitment 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008788-senior-expert-science-technology-analytical-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011399-clinical-document-management-learning-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012275-data-science-innovation-fellow 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002056-it-associate-director-fieldglass-external-workforce 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011336-snr-specialistpower-bi-embedded-analytics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011302-snr-specialistappian 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011764-buying-channels-enablement-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009578-senior-expert-science-technology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010245-head-clinical-development-capabilities-engagement 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390890br-senior-consultant-erp-assurance 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011984-oncology-sales-specialist-womens-breast-cancer-las-vegas-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011810-regional-patient-safety-manager-europe 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011786-regional-patient-safety-head-europe 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012245-senior-mr 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010464-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012172-oncology-sales-specialist-malignant-hematology-detroit-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011411-field-medical-educator 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012312-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390879br-senior-manager-erp-assurance 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012092-ra-cmc-associate-manager-ii 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012004-functional-lead-compliance-analytics-and-reporting 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012301-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393543br-buyer-german-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011770-senior-fra-specialist-inventory 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012373-senior-specialist-qualification-engineer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012091-ra-cmc-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011638-vodja-kontrole-kak-razvoja-bio-zdravil-mzd-assoc-dir-analytical-operations-si-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011488-specialist-qop-india 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009575-znanstveni-svetovalec-v-tehnicnem-razvoju-mzd-senior-expert-science-technology-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011123-manager-dobave-tretjih-dobaviteljev-mzd-supply-operations-manager-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002640-global-program-associate-director 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009803-tehnik-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010221-laboratorijski-analitik-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004520-tehnik-vzdrzevanja-ii-mzd-maintenance-technician-ii-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/385032br-tehnik-vzdrzevanja-tehnicnih-storitev-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001680-assoc-dir-ddit-opx-partnership-mgmt 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012083-globalni-vodja-poslovnega-planiranja-analiz-trd-mzd-associate-director-business-planning-and-analysis-trd-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011474-key-account-manager-hematology-iasi 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003489-operater-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011329-senior-manager-erc-monitoring-and-remediation 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010396-vivo-dmpk-expert-principal-scientist-pk-sciences-pks 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011121-global-quality-systems-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011306-principal-biostatistician 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011871-business-data-migration-expert-finance 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012095-manager-poslovnega-planiranja-analiz-trd-mfd-bpa-manager-trd-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005013-director-digital-workspace 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002403-asc-dir-dev-it-data-analytics-dsai 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009412-ad-product-manager-hpc-computational-science-environments 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012036-vodja-izmene-mzd-shift-lead-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010963-rdq-incident-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012169-business-data-migration-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011976-key-account-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007824-fra-specialist-o2c 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012236-key-account-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011975-key-account-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009061-customer-service-agent 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012486-launch-excellence-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391616br-senior-security-architect-commercial-areas 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007223-manager-credit-risk 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011864-clinical-research-associate 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012279-clinical-sourcing-manager-research-development 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/378428br-technology-product-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012035-data-engineer-data42 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392838br-global-digital-fra-automation-lead-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009383-medical-science-liaison-belux 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011500-submission-readiness-document-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011898-medical-science-liaison-neuro-krasnoyarsk 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011870-key-account-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394392br-specialist-quality-management 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010700-sr-specialist-quality-management 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007796-brand-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000947-finance-and-contract-specialist-2-years-fixed-term-hungary-home-based 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005197-community-key-account-manager-cvd-bucks-oxford-berks 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002029-associate-director-it-projectprogram-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010365-head-fra-holding-foundations-switzerland 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012327-production-supervisor-temporary-contract 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008709-senior-project-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393582br-qa-operations-specialist-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011968-junior-engineer-conferencing-ar-vr-platforms 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011966-engineer-conferencing-platforms-infrastructure-services 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012325-production-technician-temporary-contract 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010852-clinical-innovation-program-management-associate-director 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012506-human-resources-services-senior-expert-hungarian 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012372-snr-specialist-itot-operational-excellence-planning 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011781-associate-director-solutions-delivery 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012037-mehanik-i-mzd-equipment-specialist-i-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002258-automation-engineer-mfd-tehnolog-proizvodnega-inz-lokacije-za-podrocje-avtomatizacije-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003670-manager-clinical-disclosure-office 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010783-senior-principal-product-operations-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010941-associate-director-automation-leadsap-bpa 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010993-ta-medical-lead-oncology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009630-senior-consultant-pmo 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012128-cardiovascular-area-business-leader-ohio-valley 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010350-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011378-associate-director-rd-portfolio-and-engagement 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012164-oncology-sales-specialist-melanoma-charlotte-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012580-principal-biostatistician 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011368-manager-rd-communications-and-engagement 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011283-analytics-insights-manager-12-month-contract 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010726-gaojidequjingli 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012654-senior-manager-r2r 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006403-assistant-manager-fcc 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011754-senior-expert-data-science-crm-cardiovascular-renal-metabolism 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010370-head-legal-business-services 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009580-expert-science-technology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011819-material-implementation-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009372-people-organisation-intern 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012489-medical-science-liaison-neuro 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005548-product-manager-research-informatics-sample-shipping-and-compliance 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003813-laboratorijski-analitik-mzd-qc-analyst-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391682br-assoc-dir-ddit-dev-gco-tech-design-technical-business-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009489-usi-peat-solution-architect 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008186-senior-analyst-forecasting 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012626-tehnik-v-proizvodnji-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008985-ad-product-manager-drug-candidate-selection-software-applications 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/389836br-tehnik-vzdrzevanja-mzd-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390843br-field-medical-advisor 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001700-clinical-operations-program-associate-director 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011181-sr-integrated-insights-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012741-po-country-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011716-exec-director-ta-strategy-neuroscience 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006990-senior-buyer-german-indirect-procurement 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010128-ta-strategy-director-neuroscience 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006987-buyer-indirect-procurement-technical-operations 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011036-ground-services-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011995-gaojidequjingli 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011742-senior-analyst-forecasting 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011191-clinical-development-functional-head 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012601-lead-consultant-management-consulting 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012902-regional-access-manager-lancashire-south-cumbria-humber-coast-vale-south-yorkshire-bassetlaw 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010880-executive-complaint-hub 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394206br-research-development-quality-risk-management-manager-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010968-data-steward 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011717-director-therapeutic-area-strategy-neuroscience 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010967-data-engineering-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394329br-associate-director-innovation-capability-clinical-trial-diversity-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395162br-associate-and-external-engagement-lead-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010133-executive-director-therapeutic-area-ta-strategy-neuroscience 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011548-external-vigilance-engagement-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010208-sr-marketing-manager-rheumatology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011380-bioprocess-engineer-iiiiii 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009345-laboratorijski-analitik-v-bioloskih-ucinkovinah-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009882-technician-science-technology-analytical-development 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012946-subject-matter-expert-legal-compliance 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012155-regional-dir-access-reimbursement-rlt-remote-central 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008279-laboratorijski-analitik-mzd-qc-analyst-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012505-senior-vigilance-process-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011553-ra-cmc-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011522-assoc-dir-ddit-isc-gov-gxp-assessments 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012873-senior-mr 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011496-strategic-healthcare-solutions-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012199-manager-rdf-coe 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390268br-director-search-evaluation-eu 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012684-rare-diseases-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012633-sr-area-training-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011783-bpa-manager-digital-finance 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012870-senior-expert-data-science 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007711-senior-manager-video-production 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012426-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011088-knowledge-management-strategist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011145-cloud-platform-engineer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012127-sr-spec-ddit-ies-cloud-engineering 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013036-fpa-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012731-marketing-therapeutic-area-lead-brand-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003323-produktionsmitarbeiter-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011221-global-program-regulatory-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012767-ad-nps-analytics-leap-operations 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012044-human-centered-culture-design-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012076-cq-engineer-executive 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012048-people-experience-service-design-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012958-csv-technology-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012382-supervisor-manufacturing-downstream-drug-product 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011210-ad-enterprise-ops-support 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012880-head-data-science-ai 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011030-km-solutions-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394805br-senior-manager-qc-cell-based-assays 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010446-payroll-controls-specialist-temporary-12-months 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012634-digital-strategy-insights-manager-fmd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012121-senior-clinical-research-associate 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012697-assoc-dir-ddit-isc-ent-arch-network-security 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012146-payroll-services-expert-us-temporary-9-months 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005238-managed-care-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013153-medical-advisor 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012872-expert-data-science 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011220-senior-global-program-regulatory-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012016-territory-business-executive 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011593-global-labeling-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011933-specialist-network-security-engineering-proxy 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005162-sr-specialist-sap-build-process-automation 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007067-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012598-business-analyst-generative-ai-life-sciences 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005048-expert-gmp-auditor 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010989-principal-scientist-neuroscience 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012493-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10001043-sr-spec-ddit-isc-qnova-quality-management-novartis 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011520-clinical-supply-project-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011950-technical-project-leader 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012381-data-science-innovation-fellow-renal-translational-research 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011035-km-strategist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006343-principal-scientist-clinical-genetics-and-genomics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012346-clinical-research-associate-i-cra-i 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012713-key-account-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009748-operational-scheduler 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010246-director-capabilities-engagement-clinical-development 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012940-oncology-disease-area-lead-malignant-hematology-detroit-mi-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011675-principal-scientist-i-ii-pharmacology-dual-posting 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013144-manager-data-digital-compliance 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009871-director-us-reputation-corporate-storytelling 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013079-supervisor-cell-processing-team-2nd-shift 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394499br-sr-field-medical-lead-msl 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012179-research-scientist-iisenior-scientist-i-biologics-engineering-assays 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009556-director-technical-project-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013143-manager-managed-markets-finance-compliance 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012181-associate-director-business-planning-analysis 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010611-associate-director-coverage-and-access-2-positions 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011931-network-security-engineer-firewall-services 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010614-ad-curriculum-design-3-openings 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010619-ad-implementation-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011490-field-product-specialist-ho-chi-minh 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010617-ad-intake-and-inbound-teleph 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012930-medical-science-liaison-msl-hematology-so-florida-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013322-customer-engagement-partner 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/383075br-director-data-science 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008227-senior-principal-statistical-programmer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013237-senior-manager-sfe-products 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009744-sr-operational-scheduler 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008976-spec-ddit-isc-qnova 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012440-brand-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009900-senior-ux-designer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006485-ast-analitik-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006251-strategy-operations-head-data42 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003320-labortechniker-qc-analyst-ii-mwd-tirol-osterreich 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009715-clinical-scientific-expert-i 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004196-labortechniker-qc-analyst-i-mfd-kundl-schaftenau 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013211-data-science-innovation-fellow-histopathology-foundation-models 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013129-medical-representative 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10000910-qc-specialist-ii 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013061-statutory-and-tax-accounting-expert 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004198-technikermechatronikermechanikerelektrikerschlosser-mfd-kundl-schaftenau 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012590-analyst-data-quality 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012527-area-sales-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012287-associate-director-engineering-device-technology-mfd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391731br-senior-manager-data-science-analytics-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009947-senior-expert-science-technology-fmd-znanstveni-svetovalec-zmd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012737-source-pay-digital-solutions-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009902-associate-director-ux-designer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012383-talent-acquisition-administrator 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013006-specialist-snow-virtual-agent 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005491-director-integrated-insights-sma-gtx 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013297-senior-scientist-fibrosis-research-cellmolecular-biology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009914-associate-director-software-engineering 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005603-associate-director-threat-hunting-and-response-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009877-director-therapeutic-area-biomarker-lead-renal 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010604-ad-case-management-7-openings-cv-renal-oncology-rlt-gene-therapy-immunology2 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013250-medical-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008688-principal-statistical-programmer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007992-ta-strategy-lead-hematology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009635-data-science-innovation-postdoctoral-fellow-translational-bioinformatics 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013330-national-business-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012065-data-science-innovation-postdoctoral-fellow-silico-immunogenicity-prediction 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013037-gaojidequjingli 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013178-senior-system-support-integration-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009084-rlt-health-care-system-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010134-tx-product-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011470-rlt-and-lc-medical-representative 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010696-sourcing-manager-rd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006978-analyst-social-media-listening 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/392230br-ast-analitik-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007512-content-editor-creative-services 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013168-head-ta-immuno-solid-tumor-hematolog 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010356-customer-insights-and-field-force-engagement-manager-adriatic 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012885-senior-consultant-management-consulting 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006470-senior-data-engineering-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012488-global-program-head 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010473-senior-gcppv-auditor 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010471-senior-gcppv-auditor 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013532-xianyuzhurenxianyuzhuguan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013527-senior-manager-retail-marketing 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013443-responsable-dapplication-crm-hf 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/394055br-sr-specialist-aws-devops-engineer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008948-vigilance-compliance-excellence-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013116-digital-finance-project-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008972-global-esg-reporting-operations-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390263br-sales-representative-fmd-ta-ns-marburggiessen 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/388413br-sales-representative-wmd-ta-ns-siegenkoblenz 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013028-laboratorijski-analitik-mzd 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/391394br-sr-prompt-engineering-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013220-xianyuzhurenxianyuzhuguan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012511-quality-assurance-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013610-customer-engagement-partner 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013590-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013347-quality-assurance-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011542-group-head-global-aggregate-reports-risk-management 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013236-manager-ffo-field-force-operations 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011789-postgraduate-pharmaceutical-development 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010515-data-scientist-expert-ii 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013446-cdd-developpeuringenieur-data-hf 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012171-vp-acct-mgmt-and-pricing-strategy-2-positions 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012778-dermatology-territory-account-specialist-chattanooga-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011242-global-program-management-office-director 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010633-analyst-psc-workforce-management-4-positions 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012321-associate-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012768-medical-science-liaison-msl-neuroscience-dc-de-md-nj-east-pa-va-wv 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009505-customer-insights-product-manager-hematology-and-solid-tumors 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007186-kierownik-ds-kluczowych-klientow-cardiovascular 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011048-hematology-operational-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008564-immunology-vp-head-sales-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013277-data-science-innovation-fellow-multimodal-neuroscience 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10002223-sr-spec-ddit-ies-svc-support-exp 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012810-associate-analyst-master-data-management 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012672-junior-prompt-engineering-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013405-senior-principal-analyst-curation-and-ontology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10003229-territory-business-executive 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007625-assoc-director-service-management-itil-itsm-salesforce 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013154-digital-marketing-associate 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013589-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012584-operations-associate 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10006401-fcc-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013428-manager-business-planning-and-analysis 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013424-senior-financial-analyst 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/390343br-senior-expert-science-technology-photochemistry 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012574-assoc-dir-platform-analytics-architecture 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007207-associate-director-key-accounts-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10008639-gaojiyiyaodaibiao-zishenchanpinzhuanyuan 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012082-manager-digital-finance 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395327br-ast-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012100-director-ddit-gf-global-functions-solution-delivery-integration 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010277-field-medical-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009004-senior-medical-scientific-liaison 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/387390br-project-manager-ddit-usi-de-r-europe 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10004530-senior-product-specialist-hematology-central 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010280-medical-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013591-early-product-launch-excellence-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013727-country-head-uz 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010038-regional-access-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011954-associate-technical-project-leader 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012237-ast-expert-mwd-schaftenau-tirol 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012299-ldc-solution-expert-accounts-payable 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/383647br-head-protective-security-asia-pacific-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012154-global-head-novartis-knowledge-center 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009244-sales-representative 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012945-product-owner-data-hf-en-alternance 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012950-app-chef-de-produits-outils-canaux-digitaux 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007381-brand-manager-immunology 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007264-territory-sales-manager-oncology-eastern-western-bohemia 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007268-territory-sales-manager-oncology-moravia 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013656-clinical-scientific-expert-1 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011597-translation-and-artwork-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10007522-director-platform-management-operationssalesforce-or-veeva 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013700-project-coordinator-sostituzione-maternita 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012244-area-sales-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010331-senior-global-program-regulatory-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011848-nto-senior-buyer 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011623-global-regulatory-submission-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010708-manager-regulatory-affairs-process-excellence 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/395219br-director-nps-analytics-crm-0 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013636-key-account-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011609-global-regulatory-affairs-manager-medical-devices-uk-or-austria 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011827-principal-clinical-data-scientist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10010714-senior-manager-regulatory-affairs-process-excellence 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011104-regional-commercial-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011599-global-labelling-systems-project-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011598-global-labeling-compliance-project-lead 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011606-global-program-regulatory-manager-life-cycle-management 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011625-global-regulatory-publishing-specialist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/393542br-global-category-head-fleet 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011630-director-regulatory-policy-intelligence 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011616-global-regulatory-publishing-associate 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011577-global-program-regulatory-director 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011584-senior-global-program-regulatory-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011632-manager-regulatory-policy-intelligence 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011633-associate-director-regulatory-policy-intelligence 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011619-regulatory-affairs-systems-strategy-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011620-associate-director-global-regulatory-submission-management 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011574-senior-regulatory-affairs-coordinator 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011559-regulatory-affairs-cmc-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011953-patient-safety-head-us 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011591-translation-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011605-senior-global-program-regulatory-manager-life-cycle-management 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011608-regulatory-affairs-manager-precision-medicine-uk-or-austria 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011560-regulatory-affairs-cmc-associate-director 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011588-global-program-regulatory-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011592-senior-global-labelling-coordinator 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011610-regulatory-affairs-medical-device-manager-schaftenau-austria 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011561-regulatory-affairs-cmc-senior-manager 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009507-senior-clinical-data-scientist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013478-oncology-sales-specialist-wbc-san-antonio-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009350-senior-clinical-data-scientist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012675-production-technician-ii 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10013063-key-account-manager-rlt 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012910-sourcing-manager-us-meeting-congress-events 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10005943-director-dermatology-clinical-education-west-remote 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10011928-laboratory-technician-medical-device-testing 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10009349-principal-clinical-data-scientist 2024-06-29T05:30:51+00:00 daily 0.5 https://www.novartis.com/careers/career-search/job/details/req-10012328-director-business-excellence-lead 2024-06-29T05:30:51+00:00 daily 0.5